(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
29 March 2018 (29.03.2018)

WIPO | PCT

(10) International Publication Number
WO 2018/057808 A1

(51) International Patent Classification:

C07D 413/14 (2006.01)	*A61K 31/4155* (2006.01)
A61K 31/4184 (2006.01)	*A61K 31/4178* (2006.01)
A61K 31/4196 (2006.01)	*A61K 31/4245* (2006.01)
A61K 31/4709 (2006.01)	*A61K 31/427* (2006.01)
A61K 31/5375 (2006.01)	*A61K 31/433* (2006.01)
C07D 413/04 (2006.01)	*A61K 31/444* (2006.01)
A61P 29/00 (2006.01)	*A61K 31/497* (2006.01)
A61P 35/00 (2006.01)	*A61K 31/501* (2006.01)
C07D 405/14 (2006.01)	*A61K 31/506* (2006.01)
A61K 31/341 (2006.01)	*C07D 409/14* (2006.01)
A61K 31/4025 (2006.01)	*C07D 417/14* (2006.01)

(21) International Application Number:
PCT/US2017/052817

(22) International Filing Date:
21 September 2017 (21.09.2017)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/398,744 23 September 2016 (23.09.2016) US

(71) Applicant: **GILEAD SCIENCES, INC.** [US/US]; 333 Lakerside Drive, Foster City, CA 94404 (US).

(72) Inventors: **CHANDRASEKHAR, Jayaraman**; C/o Gilear Sciences, Inc., 333 Lakerside Drive, Foster City, CA 94404 (US). **CODELLI, Julian, Andrew**; C/o Gilear Sciences, Inc., 333 Lakerside Drive, Foster City, CA 94404 (US). **NADUTHAMBI, Devan**; C/o Gilear Sciences, Inc., 333 Lakerside Drive, Foster City, CA 94404 (US). **PATEL, Leena**; C/o Gilear Sciences, Inc., 333 Lakerside Drive, Foster City, CA 94404 (US). **PERREAULT, Stephane**; C/o Gilear Sciences, Inc., 333 Lakerside Drive, Foster City, CA 94404 (US). **PHILLIPS, Gary**; C/o Gilear Sciences, Inc., 333 Lakerside Drive, Foster City, CA 94404 (US). **SEDILLO, Kassandra, F.**; C/o Gilear Sciences, Inc., 333 Lakerside Drive, Foster City, CA 94404 (US). **TREIBERG, Jennifer, Anne**; C/o Gilear Sciences, Inc., 333 Lakerside Drive Foster City, Foster City, CA 94404 (US). **VAN VELDHUIZEN, Joshua**; C/o Gilear Sciences, Inc., 333 Lakerside Drive, Foster City, CA 94404 (US). **WATKINS, William, J.**; C/o Gilear Sciences, Inc., 333 Lakerside Drive, Foster City, CA 94404 (US).

(74) Agent: **REANEY, Shannon** et al.; Morrison & Foerster LLP, 755 Page Mill Road, Palo Alto, CA 94304-1018 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS



Formula I



Formula IA

(57) Abstract: The present application provides the compounds of formula I or IA or pharmaceutically acceptable salts, isomers, tautomer, or a mixture thereof, wherein s, t, m, n, R^1, R^2, R^3, R^4, R^5, R^6 and $R^7$are as described herein. The compounds of formula I or IA selectively inhibit the activities of PI3K isoforms and are therefore useful in therapeutic treatments, in particular in the treatment of cancer and inflammatory conditions.

[Continued on next page]

WO 2018/057808 A1

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

— *with international search report (Art. 21(3))*

BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS PHOSPHATIDYLINOSITOL 3-KINASE INHIBITORS

FIELD

The present application relates to novel compounds that selectively inhibit the activities of PI3K isoforms and their uses in therapeutic treatments.

BACKGROUND

Cell signaling via 3'-phosphorylated phosphoinositides has been implicated in a variety of cellular processes, *e.g.*, malignant transformation, growth factor signaling, inflammation, and immunity (Rameh *et al.*, *J. Biol. Chem.*, *274*:8347-8350, 1999). Phosphatidylinositol 3-kinase (PI 3-kinase or PI3K) is responsible for generating these phosphorylated signaling products. PI3K was initially identified as a protein associated with viral oncoproteins and growth factor receptor tyrosine kinases that phosphorylate phosphatidylinositol (PI) and its phosphorylated derivatives at the 3'-hydroxyl of the inositol ring (Panayotou *et al.*, *Trends Cell Biol.*, *2*:358-60, 1992).

Three classes of the PI 3-kinase (PI3K) are proposed based on the substrate specificities. Class I PI3Ks phosphorylate phosphatidylinositol (PI), phosphatidylinositol-4-phosphate, and phosphatidylinositol-4,5-biphosphate (PIP_2) to produce phosphatidylinositol-3-phosphate (PIP), phosphatidylinositol-3,4-biphosphate, and phosphatidylinositol-3,4,5-triphosphate, respectively. Also, Class II PI3Ks phosphorylate PI and phosphatidylinositol-4-phosphate, and Class III PI3Ks phosphorylate PI.

The initial purification and molecular cloning of PI 3-kinase revealed that it was a heterodimer consisting of p85 and p110 subunits (Otsu *et al.*, *Cell*, *65*:91-104, 1991; Hiles *et al.*, *Cell*, *70*:419-29, 1992). Later, four distinct Class I PI3Ks were identified and designated as PI3K α, β, δ, and γ isoforms. Each isoform consists of a distinct 110 kDa catalytic subunit and a regulatory subunit. The catalytic subunits of PI3K α, β, and δ (*i.e.*, p110α, p110β, and p110δ, respectively) interacts, individually, with the same regulatory subunit p85, whereas the catalytic subunit of PI3K γ (p110γ) interacts with a distinct regulatory subunit p101.

Studies have also showed that each PI3K isoform has distinct expression pattern. For example, *PIK3CA* which encodes PI3Kα is frequently mutated in human cancers (Engelman, *Nat. Rev. Cancer*, *9*: 550-562, 2009). Also, PI3Kδ is generally expressed in hematopoietic cells. Moreover, PI3K isoforms are shown to be associated with proliferation or survival signaling in cancers, inflammatory, or autoimmune diseases. As each PI3K isoform has different biological function, PI3K isoforms are potential targets to treat cancer or disorder (US Patent Nos. 6,800,620; 8,435,988; 8,673,906; US Patent Application Publication No. US 2013/0274253).

Therefore, there is a need for developing therapeutic agents that inhibit PI3K isoforms to treat diseases, disorders, or conditions that are mediated by PI3K.

SUMMARY

The present application provides novel compounds that are inhibitors of PI3K isoforms. The application also provides compositions, including pharmaceutical compositions, kits that include the compounds, and methods of using and making the compounds. The compounds provided herein are useful in treating diseases, disorders, or conditions that are mediated by PI3K isoforms. The application also provides compounds for use in therapy. The application further provides compounds for use in a method of treating a disease, disorder, or condition that is mediated by PI3K isoforms. Moreover, the application provides uses of the compounds in the manufacture of a medicament for the treatment of a disease, disorder or condition that is mediated by PI3K isoforms. In typical embodiments, provided are compounds of formula I or IA:



Formula I



Formula IA

wherein n is 1, 2, 3 or 4;

m is 1, 2, 3 or 4;

s is 1 or 2;

t is 1 or 2;

each R^1 is independently selected from hydrogen, halo, cyano, hydroxy, amino, $-C(O)R^a$, $-C(O)OR^b$, $-C(O)NR^aR^b$, $-N(R^a)C(O)R^b$, $-S(O)NR^aR^b$, $-S(O)_2NR^aR^b$, $-S(O)R^a$, $-S(O)_2R^a$, $-NR^aR^b$, $-OR^a$, $-SR^b$, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, C_{6-10} aryl, 5-10 membered heteroaryl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S, and 4-10 membered heterocyclyl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S;

wherein each C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, C_{6-10} aryl, 5-10 membered heteroaryl and 4-10 membered heterocyclyl is optionally substituted with one to four R^{100};

R^2 is selected from hydrogen, halo, cyano, hydroxy, amino, $-C(O)R^a$, $-C(O)OR^b$, $-C(O)NR^aR^b$, $-N(R^a)C(O)R^b$, $-S(O)NR^aR^b$, $-S(O)_2NR^aR^b$, $-S(O)R^a$, $-S(O)_2R^a$, $-NR^aR^b$, $-OR^a$, $-SR^b$, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, C_{6-10} aryl, 5-10 membered heteroaryl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S, and 4-10 membered heterocyclyl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S;

wherein each C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, C_{6-10} aryl, 5-10 membered heteroaryl and 4-10 membered heterocyclyl is optionally substituted with one to four R^{101};

R^3 is selected from C_{6-10} aryl, 5-10 membered heteroaryl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S, and 4-10 membered heterocyclyl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S;

wherein each C_{6-10} aryl, 5-10 membered heteroaryl and 4-10 membered heterocyclyl is optionally substituted with one to four R^{102};

R^4 is selected from hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, acyl, C_{3-8} cycloalkyl and C_{1-6} alkyl sulfonyl;

each R^5 is independently selected from hydrogen, halo, cyano, hydroxy, amino, $-C(O)R^a$, $-C(O)OR^b$, $-C(O)NR^aR^b$, $-N(R^a)C(O)R^b$, $-S(O)NR^aR^b$, $-S(O)_2NR^aR^b$, $-S(O)R^a$, $-S(O)_2R^a$, $-NR^aR^b$, $-OR^a$, $-SR^b$, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, C_{6-10} aryl, 5-10 membered heteroaryl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S, and 4-10 membered heterocyclyl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S;

wherein each C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, C_{6-10} aryl, 5-10 membered heteroaryl and 4-10 membered heterocyclyl is optionally substituted with one to four R^{103};

each R^6 is independently selected from hydrogen, halo, cyano, hydroxy, amino, $-C(O)R^a$, $-C(O)OR^b$, $-C(O)NR^aR^b$, $-N(R^a)C(O)R^b$, $-S(O)NR^aR^b$, $-S(O)_2NR^aR^b$, $-S(O)R^a$, $-S(O)_2R^a$, $-NR^aR^b$, $-OR^a$, $-SR^b$, C_{1-6} alkyl, C_{2-6} alkenyl or C_{2-6} alkynyl;

R^7 is selected from hydrogen, halo, cyano, hydroxy, amino, $-C(O)R^a$, $-C(O)OR^b$, $-C(O)NR^aR^b$, $-N(R^a)C(O)R^b$, $-S(O)NR^aR^b$, $-S(O)_2NR^aR^b$, $-S(O)R^a$, $-S(O)_2R^a$, $-NR^aR^b$, $-OR^a$, $-SR^b$, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl;

wherein each C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl is optionally substituted with one to four R^{102};

each R^a and R^b is independently selected from hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl and C_{2-6} alkynyl;

wherein each C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, is optionally substituted with one to four R^{200};

each R^{100}, R^{101}, R^{102}, and R^{103} is independently selected from hydrogen, halo, cyano, hydroxy, amino, oxo, thioxo, vinyl, $-C(O)R^c$, $-C(O)OR^c$, $-C(O)NR^cR^d$, $-N(R^c)C(O)R^d$, $-S(O)NR^cR^d$, $-S(O)_2NR^cR^d$, $-S(O)R^c$, $-S(O)_2R^c$, $-NR^cR^d$, $-OR^c$, $-SR^d$, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, C_{6-10} aryl, 5-10 membered heteroaryl and 4-10 membered heterocyclyl;

wherein each C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, C_{6-10} aryl, 5-10 membered heteroaryl and 4-10 membered heterocyclyl is optionally substituted with one to four R^{201};

each R^c and R^d is independently selected from hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl and C_{2-6} alkynyl;

each R^{200} and R^{201} is independently selected from hydrogen, halo, cyano, hydroxy, amino, oxo, thioxo, vinyl, $-C(O)R^e$, $-C(O)OR^e$, $-C(O)NR^eR^f$, $-N(R^e)C(O)R^f$, $-S(O)NR^eR^f$, $-S(O)_2NR^eR^f$, $-S(O)R^e$, $-S(O)_2R^e$, $-NR^eR^f$, $-OR^e$, $-SR^e$, C_{1-6} alkyl, C_{2-6} alkenyl and C_{2-6} alkynyl;

each R^e and R^f is independently selected from hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl and C_{2-6} alkynyl;

or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

In certain embodiments, the PI3K inhibitors are the compounds selected from Table 1, a pharmaceutically acceptable salt, isomer, or a mixture thereof. In additional embodiments, the compound is an (S)-enantiomer. In other embodiments, the compound is an (R)-enantiomer. In other additional embodiments, the compound is an atropisomer.

The application also provides a pharmaceutical composition that comprises a compound of formula (I), a pharmaceutically acceptable salt, isomer, or a mixture thereof, together with at least one pharmaceutically acceptable vehicle. Examples of a pharmaceutically acceptable vehicle may be selected from carriers, adjuvants, and excipients.

Further provided herein is a method of treating a disease, disorder, or condition in a human in need thereof by administering to the human a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, isomer, or a mixture thereof. Further provided is a compound of formula (I) for use in a method of treating a disease, disorder or condition that is mediated by PI3K isoforms. The application also provides the use of a compound of formula (I) in the manufacture of a medicament for the treatment of a disease, disorder or condition that is mediated by PI3K isoforms. In certain embodiments, the disease, disorder, or condition is associated or mediated by PI3K. In some embodiments, the disease, disorder, or condition is an

inflammatory disorder. In other embodiments, the disease, disorder, or condition is a cancer.

Also provided herein is a method of inhibiting the activity of a phosphatidylinositol 3-kinase polypeptide by contacting the polypeptide with a compound of formula (I) or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

Further provided is a method of inhibiting excessive or destructive immune reactions, comprising administering an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

Also provided is a method of inhibiting growth or proliferation of cancer cells comprising contacting the cancer cells with an effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

Also provided is a kit that includes a compound of formula (I) or a pharmaceutically acceptable salt, isomer, or a mixture thereof. The kit may further comprise a label and/or instructions for use of the compound in treating a disease, disorder, or condition in a human in need thereof. In some embodiments, the disease, disorder, or condition may be associated or mediated by PI3K activity.

Also provided are articles of manufacture that include a compound of formula (I) or a pharmaceutically acceptable salt, isomer, or a mixture thereof, and a container. In one embodiment, the container may be a vial, jar, ampoule, preloaded syringe, or an intravenous bag.

DETAILED DESCRIPTION

The following description sets forth exemplary methods, parameters and the like. Such description is not intended as a limitation on the scope of the present application but is instead provided as exemplary embodiments.

As used herein, the following words, phrases and symbols are generally intended to have the meanings as set forth below, except to the extent that the context in which they are used indicates otherwise.

A dash ("-") that is not between two letters or symbols is used to indicate a point of attachment for a substituent. For example, -$CONH_2$ is attached through the carbon atom. A dash at the front or end of a chemical group is a matter of convenience; chemical groups may be depicted with or without one or more dashes without losing their ordinary meaning. A wavy line drawn through a line in a structure indicates a point of attachment of a group. Unless chemically or structurally required, no directionality is indicated or implied by the order in which a chemical group is written or named.

The prefix "C_{u-v}" indicates that the following group has from u to v carbon atoms. For example, "C_{1-6} alkyl" indicates that the alkyl group has from 1 to 6 carbon atoms.

Reference to "about" a value or parameter herein includes (and describes) embodiments that are directed to that value or parameter per se. In certain embodiments, the term "about" includes the indicated amount ± 10%. In other embodiments, the term "about" includes the indicated amount ± 5%. In certain other embodiments, the term "about" includes the indicated amount ± 1%. Also, to the term "about X" includes description of "X". Also, the singular forms "a" and "the" include plural references unless the context clearly dictates otherwise. Thus, e.g., reference to "the compound" includes a plurality of such compounds and reference to "the assay" includes reference to one or more assays and equivalents thereof known to those skilled in the art.

"Alkyl" refers to an unbranched or branched saturated hydrocarbon chain. As used herein, alkyl has 1 to 20 carbon atoms (*i.e.*, C_{1-20} alkyl), 1 to 8 carbon atoms (*i.e.*, C_{1-8} alkyl), 1 to 6 carbon atoms (*i.e.*, C_{1-6} alkyl), or 1 to 4 carbon atoms (*i.e.*, C_{1-4} alkyl). Examples of alkyl groups include methyl, ethyl, propyl, isopropyl, n-butyl, sec-butyl, iso-butyl, tert-butyl, pentyl, 2-pentyl, isopentyl, neopentyl, hexyl, 2-hexyl, 3-hexyl, and 3-methylpentyl. When an alkyl residue having a specific number of carbons is named, all geometric isomers having that number of carbons may be encompassed; thus, for example, "butyl" includes n-butyl, sec-butyl, isobutyl and t-butyl; "propyl" includes n-propyl and isopropyl.

"Alkenyl" refers to an aliphatic group containing at least one carbon-carbon double bond and having from 2 to 20 carbon atoms (*i.e.*, C_{2-20} alkenyl), 2 to 8 carbon atoms (*i.e.*, C_{2-8} alkenyl), 2 to 6 carbon atoms (*i.e.*, C_{2-6} alkenyl), or 2 to 4 carbon atoms

(*i.e.*, C_{2-4} alkenyl). Examples of alkenyl groups include ethenyl, propenyl, butadienyl (including 1,2- butadienyl and 1,3-butadienyl).

"Alkynyl" refers to an aliphatic group containing at least one carbon-carbon triple bond and having from 2 to 20 carbon atoms (*i.e.*, C_{2-20} alkynyl), 2 to 8 carbon atoms (*i.e.*, C_{2-8} alkynyl), 2 to 6 carbon atoms (*i.e.*, C_{2-6} alkynyl), or 2 to 4 carbon atoms (*i.e.*, C_{2-4} alkynyl). The term "alkynyl" also includes those groups having one triple bond and one double bond.

"Alkoxy" refers to the group "alkyl-O-". Examples of alkoxy groups include methoxy, ethoxy, n-propoxy, iso-propoxy, n-butoxy, tert-butoxy, sec-butoxy, n-pentoxy, n-hexoxy, and 1,2-dimethylbutoxy.

"Acyl" refers to a group -C(=O)R, wherein R is hydrogen, alkyl, cycloalkyl, heterocycloalkyl, aryl, heteroalkyl, or heteroaryl; each of which may be optionally substituted, as defined herein. Examples of acyl include formyl, acetyl, cylcohexylcarbonyl, cyclohexylmethyl-carbonyl, and benzoyl.

"Amido" refers to both a "C-amido" group which refers to the group -$C(=O)NR^yR^z$ and an "N-amido" group which refers to the group -$NR^yC(=O)R^z$, wherein R^y and R^z are independently selected from the group consisting of hydrogen, alkyl, aryl, haloalkyl, or heteroaryl; each of which may be optionally substituted.

"Amino" refers to the group -NR^yR^z wherein R^y and R^z are independently selected from the group consisting of hydrogen, alkyl, haloalkyl, aryl, or heteroaryl; each of which may be optionally substituted.

"Aryl" refers to an aromatic carbocyclic group having a single ring (e.g. monocyclic) or multiple rings (e.g. bicyclic or tricyclic) including fused systems. As used herein, aryl has 6 to 20 ring carbon atoms (*i.e.*, C_{6-20} aryl), 6 to 12 carbon ring atoms (*i.e.*, C_{6-12} aryl), or 6 to 10 carbon ring atoms (*i.e.*, C_{6-10} aryl). Examples of aryl groups include phenyl, naphthyl, fluorenyl, and anthryl. Aryl, however, does not encompass or overlap in any way with heteroaryl defined below. If one or more aryl groups are fused with a heteroaryl ring, the resulting ring system is heteroaryl.

"Cyano" or "carbonitrile" refers to the group -CN.

"Cycloalkyl" refers to a saturated or partially saturated cyclic alkyl group having a single ring or multiple rings including fused, bridged, and spiro ring systems. The term "cycloalkyl" includes cycloalkenyl groups (i.e. the cyclic group having at least one alkenyl). As used herein, cycloalkyl has from 3 to 20 ring carbon atoms (*i.e.*, C_{3-20} cycloalkyl), 3 to 12 ring carbon atoms (*i.e.*, C_{3-12} cycloalkyl), 3 to 10 ring carbon atoms (*i.e.*, C_{3-10} cycloalkyl), 3 to 8 ring carbon atoms (*i.e.*, C_{3-8} cycloalkyl), or 3 to 6 ring carbon atoms (*i.e.*, C_{3-6} cycloalkyl). Examples of cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

"Halogen" or "halo" includes fluoro, chloro, bromo, and iodo. "Haloalkyl" refers to an unbranched or branched alkyl group as defined above, wherein one or more hydrogen atoms are replaced by a halogen. For example, where a residue is substituted with more than one halogen, it may be referred to by using a prefix corresponding to the number of halogen moieties attached. Dihaloalkyl and trihaloalkyl refer to alkyl substituted with two ("di") or three ("tri") halo groups, which may be, but are not necessarily, the same halogen. Examples of haloalkyl include difluoromethyl ($-CHF_2$) and trifluoromethyl ($-CF_3$).

"Heteroalkyl" refers to an alkyl group in which one or more of the carbon atoms (and any associated hydrogen atoms) are each independently replaced with the same or different heteroatomic group. By way of example, 1, 2 or 3 carbon atoms may be independently replaced with the same or different heteroatomic group. Heteroatomic groups include, but are not limited to, -NR-, -O-, -S-, -S(O)-, $-S(O)_2-$, and the like, where R is H, alkyl, aryl, cycloalkyl, heteroalkyl, heteroaryl or heterocycloalkyl, each of which may be optionally substituted. Examples of heteroalkyl groups include $-OCH_3$, $-CH_2OCH_3$, $-SCH_3$, $-CH_2SCH_3$, $-NRCH_3$, and $-CH_2NRCH_3$, where R is hydrogen, alkyl, aryl, arylalkyl, heteroalkyl, or heteroaryl, each of which may be optionally substituted. As used herein, heteroalkyl include 1 to 10 carbon atoms, 1 to 8 carbon atoms, or 1 to 4 carbon atoms; and 1 to 3 heteroatoms, 1 to 2 heteroatoms, or 1 heteroatom.

"Heteroaryl" refers to an aromatic group having a single ring, multiple rings, or multiple fused rings, with one or more ring heteroatoms independently selected from nitrogen, oxygen, and sulfur. As used herein, heteroaryl include 1 to 20 ring carbon atoms, 3 to 12 ring carbon atoms, or 3 to 8 carbon ring atoms; and 1 to 5 heteroatoms, 1 to 4 heteroatoms, 1 to 3 ring heteroatoms, 1 to 2 ring heteroatoms, or 1 ring heteroatom

independently selected from nitrogen, oxygen, and sulfur. Examples of heteroaryl groups include pyrimidinyl, purinyl, pyridyl, pyridazinyl, benzothiazolyl, and pyrazolyl. Heteroaryl does not encompass or overlap with aryl as defined above.

"Heterocycloalkyl" refers to a saturated or unsaturated cyclic alkyl group, with one or more ring heteroatoms independently selected from nitrogen, oxygen and sulfur. The term "heterocycloalkyl" includes heterocycloalkenyl groups (i.e. the heterocycloalkyl group having at least one alkenyl). A heterocycloalkyl may be a single ring or multiple rings wherein the multiple rings may be fused, bridged, or spiro. As used herein, heterocycloalkyl has 2 to 20 ring carbon atoms, 2 to 12 ring carbon atoms, 2 to 10 ring carbon atoms, 2 to 8 ring carbon atoms, 3 to 12 ring carbon atoms, 3 to 8 ring carbon atoms, or 3 to 6 ring carbon atoms; having 1 to 5 ring heteroatoms, 1 to 4 ring heteroatoms, 1 to 3 ring heteroatoms, 1 to 2 ring heteroatoms, or 1 ring heteroatom independently selected from nitrogen, sulfur or oxygen. Examples of heterocycloalkyl groups include pyrrolidinyl, piperidinyl, piperazinyl, oxetanyl, dioxolanyl, azetidinyl, and morpholinyl.

"Hydroxy" or "hydroxyl" refers to the group -OH.

"Oxo" refers to the group (=O) or (O).

"Sulfonyl" refers to the group $-S(O)_2R$, where R is alkyl, haloalkyl, cycloalkyl, heterocycloalkyl, heteroaryl, or aryl. Examples of sulfonyl are methylsulfonyl, ethylsulfonyl, phenylsulfonyl, and toluenesulfonyl.

Certain commonly used alternative chemical names may be used. For example, a divalent group such as a divalent "alkyl" group, a divalent "aryl" group, etc., may also be referred to as an "alkylene" group or an "alkylenyl" group, an "arylene" group or an "arylenyl" group, respectively. Also, unless indicated explicitly otherwise, where combinations of groups are referred to herein as one moiety, *e.g.* arylalkyl, the last mentioned group contains the atom by which the moiety is attached to the rest of the molecule.

The terms "optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not. Also, the term

"optionally substituted" refers to any one or more hydrogen atoms on the designated atom or group may or may not be replaced by a moiety other than hydrogen.

The term "substituted" means that any one or more hydrogen atoms on the designated atom or group is replaced with one or more substituents other than hydrogen, provided that the designated atom's normal valence is not exceeded. The one or more substituents include, but are not limited to, alkyl, alkenyl, alkynyl, alkoxy, acyl, amino, amido, amidino, aryl, azido, carbamoyl, carboxyl, carboxyl ester, cyano, guanidino, halo, haloalkyl, heteroalkyl, heteroaryl, heterocycloalkyl, hydroxy, hydrazino, imino, oxo, nitro, alkylsulfinyl, sulfonic acid, alkylsulfonyl, thiocyanate, thiol, thione, or combinations thereof. By way of example, there may be one, two, three, four, five, or six substituents. Polymers or similar indefinite structures arrived at by defining substituents with further substituents appended ad infinitum (e.g., a substituted aryl having a substituted alkyl which is itself substituted with a substituted aryl group, which is further substituted by a substituted heteroalkyl group, etc.) are not intended for inclusion herein. Unless otherwise noted, the maximum number of serial substitutions in compounds described herein is three. For example, serial substitutions of substituted aryl groups with two other substituted aryl groups are limited to substituted aryl (substituted aryl) substituted aryl. Similarly, the above definitions are not intended to include impermissible substitution patterns (e.g., methyl substituted with 5 fluorines or heteroaryl groups having two adjacent oxygen ring atoms). Such impermissible substitution patterns are well known to the skilled artisan. When used to modify a chemical group, the term "substituted" may describe other chemical groups defined herein. For example, the term "substituted aryl" includes, but is not limited to, "alkylaryl." Unless specified otherwise, where a group is described as optionally substituted, any substituents of the group are themselves unsubstituted.

In some embodiments, the term "substituted alkyl" refers to an alkyl group having one or more substituents including hydroxyl, halo, alkoxy, cycloalkyl, heterocycloalkyl, aryl, and heteroaryl. In additional embodiments, "substituted cycloalkyl" refers to a cycloalkyl group having one or more substituents including alkyl, haloalkyl, heterocycloalkyl, aryl, heteroaryl, alkoxy, halo, hydroxyl; "substituted aryl" refers to an aryl group having one or more substituents including halo, alkyl, haloalkyl, heterocycloalkyl, heteroaryl, alkoxy, and cyano, and "substituted sulfonyl" refers to a

group -$S(O)_2R$, in which R is substituted with one or more substituents of alkyl, cycloalkyl, heterocycloalkyl, aryl or heteroaryl. In other embodiments, the one or more substituents may be further substituted with halo, alkyl, haloalkyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, each of which is substituted. In other embodiments, the substituents may be further substituted with halo, alkyl, haloalkyl, alkoxy, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl, each of which is unsubstituted.

List of Abbreviations and Acronyms

Abbreviation	**Meaning**
°C	Degree Celsius
Ac	Acetyl
aq.	Aqueous
ATP	Adenosine triphosphate
br	Broad
BSA	Bovine serum albumin
Cbz	Carboxybenzyl
COD	Cyclooctadiene
COPD	Chronic obstructive pulmonary disease
d	Doublet
DCE	Dichloroethene
DCM	Dichloromethane
dd	Doublet of doublets
DIEA	Diisopropylethylamine
DMF	Dimethylformamide

DMSO	Dimethylsulfoxide
dt	Doublet-triplet
DTT	Dithiothreitol
EC_{50}	The half maximal effective concentration
eq	Equivalents
ES/MS	Electrospray mass spectrometry
Et	Ethyl
FBS	Fetal bovine serum
g	Grams
HEPES	2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid
HPLC	High pressure liquid chromatography
hr or h or hrs	Hours
Hz	Hertz
IBD	Inflammatory bowel disease
i-pr	Isopropyl
J	Coupling constant (MHz)
Kg/kg	Kilogram
LCMS	Liquid chromatography–mass spectrometry
LPS	Lipopolysaccharide
M	Molar
m	multiplet
M+	Mass peak
M+H+	Mass peak plus hydrogen

Me	Methyl
mg	Milligram
MHz	Megahertz
ml/mL	Milliliter
mM	Millimolar
mmol	Millimole
MOPS	3-Morpholinopropane-1-sulfonic acid
MS	Mass spectroscopy
Ms	Mesyl
nBu/Bu	Butyl
nL	Nanoliter
nm	Nanometer
NMR	Nuclear magnetic resonance
NMP	N-methylpyrrolidinone
NP-40	Nonyl phenoxypolyethoxylethanol
Pd-C/ Pd/C	Palladium on Carbon
Ph	Phenyl
q	Quartet
q.s.	Quantity sufficient to achieve a stated function
RP	Reverse phase
rt	Room temperature
s	Singlet
sat.	Saturated

t	Triplet
TEA	Triethylamine
Tf	Trifluoromethanesulfonyl
TFA	Trifluoroacetic acid
THF	Tetrahydrofuran
TR-FRET	Time-resolved fluorescence energy transfer
δ	Chemical shift (ppm)
μL/ μl	Microliter
μM	Micromolar

Compounds

The present application provides compounds that function as inhibitors of PI3K isoforms. In one aspect, provided are the compounds having the structure of formula I or IA:



Formula I



Formula IA

wherein n is 1, 2, 3 or 4;

m is 1, 2, 3 or 4;

s is 1 or 2;

t is 1 or 2;

each R^1 is independently selected from hydrogen, halo, cyano, hydroxy, amino, $-C(O)R^a$, $-C(O)OR^b$, $-C(O)NR^aR^b$, $-N(R^a)C(O)R^b$, $-S(O)NR^aR^b$, $-S(O)_2NR^aR^b$, $-S(O)R^a$, $-S(O)_2R^a$, $-NR^aR^b$, $-OR^a$, $-SR^b$, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, C_{6-10} aryl, 5-10 membered heteroaryl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S, and 4-10 membered heterocyclyl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S;

wherein each C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, C_{6-10} aryl, 5-10 membered heteroaryl and 4-10 membered heterocyclyl is optionally substituted with one to four R^{100};

R^2 is selected from hydrogen, halo, cyano, hydroxy, amino, $-C(O)R^a$, $-C(O)OR^b$, $-C(O)NR^aR^b$, $-N(R^a)C(O)R^b$, $-S(O)NR^aR^b$, $-S(O)_2NR^aR^b$, $-S(O)R^a$, $-S(O)_2R^a$, $-NR^aR^b$, $-OR^a$, $-SR^b$, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, C_{6-10} aryl, 5-10 membered heteroaryl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S, and 4-10 membered heterocyclyl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S;

wherein each C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, C_{6-10} aryl, 5-10 membered heteroaryl and 4-10 membered heterocyclyl is optionally substituted with one to four R^{101};

R^3 is selected from C_{6-10} aryl, 5-10 membered heteroaryl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S, and 4-10 membered heterocyclyl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S;

wherein each C_{6-10} aryl, 5-10 membered heteroaryl and 4-10 membered heterocyclyl is optionally substituted with one to four R^{102};

R^4 is selected from hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, acyl, C_{3-8} cycloalkyl and C_{1-6} alkyl sulfonyl;

each R^5 is independently selected from hydrogen, halo, cyano, hydroxy, amino, $-C(O)R^a$, $-C(O)OR^b$, $-C(O)NR^aR^b$, $-N(R^a)C(O)R^b$, $-S(O)NR^aR^b$, $-S(O)_2NR^aR^b$, $-S(O)R^a$, $-S(O)_2R^a$, $-NR^aR^b$, $-OR^a$, $-SR^b$, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, C_{6-10} aryl, 5-10 membered heteroaryl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S, and 4-10 membered heterocyclyl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S;

wherein each C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, C_{6-10} aryl, 5-10 membered heteroaryl and 4-10 membered heterocyclyl is optionally substituted with one to four R^{103};

each R^6 is independently selected from hydrogen, halo, cyano, hydroxy, amino, $-C(O)R^a$, $-C(O)OR^b$, $-C(O)NR^aR^b$, $-N(R^a)C(O)R^b$, $-S(O)NR^aR^b$, $-S(O)_2NR^aR^b$, $-S(O)R^a$, $-S(O)_2R^a$, $-NR^aR^b$, $-OR^a$, $-SR^b$, C_{1-6} alkyl, C_{2-6} alkenyl or C_{2-6} alkynyl;

each R^a and R^b is independently selected from hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl and C_{2-6} alkynyl;

wherein each C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, is optionally substituted with one to four R^{200};

each R^{100}, R^{101}, R^{102}, and R^{103} is independently selected from hydrogen, halo, cyano, hydroxy, amino, oxo, thioxo, vinyl, $-C(O)R^c$, $-C(O)OR^c$, $-C(O)NR^cR^d$, $-N(R^c)C(O)R^d$, $-S(O)NR^cR^d$, $-S(O)_2NR^cR^d$, $-S(O)R^c$, $-S(O)_2R^c$, $-NR^cR^d$, $-OR^c$, $-SR^d$, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, C_{6-10} aryl, 5-10 membered heteroaryl and 4-10 membered heterocyclyl;

wherein each C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, C_{6-10} aryl, 5-10 membered heteroaryl and 4-10 membered heterocyclyl is optionally substituted with one to four R^{201};

each R^c and R^d is independently selected from hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl and C_{2-6} alkynyl;

each R^{200} and R^{201} is independently selected from hydrogen, halo, cyano, hydroxy, amino, oxo, thioxo, vinyl, $-C(O)R^e$, $-C(O)OR^e$, $-C(O)NR^eR^f$, $-N(R^e)C(O)R^f$, $-S(O)NR^eR^f$, $-S(O)_2NR^eR^f$, $-S(O)R^e$, $-S(O)_2R^e$, $-NR^eR^f$, $-OR^e$, $-SR^e$, C_{1-6} alkyl, C_{2-6} alkenyl and C_{2-6} alkynyl;

each R^e and R^f is independently selected from hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl and C_{2-6} alkynyl;

or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

In another aspect, provided are compounds of Formula IB:



Formula IB

wherein n, s, m, t, R^1, R^2, R^4, $R^5$and R^6 are as defined above;

------ represents a single or double bond;

X^1 is N or C;

each X^2, X^3, X^4 and X^5 is independently selected from S, O, CR^{10} and NR^{11};

wherein each R^{10} is independently selected from hydrogen, halo, cyano, hydroxy, amino, $-C(O)R^a$, $-C(O)OR^b$, $-C(O)NR^aR^b$, $-N(R^a)C(O)R^b$, $-S(O)NR^aR^b$, $-S(O)_2NR^aR^b$, $-S(O)R^a$, $-S(O)_2R^a$, $-NR^aR^b$, $-OR^a$, $-SR^b$, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, C_{6-10} aryl, 5-10 membered heteroaryl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S, and 4-10 membered heterocyclyl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S;

wherein each C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, C_{6-10} aryl, 5-10 membered heteroaryl and 4-10 membered heterocyclyl is optionally substituted with one to four R^{104};

wherein each R^{11} is independently selected from absent, hydrogen, halo, cyano, hydroxy, amino, $-C(O)R^a$, $-C(O)OR^b$, $-C(O)NR^aR^b$, $-N(R^a)C(O)R^b$, $-S(O)NR^aR^b$, $-S(O)_2NR^aR^b$, $-S(O)R^a$, $-S(O)_2R^a$, $-NR^aR^b$, $-OR^a$, $-SR^b$, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, C_{6-10} aryl, 5-10 membered heteroaryl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S, and 4-10 membered heterocyclyl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S;

alternatively, one R^{10} and one R^{11} group, together with the atoms to which they are attached form a five, six or seven membered fused or bridged ring;

or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

In another aspect, provided are compounds of Formula IC:



Formula IC

wherein n, s, m, t, R^1, R^2, R^4 and R^5 are as defined above;

each R^{13} is independently selected from hydrogen, halo, cyano, hydroxy, amino, -$C(O)R^a$, -$C(O)OR^b$, -$C(O)NR^aR^b$, -$N(R^a)C(O)R^b$, -$S(O)NR^aR^b$, -$S(O)_2NR^aR^b$, -$S(O)R^a$, -$S(O)_2R^a$, -NR^aR^b, -OR^a, -SR^b, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, C_{6-10} aryl, 5-10 membered heteroaryl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S, and 4-10 membered heterocyclyl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S;

each R^a and R^b is independently selected from hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl and C_{2-6} alkynyl;

wherein each C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, is optionally substituted with one to four R^{200};

each R^{200} is independently selected from hydrogen, halo, cyano, hydroxy, amino, oxo, thioxo, vinyl, -$C(O)R^e$, -$C(O)OR^e$, -$C(O)NR^eR^f$, -$N(R^e)C(O)R^f$, -$S(O)NR^eR^f$, -$S(O)_2NR^eR^f$, -$S(O)R^e$, -$S(O)_2R^e$, -NR^eR^f, -OR^e, -SR^e, C_{1-6} alkyl, C_{2-6} alkenyl and C_{2-6} alkynyl;

each R^e and R^f is independently selected from hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl and C_{2-6} alkynyl;

or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

In another aspect, provided are compounds of Formula ID:



Formula ID

wherein n, s, m, R^1, R^2, R^4, R^5, and R^{13} are as defined above;

or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

In another aspect, provided are compounds of Formula IE:



Formula IE

wherein n, s, m, R^1, R^2, R^4, R^5, X^1, X^2, X^3, X^4 and X^5 are as defined above;

or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

In another aspect, provided are compounds of Formula IF:



Formula IF

wherein n, s, m, t, R^1, R^2, R^4, R^5, and R^{13} are as defined above;

or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

In another aspect, provided are compounds of Formula IG:



Formula IG

wherein n, s, m, R^1, R^2, R^4, R^5, and R^{13} are as defined above;

or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

In another aspect, provided are compounds of Formula IH:



Formula IH

wherein n, s, m, R^1, R^2, R^4, R^5, X^1, X^2, X^3, X^4 and X^5 are as defined above;

or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

In another aspect, provided are compounds of Formula IJ:



Formula IJ

wherein n, s, m, t, R^1, R^2, R^4, R^5, and R^{13} are as defined above;

or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

In another aspect, provided are compounds of Formula IK:



Formula IK

wherein n, s, m, R^1, R^2, R^4, R^5, and R^{13} are as defined above;

or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

In another aspect, provided are compounds of Formula (IL) or (IM)



Formula IL



Formula IM

wherein n, s, m, R^1, R^2, R^4, R^5, and R^7 are as defined above;

or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

In certain embodiments, provided is a compound of Formula I, wherein R^3 is





wherein t is 1 or 2;

each R^{13} is independently selected from hydrogen, halo, cyano, hydroxy, amino, oxo, thioxo, vinyl, $-C(O)R^a$, $-C(O)OR^b$, $-C(O)NR^aR^b$, $-N(R^a)C(O)R^b$, $-S(O)NR^aR^b$, $-S(O)_2NR^aR^b$, $-S(O)R^a$, $-S(O)_2R^a$, $-NR^aR^b$, $-OR^a$, $-SR^b$, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, C_{6-10} aryl, 5-10 membered heteroaryl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S, and 4-10 membered heterocyclyl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S;

or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

In certain embodiments, provided is a compound of Formula IE or IH,, or a pharmaceutically acceptable salt, isomer, or a mixture thereof; wherein the substituent  is selected from:



or .

One of skill in the art understands that t=1 for compounds having only one atom available for substitution.

In certain embodiments, provided is a compound of Formula I, IA, IB, IC, ID, IE, IF, IG, IH, IJ, IK, IL or IM, wherein R^1 is selected from hydrogen, fluoro, chloro, bromo, iodo, methyl, ethyl, propyl, butyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl and trifluoroethyl; or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

In certain embodiments, provided is a compound of Formula I, IA, IB, IC, ID, IE, IF, IG, IH, IJ, IK, IL or IM, wherein R^1 is fluoro or chloro; or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

In certain embodiments, provided is a compound of Formula I, IA, IB, IC, ID, IE, IF, IG, IH, IJ, IK, IL or IM, wherein R^2 is C_{1-6} alkyl, C_{3-8} cycloalkyl, 5-6 membered heteroaryl containing 1 to 3 heteroatoms selected from the group consisting of N, O, and S, and 4-6 membered heterocyclyl containing 1 to 4 heteroatoms selected from the group consisting

of N, O, and S; wherein each C_{1-6} alkyl, C_{3-8} cycloalkyl, 5-6 membered heteroaryl and 4-6 membered heterocyclyl is optionally substituted with one to four R^{101}; or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

In certain embodiments, provided is a compound of Formula I, IA, IB, IC, ID, IE, IF, IG, IH, IJ, IK, IL or IM, wherein R^2 is selected from hydrogen, amino, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, furanyl, tetrahydrofuranyl, oxetanyl, and cyclopropyl; or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

In certain embodiments, provided is a compound of Formula I, IA, IB, IC, ID, IE, IF, IG, IH, IJ, IK, IL or IM, wherein R^4 is selected from hydrogen and methyl; or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

In certain embodiments, provided is a compound of Formula I, IA, IB, IC, ID, IE, IF, IG, IH, IJ, IK, IL or IM, wherein R^5 is selected from hydrogen, methyl, ethyl, trifluoromethyl, carboxamide, cyano, piperazinyl, cyclopropyl, phenyl and triazolyl; or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

In certain embodiments, provided is a compound of Formula I, IA, IB, IC, ID, IE, IF, IG, IH, IJ, IK, IL or IM, wherein R^1 is selected from hydrogen or a substituent selected from the table below:

			
			
			

or a pharmaceutically acceptable salt thereof.

In certain embodiments, provided is a compound of Formula I, IA, IB, IC, ID, IE, IF, IG, IH, IJ, IK, IL or IM, wherein R^2 is selected from hydrogen or a substituent selected from the table below:



or a pharmaceutically acceptable salt thereof.

In certain embodiments, provided is a compound of Formula I, wherein R^3 is selected from hydrogen or a substituent selected from the table below:



			
			
			
			
			
			
			
			
			
			

or a pharmaceutically acceptable salt thereof.

In certain embodiments, provided is a compound of Formula I, IA, IB, IC, ID, IE, IF, IG, IH, IJ, IK, IL or IM, wherein R^5 is selected from hydrogen or a substituent selected from the table below:

			
			
			
			

or a pharmaceutically acceptable salt thereof.

In certain embodiments, provided is a compound selected from Table A, or a pharmaceutically acceptable salt, isomer, or a mixture thereof:

Table A

Example	Structure	Example	Structure
1		172	
2		173	

3		174	
4		175	
5		176	
6		177	
7		178	

8		179	
9		180	
10		181	
11		182	
12		183	

13		198	
14		199	
15		200	
16		201	
17		202	

18		203	
19		204	
20		205	
21		206	
22		207	
23		208	

24		209	
25		210	
26		211	
27		212	
28		213	

29		214	
30		215	
31		216	
32		217	
33		218	

34		219	
35		220	
36		221	
37		222	
38		223	

39		224	
40		225	
41		226	
42		227	
43		228	
44		229	

45		230	
46		231	
47		232	
48		233	
49		234	

50		235	
51		236	
52		237	
53		238	
54		239	

55		240	
56		241	
57		242	
58		243	
59		244	
60		245	

61		246	
62		260	
63		261	
64		262	
65		263	

66		264	
67		265	
68		266	
69		267	
70		268	

71		269	
72		270	
73		271	
74		272	
75		273	
76		274	

77		275	
78		276	
79		277	
80		278	
81		279	

82		280	
83		281	
84		282	
85		283	
86		284	

87		285	
88		286	
89		287	
90		288	
91		289	

92		290	
93		291	
94		292	
95		293	
96		294	

97		295	
98		296	
99		297	
100		298	
101		299	

102		300	
103		301	
104		302	
105		303	
106		304	

107		305	
108		306	
109		307	
110		308	
111		309	

112		310	
113		311	
114		312	
115		313	
116		314	

117		315	
118		316	
119		317	
120		318	
121		319	

122		320	
123		321	
124		322	
125		323	
126		329	

127		330	
128		331	
129		332	
130		333	
131		334	

132		335	
133		336	
134		337	
135		340	
136		341	

137		342	
138		343	
139		344	
140		345	
141		346	

142		347	
143		348	
144		349	
145		350	
146		351	

160		352	
161		353	
162		354	
163		355	
164		356	

165		357	
166		358	
167		359	
168		360	
169		361	

170		362	
171		363	

In certain embodiments, provided is a compound selected from Table B, or a pharmaceutically acceptable salt, isomer, or a mixture thereof:

TABLE B

Example	Image
149	
150	

Example	Image
151	
152	
153	
154	
155	

Example	Image
156	
157	
247	
364	
365	

Example	Image
366	
367	
368	
369	
370	

Example	Image
371	
372	
373	
374	
375	

Example	Image
376	
377	
378	
379	
380	

Example	Image
381	
382	
383	
387	
388	

Example	Image
389	
390	
391	
392	
393	

Example	Image
394	

The present application provides pharmaceutically acceptable salts, hydrates, solvates, isomers, tautomers, stereoisomers, enantiomers, racemates, atropisomers, polymorphs, prodrugs, or a mixture thereof, of the compounds described herein. The terms "a compound of the present application," "a compound described herein," "a compound of any of the formulae described herein," or variant thereof refer to a compound having the structure of any of the formulae, I, IA, IB, IC, ID, IE, IF, IG, IH, IJ, IK, IL and IM.). In some embodiments, compounds of the present application are Compounds 1-363 as described herein.

"Pharmaceutically acceptable" or "physiologically acceptable" refer to compounds, salts, compositions, dosage forms and other materials which are useful in preparing a pharmaceutical composition that is suitable for veterinary or human pharmaceutical use. "Pharmaceutically acceptable salts" or "physiologically acceptable salts" refer to salts of pharmaceutical compounds that retain the biological effectiveness and properties of the underlying compound, and which are not biologically or otherwise undesirable. There are acid addition salts and base addition salts. Pharmaceutically acceptable acid addition salts may be prepared from inorganic and organic acids. Acids and bases useful for reaction with an underlying compound to form pharmaceutically acceptable salts (acid addition or base addition salts respectively) are known to one of skill in the art. Similarly, methods of preparing pharmaceutically acceptable salts from an underlying compound (upon disclosure) are known to one of skill in the art and are disclosed in for example, Berge, at al. Journal of Pharmaceutical Science, Jan. 1977 vol. 66, No.1, and other sources. If the compounds described herein are obtained as an acid addition salt, the free base can be obtained by basifying a solution of the acid salt. Conversely, if the product is a free base, an addition salt, particularly a pharmaceutically acceptable

addition salt, may be produced by dissolving the free base in a suitable organic solvent and treating the solution with an acid, in accordance with conventional procedures for preparing acid addition salts from base compounds. Salts derived from organic acids include acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluene-sulfonic acid, salicylic acid, and the like. Salts derived from mineral acids include, hydrochloride, hydrobromide, hydroiodide, nitrate, phosphate, and sulfate. Likewise, pharmaceutically acceptable base addition salts can be prepared from inorganic and organic bases. Salts derived from inorganic bases include, by way of example only, sodium, potassium, lithium, ammonium, calcium and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary and tertiary amines, such as alkyl amines (i.e., $NH_2(alkyl)$), dialkyl amines (i.e., $HN(alkyl)_2$), trialkyl amines (i.e., $N(alkyl)_3$), substituted alkyl amines (i.e., $NH_2(substituted\ alkyl)$), di(substituted alkyl) amines (i.e., $HN(substituted\ alkyl)_2$), tri(substituted alkyl) amines (i.e., $N(substituted\ alkyl)_3$), alkenyl amines (i.e., $NH_2(alkenyl)$), dialkenyl amines (i.e., $HN(alkenyl)_2$), trialkenyl amines (i.e., $N(alkenyl)_3$), substituted alkenyl amines (i.e., $NH_2(substituted\ alkenyl)$), di(substituted alkenyl) amines (i.e., $HN(substituted\ alkenyl)_2$), tri(substituted alkenyl) amines (i.e., $N(substituted\ alkenyl)_3$, mono-, di- or tri- cycloalkyl amines (i.e., $NH_2(cycloalkyl)$, $HN(cycloalkyl)_2$, $N(cycloalkyl)_3$), mono-, di- or tri-arylamines (i.e., $NH_2(aryl)$, $HN(aryl)_2$, $N(aryl)_3$), or mixed amines, etc. Specific examples of suitable amines include, by way of example only, isopropylamine, trimethyl amine, diethyl amine, tri(iso-propyl) amine, tri(n-propyl) amine, ethanolamine, 2-dimethylaminoethanol, piperazine, piperidine, morpholine, N-ethylpiperidine, and the like.

"Isomers" refers to compounds that have the same molecular formula. As used herein, the term isomers include double bond isomers, racemates, stereoisomers, enantiomers, diastereomers, and atropisomers. Single isomers, such as enantiomers or diastereomers, can be obtained by asymmetric synthesis or by resolution of a mixture of isomers. Resolution of a mixture of isomers (e.g. racemates) maybe accomplished, for example, by conventional methods such as crystallization in the presence of a resolving agent, or chromatography, using, for example a chiral high pressure liquid

chromatography (HPLC) column. "Double bond isomers" refer to Z- and E- forms (or *cis*- and *trans*- forms) of the compounds with carbon-carbon double bonds.

"Atropisomers" refers to conformational stereoisomers which occur when rotation about a single bond in the molecule is prevented, or greatly hindered, as a result of steric interactions with other parts of the molecule and the substituents at both ends of the single bond are asymmetrical, *i.e.*, they do not require a stereocenter. Where the rotational barrier about the single bond is high enough, and interconversion between conformations is slow enough, separation and isolation of the isomeric species may be permitted. Atropisomers may be separated by the methods well known in the art. Unless otherwise indicated, the description is intended to include individual atropisomers as well as mixtures. Also, as understood by those skilled in the art, the atropisomers may be represented by the same chemical name with different atropisomer designations. By way of example, the below structures are atropisomers of compound 230 (4-(1-(5,8-difluoroquinolin-4-yl)-4-(oxazol-2-yl)-2-propyl-1H-benzo[d]imidazol-6-yl)morpholine).



Compound-356



Compound-357

Compounds of the invention are named using Chembiodraw Ultra (version 14).

"Racemates" refers to a mixture of enantiomers.

"Stereoisomers" or "stereoisomeric forms" refer to compounds that differ in the chirality of one or more stereocenters. Stereoisomers include enantiomers and diastereomers. The compounds may exist in stereoisomeric form if they possess one or more asymmetric centers or a double bond with asymmetric substitution and, therefore, can be produced as individual stereoisomers or as mixtures. Unless otherwise indicated, the description is intended to include individual stereoisomers as well as mixtures. The

methods for the determination of stereochemistry and the separation of stereoisomers are well-known in the art (*see, e.g.,* Chapter 4 of Advanced Organic Chemistry, 4th ed., J. March, John Wiley and Sons, New York, 1992).

"Tautomers" or "tautomeric forms" refer to alternate forms of a compound that differ in the position of a proton, such as enol-keto and imine-enamine tautomers, or heteroaryls such as pyrazoles, imidazoles, benzimidazoles, triazoles, and tetrazoles.

A "solvate" is formed by the interaction of a solvent and a compound. Solvates of salts of the compounds of any of the formulae described herein are also provided. Hydrates of the compounds of any of the formulae are also provided.

A "prodrug" is defined in the pharmaceutical field as a biologically inactive derivative of a drug that upon administration to the human body is converted to the biologically active parent drug according to some chemical or enzymatic pathway. A prodrug is thus a covalently modified analog or latent form of a therapeutically active compound. Non-limiting examples of prodrugs include ester moieties, quaternary ammonium moieties, glycol moieties, and the like.

In any one of the foregoing embodiments, the compound described herein or a pharmaceutically acceptable salt thereof is an (*S*)-enantiomer. In any one of the foregoing embodiments, the compound described herein or a pharmaceutically acceptable salt thereof is an (*R*)-enantiomer. In any one of the foregoing embodiments, the compound described herein or a pharmaceutically acceptable salt thereof is an atropisomer.

The application also provides a composition containing a mixture of enantiomers of the compound or a pharmaceutically acceptable salt thereof. In one embodiment, the mixture is a racemic mixture. In other embodiments, the composition comprises the (*S*)-enantiomer of a compound in excess of the corresponding (*R*)-enantiomer of the compound. In some embodiments, the composition contains the (*S*)-enantiomer of the compound and is substantially free of its corresponding (*R*)-enantiomer. In certain embodiments, a composition substantially free of the (*R*)-enantiomer has less than or about 40%, 35%, 30%, 25%, 20%, 15%, 10%, 5%, 1%, 0.05%, or 0.01% of the (*R*)-enantiomer. In other embodiments, the composition containing the (*S*)-enantiomer of a compound or a pharmaceutically acceptable salt thereof, predominates over its

corresponding (R)-enantiomer by a molar ratio of at least or about 9:1, at least or about 19:1, at least or about 40:1, at least or about 80:1, at least or about 160:1, or at least or about 320:1.

The composition containing a compound according to any of the formulae described herein or a pharmaceutically acceptable salt thereof, may also contain the compound in enantiomeric excess (e.e.). By way of example, a compound with 95% (*S*)-isomer and 5% (*R*)-isomer will have an e.e. of 90%. In some embodiments, the compound has an e.e. of at least or about 60%, 75%, 80%, 85%, 90%, 95%, 98% or 99%.

In any one of the foregoing embodiments, the compound or a pharmaceutically acceptable salt thereof, is an atropisomer. Another embodiment provides the composition containing a mixture of atropisomers of the compound or a pharmaceutically acceptable salt thereof. By way of example, a compound with 95% of one atropisomer and 5% of the other atropisomers. In some embodiments, a compound with about 90, 80, 70, 60, 50, 40, 30, 20, or 10% of one atropisomer and 10, 20, 30, 40, 50, 60, 70, 80, or 90%, respectively, of the other atropisomers.

The application also provides the free base forms of the compounds described herein. In certain embodiments, provided herein are the enantiomers, (*R*) or (*S*), of the compounds of the formulae described herein. In other embodiments, provided herein are the atropisomers of the compounds of the formulae described herein.

The application further provides compositions comprising the compounds described herein or a pharmaceutically acceptable salt, isomer, prodrug, or solvate thereof. The composition may include racemic mixtures, mixtures containing an enantiomeric excess of one enantiomer or single diastereomers or diastereomeric mixtures. All such isomeric forms of these compounds are expressly included herein, the same as if each and every isomeric form were specifically and individually listed.

In certain embodiments, provided herein are also polymorphs, such as crystalline and amorphous forms, of the compounds described herein. In some embodiments, provided are also chelates, non-covalent complexes, and mixtures thereof, of the compounds of the formula described herein or pharmaceutically acceptable salts, prodrugs, or solvates thereof. A “chelate” is formed by the coordination of a compound

to a metal ion at two (or more) points. A "non-covalent complex" is formed by the interaction of a compound and another molecule wherein a covalent bond is not formed between the compound and the molecule. For example, complexation can occur through van der Waals interactions, hydrogen bonding, and electrostatic interactions (also called ionic bonding).

In certain embodiments, provided are also chelates, non-covalent complexes, and mixtures thereof, of the compounds described herein or a pharmaceutically acceptable salt, tautomer, stereoisomer, mixture of stereoisomers, prodrug, or deuterated analog thereof. A "chelate" is formed by the coordination of a compound to a metal ion at two (or more) points. A "non-covalent complex" is formed by the interaction of a compound and another molecule wherein a covalent bond is not formed between the compound and the molecule. For example, complexation can occur through van der Waals interactions, hydrogen bonding, and electrostatic interactions (also called ionic bonding).

Some of the compounds exist as tautomers. Tautomers are in equilibrium with one another. For example, amide containing compounds may exist in equilibrium with imidic acid tautomers. Regardless of which tautomer is shown, and regardless of the nature of the equilibrium among tautomers, the compounds are understood by one of ordinary skill in the art to comprise both amide and imidic acid tautomers. Thus, the amide containing compounds are understood to include their imidic acid tautomers. Likewise, the imidic acid containing compounds are understood to include their amide tautomers.

Any formula or structure given herein is also intended to represent unlabeled forms as well as isotopically labeled forms of the compounds. Isotopically labeled compounds have structures depicted by the formulas given herein except that one or more atoms are replaced by an atom having a selected atomic mass or mass number. Examples of isotopes that can be incorporated into compounds of the disclosure include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, such as, but not limited to ^{2}H (deuterium, D), ^{3}H (tritium), ^{11}C, ^{13}C, ^{14}C, ^{15}N, ^{18}F, ^{31}P, ^{32}P, ^{35}S, ^{36}Cl and ^{125}I. Various isotopically labeled compounds of the present disclosure, for example those into which radioactive isotopes such as ^{3}H, ^{13}C and ^{14}C are incorporated. Such isotopically labeled compounds may be useful in metabolic studies, reaction kinetic studies, detection or imaging techniques, such as positron emission

tomography (PET) or single-photon emission computed tomography (SPECT) including drug or substrate tissue distribution assays or in radioactive treatment of patients.

The disclosure also includes "deuterated analogs" of compounds of Formula I in which from 1 to n hydrogens attached to a carbon atom is/are replaced by deuterium, in which n is the number of hydrogens in the molecule. Such compounds exhibit increased resistance to metabolism and are thus useful for increasing the half-life of any compound of Formula I when administered to a mammal, particularly a human. See, for example, Foster, "Deuterium Isotope Effects in Studies of Drug Metabolism," Trends Pharmacol. Sci. 5(12):524-527 (1984). Such compounds are synthesized by means well known in the art, for example by employing starting materials in which one or more hydrogens have been replaced by deuterium.

Deuterium labeled or substituted therapeutic compounds of the disclosure may have improved DMPK (drug metabolism and pharmacokinetics) properties, relating to distribution, metabolism and excretion (ADME). Substitution with heavier isotopes such as deuterium may afford certain therapeutic advantages resulting from greater metabolic stability, for example increased *in vivo* half-life, reduced dosage requirements and/or an improvement in therapeutic index. An ^{18}F labeled compound may be useful for PET or SPECT studies. Isotopically labeled compounds of this disclosure and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the schemes or in the examples and preparations described below by substituting a readily available isotopically labeled reagent for a non-isotopically labeled reagent. It is understood that deuterium in this context is regarded as a substituent in the compound of Formula I.

The concentration of such a heavier isotope, specifically deuterium, may be defined by an isotopic enrichment factor. In the compounds of this disclosure any atom not specifically designated as a particular isotope is meant to represent any stable isotope of that atom. Unless otherwise stated, when a position is designated specifically as "H" or "hydrogen", the position is understood to have hydrogen at its natural abundance isotopic composition. Accordingly, in the compounds of this disclosure any atom specifically designated as a deuterium (D) is meant to represent deuterium.

Therapeutic Uses of the Compounds

The compounds of the formulae described herein or a pharmaceutically acceptable salt, isomer, prodrug, or solvate thereof may be used for the treatment of diseases and/or conditions mediated by PI3K isoforms. In addition, the application provides the compounds for use in therapy. Also, provided herein are methods for inhibiting one or more PI3K isoforms. In one embodiment, provided are methods for inhibiting PI3Kβ activity using the compound described herein or a pharmaceutically acceptable salt, isomer, prodrug, or solvate thereof. In other embodiment, provided are methods for inhibiting PI3Kβ activity using the compound or a pharmaceutically acceptable salt, isomer, prodrug, or solvate thereof. The application further provides methods for use in such methods. The PI3K isoforms may be selectively or specifically inhibited. Additionally, the compounds may be used to inhibit PI3K activity therapeutically or prophylactically, such as PI3Kβ.

The compounds according to the present application may be used in combination with one or more additional therapeutic agents. The therapeutic agents may be in the forms of compounds, antibodies, polypeptides, or polynucleotides. The therapeutic agent includes, but is not limited to, a chemotherapeutic agent, an immunotherapeutic agent, a radiotherapeutic agent, an anti-neoplastic agent, an anti-cancer agent, an anti-proliferation agent, an anti-fibrotic agent, an anti-angiogenic agent, a therapeutic antibody, or any combination thereof. In one embodiment, the application provides a product comprising a compound described herein and an additional therapeutic agent as a combined preparation for simultaneous, separate or sequential use in therapy, *e.g.* a method of treating a disease, disorder, or condition that is mediated by PI3K isoforms. The compounds of the invention can be used in combination with compounds that inhibit or modulate the activities of poly(ADP-ribose) polymerases (PARP), such as PARP-1, PARP-2, PARP-3 and Vault-PARP; Tankyrases (TANKs), such as, TANK-1, TANK-2 and TANK-3; matrix metalloproteinases such as MMP-2 and MMP-9; and the androgen receptor.

Therapeutic agents that can be used in combination with compounds of the invention include enzalutamide, abiraterone, abiraterone acetate, apalutamide, galeterone, olaparib, niraparib, veliparib, rucaparib, flutamide, nilutamide, bicalutamide, ketonazole, orteronel, finasteride, dutasteride, bexlosteride, izonsteride, turosteride, episteride, dexamethasone, prednisone, leuprolide, goserelin, triptorelin, histrelin,

estrogen, cyproterone acetate, spironolactone, flutamide, hydroxyflutamide, docetaxel, cabazitaxel, sipuleucel-T, ODM-201, VT-464, EPI-506, and combinations thereof.

Also, the therapeutic agents may be those that inhibit or modulate the activities of Bruton's tyrosine kinase, spleen tyrosine kinase, apoptosis signal-regulating kinase, Janus kinase, lysyl oxidase, lysyl oxidase-like proteins, matrix metallopeptidase, bromodomain-containing protein, adenosine A2B receptor, isocitrate dehydrogenase, serine/threonine kinase TPL2, discoidin domain receptor, serine/threonine-protein kinases, IKK, MEK, EGFR, histone deacetylase, protein kinase C, or any combination thereof. In certain embodiments, the therapeutic agent may be selected from a PI3K (including PI3Kγ, PI3Kδ, PI3Kβ, PI3Kα, and/or pan-PI3K) inhibitor, a JAK (Janus kinase, including JAK1, JAK2, and/or JAK3) inhibitor, a SYK (spleen tyrosine kinase) inhibitor, a BTK (Bruton's tyrosine kinase) inhibitor, an A2B (adenosine A2B receptor) inhibitor, an ACK (activated CDC kinase, including ACK1) inhibitor, an ASK (apoptosis signal-regulating kinase, including ASK1) inhibitor, Aurora kinase, a BRD (bromodomain-containing protein, including BRD4) inhibitor, a Bcl (B-cell CLL/lymphoma, including Bcl-1 and/or Bcl-2) inhibitor, a CAK (CDK-activating kinase) inhibitor, a CaMK (calmodulin-dependent protein kinases) inhibitor, a CDK (cyclin-dependent kinases, including CDK1, 2, 3, 4, and/or 6) inhibitor, a CK (casein kinase, including CK1 and/or CK2) inhibitor, a DDR (discoidin domain receptor, including DDR1 and/or DDR2) inhibitor, a EGFR inhibitor, a FXR (farnesoid x receptor) inhibitor, a FAK (focal adhesion kinase) inhibitor, a GSK (glycogen synthase kinase) inhibitor, a HDAC (histone deacetylase) inhibitor, an IDO (indoleamine 2,3-dioxygenase) inhibitor, an IDH (isocitrate dehydrogenase, including IDH1) inhibitor, an IKK (l-Kappa-B kinase) inhibitor, a KDM5 (lysine demethylase) inhibitor, a LCK (lymphocyte-specific protein tyrosine kinase) inhibitor, a LOX (lysyl oxidase) inhibitor, a LOXL (lysyl oxidase like protein, including LOXL1, LOXL2, LOXL3, LOXL4, and/or LOXL5) inhibitor, a MTH (mut T homolog) inhibitor, a MEK (mitogen-activated protein kinase kinase) inhibitor, a matrix metalloprotease (MMP, including MMP2 and/or MMP9) inhibitor, a mitogen-activated protein kinases (MAPK) inhibitor, a PD-1 (programmed cell death protein 1) inhibitor, a PD-L1 (programmed death-ligand 1) inhibitor, a PDGF (platelet-derived growth factor) inhibitor, a phosphorylase kinase (PK) inhibitor, a PLK (polo-like kinase, including PLK1, 2, 3) inhibitor, a protein kinase (PK, including protein kinase A, B, C) inhibitor, a STK (serine/threonine kinase) inhibitor, a

STAT (signal transduction and transcription) inhibitor, a serine/threonine-protein kinase inhibitor, a TBK (tank-binding kinase) inhibitor, a TLR (toll-like receptor modulators, including TLR-1, TLR-2, TLR-3, TLR-4, TLR-5, TLR-6, TLR-7, TLR-8, TLR-9, TLR-10, TLR-11, TLR-12, and/or TLR-13) inhibitor, a TK (tyrosine kinase) inhibitor, a TPL2 (serine/threonine kinase) inhibitor, a NEK9 inhibitor, an Abl inhibitor, a p38 kinase inhibitor, a PYK inhibitor, a PYK inhibitor, a c-Kit inhibitor, a NPM-ALK inhibitor, a Flt-3 inhibitor, a c-Met inhibitor, a KDR inhibitor, a TIE-2 inhibitor, a VEGFR inhibitor, a SRC inhibitor, a HCK inhibitor, a LYN inhibitor, a FYN inhibitor, a YES inhibitor, a chemotherapeutic agent, an immunotherapeutic agent, a radiotherapeutic agent, an anti-neoplastic agent, an anti-cancer agent, an anti-proliferation agent, an anti-fibrotic agent, an anti-angiogenic agent, a therapeutic antibody, or any combination thereof. In some embodiments, the JAK inhibitor is N-(cyanomethyl)-4-[2-(4-morpholinoanilino)pyrimidin-4-yl]benzamide as named by ChemDraw (may also be referred to as CYT0387 or momelotinib) and may be synthesized by the methods described in U.S. Patent No. 8,486,941. In certain embodiment, the SyK inhibitor is 6-(1H-indazol-6-yl)-N-(4-morpholinophenyl)imidazo[1,2-a]pyrazin-8-amine as named by ChemDraw (may also be referred to as 6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine) and may be synthesized by the methods described in U.S. Patent No. 8,450,321. In other embodiments, the BTK inhibitor is (S)-6-amino-9-(1-(but-2-ynoyl)pyrrolidin-3-yl)-7-(4-phenoxyphenyl)-7H-purin-8(9H)-one as named by ChemDraw (may also be 6-amino-9-[(3R)-1-(2-butynoyl)-3-pyrrolidinyl]-7-(4-phenoxyphenyl)-7,9-dihydro-8H -purin-8-one) and may be synthesized by the methods in U.S. Pat. No. 8,557,803.

Chemotherapeutic agents may be categorized by their mechanism of action into, for example, the following groups: anti-metabolites/anti-cancer agents, such as pyrimidine analogs (floxuridine, capecitabine, and cytarabine); purine analogs, folate antagonists and related inhibitors, antiproliferative/antimitotic agents including natural products such as vinca alkaloid (vinblastine, vincristine) and microtubule such as taxane (paclitaxel, docetaxel), vinblastin, nocodazole, epothilones and navelbine, epidipodophyllotoxins (etoposide, teniposide); DNA damaging agents (actinomycin, amsacrine, busulfan, carboplatin, chlorambucil, cisplatin, cyclophosphamide, Cytoxan, dactinomycin, daunorubicin, doxorubicin, epirubicin, iphosphamide, melphalan, merchlorehtamine, mitomycin, mitoxantrone, nitrosourea, procarbazine, taxol, taxotere,

teniposide, etoposide, triethylenethiophosphoramide); antibiotics such as dactinomycin (actinomycin D), daunorubicin, doxorubicin (adriamycin), idarubicin, anthracyclines, mitoxantrone, bleomycins, plicamycin (mithramycin) and mitomycin; enzymes (L-asparaginase which systemically metabolizes L-asparagine and deprives cells which do not have the capacity to synthesize their own asparagine); antiplatelet agents; antiproliferative/ antimitotic alkylating agents such as nitrogen mustards cyclophosphamide and analogs, melphalan, chlorambucil), and (hexamethylmelamine and thiotepa), alkyl nitrosoureas (BCNU) and analogs, streptozocin), trazenes-dacarbazinine (DTIC); antiproliferative/antimitotic antimetabolites such as folic acid analogs (methotrexate); platinum coordination complexes (cisplatin, oxiloplatinim, carboplatin), procarbazine, hydroxyurea, mitotane, aminoglutethimide; hormones, hormone analogs (estrogen, tamoxifen, goserelin, bicalutamide, nilutamide) and aromatase inhibitors (letrozole, anastrozole); anticoagulants (heparin, synthetic heparin salts and other inhibitors of thrombin); fibrinolytic agents (such as tissue plasminogen activator, streptokinase and urokinase), aspirin, dipyridamole, ticlopidine, clopidogrel; antimigratory agents; antisecretory agents (breveldin); immunosuppressives (tacrolimus, sirolimus azathioprine, mycophenolate); phytoestrogens (daidzein, glycitein, genisteinand growth factor inhibitors (vascular endothelial growth factor inhibitors, fibroblast growth factor inhibitors); angiotensin receptor blocker, nitric oxide donors; anti-sense oligonucleotides; antibodies (trastuzumab, rituximab); cell cycle inhibitors and differentiation inducers (tretinoin); inhibitors, topoisomerase inhibitors (doxorubicin (adriamycin), daunorubicin, dactinomycin, eniposide, epirubicin, etoposide, idarubicin, irinotecan and mitoxantrone, topotecan, irinotecan, camptothesin), corticosteroids (cortisone, dexamethasone, hydrocortisone, methylprednisolone, prednisone, and prednisolone); growth factor signal transduction kinase inhibitors; dysfunction inducers, toxins such as Cholera toxin, ricin, Pseudomonas exotoxin, Bordetella pertussis adenylate cyclase toxin, or diphtheria toxin, and caspase activators; and chromatin.

As used herein the term "chemotherapeutic agent" or "chemotherapeutic" (or "chemotherapy," in the case of treatment with a chemotherapeutic agent) is meant to encompass any non-proteinaceous (i.e, non-peptidic) chemical compound useful in the treatment of cancer. Examples of chemotherapeutic agents include alkylating agents such as thiotepa and cyclophosphamide (CYTOXAN); alkyl sulfonates such as busulfan, improsulfan and piposulfan; aziridines such as benzodopa, carboquone, meturedopa, and

uredopa; emylerumines and memylamelamines including alfretamine, triemylenemelamine, triethylenephosphoramide, triethylenethiophosphoramide and trimemylolomelamine; acetogenins (especially bullatacin and bullatacinone); a camptothecin (including synthetic analogue topotecan); bryostatin; callystatin; CC-1065 (including its adozelesin, carzelesin and bizelesin synthetic analogues); cryptophycins (articularly cryptophycin 1 and cryptophycin 8); dolastatin; duocarmycin (including the synthetic analogues, KW-2189 and CBI-TMI); eleutherobin; pancratistatin; a sarcodictyin; spongistatin; nitrogen mustards such as chlorambucil, chlornaphazine, cholophosphamide, estramustine, ifosfamide, mechlorethamine, mechlorethamine oxide hydrochloride, melphalan, novembichin, phenesterine, prednimustine, trofosfamide, uracil mustard; nitrosoureas such as carmustine, chlorozotocin, foremustine, lomustine, nimustine, ranimustine; antibiotics such as the enediyne antibiotics (e.g., calicheamicin, especially calicheamicin gammaII and calicheamicin phiI1, see, e.g., Agnew, Chem. Intl. Ed. Engl, 33:183-186 (1994); dynemicin, including dynemicin A; bisphosphonates, such as clodronate; an esperamicin; as well as neocarzinostatin chromophore and related chromoprotein enediyne antibiotic chromomophores), aclacinomysins, actinomycin, authramycin, azaserine, bleomycins, cactinomycin, carabicin, carrninomycin, carzinophilin, chromomycins, dactinomycin, daunorubicin, detorubicin, 6-diazo-5-oxo-L-norleucine, doxorubicin (including morpholino-doxorubicin, cyanomorpholino-doxorubicin, 2-pyrrolino-doxorubicin and deoxydoxorubicin), epirubicin, esorubicin, idarubicin, marcellomycin, mitomycins such as mitomycin C, mycophenolic acid, nogalamycin, olivomycins, peplomycin, potfiromycin, puromycin, quelamycin, rodorubicin, streptonigrin, streptozocin, tubercidin, ubenimex, zinostatin, zorubicin; anti-metabolites such as methotrexate and 5-fluorouracil (5-FU); folic acid analogues such as demopterin, methotrexate, pteropterin, trimetrexate; purine analogs such as fludarabine, 6-mercaptopurine, thiamiprine, thioguanine; pyrimidine analogues such as ancitabine, azacitidine, 6-azauridine, carmofur, cytarabine, dideoxyuridine, doxifluridine, enocitabine, floxuridine; androgens such as calusterone, dromostanolone propionate, epitiostanol, mepitiostane, testolactone; anti-adrenals such as aminoglutethimide, mitotane, trilostane; folic acid replinisher such as frolinic acid; aceglatone; aldophosphamide glycoside; aminolevulinic acid; eniluracil; amsacrine; hestrabucil; bisantrene; edatraxate; defofamine; demecolcine; diaziquone; elformthine; elliptinium acetate; an epothilone; etoglucid; gallium nitrate; hydroxyurea; lentinan; leucovorin; lonidamine; maytansinoids such as maytansine and ansamitocins; mitoguazone;

mitoxantrone; mopidamol; nitracrine; pentostatin; phenamet; pirarubicin; losoxantrone; fluoropyrimidine; folinic acid; podophyllinic acid; 2-ethylhydrazide; procarbazine; PSK®; razoxane; rhizoxin; sizofiran; spirogermanium; tenuazonic acid; triaziquone; 2,2',2"-tricUorotriemylamine; trichothecenes (especially T-2 toxin, verracurin A, roridin A and anguidine); urethane; vindesine; dacarbazine; mannomustine; mitobronitol; mitolactol; pipobroman; gacytosine; arabinoside ("Ara-C"); cyclophosphamide; thiopeta; taxoids, e.g., paclitaxel (TAXOL®and docetaxel (TAXOTERE®); chlorambucil; gemcitabine (Gemzar®); 6-thioguanine; mercaptopurine; methotrexate; platinum analogs such as cisplatin and carboplatin; vinblastine; platinum; etoposide (VP-16); ifosfamide; mitroxantrone; vancristine; vinorelbine (Navelbine®); novantrone; teniposide; edatrexate; daunomycin; aminopterin; xeoloda; ibandronate; CPT-11; topoisomerase inhibitor RFS 2000; difluoromethylornithine (DMFO); retinoids such as retinoic acid; capecitabine; FOLFIRI (fluorouracil, leucovorin, and irinotecan) and pharmaceutically acceptable salts, acids or derivatives of any of the above. One or more chemotherapeutic agent are used or included in the present application.

Also included in the definition of "chemotherapeutic agent" are anti-hormonal agents that act to regulate or inhibit hormone action on tumors such as anti-estrogens and selective estrogen receptor modulators (SERMs), including, for example, tamoxifen (including Nolvadex™), raloxifene, droloxifene, 4-hydroxytamoxifen, trioxifene, keoxifene, LY117018, onapristone, and toremifene (Fareston®); inhibitors of the enzyme aromatase, which regulates estrogen production in the adrenal glands, such as, for example, 4(5)-imidazoles, aminoglutethimide, megestrol acetate (Megace®), exemestane, formestane, fadrozole, vorozole (Rivisor®), letrozole (Femara®), and anastrozole (Arimidex®); and anti-androgens such as flutamide, nilutamide, bicalutamide, leuprohde, and goserelin; and pharmaceutically acceptable salts, acids or derivatives of any of the above.

The anti-angiogenic agents include, but are not limited to, retinoid acid and derivatives thereof, 2-methoxyestradiol, ANGIOSTATIN®, ENDOSTATIN®, suramin, squalamine, tissue inhibitor of metalloproteinase-1, tissue inhibitor of metalloproternase-2, plasminogen activator inhibitor-1, plasminogen activator inbibitor-2, cartilage-derived inhibitor, paclitaxel (nab-paclitaxel), platelet factor 4, protamine sulphate (clupeine), sulphated chitin derivatives (prepared from queen crab shells), sulphated polysaccharide

peptidoglycan complex (sp-pg), staurosporine, modulators of matrix metabolism, including for example, proline analogs ((1-azetidine-2-carboxylic acid (LACA), cishydroxyproline, d,I-3,4-dehydroproline, thiaproline, .alpha.-dipyridyl, beta-aminopropionitrile fumarate, 4-propyl-5-(4-pyridinyl)-2(3h)-oxazolone; methotrexate, mitoxantrone, heparin, interferons, 2 macroglobulin-serum, chimp-3, chymostatin, beta-cyclodextrin tetradecasulfate, eponemycin; fumagillin, gold sodium thiomalate, d-penicillamine (CDPT), beta-1-anticollagenase-serum, alpba-2-antiplasmin, bisantrene, lobenzarit disodium, n-2-carboxyphenyl-4-chloroanthronilic acid disodium or "CCA", thalidomide; angiostatic steroid, cargboxynaminolmidazole; metalloproteinase inhibitors such as BB94. Other anti-angiogenesis agents include antibodies, preferably monoclonal antibodies against these angiogenic growth factors: beta-FGF, alpha-FGF, FGF-5, VEGF isoforms, VEGF-C, HGF/SF and Ang-1/Ang-2. See Ferrara N. and Alitalo, K. "Clinical application of angiogenic growth factors and their inhibitors" (1999) Nature Medicine 5:1359-1364.

The anti-fibrotic agents include, but are not limited to, the compounds such as beta-aminoproprionitrile (BAPN), as well as the compounds disclosed in U.S. Pat. No. 4,965,288 to Palfreyman, et al., issued Oct. 23, 1990, entitled "Inhibitors of lysyl oxidase," relating to inhibitors of lysyl oxidase and their use in the treatment of diseases and conditions associated with the abnormal deposition of collagen; U.S. Pat. No. 4,997,854 to Kagan, et al., issued Mar. 5, 1991, entitled "Anti-fibrotic agents and methods for inhibiting the activity of lysyl oxidase in situ using adjacently positioned diamine analogue substrate," relating to compounds which inhibit LOX for the treatment of various pathological fibrotic states, which are herein incorporated by reference. Further exemplary inhibitors are described in U.S. Pat. No. 4,943,593 to Palfreyman, et al., issued Jul. 24, 1990, entitled "Inhibitors of lysyl oxidase," relating to compounds such as 2-isobutyl-3-fluoro-, chloro-, or bromo-allylamine; as well as, e.g., U.S. Pat. No. 5,021,456; U.S. Pat. No. 5,5059,714; U.S. Pat. No. 5,120,764; U.S. Pat. No. 5,182,297; U.S. Pat. No. 5,252,608 (relating to 2-(1-naphthyloxymemyl)-3-fluoroallylamine); and U.S. Patent Application No. 2004/0248871, which are herein incorporated by reference. Exemplary anti-fibrotic agents also include the primary amines reacting with the carbonyl group of the active site of the lysyl oxidases, and more particularly those which produce, after binding with the carbonyl, a product stabilized by resonance, such as the following primary amines: emylenemamine, hydrazine, phenylhydrazine, and their

derivatives, semicarbazide, and urea derivatives, aminonitriles, such as beta-aminopropionitrile (BAPN), or 2-nitroethylamine, unsaturated or saturated haloamines, such as 2-bromo-ethylamine, 2-chloroethylamine, 2-trifluoroethylamine, 3-bromopropylamine, p-halobenzylamines, selenohomocysteine lactone. Also, the anti-fibrotic agents are copper chelating agents, penetrating or not penetrating the cells. Exemplary compounds include indirect inhibitors such compounds blocking the aldehyde derivatives originating from the oxidative deamination of the lysyl and hydroxylysyl residues by the lysyl oxidases, such as the thiolamines, in particular D-penicillamine, or its analogues such as 2-amino-5-mercapto-5-methylhexanoic acid, D-2-amino-3-methyl-3-((2-acetamidoethyl)dithio)butanoic acid, p-2-amino-3-methyl-3-((2-aminoethyl)dithio)butanoic acid, sodium-4-((p-1-dimethyl-2-amino-2-carboxyethyl)dithio)butane sulphurate, 2-acetamidoethyl-2-acetamidoethanethiol sulphanate, sodium-4-mercaptobutanesulphinate trihydrate.

The immunotherapeutic agents include and are not limited to therapeutic antibodies suitable for treating patients; such as abagovomab, adecatumumab, afutuzumab, alemtuzumab, altumomab, amatuximab, anatumomab, arcitumomab, bavituximab, bectumomab, bevacizumab, bivatuzumab, blinatumomab, brentuximab, cantuzumab, catumaxomab, cetuximab, citatuzumab, cixutumumab, clivatuzumab, conatumumab, daratumumab, drozitumab, duligotumab, dusigitumab, detumomab, dacetuzumab, dalotuzumab, ecromeximab, elotuzumab, ensituximab, ertumaxomab, etaracizumab, farietuzumab, ficlatuzumab, figitumumab, flanvotumab, futuximab, ganitumab, gemtuzumab, girentuximab, glembatumumab, ibritumomab, igovomab, imgatuzumab, indatuximab, inotuzumab, intetumumab, ipilimumab, iratumumab, labetuzumab, lexatumumab, lintuzumab, lorvotuzumab, lucatumumab, mapatumumab, matuzumab, milatuzumab, minretumomab, mitumomab, moxetumomab, narnatumab, naptumomab, necitumumab, nimotuzumab, nofetumomabn, ocaratuzumab, ofatumumab, olaratumab, onartuzumab, oportuzumab, oregovomab, panitumumab, parsatuzumab, patritumab, pemtumomab, pertuzumab, pintumomab, pritumumab, racotumomab, radretumab, rilotumumab, rituximab, robatumumab, satumomab, sibrotuzumab, siltuximab, simtuzumab, solitomab, tacatuzumab, taplitumomab, tenatumomab, teprotumumab, tigatuzumab, tositumomab, trastuzumab, tucotuzumab, ublituximab, veltuzumab, vorsetuzumab, votumumab, zalutumumab, obinutuzumab,

CC49 and 3F8. The exemplified therapeutic antibodies may be further labeled or combined with a radioisotope particle, such as indium In 111, yttrium Y 90, iodine I-131.

The application also provides method for treating a subject who is undergoing one or more standard therapies, such as chemotherapy, radiotherapy, immunotherapy, surgery, or combination thereof. Accordingly, one or more therapeutic agent or inhibitors may be administered before, during, or after administration of chemotherapy, radiotherapy, immunotherapy, surgery or combination thereof.

Other examples of chemotherapy treatments (including standard or experimental chemotherapies) are described below. In addition, treatment of certain lymphomas is reviewed in Cheson, B.D., Leonard, J.P., "Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma" *The New England Journal of Medicine* 2008, 359(6), p. 613-626; and Wierda, W.G., "Current and Investigational Therapies for Patients with CLL" *Hematology* 2006, p. 285-294. Lymphoma incidence patterns in the United States are profiled in Morton, L.M., *et al.* "Lymphoma Incidence Patterns by WHO Subtype in the United States, 1992-2001" *Blood* 2006, 107(1), p. 265-276.

Examples of immunotherapeutic agents include, but are not limited to, rituximab (such as Rituxan), alemtuzumab (such as Campath, MabCampath), anti-CD19 antibodies, anti-CD20 antibodies, anti-MN-14 antibodies, anti-TRAIL, Anti-TRAIL DR4 and DR5 antibodies, anti-CD74 antibodies, apolizumab, bevacizumab, CHIR-12.12, epratuzumab (hLL2- anti-CD22 humanized antibody), galiximab, ha20, ibritumomab tiuxetan, lumiliximab, milatuzumab, ofatumumab, PRO131921, SGN-40, WT-1 analog peptide vaccine, WT1 126-134 peptide vaccine, tositumomab, autologous human tumor-derived HSPPC-96, and veltuzumab. Additional immunotherapy agents includes using cancer vaccines based upon the genetic makeup of an individual patient's tumor, such as lymphoma vaccine example is GTOP-99 (MyVax®).

Examples of chemotherapy agents include aldesleukin, alvocidib, antineoplaston AS2-1, antineoplaston A10, anti-thymocyte globulin, amifostine trihydrate, aminocamptothecin, arsenic trioxide, beta alethine, Bcl-2 family protein inhibitor ABT-263, ABT-199, BMS-345541, bortezomib (Velcade®), bryostatin 1, busulfan, carboplatin, campath-1H, CC-5103, carmustine, caspofungin acetate, clofarabine, cisplatin, Cladribine (Leustarin), Chlorambucil (Leukeran), Curcumin, cyclosporine,

Cyclophosphamide (Cyloxan, Endoxan, Endoxana, Cyclostin), cytarabine, denileukin diftitox, dexamethasone, DT PACE, docetaxel, dolastatin 10, Doxorubicin (Adriamycin®, Adriblastine), doxorubicin hydrochloride, enzastaurin, epoetin alfa, etoposide, Everolimus (RAD001), fenretinide, filgrastim, melphalan, mesna, Flavopiridol, Fludarabine (Fludara), Geldanamycin (17-AAG), ifosfamide, irinotecan hydrochloride, ixabepilone, Lenalidomide (Revlimid®, CC-5013), lymphokine-activated killer cells, melphalan, methotrexate, mitoxantrone hydrochloride, motexafin gadolinium, mycophenolate mofetil, nelarabine, oblimersen (Genasense) Obatoclax (GX15-070), oblimersen, octreotide acetate, omega-3 fatty acids, oxaliplatin, paclitaxel, PD0332991, PEGylated liposomal doxorubicin hydrochloride, pegfilgrastim, Pentstatin (Nipent), perifosine, Prednisolone, Prednisone, R-roscovitine (Selicilib, CYC202), recombinant interferon alfa, recombinant interleukin-12, recombinant interleukin-11, recombinant flt3 ligand, recombinant human thrombopoietin, rituximab, sargramostim, sildenafil citrate, simvastatin, sirolimus, Styryl sulphones, tacrolimus, tanespimycin, Temsirolimus (CCl-779), Thalidomide, therapeutic allogeneic lymphocytes, thiotepa, tipifarnib, Velcade® (bortezomib or PS-341), Vincristine (Oncovin), vincristine sulfate, vinorelbine ditartrate, Vorinostat (SAHA), vorinostat, and FR (fludarabine, rituximab), CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone), CVP (cyclophosphamide, vincristine and prednisone), FCM (fludarabine, cyclophosphamide, mitoxantrone), FCR (fludarabine, cyclophosphamide, rituximab), hyperCVAD (hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, cytarabine), ICE (iphosphamide, carboplatin and etoposide), MCP (mitoxantrone, chlorambucil, and prednisolone), R-CHOP (rituximab plus CHOP), R-CVP (rituximab plus CVP), R-FCM (rituximab plus FCM), R-ICE (rituximab-ICE), and R-MCP (R-MCP).

The therapeutic treatments can be supplemented or combined with any of the abovementioned therapies with stem cell transplantation or treatment. One example of modified approach is radioimmunotherapy, wherein a monoclonal antibody is combined with a radioisotope particle, such as indium In 111, yttrium Y 90, iodine I-131. Examples of combination therapies include, but are not limited to, Iodine-131 tositumomab (Bexxar®), Yttrium-90 ibritumomab tiuxetan (Zevalin®), Bexxar® with CHOP.

Other therapeutic procedures include peripheral blood stem cell transplantation, autologous hematopoietic stem cell transplantation, autologous bone marrow transplantation, antibody therapy, biological therapy, enzyme inhibitor therapy, total body irradiation, infusion of stem cells, bone marrow ablation with stem cell support, *in vitro*-treated peripheral blood stem cell transplantation, umbilical cord blood transplantation, immunoenzyme technique, pharmacological study, low-LET cobalt-60 gamma ray therapy, bleomycin, conventional surgery, radiation therapy, and nonmyeloablative allogeneic hematopoietic stem cell transplantation.

In some embodiments, the methods include administering a compound of the formula described herein or a pharmaceutically acceptable salt, isomer, prodrug, or solvate thereof, in a therapeutically effective amount to a human in need thereof. The method can be employed to treat a patient who has or is believed to have a disease or condition whose symptoms or pathology is mediated by expression or activity of PI3Kβ. The patient may be a mammal or a human. In certain embodiment, the patient may be a human.

"Treatment" or "treating" is an approach for obtaining beneficial or desired results including clinical results. Beneficial or desired clinical results may include one or more of the following: a) inhibiting the disease or condition (*e.g.*, decreasing one or more symptoms resulting from the disease or condition, and/or diminishing the extent of the disease or condition); b) slowing or arresting the development of one or more clinical symptoms associated with the disease or condition (*e.g.*, stabilizing the disease or condition, preventing or delaying the worsening or progression of the disease or condition, and/or preventing or delaying the spread (*e.g.*, metastasis) of the disease or condition); and/or c) relieving the disease, that is, causing the regression of clinical symptoms (*e.g.*, ameliorating the disease state, providing partial or total remission of the disease or condition, enhancing the effect of another medication, delaying the progression of the disease, increasing the quality of life, and/or prolonging survival.

"Prevention" or "preventing" means any treatment of a disease or condition that causes the clinical symptoms of the disease or condition not to develop. Compounds may, in some embodiments, be administered to a subject (including a human) who is at risk or has a family history of the disease or condition.

"Subject" or "patient" refer to an animal, such as a mammal (including a human), that has been or will be the object of treatment, observation or experiment. The methods described herein may be useful in human therapy and/or veterinary applications. In some embodiments, the subject is a mammal. In one embodiment, the subject is a human. "Human in need thereof" refers to a human who may have or is suspect to have diseases, or disorders, or conditions that would benefit from certain treatment; for example, being treated with the PI3K inhibitor of the compounds according to the present application. In certain embodiments, the subject may be a human who (i) has not received any treatment including chemotherapy treatment, (ii) is substantially refractory to at least one chemotherapy treatment, (iii) is in relapse after treatment with chemotherapy, or both (i) and (ii). In some of embodiments, the subject is refractory to at least one, at least two, at least three, or at least four chemotherapy treatments (including standard or experimental chemotherapies).

The terms "therapeutically effective amount" or "effective amount" of a compound of the present application or a pharmaceutically acceptable salt, isomers, prodrug, or solvate thereof, mean an amount sufficient to effect treatment when administered to a subject, to provide a therapeutic benefit such as amelioration of symptoms or slowing of disease progression. For example, a therapeutically effective amount may be an amount sufficient to decrease a symptom of a disease or condition responsive to inhibition of PI3Kδ and PI3Kβ activity. The therapeutically effective amount may vary depending on the subject, and disease or condition being treated, the weight and age of the subject, the severity of the disease or condition, and the manner of administering, which can readily be determined by one or ordinary skill in the art.

In addition to the therapeutic uses, the compounds described herein have the selectivity or selective inhibition to certain PI3K isoforms. In one embodiment, the compounds have selectivity to PI3Kβ. The selectivity to PI3K isoforms may be determined by measuring the compound's activity in inhibiting certain PI3K isoforms using the assay described in the example below or the methods commonly used. It is understood that the conditions (e.g. the reagent concentration or the incubation temperature) may be varied and the results of the assay may vary. In some instances, the value may vary within a range of one to three-fold.

The term "inhibition" indicates a decrease in the baseline activity of a biological activity or process. The term "inhibition of activity of PI3K isoforms" or variants thereof refer to a decrease in activity in any PI3K isoform (*e.g.*, alpha, beta, gamma, or delta) as a direct or indirect response to the presence of a compound of any of the formula described herein relative to the activity of PI3K isoform in the absence of such compound. "Inhibition of PI3Kδ and/or PI3Kβ activities" or variants thereof refer to a decrease in PI3Kδ and/or PI3Kβ activities as a direct or indirect response to the presence of the compounds described herein, relative to the activities of PI3Kδ and/or PI3Kβ in the absence of such compound. In some embodiments, the inhibition of PI3K isoform activities may be compared in the same subject prior to treatment, or other subjects not receiving the treatment.

Without being bound to any theory, the decrease in the activity of PI3K may be due to the direct interaction of the compound with PI3K, or due to the interaction of the compounds described herein with one or more other factors that affect PI3K activity. For example, the presence of the compounds may decrease the activities of PI3Kδ and/or PI3Kβ by directly binding to PI3Kδ and/or PI3Kβ, by causing (directly or indirectly) another factor to decrease PI3Kδ and/or PI3Kβ activities, or by (directly or indirectly) decreasing the amount of PI3Kδ and/or PI3Kβ present in the cell or organism.

The term "PI3K inhibitor" or variant thereof refers to a compound that inhibits the activity of PI3K. The term "PI3K isoform selective inhibitor" or variant thereof refers to a compound that inhibits the activity of one or more PI3K isoforms more effectively than the other remaining PI3K isoforms. By way of example, the term "PI3Kβ selective inhibitor" generally refers to a compound that inhibits the activity of the PI3Kβ isoform more effectively than other isoforms of the PI3K family, and the term "PI3Kδ selective inhibitor" generally refers to a compound that inhibits the activity of the PI3Kδ isoform more effectively than other isoforms of the PI3K family. The term "dual PI3Kδ/β selective inhibitor" generally refers to a compound that inhibits the activity of both PI3Kδ and PI3Kβ isoforms more effectively than other isoforms of the PI3K family (*e.g.*, PI3K α or γ).

The relative efficacies of compounds as inhibitors of an enzyme activity (or other biological activity) can be established by determining the concentrations at which each

compound inhibits the activity to a predefined extent and then comparing the results. In one embodiment, the efficacy of a compound as an inhibitor of one or more PI3K isoforms can be measured by the compound concentration that inhibits 50% of the activity in a biochemical assay, *i.e.*, the 50% inhibitory concentration or "IC_{50}". The determination of IC_{50} values can be accomplished using conventional techniques known in the art, including the techniques described in the Examples below. In general, an IC_{50} can be determined by measuring the activity of a given enzyme in the presence of a range of concentrations of the compound under the study. The experimentally obtained values of enzyme activity may then be plotted against the compound concentrations used. The concentration of the inhibitor that shows 50% enzyme activity (as compared to the activity in the absence of any inhibitor) is taken as the IC_{50} value. Analogously, other inhibitory concentrations can be defined through appropriate determinations of activity. For example, in some settings it may be desirable to establish a 90% inhibitory concentration, *i.e.*, IC_{90}.

According to the present application, a PI3Kβ selective inhibitor is a compound that exhibits a 50% inhibitory concentration (IC_{50}) with respect to PI3Kβ that is at least 10-fold, at least 20-fold, at least 30-fold, at least 50-fold, at least 100-fold, at least 200-fold, or at least 500-fold lower than the IC_{50} with respect to either PI3Kα or PI3Kγ or both PI3Kα and PI3Kγ. In addition, a PI3Kδ/β selective inhibitor is a compound that exhibits a 50% inhibitory concentration (IC_{50}) with respect to PI3Kβ and PI3Kδ that is at least 10-fold, at least 20-fold, at least 30-fold, at least 50-fold, at least 75-fold, at least 100-fold, at least 200-fold, and at least 500-fold lower than the IC_{50} with respect to either PI3Kα or PI3Kγ. The dual PI3Kδ/β selective inhibitor may have the same or similar IC_{50} to both PI3Kδ and PI3Kβ or may have different IC_{50} to either PI3Kδ or PI3Kβ. As used herein, the term "potency," "potent," or variants thereof refer to the compound exhibiting an IC_{50} value that is less than 100 nM. When comparing two compounds, the compound that exhibits a lower IC_{50} value is referred to as a more potent inhibitor.

The compounds of the present application exhibit unexpected selectivity to PI3Kβ. As shown in the example, certain compounds in Table 1 exhibit low IC_{50} values (e.g. 1 to 100 nM) against PI3Kβ. Certain compounds in Table 1a also exhibited such selectivity to PI3K isoforms. Also, certain compounds of formula (I) exhibited at least between 10-fold to 400-fold lower IC_{50} values for PI3Kβ than PI3Kγ, suggesting the

compounds exhibit more selectivity to PI3Kβ compared to PI3Kγ (i.e., inhibits the activity of the PI3Kβ isoform more effectively than the PI3Kγ isoform as shown by the PI3Kγ/PI3Kβ ratio).

The methods described herein may be applied to cell populations *in vivo* or *ex vivo*. "*In vivo*" means within a living individual, as within an animal or human. In this context, the methods described herein may be used therapeutically in an individual. "*Ex vivo*" means outside of a living individual. Examples of *ex vivo* cell populations include in vitro cell cultures and biological samples including fluid or tissue samples obtained from individuals. Such samples may be obtained by methods well known in the art. Exemplary biological fluid samples include blood, cerebrospinal fluid, urine, and saliva. Exemplary tissue samples include tumors and biopsies thereof. In this context, the compounds may be used for a variety of purposes, including therapeutic and experimental purposes. For example, it may be used *ex vivo* to determine the optimal schedule and/or dosing of administration of a PI3K selective inhibitor for a given indication, cell type, individual, and other parameters. Information gleaned from such use may be used for experimental purposes or in the clinic to set protocols for *in vivo* treatment. Other *ex vivo* uses for which the compound described herein may be suited are described below or will become apparent to those skilled in the art. The compounds of the formula described herein or a pharmaceutically acceptable salt, prodrug, or solvate thereof, may be further characterized to examine the safety or tolerance dosage in human or non-human subjects. Such properties may be examined using commonly known methods to those skilled in the art.

Compared to other PI3K isoforms, PI3Kβ is generally mis-regulated in certain cancer cells. Aberrant proliferation of cells often interferes with normal tissue function, which may result in abnormal cellular response such as immunity, inflammation, and/or apoptosis. The selective inhibitors to PI3Kβ are useful in treating, inhibiting, or preventing aberrant proliferation of cancerous and/or hematopoietic cells and ameliorating the symptoms and secondary conditions.

The compounds described herein may be used to treat subjects having various disease states, disorders, and conditions (also collectively referred to as "indications") associated with PI3K isoforms or their activities. As used herein, the terms "diseases," "disorders," "conditions" are used interchangeably. Such indications may include, for

example, cancer, including hematologic malignancies (e.g. leukemias and lymphomas, myeloproliferative disorders, myelodysplastic syndromes, plasma cell neoplasms) and solid tumors, inflammation, fibrosis, allergic conditions (including hypersensitivity), cardiovascular diseases, neurodegenerative diseases, renal disorders, viral infections, obesity, and autoimmune diseases.

In other embodiments, the compounds described herein may be used to treat cancers that are mediated by, dependent on, or associated with PI3K activity. In certain embodiments, the disease or condition is an autoimmune disease, an inflammatory disease, or a cancer. In some embodiments, the disease or condition is chosen from rheumatoid arthritis, osteoarthritis, atherosclerosis, psoriasis, systemic lupus erythematosus, multiple sclerosis, inflammatory bowel disease, asthma, chronic obstructive airways disease, pneumonitis, dermatitis, alopecia, nephritis, vasculitis, atherosclerosis, Alzheimer's disease, hepatitis, primary biliary cirrhosis, sclerosing cholangitis, diabetes (including type I diabetes), acute rejection of transplanted organs, lymphomas, multiple myelomas, leukemias, neoplasms and solid tumors.

In other embodiments, the disease is a solid tumor. By way of examples, the solid tumor includes but is not limited to prostate cancer, pancreatic cancer, bladder cancer, colorectal cancer, breast cancer, renal cancer, hepatocellular cancer, lung cancer, ovarian cancer, cervical cancer, rectum cancer, liver cancer, kidney cancer, stomach cancer, skin cancer, gastric cancer, esophageal cancer, head and neck cancer, melanoma, neuroendocrine cancers, CNS cancers (e.g., neuroblastoma), brain tumors (*e.g.*, glioma, anaplastic oligodendroglioma, adult glioblastoma multiforme, and adult anaplastic astrocytoma), bone cancer, or soft tissue sarcoma. In some embodiments, the solid tumor is non-small cell lung cancer, small-cell lung cancer, colon cancer, CNS cancer, melanoma, ovarian cancer, renal cancer, pancreatic cancer, prostate cancer, or breast cancer.

The present application also provides a method for treating a human in need thereof, who has or is suspected of having a disease or condition responsive or believed to be responsive to the inhibition PI3Kβ activity by administering to the subject a compound of the formulae described herein or a pharmaceutically acceptable salt, enantiomer, atropisomer, tautomer, prodrug, or solvate thereof.

Additionally, the application provides a method of inhibiting kinase activity of a PI3Kβ polypeptides by contacting the polypeptides with a compound of the formulae described herein or a pharmaceutically acceptable salt, isomer, prodrug, solvate, or a mixture thereof.

Moreover, the application provides a method of decreasing cell viability, increasing cell death or apoptosis, increasing interference with PI3K signaling pathways (including AKT, S6RP, ERK phosphorylation), and/or reduction in chemokine production with an effective amount of a compound of any of the formulae described herein or a pharmaceutically acceptable salt, isomer, prodrug, solvate, or a mixture thereof.

The application further provides a method of disrupting leukocyte function comprising contacting the leukocytes with an effective amount of a compound of any of the formulae described herein or a pharmaceutically acceptable salt, isomer, prodrug, solvate, or a mixture thereof, in a human in need thereof.

Provided is also a method of inhibiting growth or proliferation of cancer cells comprising contacting the cancer cells with an effective amount of a compound of the formulae described herein or a pharmaceutically acceptable salt, isomer, prodrug, solvate, or a mixture thereof.

Kits

Provided herein are also kits that include a compound of the formulae of the present application or a pharmaceutically acceptable salt, isomer, prodrug, or solvate thereof, and suitable packaging. In one embodiment, a kit further includes instructions for use. In one aspect, a kit includes a compound of the formulae described herein or a pharmaceutically acceptable salt, isomer, prodrug, or solvate thereof, and a label and/or instructions for use of the compounds in the treatment of the indications, including the diseases or conditions, described herein.

Provided herein are also articles of manufacture that include a compound of any of the formulae described herein or a pharmaceutically acceptable salt, isomer, prodrug, or solvate thereof, in a suitable container. The container may be a vial, jar, ampoule, preloaded syringe, and intravenous bag.

Pharmaceutical Compositions and Modes of Administration

Compounds provided herein are usually administered in the form of pharmaceutical compositions. Thus, provides herein are also pharmaceutical compositions that contain one or more of the compounds of any of the formulae disclosed herein or a pharmaceutically acceptable salt, isomers, prodrug, or solvate thereof, and one or more pharmaceutically acceptable vehicles selected from carriers, adjuvants and excipients. Suitable pharmaceutically acceptable vehicles may include, for example, inert solid diluents and fillers, diluents, including sterile aqueous solution and various organic solvents, permeation enhancers, solubilizers and adjuvants. Such compositions are prepared in a manner well known in the pharmaceutical art. *See, e.g.*, Remington's Pharmaceutical Sciences, Mace Publishing Co., Philadelphia, Pa. 17th Ed. (1985); and Modern Pharmaceutics, Marcel Dekker, Inc. 3rd Ed. (G.S. Banker & C.T. Rhodes, Eds.).

The pharmaceutical compositions may be administered in either single or multiple doses. The pharmaceutical composition may be administered by various methods including, for example, rectal, buccal, intranasal and transdermal routes. In certain embodiments, the pharmaceutical composition may be administered by intra-arterial injection, intravenously, intraperitoneally, parenterally, intramuscularly, subcutaneously, orally, topically, or as an inhalant. In some embodiments, the pharmaceutical composition is administered orally.

One mode for administration is parenteral, for example, by injection. The forms in which the pharmaceutical compositions described herein may be incorporated for administration by injection include, for example, aqueous or oil suspensions, or emulsions, with sesame oil, corn oil, cottonseed oil, or peanut oil, as well as elixirs, mannitol, dextrose, or a sterile aqueous solution, and similar pharmaceutical vehicles.

Oral administration may be another route for administration of the compounds described herein. Administration may be via, for example, capsule or enteric coated tablets. In making the pharmaceutical compositions that include at least one compound of any of the formulae described herein or a pharmaceutically acceptable salt, prodrug, or solvate thereof, the active ingredient is usually diluted by an excipient and/or enclosed within such a carrier that can be in the form of a capsule, sachet, paper or other container.

When the excipient serves as a diluent, it can be in the form of a solid, semi-solid, or liquid material, which acts as a vehicle, carrier or medium for the active ingredient. Thus, the compositions can be in the form of tablets, pills, powders, lozenges, sachets, cachets, elixirs, suspensions, emulsions, solutions, syrups, aerosols (as a solid or in a liquid medium), ointments containing, for example, up to 10% by weight of the active compound, soft and hard gelatin capsules, sterile injectable solutions, and sterile packaged powders. In certain embodiments, the pharmaceutical composition is in the form of tablets.

As used herein, "pharmaceutically acceptable carrier" or "pharmaceutically acceptable excipient" includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.

Some examples of suitable excipients include lactose, dextrose, sucrose, sorbitol, mannitol, starches, gum acacia, calcium phosphate, alginates, tragacanth, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, sterile water, syrup, and methyl cellulose. The formulations can additionally include lubricating agents such as talc, magnesium stearate, and mineral oil; wetting agents; emulsifying and suspending agents; preserving agents such as methyl and propylhydroxy-benzoates; sweetening agents; and flavoring agents.

The compositions that include at least one compound of any of the formulae described herein or a pharmaceutically acceptable salt, isomer, prodrug, or solvate thereof, can be formulated so as to provide quick, sustained or delayed release of the active ingredient after administration to the subject by employing procedures known in the art. Controlled release drug delivery systems for oral administration include osmotic pump systems and dissolutional systems containing polymer-coated reservoirs or drug-polymer matrix formulations. Examples of controlled release systems are given in U.S. Patent Nos. 3,845,770; 4,326,525; 4,902,514; and 5,616,345. Another formulation for use in the methods of the present invention employs transdermal delivery devices ("patches"). Such transdermal patches may be used to provide continuous or

discontinuous infusion of the compounds described herein in controlled amounts. The construction and use of transdermal patches for the delivery of pharmaceutical agents is well known in the art. *See, e.g.*, U.S. Patent Nos. 5,023,252, 4,992,445 and 5,001,139. Such patches may be constructed for continuous, pulsatile, or on demand delivery of pharmaceutical agents.

For preparing solid compositions such as tablets, the principal active ingredient may be mixed with a pharmaceutical excipient to form a solid preformulation composition containing a homogeneous mixture of a compound of any of the above formulae or a pharmaceutically acceptable salt, prodrug, or solvate thereof. When referring to these preformulation compositions as homogeneous, the active ingredient may be dispersed evenly throughout the composition so that the composition may be readily subdivided into equally effective unit dosage forms such as tablets, pills and capsules.

The tablets or pills of the compounds described herein may be coated or otherwise compounded to provide a dosage form affording the advantage of prolonged action, or to protect from the acid conditions of the stomach. For example, the tablet or pill can include an inner dosage and an outer dosage component, the latter being in the form of an envelope over the former. The two components can be separated by an enteric layer that serves to resist disintegration in the stomach and permit the inner component to pass intact into the duodenum or to be delayed in release. A variety of materials can be used for such enteric layers or coatings, such materials including a number of polymeric acids and mixtures of polymeric acids with such materials as shellac, cetyl alcohol, and cellulose acetate.

Compositions for inhalation or insufflation may include solutions and suspensions in pharmaceutically acceptable, aqueous or organic solvents, or mixtures thereof, and powders. The liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as described supra. In some embodiments, the compositions are administered by the oral or nasal respiratory route for local or systemic effect. In other embodiments, compositions in pharmaceutically acceptable solvents may be nebulized by use of inert gases. Nebulized solutions may be inhaled directly from the nebulizing device or the nebulizing device may be attached to a facemask tent, or intermittent positive pressure breathing machine. Solution, suspension, or powder

compositions may be administered, preferably orally or nasally, from devices that deliver the formulation in an appropriate manner.

Dosing

The specific dose level of a compound of the formulae described herein for any particular subject will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, route of administration, and rate of excretion, drug combination and the severity of the particular disease in the subject undergoing therapy. For example, a dosage may be expressed as a number of milligrams of a compound of the formula per kilogram of the subject's body weight (mg/kg). Dosages of between about 0.01 and 200 mg/kg may be appropriate. In some embodiments, about 0.01 and 150 mg/kg may be appropriate. In other embodiments a dosage of between 0.05 and 100 mg/kg may be appropriate. Normalizing according to the subject's body weight is particularly useful when adjusting dosages between subjects of widely disparate size, such as occurs when using the drug in both children and adult humans or when converting an effective dosage in a non-human subject such as dog to a dosage suitable for a human subject.

The daily dosage may also be described as a total amount of a compound of the formulae administered per dose or per day. Daily dosage of a compound may be between about 1 mg and 2,000 mg, between about 1,000 to 2,000 mg/day, between about 1 to 1,000 mg/day, between about 1 to 500 mg/day, between about 100 to 150 mg/day, between about 1 to 100 mg/day, between about between about 1 to 50 mg/day, between about 50 to 100 mg/day, between about 100 to 125 mg/day, between about 100 to 150 mg/day, between about 100 to 175 mg/day, between about 100 to 200 mg/day, between about 100 to 225 mg/day, between about 100 to 250 mg/day, between about 100 to 350 mg/day, between about 100 to 400 mg/day, between about 100 to 450 mg/day, or between about 100 to 500 mg/day.

When administered orally, the total daily dosage for a human subject may be between 1 mg and 1,000 mg/day, between about 1 to 100 mg/day, between about 1 to 50 mg/day, between about 50 to 100 mg/day, between 50 to 300 mg/day, between 50 to 200 mg/day, between 75 to 200 mg/day, between 75 to 150 mg/day, between 100 to 200 mg/day, between about 200 to 300 mg/day, between about 300 to 400 mg/day, between

about 400 to 500 mg/day, between about 100 to 150 mg/day, between about 150 to 200 mg/day, between about 200 to 250 mg/day, between about 75 to 150 mg/day, or between about 150 to 300 mg/day.

The compounds of the present application or the compositions thereof may be administered once, twice, three, or four times daily, using any suitable mode described above. Also, administration or treatment with the compounds according to any of the formulae described herein may be continued for a number of days; for example, commonly treatment would continue for at least 7 days, 14 days, or 28 days, for one cycle of treatment. In some treatment, the compound or the composition thereof is administered continuously, i.e. every day. Treatment cycles are well known in cancer chemotherapy, and are frequently alternated with resting periods of about 1 to 28 days, commonly about 7 days or about 14 days, between cycles. The treatment cycles, in other embodiments, may also be continuous.

In a particular embodiment, the method comprises administering to the subject an initial daily dose of about 1 to 500 mg of a compound of the above formula and increasing the dose by increments until clinical efficacy is achieved. Increments of about 1, 5, 10, 25, 50, 75, or 100 mg can be used to increase the dose. The dosage can be increased daily, every other day, twice per week, or once per week.

Synthesis of the Compounds

The compounds of the present application may be prepared using the methods disclosed herein and routine modifications thereof, which will be apparent given the disclosure herein and methods well known in the art. Conventional and well-known synthetic methods may be used in addition to the teachings herein. The synthesis of typical compounds described herein may be accomplished as described in the following examples. If available, reagents may be purchased commercially, *e.g.*, from Sigma Aldrich or other chemical suppliers. In general, compounds described herein are typically stable and isolatable at room temperature and pressure.

General Synthesis

Typical embodiments of compounds described herein may be synthesized using the general reaction schemes described below. It will be apparent given the description

herein that the general schemes may be altered by substitution of the starting materials with other materials having similar structures to result in products that are correspondingly different. Descriptions of syntheses follow to provide numerous examples of how the starting materials may vary to provide corresponding products. Given a desired product for which the substituent groups are defined, the necessary starting materials generally may be determined by inspection. Starting materials are typically obtained from commercial sources or synthesized using published methods. For synthesizing compounds which are embodiments described in the present disclosure, inspection of the structure of the compound to be synthesized will provide the identity of each substituent group. The identity of the final product will generally render apparent the identity of the necessary starting materials by a simple process of inspection, given the examples herein.

Synthetic Reaction Parameters

The terms "solvent", "inert organic solvent", or "inert solvent" refer to a solvent inert under the conditions of the reaction being described in conjunction therewith (including, for example, benzene, toluene, acetonitrile, tetrahydrofuran ("THF"), dimethylformamide ("DMF"), chloroform, methylene chloride (or dichloromethane), diethyl ether, methanol, and the like). Unless specified to the contrary, the solvents used in the reactions of the present invention are inert organic solvents, and the reactions are carried out under an inert gas, preferably nitrogen or argon.

The compounds of formula (I) may be prepared using the method similar to the Reaction Scheme I shown below:

Reaction Scheme I



Step 1 – Preparation of a compound of formula (1) The compounds of formula 1 can be prepared by treating an appropriately substituted haloquinoline (A, X=halide, preferably bromo or chloro) with an appropriately substituted aniline in the presence of a palladium catalyst, such as $Pd(OAc)_2$, a phosphine ligand, such as dicyclohexyl(2',4',6'-triisopropyl-[1,1'-biphenyl]-2-yl)phosphine, and a base, such as potassium phosphate in a neutral solvent such as toluene. The reaction can be carried out between 30°C and 120°C for between 4 and 72 hours or until the reaction is complete. Upon completion, the solvent is removed in vacuo and the material can be purified by known methods such as chromatography, precipitation, or crystallization. Alternatively, compounds of formula 1 can be prepared by reacting an appropriately substituted aminoquinoline ($X=NH_2$) with an appropriately substituted 2-halonitroaromatic compound in the presence of a base,

such as cesium carbonate or potassium carbonate, in a solvent, such as DMF or DMSO. The reaction is carried out between 30°C and 120°C for between 4 and 72 hours or until the reaction is complete. Upon completion, the solvent is removed in vacuo and the material may be purified by known methods such as chromatography, precipitation, or crystallization.

Step 2-Preparation of a compound of formula 2

The compounds of formula 2 can be made by treating the nitroaniline with the appropriate aldehyde and a reducing agent, such as sodium dithionite in a solvent to assure dissolution of the nitro containing compound. The reaction is carried out between 30°C and 120°C for between 4 and 72 hours or until the reaction is complete and partitioned between water and an organic solvent such as ethyl acetate or methylene chloride. The organic phase was separated and the solvent removed to leave a residue, which may be purified by known methods such as chromatography, precipitation or crystallization. The compounds of formula 2 may also be made in two steps by first reducing the compound of formula 1 by standard methods, with appropriate reagents such as tin chloride, ferric chloride, or hydrogen and a palladium or platinum catalyst. The resulting ortho dianiline can be cyclized with the appropriate ortho ester to give the benzimidazole, 2.

Step 3-Preparation of a compound of formula 3

The compounds of formula 3 may be prepared by deesterifying a compound of formula 2, in which Y is CO_2Me by standard methods. A compound of formula 2 is dissolved or slurried in a solvent such as THF or dioxane and LiOH may be added either as a solution in water or with some water. The reaction is carried out at ambient temperature for between 4 and 72 hours or until the reaction is complete and acidified with an acid such as HCl. The solvent is removed in vacuo to give a compound of formula 3. Alternatively, t-butyl esters (Y is CO_2t-butyl) can be converted to the corresponding acid by treatment with an acid, such as TFA or aqueous HCl, in a solvent such as dichloromethane. The reaction is carried out between 0°C and 60°C for between 4 and 72 hours or until the reaction is complete at which time the solvent is removed in vacuo.

Step 4-Preparation of a compound of formula 4

The compound of formula 4 may be prepared by amidation of a compound of formula 3 by standard coupling conditions. For example, the acid, 3, may be reacted with ammonium chloride in the presence of HOBT or HATU, a base such as triethylamine, diisopropylethylamine, or methylmorpholine, and diethyldiazodicarboxylate or N1-((ethylimino)methylene)-N3,N3-dimethylpropane-1,3-diamine hydrochloride in a solvent such as DMF. The reaction is carried out at ambient temperature for between 12 and 96 hours or until the reaction is complete. The amide may precipitate with the addition of water or can be isolated by standard extractive methods.

Step 5-Preparation of a compound of formula 5

Compounds of formula 5 may be prepared from a compound of formula 4 by first reacting a compound of formula 4 with the appropriate reagent such as 1,1-dimethoxy-N,N-dimethylethanamine to prepare methyltriazoles or 1,1-dimethoxy-N,N-dimethylmethanamine to make unsubstituted triazoles between 80°C and 150°C for between 0.5 and 5 hours or until the reaction is complete. Alternatively substituted triazoles may be prepared by using alternative reagents. The solvent is removed in vacuo and the residue is dissolved in acetic acid and hydrazine hydrate and stirred for between 80°C and 150°C for between 0.5 and 5 hours or until the reaction is complete. The solvent was removed in vacuo and the residue was purified by standard methods. If protecting groups are present on the compound at this point, they may be removed by appropriate methods. For example, trityl or Boc groups may be removed by treatment with an acid, such as HCl or trifluoroacetic acid in a solvent such as methylene chloride. If the compound is a mixture of atropisomers, the isomers may be separated using a chiral chromatography method. The solvents and chromatography column used will depend on the specific compound being separated, but normal phase, reverse phase or supercritical fluid chromatography may be used. Alternatively, a compound of formula 5 may be prepared by reacting a compound of formula 2 with ammonium chloride and trimethylaluminum in a solvent such as DCE between -20°C and 100°C for between 3 hours and 3 days or until the reaction is complete. Work-up and purification gives the nitrile which can be further reacted with sodium azide and ammonium chloride in a solvent such as DMF between 80°C and 150°C for between 2 and 24 hours or until the reaction is complete. Alternatively a compound of formula 5 may be prepared by

reacting a compound of formula 2 where Y=CO_2Me with a diamine, such as ethylenediamine, in the presence of trimethylaluminum in a solvent such as toluene between 10°C and 150°C for between 1 and 24 hours or until the reaction is complete. Alternatively a compound of formula 5 may be prepared by reacting a compound of formula 2 where Y=CO_2Me with hydrazine hydrate in an appropriate solvent such as ethanol between 40°C and reflux for between 2 and 24 hours or until the reaction is complete. Work-up and purification gives the hydrazide which can be further reacted with an orthoester, such as trimethylorthoformate, triethylorthoacetate, and the like, to give an 1,3,4-oxadiazole, cyanogen bromide to give a 2-amino-1,3,4-oxadiazole, carbon disulfide to give an 1,3,4-oxadiazole-2-thione, trimethylisocyante to give an 2-amino-1,3,4-thiadiazole, or phosgene or an equivalent, such as carbonyldiimidazole to give an 1,3,4-oxadiazol-2(3H)-one.

Reaction Scheme 2



2 5

Step 6-Preparation of a compound of formula 5

Compounds of formula 5 may also be prepared by reacting a compound of formula 2, Y is a halogen, preferably bromide, with an appropriately substituted tributylstannyl substituted reagent in the presence of catalysts, such as copper iodide and palladium in a solvent, such as dioxane between 50°C and 150°C for between 12 hours and 7 days, or until the reaction is complete under an inert atmosphere such as Argon. The reaction may be worked up by standard means and purified by standard methods, such as chromatography. Alternatively, a compound of formula 5 may be prepared by reacting a compound of formula 2, where Y is a halogen, preferably bromide, with an appropriately substituted boronic acid, a MIDA ester of a boronic acid, or pinacol ester of a boronic acid in the presence of cesium fluoride in the presence of catalysts, such as copper iodide and palladium in a solvent, such as dioxane between 50°C and 150°C for between 12

hours and 7 days, or until the reaction is complete under an inert atmosphere such as Argon. The reaction may be worked up by standard means and purified by standard methods, such as chromatography. In some cases the product may have had a protecting group and deprotection would proceed by methods known to those skilled in the art. For example, a THP or Boc group would be removed by treatment with an acid such as TFA or aqueous HCl. Alternatively a compound of formula 5 may be prepared by reacting a compound of formula 2 (Y=Br) with ethynyltributylstannane in the presence of $Pd(dppf)Cl_2$ and copper iodide in a solvent such as dioxane between 50°C and 150°C for between 12 hours and 7 days, or until the reaction is complete under an inert atmosphere such as Argon. The resulting acetylene containing compound is subsequently reacted with azidotrimethylsilane in the presence of a catalyst such as copper iodide or a solvent such as a mixture of DMF and MeOH between 50°C and 150°C for between 8 and 24 hours or until the reaction is complete to give a 1,2,3-triazole after purification by standard means.

Reaction Scheme 3



1 1a 5

Step 7-Preparation of a compound of formula 1a

Compounds of formula 1a may be prepared by methods similar to that described in step 6 from compounds of formula 1 (Y=Br).

Step 8-Preparation of compounds of formula 5

Compounds of formula 5 may be prepared by methods similar to that described in step 2.

Examples

Step 1. Methyl 3-((8-chloroquinolin-4-yl)amino)-5-morpholino-2-nitrobenzoate



Palladium (II) acetate (0.14 g, 0.61 mmol) was added to a mixture of methyl 3-amino-5-morpholino-2-nitrobenzoate (1.50 g, 5.33 mmol), 4,8-dichloroquinoline (1.16 g, 5.87 mmol), dicyclohexyl(2',4',6'-triisopropyl-[1,1'-biphenyl]-2-yl)phosphine (0.87 g, 1.82 mmol), and potassium phosphate (3.22 g, 15.15 mmol) in toluene (10 mL). The resultant was degassed and stirred at 90 °C for 16 hours. The reaction mixture was cooled to room temperature and dry loaded onto silica gel and purified eluting with 0 to 100% ethyl acetate in hexanes to afford the title compound as a brown solid. ES/MS *m/z* = 443.30 $(M+H)^+$.

The compounds listed below were prepared in a manner similar to that described in step 1 above using appropriate intermediates and chemistry:

methyl 3-((5,8-difluoroquinolin-4-yl)amino)-5-morpholino-2-nitrobenzoate;

methyl 3-((5-chloro-8-fluoroquinolin-4-yl)amino)-5-morpholino-2-nitrobenzoate;

methyl 3-((8-chloroquinolin-4-yl)amino)-5-morpholino-2-nitrobenzoate;

methyl 3-((7-fluoroquinolin-4-yl)amino)-5-morpholino-2-nitrobenzoate;

methyl 5-morpholino-2-nitro-3-(quinolin-4-ylamino)benzoate;

methyl 3-((8-chloro-5-fluoroquinolin-4-yl)amino)-5-morpholino-2-nitrobenzoate;

methyl 3-((8-chloro-6-fluoroquinolin-4-yl)amino)-5-morpholino-2-nitrobenzoate;

methyl 3-((8-chloro-7-fluoroquinolin-4-yl)amino)-5-morpholino-2-nitrobenzoate;

methyl 3-((5-fluoro-8-methylquinolin-4-yl)amino)-5-morpholino-2-nitrobenzoate;

methyl 3-((7,8-difluoroquinolin-4-yl)amino)-5-morpholino-2-nitrobenzoate;

methyl 3-((8-fluoroquinolin-4-yl)amino)-5-morpholino-2-nitrobenzoate;

methyl 3-((2-cyclopropyl-3-methylquinolin-4-yl)amino)-5-morpholino-2-nitrobenzoate;

methyl 3-((2-ethyl-3-methylquinolin-4-yl)amino)-5-morpholino-2-nitrobenzoate;

methyl 3-((8-chloro-2-(trifluoromethyl)quinolin-4-yl)amino)-5-morpholino-2-nitrobenzoate;

methyl 5-morpholino-2-nitro-3-((2-phenylquinolin-4-yl)amino)benzoate;

methyl 3-((2-methyl-8-(trifluoromethyl)quinolin-4-yl)amino)-5-morpholino-2-nitrobenzoate;

methyl 3-((3-ethyl-2-methylquinolin-4-yl)amino)-5-morpholino-2-nitrobenzoate;

methyl 3-((7-fluoro-2-methylquinolin-4-yl)amino)-5-morpholino-2-nitrobenzoate;

methyl 3-((8-fluoro-2,3-dimethylquinolin-4-yl)amino)-5-morpholino-2-nitrobenzoate;

methyl 3-((2-cyanoquinolin-4-yl)amino)-5-morpholino-2-nitrobenzoate;

methyl 3-((3-cyclopropylquinolin-4-yl)amino)-5-morpholino-2-nitrobenzoate;

methyl 3-((3-methylquinolin-4-yl)amino)-5-morpholino-2-nitrobenzoate;

methyl 3-((8-chloro-2-methylquinolin-4-yl)amino)-5-morpholino-2-nitrobenzoate;

methyl 3-((2-methylquinolin-4-yl)amino)-5-morpholino-2-nitrobenzoate;

methyl 3-((8-chloro-2,3-dimethylquinolin-4-yl)amino)-5-morpholino-2-nitrobenzoate;

methyl 3-((8-chloro-3-methylquinolin-4-yl)amino)-5-morpholino-2-nitrobenzoate;

methyl 3-((2-ethyl-8-fluoro-3-methylquinolin-4-yl)amino)-5-morpholino-2-nitrobenzoate;

methyl 3-((5-(difluoromethyl)quinolin-4-yl)amino)-5-morpholino-2-nitrobenzoate;

methyl 3-((5-chloroquinolin-4-yl)amino)-5-morpholino-2-nitrobenzoate;

methyl 3-((5-fluoroquinolin-4-yl)amino)-5-morpholino-2-nitrobenzoate;

methyl 3-((5-methylquinolin-4-yl)amino)-5-morpholino-2-nitrobenzoate;

methyl 3-((8-(difluoromethyl)quinolin-4-yl)amino)-5-morpholino-2-nitrobenzoate;

methyl 3-((7-fluoroquinolin-4-yl)amino)-5-morpholino-2-nitrobenzoate;

methyl 3-((8-chloro-2-(difluoromethyl)quinolin-4-yl)amino)-5-morpholino-2-nitrobenzoate;

methyl 3-((8-chloro-5-fluoroquinolin-4-yl)amino)-5-morpholino-2-nitrobenzoate;

methyl 3-((8-cyanoquinolin-4-yl)amino)-5-morpholino-2-nitrobenzoate;

methyl 3-((5,8-dichloroquinolin-4-yl)amino)-5-morpholino-2-nitrobenzoate;

methyl 5-morpholino-2-nitro-3-((2-(thiazol-4-yl)quinolin-4-yl)amino)benzoate;

methyl 3-((3-chloroquinolin-4-yl)amino)-5-morpholino-2-nitrobenzoate;

methyl 3-((5,7-difluoroquinolin-4-yl)amino)-5-morpholino-2-nitrobenzoate;

methyl 3-((6,8-difluoroquinolin-4-yl)amino)-5-morpholino-2-nitrobenzoate;

methyl 3-((3,8-dichloroquinolin-4-yl)amino)-5-morpholino-2-nitrobenzoate;

methyl 3-((3-chloro-8-fluoroquinolin-4-yl)amino)-5-morpholino-2-nitrobenzoate;

methyl 3-((8-methylquinolin-4-yl)amino)-5-morpholino-2-nitrobenzoate;

methyl 5-morpholino-2-nitro-3-((8-(trifluoromethyl)quinolin-4-yl)amino)benzoate;

tert-butyl 3-((8-chloroquinolin-4-yl)amino)-4-fluoro-5-morpholino-2-nitrobenzoate;

methyl (S)-3-((8-chloroquinolin-4-yl)amino)-5-(3-methylmorpholino)-2-nitrobenzoate;

methyl (R)-3-((8-chloroquinolin-4-yl)amino)-5-(3-methylmorpholino)-2-nitrobenzoate;

tert-butyl 3-((8-chloroquinolin-4-yl)amino)-6-fluoro-5-morpholino-2-nitrobenzoate;

8-chloro-N-(5-morpholino-2-nitro-3-(pyridin-3-yl)phenyl)quinolin-4-amine;

8-chloro-N-(5-morpholino-2-nitro-[1,1'-biphenyl]-3-yl)quinolin-4-amine;

methyl 5-morpholino-2-nitro-3-((2-(1-trityl-1H-pyrazol-4-yl)quinolin-4-yl)amino)benzoate;

tert-butyl 4-(4-((3-(methoxycarbonyl)-5-morpholino-2-nitrophenyl)amino)quinolin-2-yl)piperazine-1-carboxylate;

methyl 3-((3-fluoroquinolin-4-yl)amino)-5-morpholino-2-nitrobenzoate;

methyl 3-((8-chloro-5-fluoroquinolin-4-yl)amino)-4-fluoro-5-morpholino-2-nitrobenzoate;

methyl 3-((8-chloroquinolin-4-yl)amino)-4-fluoro-5-morpholino-2-nitrobenzoate;

methyl 3-((8-cyano-3-methylquinolin-4-yl)amino)-5-morpholino-2-nitrobenzoate;

tert-butyl 4-(4-((3-(methoxycarbonyl)-5-morpholino-2-nitrophenyl)amino)quinolin-2-yl)piperazine-1-carboxylate;

methyl 5-morpholino-2-nitro-3-((2-(1-trityl-1H-pyrazol-3-yl)quinolin-4-yl)amino)benzoate;

methyl 5-morpholino-2-nitro-3-((2-(1-trityl-1H-pyrazol-4-yl)quinolin-4-yl)amino)benzoate;

methyl 3-((3-cyanoquinolin-4-yl)amino)-5-morpholino-2-nitrobenzoate.

Step 1a: N-(3-bromo-5-morpholino-2-nitrophenyl)-8-fluoroquinolin-4-amine



4-amino-8-fluoroquinoline (500 mg, 3.1 mmol), 4-(3-bromo-5-fluoro-4-nitrophenyl)morpholine (941 mg, 3.1 mmol), and cesium carbonate (2.2 g, 6.8 mmol) were combined in DMF (4 mL). The resulting mixture was heated to 90°C. After 18 hours the reaction was allowed to cool and poured into water. The resulting precipitate was washed with water, then methanol, and dried to afford N-(3-bromo-5-morpholino-2-nitrophenyl)-8-fluoroquinolin-4-amine. ES/MS m/z 447.07.

The compounds listed below were prepared in a manner similar to that described above using appropriate intermediates:

N-(3-bromo-5-morpholino-2-nitrophenyl)-5,8-difluoroquinolin-4-amine;

N-(3-bromo-5-morpholino-2-nitrophenyl)-8-chloroquinolin-4-amine;

N-(3-bromo-5-morpholino-2-nitrophenyl)-8-fluoro-2-methylquinolin-4-amine;

N-(3-bromo-5-morpholino-2-nitrophenyl)-8-chloro-6-fluoroquinolin-4-amine;

N-(3-bromo-5-morpholino-2-nitrophenyl)-8-chloro-7-fluoroquinolin-4-amine;

N-(3-bromo-5-morpholino-2-nitrophenyl)-8-chloro-5-fluoroquinolin-4-amine;

N-(3-bromo-5-morpholino-2-nitrophenyl)-7-fluoroquinolin-4-amine;

N-(3-bromo-5-morpholino-2-nitrophenyl)quinolin-4-amine;

N-(3-bromo-5-morpholino-2-nitrophenyl)-5-chloro-8-fluoroquinolin-4-amine.

Step 2. Methyl 1-(8-chloroquinolin-4-yl)-6-morpholino-2-propyl-1H-benzo[d]imidazole-4-carboxylate



Butyraldehyde (0.9 mL, 10.44 mmol) was added to a solution of methyl 3-((8-chloroquinolin-4-yl)amino)-5-morpholino-2-nitrobenzoate (600 mg, 1.36 mmol) and sodium dithionite (833 mg, 4.07 mmol) in ethanol (3 mL) and DMSO (3 mL). The reagents were stirred at 80°C for 16 hours, after which time the reaction mixture was cooled to ambient temperature and partitioned between ethyl acetate (50 mL) and water (50 mL). The aqueous layer was extracted 3 times with ethyl acetate. The combined organic phases were dried with sodium sulfate and filtered. The resultant residue was purified on silica gel with 0 to 15% methanol in ethyl acetate to afford the title compound as an orange solid. ES/MS m/z = 465.235 $(M+H)^+$.

The compounds listed below were prepared in a manner similar to that described above using appropriate intermediates:

methyl 1-(5,8-difluoroquinolin-4-yl)-6-morpholino-2-propyl-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(5-chloro-8-fluoroquinolin-4-yl)-2-ethyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(8-chloroquinolin-4-yl)-2-(1-methylcyclopropyl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(8-chloroquinolin-4-yl)-2-isobutyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(7-fluoroquinolin-4-yl)-6-morpholino-2-propyl-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(8-chloroquinolin-4-yl)-2-(cyclopropylmethyl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(8-chloroquinolin-4-yl)-6-morpholino-2-(tetrahydrofuran-3-yl)-1H-benzo[d]imidazole-4-carboxylate;

methyl 6-morpholino-2-(pyridin-2-yl)-1-(quinolin-4-yl)-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(8-chloro-5-fluoroquinolin-4-yl)-6-morpholino-2-propyl-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(8-chloroquinolin-4-yl)-2-(1-methoxyethyl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(8-chloroquinolin-4-yl)-2-cyclobutyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(8-chloroquinolin-4-yl)-6-morpholino-2-(pyridin-3-yl)-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(8-chloroquinolin-4-yl)-2-isopropyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(8-chloroquinolin-4-yl)-6-morpholino-2-(pyridin-4-yl)-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(8-chloroquinolin-4-yl)-6-morpholino-2-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazole-4-carboxylate;

methyl 2-cyclopropyl-6-morpholino-1-(quinolin-4-yl)-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(7-fluoroquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(8-chloro-6-fluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 2-(tert-butyl)-1-(8-chloroquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 2-methyl-6-morpholino-1-(quinolin-4-yl)-1H-benzo[d]imidazole-4-carboxylate;

methyl (S)-1-(5,8-difluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(5,8-difluoroquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(8-chloro-7-fluoroquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 6-morpholino-2-(oxetan-3-yl)-1-(quinolin-4-yl)-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(5-fluoro-8-methylquinolin-4-yl)-6-morpholino-2-propyl-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(8-chloro-6-fluoroquinolin-4-yl)-6-morpholino-2-propyl-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(8-chloro-7-fluoroquinolin-4-yl)-2-(cyclopropylmethyl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(8-chloro-7-fluoroquinolin-4-yl)-6-morpholino-2-propyl-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(8-chloro-7-fluoroquinolin-4-yl)-2-cyclopropyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(8-chloro-7-fluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(8-chloro-7-fluoroquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 6-morpholino-2-propyl-1-(quinolin-4-yl)-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(5,8-difluoroquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(7,8-difluoroquinolin-4-yl)-6-morpholino-2-propyl-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(8-chloroquinolin-4-yl)-2-cyclopropyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(8-fluoroquinolin-4-yl)-2-(2-methoxyethyl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(7,8-difluoroquinolin-4-yl)-6-morpholino-2-propyl-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(7-fluoroquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(8-chloroquinolin-4-yl)-2-(1-fluorocyclopropyl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(2-cyclopropyl-3-methylquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(2-ethyl-3-methylquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(8-chloro-2-(trifluoromethyl)quinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 2-methyl-6-morpholino-1-(2-phenylquinolin-4-yl)-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(3-ethyl-2-methylquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(7-fluoro-2-methylquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(8-fluoro-2,3-dimethylquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 2-methyl-1-(2-methyl-8-(trifluoromethyl)quinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(2-cyanoquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(3-cyclopropylquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(8-chloro-2-methylquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 2-methyl-1-(3-methylquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(2-ethyl-3-methylquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(3-ethyl-2-methylquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(8-chloro-2,3-dimethylquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(8-chloro-3-methylquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 2-methyl-1-(2-methylquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(2-ethyl-8-fluoro-3-methylquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(5-(difluoromethyl)quinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(5-chloroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(5-fluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(8-(difluoromethyl)quinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 2-methyl-1-(5-methylquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(7-fluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(8-chloro-2-(difluoromethyl)quinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(8-chloro-5-fluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(8-cyanoquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(5,8-dichloroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(5,8-difluoroquinolin-4-yl)-2-ethyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(5,8-difluoroquinolin-4-yl)-6-morpholino-2-(oxetan-3-yl)-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(5-chloro-8-fluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(5-fluoro-8-methylquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 2-methyl-6-morpholino-1-(2-(thiazol-4-yl)quinolin-4-yl)-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(3-chloroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(5,7-difluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(5-methylquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(8-chloroquinolin-4-yl)-2-ethyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(8-chloroquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(8-fluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(6,8-difluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(7,8-difluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(8-fluoroquinolin-4-yl)-6-morpholino-2-propyl-1H-benzo[d]imidazole-4-carboxylate;

methyl 2-cyclopropyl-1-(7,8-difluoroquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 2-cyclopropyl-1-(8-fluoroquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 2-ethyl-1-(8-fluoroquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(3,8-dichloroquinolin-4-yl)-2-ethyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(3,8-dichloroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(3-chloro-8-fluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(5-chloro-8-fluoroquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(6,8-difluoroquinolin-4-yl)-6-morpholino-2-propyl-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(8-fluoroquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(8-chloroquinolin-4-yl)-2-cyclopropyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(8-chloroquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 2-ethyl-6-morpholino-1-(quinolin-4-yl)-1H-benzo[d]imidazole-4-carboxylate;

methyl 2-methyl-1-(8-methylquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 2-methyl-6-morpholino-1-(8-(trifluoromethyl)quinolin-4-yl)-1H-benzo[d]imidazole-4-carboxylate;

methyl 2-methyl-6-morpholino-1-(quinolin-4-yl)-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(5,8-difluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(8-chloroquinolin-4-yl)-2-(2-methoxyethyl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(8-chloroquinolin-4-yl)-6-morpholino-2-(oxazol-5-yl)-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(8-chloroquinolin-4-yl)-6-morpholino-2-(pyridin-2-yl)-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(8-chloroquinolin-4-yl)-6-morpholino-2-(thiazol-5-yl)-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(8-chloroquinolin-4-yl)-6-morpholino-2-(oxetan-3-yl)-1H-benzo[d]imidazole-4-carboxylate;

4-(4-bromo-1-(8-fluoroquinolin-4-yl)-2-methyl-1H-benzo[d]imidazol-6-yl)morpholine (ES/MS m/z 443.1);

4-(4-bromo-1-(5,8-difluoroquinolin-4-yl)-2-ethyl-1H-benzo[d]imidazol-6-yl)morpholine;

4-(4-bromo-1-(8-chloroquinolin-4-yl)-2-methyl-1H-benzo[d]imidazol-6-yl)morpholine;

4-(4-bromo-1-(8-chloroquinolin-4-yl)-2-propyl-1H-benzo[d]imidazol-6-yl)morpholine;

4-(4-bromo-1-(8-fluoro-2-methylquinolin-4-yl)-2-methyl-1H-benzo[d]imidazol-6-yl)morpholine;

4-(4-bromo-2-ethyl-1-(8-fluoro-2-methylquinolin-4-yl)-1H-benzo[d]imidazol-6-yl)morpholine;

4-(4-bromo-2-ethyl-1-(8-fluoroquinolin-4-yl)-1H-benzo[d]imidazol-6-yl)morpholine;

4-(4-bromo-1-(5,8-difluoroquinolin-4-yl)-2-isobutyl-1H-benzo[d]imidazol-6-yl)morpholine;

4-(4-bromo-1-(8-chloro-6-fluoroquinolin-4-yl)-2-propyl-1H-benzo[d]imidazol-6-yl)morpholine;

4-(4-bromo-1-(8-chloro-7-fluoroquinolin-4-yl)-2-ethyl-1H-benzo[d]imidazol-6-yl)morpholine;

4-(4-bromo-1-(8-chloroquinolin-4-yl)-2-(cyclopropylmethyl)-1H-benzo[d]imidazol-6-yl)morpholine;

4-(4-bromo-2-(cyclopropylmethyl)-1-(5,8-difluoroquinolin-4-yl)-1H-benzo[d]imidazol-6-yl)morpholine;

4-(4-bromo-2-cyclopropyl-1-(8-fluoroquinolin-4-yl)-1H-benzo[d]imidazol-6-yl)morpholine;

4-(4-bromo-1-(5,8-difluoroquinolin-4-yl)-2-methyl-1H-benzo[d]imidazol-6-yl)morpholine;

4-(4-bromo-1-(5,8-difluoroquinolin-4-yl)-2-propyl-1H-benzo[d]imidazol-6-yl)morpholine;

4-(4-bromo-1-(8-chloroquinolin-4-yl)-1H-benzo[d]imidazol-6-yl)morpholine;

4-(4-bromo-1-(8-chloroquinolin-4-yl)-2-cyclopropyl-1H-benzo[d]imidazol-6-yl)morpholine;

4-(4-bromo-1-(8-chloroquinolin-4-yl)-2-ethyl-1H-benzo[d]imidazol-6-yl)morpholine;

4-(4-bromo-1-(8-fluoroquinolin-4-yl)-2-propyl-1H-benzo[d]imidazol-6-yl)morpholine;

4-(4-bromo-1-(8-chloro-5-fluoroquinolin-4-yl)-2-cyclopropyl-1H-benzo[d]imidazol-6-yl)morpholine;

4-(4-bromo-1-(8-chloro-5-fluoroquinolin-4-yl)-2-methyl-1H-benzo[d]imidazol-6-yl)morpholine;

4-(4-bromo-2-cyclopropyl-1-(5,8-difluoroquinolin-4-yl)-1H-benzo[d]imidazol-6-yl)morpholine;

4-(4-bromo-1-(7-fluoroquinolin-4-yl)-2-methyl-1H-benzo[d]imidazol-6-yl)morpholine;

4-(4-bromo-1-(8-chloro-6-fluoroquinolin-4-yl)-2-propyl-1H-benzo[d]imidazol-6-yl)morpholine;

4-(4-bromo-1-(8-chloroquinolin-4-yl)-2-(oxetan-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine;

4-(4-bromo-1-(8-fluoroquinolin-4-yl)-1H-benzo[d]imidazol-6-yl)morpholine;

4-(4-bromo-2-(cyclopropylmethyl)-1-(8-fluoroquinolin-4-yl)-1H-benzo[d]imidazol-6-yl)morpholine;

4-(4-bromo-2-methyl-1-(quinolin-4-yl)-1H-benzo[d]imidazol-6-yl)morpholine;

4-(4-bromo-1-(5,8-difluoroquinolin-4-yl)-1H-benzo[d]imidazol-6-yl)morpholine;

4-(4-bromo-1-(5-chloro-8-fluoroquinolin-4-yl)-2-ethyl-1H-benzo[d]imidazol-6-yl)morpholine;

4-(4-bromo-1-(5-chloro-8-fluoroquinolin-4-yl)-2-methyl-1H-benzo[d]imidazol-6-yl)morpholine;

4-(4-bromo-1-(8-chloro-7-fluoroquinolin-4-yl)-2-cyclopropyl-1H-benzo[d]imidazol-6-yl)morpholine;

4-(4-bromo-1-(8-chloro-7-fluoroquinolin-4-yl)-2-methyl-1H-benzo[d]imidazol-6-yl)morpholine;

tert-butyl 1-(8-chloroquinolin-4-yl)-7-fluoro-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl (S)-1-(8-chloroquinolin-4-yl)-2-methyl-6-(3-methylmorpholino)-1H-benzo[d]imidazole-4-carboxylate;

methyl (R)-1-(8-chloroquinolin-4-yl)-2-methyl-6-(3-methylmorpholino)-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(8-chloroquinolin-4-yl)-6-morpholino-2-(1H-pyrazol-5-yl)-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(8-chloroquinolin-4-yl)-2-(isothiazol-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(8-chloroquinolin-4-yl)-6-morpholino-2-(1H-pyrazol-4-yl)-1H-benzo[d]imidazole-4-carboxylate;

tert-butyl 1-(8-chloroquinolin-4-yl)-5-fluoro-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 2-methyl-6-morpholino-1-(2-(1-trityl-1H-pyrazol-4-yl)quinolin-4-yl)-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(2-(4-(tert-butoxycarbonyl)piperazin-1-yl)quinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(3-fluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(8-chloro-5-fluoroquinolin-4-yl)-7-fluoro-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(8-chloroquinolin-4-yl)-7-fluoro-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(8-cyano-3-methylquinolin-4-yl)-2-ethyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(8-cyano-3-methylquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylate

methyl 1-(2-(4-(tert-butoxycarbonyl)piperazin-1-yl)quinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 6-morpholino-1-(2-(1-trityl-1H-pyrazol-4-yl)quinolin-4-yl)-1H-benzo[d]imidazole-4-carboxylate;

methyl 6-morpholino-1-(2-(1-trityl-1H-pyrazol-3-yl)quinolin-4-yl)-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(3-cyanoquinolin-4-yl)-2-ethyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

methyl 1-(3-cyanoquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylate;

Step 3: 1-(8-Chloroquinolin-4-yl)-6-morpholino-2-propyl-1H-benzo[d]imidazole-4-carboxylic acid



Aqueous lithium hydroxide (1M, 3.8 mL) was added to methyl 1-(8-chloroquinolin-4-yl)-6-morpholino-2-propyl-1H-benzo[d]imidazole-4-carboxylate (443 mg, 0.95 mmol) in THF (2 mL). The reaction was stirred at ambient temperature for 16 hours. The reaction mixture was acidified to pH 6 with the addition of 6M HCl. The resultant solution was concentrated *in vacuuo* to afford the title compound. ES/MS *m/z* 451.40 $(M+H)^+$.

The compounds listed below were prepared in a manner similar to that described above using appropriate intermediates:

1-(5,8-difluoroquinolin-4-yl)-6-morpholino-2-propyl-1H-benzo[d]imidazole-4-carboxylic acid;

1-(5-chloro-8-fluoroquinolin-4-yl)-2-ethyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(8-chloroquinolin-4-yl)-2-(1-methylcyclopropyl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(8-chloroquinolin-4-yl)-2-isobutyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(7-fluoroquinolin-4-yl)-6-morpholino-2-propyl-1H-benzo[d]imidazole-4-carboxylic acid;

1-(8-chloroquinolin-4-yl)-2-(cyclopropylmethyl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(8-chloroquinolin-4-yl)-6-morpholino-2-(tetrahydrofuran-3-yl)-1H-benzo[d]imidazole-4-carboxylic acid;

6-morpholino-2-(pyridin-2-yl)-1-(quinolin-4-yl)-1H-benzo[d]imidazole-4-carboxylic acid;

1-(8-chloro-5-fluoroquinolin-4-yl)-6-morpholino-2-propyl-1H-benzo[d]imidazole-4-carboxylic acid;

1-(8-chloroquinolin-4-yl)-2-(1-methoxyethyl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(8-chloroquinolin-4-yl)-2-cyclobutyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(8-chloroquinolin-4-yl)-6-morpholino-2-(pyridin-3-yl)-1H-benzo[d]imidazole-4-carboxylic acid;

1-(8-chloroquinolin-4-yl)-2-isopropyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(8-chloroquinolin-4-yl)-6-morpholino-2-(pyridin-4-yl)-1H-benzo[d]imidazole-4-carboxylic acid;

1-(8-chloroquinolin-4-yl)-6-morpholino-2-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazole-4-carboxylic acid;

2-cyclopropyl-6-morpholino-1-(quinolin-4-yl)-1H-benzo[d]imidazole-4-carboxylic acid;

1-(7-fluoroquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(8-chloro-6-fluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

2-(tert-butyl)-1-(8-chloroquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

2-methyl-6-morpholino-1-(quinolin-4-yl)-1H-benzo[d]imidazole-4-carboxylic acid;

(S)-1-(5,8-difluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(5,8-difluoroquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(8-chloro-7-fluoroquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

6-morpholino-2-(oxetan-3-yl)-1-(quinolin-4-yl)-1H-benzo[d]imidazole-4-carboxylic acid;

1-(5-fluoro-8-methylquinolin-4-yl)-6-morpholino-2-propyl-1H-benzo[d]imidazole-4-carboxylic acid;

1-(8-chloro-6-fluoroquinolin-4-yl)-6-morpholino-2-propyl-1H-benzo[d]imidazole-4-carboxylic acid;

1-(8-chloro-7-fluoroquinolin-4-yl)-2-(cyclopropylmethyl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(8-chloro-7-fluoroquinolin-4-yl)-6-morpholino-2-propyl-1H-benzo[d]imidazole-4-carboxylic acid;

1-(8-chloro-7-fluoroquinolin-4-yl)-2-cyclopropyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(8-chloro-7-fluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(8-chloro-7-fluoroquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

6-morpholino-2-propyl-1-(quinolin-4-yl)-1H-benzo[d]imidazole-4-carboxylic acid;

1-(5,8-difluoroquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(7,8-difluoroquinolin-4-yl)-6-morpholino-2-propyl-1H-benzo[d]imidazole-4-carboxylic acid;

1-(8-chloroquinolin-4-yl)-2-cyclopropyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(8-fluoroquinolin-4-yl)-2-(2-methoxyethyl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(7,8-difluoroquinolin-4-yl)-6-morpholino-2-propyl-1H-benzo[d]imidazole-4-carboxylic acid;

1-(7-fluoroquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(8-chloroquinolin-4-yl)-2-(1-fluorocyclopropyl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(2-cyclopropyl-3-methylquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(2-ethyl-3-methylquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(8-chloro-2-(trifluoromethyl)quinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

2-methyl-6-morpholino-1-(2-phenylquinolin-4-yl)-1H-benzo[d]imidazole-4-carboxylic acid;

1-(3-ethyl-2-methylquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(7-fluoro-2-methylquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(8-fluoro-2,3-dimethylquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

2-methyl-1-(2-methyl-8-(trifluoromethyl)quinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(2-cyanoquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(3-cyclopropylquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(8-chloro-2-methylquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

2-methyl-1-(3-methylquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(2-ethyl-3-methylquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(3-ethyl-2-methylquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(8-chloro-2,3-dimethylquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(8-chloro-3-methylquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

2-methyl-1-(2-methylquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(2-ethyl-8-fluoro-3-methylquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(5-(difluoromethyl)quinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(5-chloroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(5-fluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(8-(difluoromethyl)quinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

2-methyl-1-(5-methylquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(7-fluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(8-chloro-2-(difluoromethyl)quinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(8-chloro-5-fluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(8-cyanoquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(5,8-dichloroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(5,8-difluoroquinolin-4-yl)-2-ethyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(5,8-difluoroquinolin-4-yl)-6-morpholino-2-(oxetan-3-yl)-1H-benzo[d]imidazole-4-carboxylic acid;

1-(5-chloro-8-fluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(5-fluoro-8-methylquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

2-methyl-6-morpholino-1-(2-(thiazol-4-yl)quinolin-4-yl)-1H-benzo[d]imidazole-4-carboxylic acid;

1-(3-chloroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(5,7-difluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(5-methylquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(8-chloroquinolin-4-yl)-2-ethyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(8-chloroquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(8-fluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(6,8-difluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(7,8-difluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(8-fluoroquinolin-4-yl)-6-morpholino-2-propyl-1H-benzo[d]imidazole-4-carboxylic acid;

2-cyclopropyl-1-(7,8-difluoroquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

2-cyclopropyl-1-(8-fluoroquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

2-ethyl-1-(8-fluoroquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(3,8-dichloroquinolin-4-yl)-2-ethyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(3,8-dichloroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(3-chloro-8-fluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(5-chloro-8-fluoroquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(6,8-difluoroquinolin-4-yl)-6-morpholino-2-propyl-1H-benzo[d]imidazole-4-carboxylic acid;

1-(8-fluoroquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(8-chloroquinolin-4-yl)-2-cyclopropyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(8-chloroquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

2-ethyl-6-morpholino-1-(quinolin-4-yl)-1H-benzo[d]imidazole-4-carboxylic acid;

2-methyl-1-(8-methylquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

2-methyl-6-morpholino-1-(8-(trifluoromethyl)quinolin-4-yl)-1H-benzo[d]imidazole-4-carboxylic acid;

2-methyl-6-morpholino-1-(quinolin-4-yl)-1H-benzo[d]imidazole-4-carboxylic acid;

1-(5,8-difluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(8-chloroquinolin-4-yl)-2-(2-methoxyethyl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(8-chloroquinolin-4-yl)-6-morpholino-2-(oxazol-5-yl)-1H-benzo[d]imidazole-4-carboxylic acid;

1-(8-chloroquinolin-4-yl)-6-morpholino-2-(pyridin-2-yl)-1H-benzo[d]imidazole-4-carboxylic acid;

1-(8-chloroquinolin-4-yl)-6-morpholino-2-(thiazol-5-yl)-1H-benzo[d]imidazole-4-carboxylic acid;

1-(8-chloroquinolin-4-yl)-6-morpholino-2-(oxetan-3-yl)-1H-benzo[d]imidazole-4-carboxylic acid;

(S)-1-(8-chloroquinolin-4-yl)-2-methyl-6-(3-methylmorpholino)-1H-benzo[d]imidazole-4-carboxylic acid;

(R)-1-(8-chloroquinolin-4-yl)-2-methyl-6-(3-methylmorpholino)-1H-benzo[d]imidazole-4-carboxylic acid;

1-(8-chloroquinolin-4-yl)-6-morpholino-2-(1H-pyrazol-5-yl)-1H-benzo[d]imidazole-4-carboxylic acid;

1-(8-chloroquinolin-4-yl)-2-(isothiazol-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(8-chloroquinolin-4-yl)-6-morpholino-2-(1H-pyrazol-4-yl)-1H-benzo[d]imidazole-4-carboxylic acid;

2-methyl-6-morpholino-1-(2-(1-trityl-1H-pyrazol-4-yl)quinolin-4-yl)-1H-benzo[d]imidazole-4-carboxylic acid;

1-(2-(4-(tert-butoxycarbonyl)piperazin-1-yl)quinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(3-fluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(8-chloro-5-fluoroquinolin-4-yl)-7-fluoro-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(8-chloroquinolin-4-yl)-7-fluoro-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(8-cyano-3-methylquinolin-4-yl)-2-ethyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(8-cyano-3-methylquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(3-carbamoylquinolin-4-yl)-2-ethyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(3-carbamoylquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

1-(2-(4-(tert-butoxycarbonyl)piperazin-1-yl)quinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid;

6-morpholino-1-(2-(1-trityl-1H-pyrazol-3-yl)quinolin-4-yl)-1H-benzo[d]imidazole-4-carboxylic acid;

6-morpholino-1-(2-(1-trityl-1H-pyrazol-4-yl)quinolin-4-yl)-1H-benzo[d]imidazole-4-carboxylic acid;

Step 3a: 1-(8-chloroquinolin-4-yl)-5-fluoro-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid.



To a solution of *tert*-butyl 1-(8-chloroquinolin-4-yl)-5-fluoro-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylate (170 mg, 0.34 mmol) in DCM (3.0 mL) was added TFA (0.4 mL). The mixture was stirred at room temperature for 20 hours and concentrated in vacuuo to afford 1-(8-chloroquinolin-4-yl)-5-fluoro-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid which was used without further purification in the next step.

The following compound was prepared in a manner similar to that described above using appropriate intermediates:

1-(8-chloroquinolin-4-yl)-7-fluoro-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylic acid.

Step: 1-(8-Chloroquinolin-4-yl)-6-morpholino-2-propyl-1H-benzo[d]imidazole-4-carboxamide.



Hünig's base (1.35 mL, 7.74 mmol) was added to 1-(8-chloroquinolin-4-yl)-6-morpholino-2-propyl-1H-benzo[d]imidazole-4-carboxylic acid (349 mg, 0.77 mmol), ammonium hydrochloride (248 mg, 4.64 mmol), 1H-benzo[d][1,2,3]triazol-1-ol hydrate (356 mg, 2.32 mmol), and N1-((ethylimino)methylene)-N3,N3-dimethylpropane-1,3-diamine hydrochloride (445 mg, 2.32 mmol) in DMF (3 mL). The reagents were stirred at ambient temperature for 72 hours. Material precipitated with the addition of water. The resulting solid was filtered, washed with water, and dried under high vacuum to afford the title compound as a white solid. ^{1}H NMR (400 MHz, DMSO-d_6) δ 9.30 (d, 1H), 9.20 (d, 1H), 8.10 (d, 1H), 7.98 (d, 1H), 7.89 (d, 1H), 7.65 – 7.55 (m, 2H), 7.20 (d, 1H), 6.64 (d, 1H), 3.64 (t, J = 4.7 Hz, 4H), 3.03 – 2.92 (m, 4H), 2.66 – 2.52 (m, 2H), 1.72 – 1.58 (m, 2H), 0.82 (t, J = 7.4, 0.6 Hz, 3H). ES/MS m/z 450.20 $(M+H)^+$.

The compounds listed below were prepared in a manner similar to that described above using appropriate intermediates and chemistry:

1-(5,8-difluoroquinolin-4-yl)-6-morpholino-2-propyl-1H-benzo[d]imidazole-4-carboxamide;

1-(5-chloro-8-fluoroquinolin-4-yl)-2-ethyl-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(8-chloroquinolin-4-yl)-2-(1-methylcyclopropyl)-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(8-chloroquinolin-4-yl)-2-isobutyl-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(7-fluoroquinolin-4-yl)-6-morpholino-2-propyl-1H-benzo[d]imidazole-4-carboxamide;

1-(8-chloroquinolin-4-yl)-2-(cyclopropylmethyl)-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(8-chloroquinolin-4-yl)-6-morpholino-2-(tetrahydrofuran-3-yl)-1H-benzo[d]imidazole-4-carboxamide;

6-morpholino-2-(pyridin-2-yl)-1-(quinolin-4-yl)-1H-benzo[d]imidazole-4-carboxamide;

1-(8-chloro-5-fluoroquinolin-4-yl)-6-morpholino-2-propyl-1H-benzo[d]imidazole-4-carboxamide;

1-(8-chloroquinolin-4-yl)-2-(1-methoxyethyl)-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(8-chloroquinolin-4-yl)-2-cyclobutyl-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(8-chloroquinolin-4-yl)-6-morpholino-2-(pyridin-3-yl)-1H-benzo[d]imidazole-4-carboxamide;

1-(8-chloroquinolin-4-yl)-2-isopropyl-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(8-chloroquinolin-4-yl)-6-morpholino-2-(pyridin-4-yl)-1H-benzo[d]imidazole-4-carboxamide;

1-(8-chloroquinolin-4-yl)-6-morpholino-2-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazole-4-carboxamide;

2-cyclopropyl-6-morpholino-1-(quinolin-4-yl)-1H-benzo[d]imidazole-4-carboxamide;

1-(7-fluoroquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(8-chloro-6-fluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

2-(tert-butyl)-1-(8-chloroquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

2-methyl-6-morpholino-1-(quinolin-4-yl)-1H-benzo[d]imidazole-4-carboxamide;

(S)-1-(5,8-difluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(5,8-difluoroquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(8-chloro-7-fluoroquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

6-morpholino-2-(oxetan-3-yl)-1-(quinolin-4-yl)-1H-benzo[d]imidazole-4-carboxamide;

1-(5-fluoro-8-methylquinolin-4-yl)-6-morpholino-2-propyl-1H-benzo[d]imidazole-4-carboxamide;

1-(8-chloro-6-fluoroquinolin-4-yl)-6-morpholino-2-propyl-1H-benzo[d]imidazole-4-carboxamide;

1-(8-chloro-7-fluoroquinolin-4-yl)-2-(cyclopropylmethyl)-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(8-chloro-7-fluoroquinolin-4-yl)-6-morpholino-2-propyl-1H-benzo[d]imidazole-4-carboxamide;

1-(8-chloro-7-fluoroquinolin-4-yl)-2-cyclopropyl-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(8-chloro-7-fluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(8-chloro-7-fluoroquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

6-morpholino-2-propyl-1-(quinolin-4-yl)-1H-benzo[d]imidazole-4-carboxamide;

1-(5,8-difluoroquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(7,8-difluoroquinolin-4-yl)-6-morpholino-2-propyl-1H-benzo[d]imidazole-4-carboxamide;

1-(8-chloroquinolin-4-yl)-2-cyclopropyl-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(8-fluoroquinolin-4-yl)-2-(2-methoxyethyl)-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(7,8-difluoroquinolin-4-yl)-6-morpholino-2-propyl-1H-benzo[d]imidazole-4-carboxamide;

1-(7-fluoroquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(8-chloroquinolin-4-yl)-2-(1-fluorocyclopropyl)-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(2-cyclopropyl-3-methylquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(2-ethyl-3-methylquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(8-chloro-2-(trifluoromethyl)quinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

2-methyl-6-morpholino-1-(2-phenylquinolin-4-yl)-1H-benzo[d]imidazole-4-carboxamide;

1-(3-ethyl-2-methylquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(7-fluoro-2-methylquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(8-fluoro-2,3-dimethylquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

2-methyl-1-(2-methyl-8-(trifluoromethyl)quinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(2-cyanoquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(3-cyclopropylquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(8-chloro-2-methylquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

2-methyl-1-(3-methylquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(2-ethyl-3-methylquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(3-ethyl-2-methylquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(8-chloro-2,3-dimethylquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(8-chloro-3-methylquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

2-methyl-1-(2-methylquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(2-ethyl-8-fluoro-3-methylquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(5-(difluoromethyl)quinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(5-chloroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(5-fluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(8-(difluoromethyl)quinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

2-methyl-1-(5-methylquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(7-fluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(8-chloro-2-(difluoromethyl)quinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(8-chloro-5-fluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(8-cyanoquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(5,8-dichloroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(5,8-difluoroquinolin-4-yl)-2-ethyl-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(5,8-difluoroquinolin-4-yl)-6-morpholino-2-(oxetan-3-yl)-1H-benzo[d]imidazole-4-carboxamide;

1-(5-chloro-8-fluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(5-fluoro-8-methylquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

2-methyl-6-morpholino-1-(2-(thiazol-4-yl)quinolin-4-yl)-1H-benzo[d]imidazole-4-carboxamide;

1-(3-chloroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(5,7-difluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(5-methylquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(8-chloroquinolin-4-yl)-2-ethyl-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(8-chloroquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(8-fluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(6,8-difluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(7,8-difluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(8-fluoroquinolin-4-yl)-6-morpholino-2-propyl-1H-benzo[d]imidazole-4-carboxamide;

2-cyclopropyl-1-(7,8-difluoroquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

2-cyclopropyl-1-(8-fluoroquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

2-ethyl-1-(8-fluoroquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(3,8-dichloroquinolin-4-yl)-2-ethyl-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(3,8-dichloroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(3-chloro-8-fluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(5-chloro-8-fluoroquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(6,8-difluoroquinolin-4-yl)-6-morpholino-2-propyl-1H-benzo[d]imidazole-4-carboxamide;

1-(8-fluoroquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(8-chloroquinolin-4-yl)-2-cyclopropyl-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(8-chloroquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

2-ethyl-6-morpholino-1-(quinolin-4-yl)-1H-benzo[d]imidazole-4-carboxamide;

2-methyl-1-(8-methylquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

2-methyl-6-morpholino-1-(8-(trifluoromethyl)quinolin-4-yl)-1H-benzo[d]imidazole-4-carboxamide;

2-methyl-6-morpholino-1-(quinolin-4-yl)-1H-benzo[d]imidazole-4-carboxamide;

1-(5,8-difluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(8-chloroquinolin-4-yl)-2-(2-methoxyethyl)-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(8-chloroquinolin-4-yl)-6-morpholino-2-(oxazol-5-yl)-1H-benzo[d]imidazole-4-carboxamide;

1-(8-chloroquinolin-4-yl)-6-morpholino-2-(pyridin-2-yl)-1H-benzo[d]imidazole-4-carboxamide;

1-(8-chloroquinolin-4-yl)-6-morpholino-2-(thiazol-5-yl)-1H-benzo[d]imidazole-4-carboxamide;

1-(8-chloroquinolin-4-yl)-6-morpholino-2-(oxetan-3-yl)-1H-benzo[d]imidazole-4-carboxamide;

1-(8-chloroquinolin-4-yl)-7-fluoro-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

(S)-1-(8-chloroquinolin-4-yl)-2-methyl-6-(3-methylmorpholino)-1H-benzo[d]imidazole-4-carboxamide;

(R)-1-(8-chloroquinolin-4-yl)-2-methyl-6-(3-methylmorpholino)-1H-benzo[d]imidazole-4-carboxamide;

1-(8-chloroquinolin-4-yl)-6-morpholino-2-(1H-pyrazol-5-yl)-1H-benzo[d]imidazole-4-carboxamide;

1-(8-chloroquinolin-4-yl)-2-(isothiazol-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(8-chloroquinolin-4-yl)-6-morpholino-2-(1H-pyrazol-4-yl)-1H-benzo[d]imidazole-4-carboxamide;

1-(8-chloroquinolin-4-yl)-5-fluoro-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

2-methyl-6-morpholino-1-(2-(1-trityl-1H-pyrazol-4-yl)quinolin-4-yl)-1H-benzo[d]imidazole-4-carboxamide;

tert-butyl 4-(4-(4-carbamoyl-2-methyl-6-morpholino-1H-benzo[d]imidazol-1-yl)quinolin-2-yl)piperazine-1-carboxylate;

tert-butyl 4-(4-(4-carbamoyl-2-methyl-6-morpholino-1H-benzo[d]imidazol-1-yl)quinolin-2-yl)piperazine-1-carboxylate;

1-(3-fluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(8-chloro-5-fluoroquinolin-4-yl)-7-fluoro-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(8-chloroquinolin-4-yl)-7-fluoro-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(8-cyano-3-methylquinolin-4-yl)-2-ethyl-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

1-(8-cyano-3-methylquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxamide;

tert-butyl 4-(4-(4-carbamoyl-6-morpholino-1H-benzo[d]imidazol-1-yl)quinolin-2-yl)piperazine-1-carboxylate;

6-morpholino-1-(2-(1-trityl-1H-pyrazol-4-yl)quinolin-4-yl)-1H-benzo[d]imidazole-4-carboxamide;

6-morpholino-1-(2-(1-trityl-1H-pyrazol-3-yl)quinolin-4-yl)-1H-benzo[d]imidazole-4-carboxamide;

4-(4-carbamoyl-2-ethyl-6-morpholino-1H-benzo[d]imidazol-1-yl)quinoline-3-carboxamide;

4-(4-carbamoyl-2-methyl-6-morpholino-1H-benzo[d]imidazol-1-yl)quinoline-3-carboxamide;

Step 5: 4-(1-(8-Chloroquinolin-4-yl)-2-propyl-4-(4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine 2,2,2-trifluoroacetate.



1-(8-chloroquinolin-4-yl)-6-morpholino-2-propyl-1H-benzo[d]imidazole-4-carboxamide (60 mg, 0.13 mmol) was suspended in 1,1-dimethoxy-N,N-dimethylmethanamine (2.3 mL, 17 mmol) and stirred at 120°C for 1 hour. The solution was cooled to ambient temperature and concentrated *in vacuuo*. The residue was dissolved in acetic acid (1 mL) and hydrazine hydrate (8 µL, 0.17 mmol) was added. The reaction mixture was stirred at

90°C for 1 hour, after which the reaction was cooled to ambient temperature. The resultant was purified by HPLC eluting with 5-95% water/ acetonitrile (0.1%v/v trifluoroacetic acid). The appropriate fractions were pooled and lyophilized to afford 4-(1-(8-chloroquinolin-4-yl)-2-propyl-4-(4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine 2,2,2-trifluoroacetate (Compound 1). ^{1}H NMR (400 MHz, DMSO-d6) δ 9.37 (d, J = 4.5 Hz, 1H), 8.68 (s, 1H), 8.16 - 8.10 (m, 2H), 7.79 (d, J = 1.6 Hz, 1H), 7.66 - 7.59 (m, 1H), 7.47 (d, J = 8.8 Hz, 1H), 6.68 (d, J = 2.2 Hz, 1H), 3.66 (t, J = 4.7 Hz, 4H), 3.09 - 3.02 (m, 4H), 2.88 - 2.80 (m, 2H), 1.62 - 1.45 (m, 2H), 0.78 (t, J = 7.4 Hz, 3H). ES/MS *m/z* 474.20 $(M+H)^+$.

The compounds listed in the table below were prepared in a manner similar to that described above using appropriate intermediates and chemistry:

Compound	Compound Name	MS	NMR
2	4-(1-(8-chloroquinolin-4-yl)-2-isobutyl-4-(5-methyl-4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	502.3	1H NMR (400 MHz, DMSO-d6) δ 9.36 (d, J = 4.5 Hz, 1H), 8.13 (dd, J = 7.6, 1.2 Hz, 1H), 8.10 (d, J = 4.5 Hz, 1H), 7.73 (d, J = 2.1 Hz, 1H), 7.63 (dd, J = 8.5, 7.5 Hz, 1H), 7.42 (d, J = 8.4 Hz, 1H), 6.64 (d, J = 2.2 Hz, 1H), 3.65 (t, J = 4.7 Hz, 4H), 3.04 (d, J = 3.8 Hz, 4H), 2.81 (s, 1H), 2.76 - 2.66 (m, 1H), 2.58 - 2.51 (m, 3H), 2.32 (s, 1H), 0.78 (d, J = 6.6 Hz, 3H), 0.73 (d, J = 6.6 Hz, 3H).
3	4-(1-(5,8-difluoroquinolin-4-yl)-4-(5-methyl-4H-1,2,4-triazol-3-yl)-2-propyl-1H-benzo[d]imidazol-6-yl)morpholine	490.33	1H NMR (400 MHz, DMSO-d6) δ 9.37 (dd, J = 4.5, 2.0 Hz, 1H), 8.17 (dd, J = 4.5, 1.5 Hz, 1H), 7.83 (td, J = 9.8, 3.6 Hz, 1H), 7.74 (t, J = 1.8 Hz, 1H), 7.57 - 7.48 (m, 1H), 6.81 (d, J = 2.2 Hz, 1H), 3.67 (q, J = 3.7, 2.2 Hz, 4H), 3.10 (d, J = 5.1 Hz, 4H), 2.90 (t, J = 8.1 Hz, 2H), 2.53 (d, J = 1.9 Hz, 3H), 1.57 (d, J = 8.3 Hz, 2H), 0.81 (td, J = 7.3, 2.4 Hz, 3H).
4	4-(1-(8-chloroquinolin-4-yl)-2-(1-methylcyclopropyl)-4-(4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	486.2	1H NMR (400 MHz, DMSO-d6) δ 9.36 (d, J = 4.5 Hz, 1H), 8.52 (s, 1H), 8.13 (d, J = 1.4 Hz, 1H), 8.12 - 8.11 (m, 1H), 7.70 (d, J = 2.3 Hz, 1H), 7.62 (dd, J = 8.5, 7.5 Hz, 1H), 7.41 (dd, J = 8.5, 1.2 Hz, 1H), 6.53 (d, J = 2.3 Hz, 1H), 3.64 (t, J = 4.8 Hz, 4H), 3.06 - 2.98 (m, 4H), 1.39 (ddd, J = 10.2, 6.3, 4.2 Hz, 1H), 1.26 (d, J = 5.1 Hz, 1H), 1.02 (s, 3H),

			0.69 (ddd, J = 8.9, 6.3, 4.1 Hz, 1H), 0.55 (ddd, J = 9.0, 6.3, 4.3 Hz, 1H).
5	4-(1-(5-chloro-8-fluoroquinolin-4-yl)-2-ethyl-4-(4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	478.22	1H NMR (400 MHz, DMSO-d6) δ 9.36 (d, J = 4.4 Hz, 1H), 8.69 (s, 1H), 8.17 (d, J = 4.4 Hz, 1H), 7.84 (d, J = 7.2 Hz, 2H), 7.78 (d, J = 2.3 Hz, 1H), 6.79 (d, J = 1.7 Hz, 1H), 3.68 (t, J = 4.8 Hz, 4H), 3.11 (t, J = 4.9 Hz, 4H), 2.87 (p, J = 7.6, 7.1 Hz, 2H), 1.18 (t, J = 7.5 Hz, 3H).
6	4-(2-(pyridin-2-yl)-1-(quinolin-4-yl)-4-(4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	475.19	1H NMR (400 MHz, DMSO-d6) δ 9.14 (dd, J = 4.6, 2.2 Hz, 1H), 8.88 (d, J = 7.9 Hz, 1H), 8.31 (s, 1H), 8.20 (d, J = 8.5 Hz, 1H), 7.95 - 7.88 (m, 2H), 7.82 - 7.74 (m, 3H), 7.49 - 7.43 (m, 1H), 7.23 (dd, J = 7.9, 4.9 Hz, 2H), 6.48 (s, 1H), 3.65 (t, J = 4.8 Hz, 4H), 3.04 (q, J = 4.5 Hz, 4H).
7	4-(1-(7-fluoroquinolin-4-yl)-2-propyl-4-(4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	458.4	1H NMR (400 MHz, DMSO-d6) δ 9.26 (dd, J = 4.7, 2.5 Hz, 1H), 8.70 (s, 1H), 8.10 - 8.04 (m, 1H), 7.98 (dd, J = 4.7, 2.5 Hz, 1H), 7.80 (t, J = 2.5 Hz, 1H), 7.68 - 7.55 (m, 2H), 6.62 (d, J = 2.4 Hz, 1H), 3.71 - 3.58 (m, 4H), 3.12 - 2.99 (m, 4H), 2.90 - 2.77 (m, 2H), 1.59 - 1.41 (m, 2H), 0.79 - 0.70 (m, 3H).
8	4-(1-(8-chloroquinolin-4-yl)-2-(cyclopropylmethyl)-4-(5-methyl-4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	500.3	1H NMR (400 MHz, DMSO-d6) δ 9.36 (d, J = 4.5 Hz, 1H), 8.16 - 8.11 (m, 2H), 7.76 (d, J = 2.2 Hz, 1H), 7.62 (dd, J = 8.5, 7.5 Hz, 1H), 7.45 (d, J = 8.4 Hz, 1H), 6.67 (d, J = 2.3 Hz, 1H), 3.65 (t, J = 4.8 Hz, 4H), 3.06 (s, 4H), 2.88 (dt, J = 15.2, 7.4 Hz, 2H), 2.53 (d, J = 5.9 Hz, 3H), 0.78 (s, 1H), 0.27 (dd, J = 9.6, 4.3 Hz, 2H), 0.08 (ddd, J = 17.4, 8.9, 4.4 Hz, 2H).
9	4-(1-(8-chloroquinolin-4-yl)-2-(tetrahydrofuran-3-yl)-4-(4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	502.37	1H NMR (400 MHz, DMSO-d6) δ 9.35 - 9.28 (m, 1H), 8.34 (s, 1H), 8.15 - 8.07 (m, 1H), 8.06 - 7.99 (m, 1H), 7.68 - 7.63 (m, 1H), 7.65 - 7.55 (m, 1H), 7.27 - 7.18 (m, 1H), 6.63 - 6.56 (m, 1H), 4.22 - 3.98 (m, 1H), 3.95 - 3.82 (m, 2H), 3.70 - 3.56 (m, 5H), 3.35 - 3.24 (m, 1H), 3.06 - 2.97 (m, 4H), 2.56 - 2.44 (m, 0.5H), 2.39 - 2.28 (m, 0.5H), 2.13 - 2.03 (m, 0.5H), 1.85 - 1.75 (m, 0.5H).

10	4-(1-(8-chloroquinolin-4-yl)-2-(pyridin-3-yl)-4-(4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	509.38	1H NMR (400 MHz, DMSO-d6) δ 9.29 (dd, J = 4.5, 1.7 Hz, 1H), 8.96 (d, J = 1.6 Hz, 1H), 8.55 (dd, J = 4.9, 1.6 Hz, 1H), 8.36 (s, 1H), 8.08 (dd, J = 7.5, 1.2 Hz, 1H), 8.03 (dd, J = 4.5, 1.6 Hz, 1H), 7.92 (dt, J = 8.1, 1.9 Hz, 1H), 7.77 (d, J = 2.2 Hz, 1H), 7.56 (ddd, J = 9.2, 7.6, 1.7 Hz, 1H), 7.40 - 7.32 (m, 2H), 6.66 (d, J = 2.2 Hz, 1H), 3.68 (t, J = 4.6 Hz, 4H), 3.14 - 3.02 (m, 4H).
11	4-(1-(8-chloro-5-fluoroquinolin-4-yl)-4-(5-methyl-4H-1,2,4-triazol-3-yl)-2-propyl-1H-benzo[d]imidazol-6-yl)morpholine	506.33	1H NMR (400 MHz, DMSO-d6) δ 9.44 (t, J = 4.2 Hz, 1H), 8.18 (dt, J = 8.5, 4.4 Hz, 2H), 7.75 (d, J = 2.5 Hz, 1H), 7.54 (ddd, J = 12.3, 8.5, 3.9 Hz, 1H), 6.85 - 6.80 (m, 1H), 3.67 (q, J = 4.2 Hz, 4H), 3.14 - 3.06 (m, 4H), 2.91 (s, 2H), 2.55 (d, J = 4.0 Hz, 3H), 1.57 (dd, J = 7.9, 3.8 Hz, 2H), 0.81 (td, J = 7.3, 3.6 Hz, 3H).
12	4-(1-(8-chloroquinolin-4-yl)-2-(1-methoxyethyl)-4-(4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	490.2	1H NMR (400 MHz, DMSO-d6) δ 9.33 - 9.27 (m, 1H), 8.43 - 8.30 (m, 1H), 8.13 - 8.05 (m, 1H), 7.99 - 7.95 (m, 1H), 7.68 - 7.63 (m, 1H), 7.61 - 7.54 (m, 1H), 7.26 - 7.18 (m, 1H), 6.61 - 6.48 (m, 1H), 4.67 - 4.35 (m, 1H), 3.70 - 3.61 (m, 4H), 3.07 - 2.96 (m, 4H), 2.95 - 2.78 (m, 3H), 1.57 - 1.47 (m, 3H).
13	4-(1-(8-chloroquinolin-4-yl)-2-cyclobutyl-4-(5-methyl-4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	500.37	1H NMR (400 MHz, DMSO-d6) δ 9.32 (d, J = 8.3 Hz, 1H), 8.12 (d, J = 4.7 Hz, 1H), 7.96 (d, J = 4.4 Hz, 1H), 7.71 - 7.57 (m, 2H), 7.27 (d, J = 7.6 Hz, 1H), 6.64 (s, 1H), 3.65 (s, 4H), 3.48 (s, 1H), 3.04 (s, 4H), 2.65 (d, J = 8.2 Hz, 2H), 2.50 (s, 3H), 2.08 (s, 2H), 1.82 (s, 3H).
14	4-(1-(8-chloroquinolin-4-yl)-2-isopropyl-4-(5-methyl-4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	488.2	1H NMR (400 MHz, DMSO-d6) δ 9.33 (dd, J = 4.5, 1.9 Hz, 1H), 8.14 - 8.09 (m, 1H), 8.09 - 8.04 (m, 1H), 7.65 - 7.58 (m, 2H), 7.27 (d, J = 8.5 Hz, 1H), 6.58 (s, 1H), 3.65 (t, J = 4.5 Hz, 4H), 3.01 (s, 4H), 2.67 (s, 1H), 2.47 (d, J = 1.8 Hz, 3H), 1.31 (dd, J = 6.8, 1.8 Hz, 3H), 1.19 (dd, J = 6.9, 1.8 Hz, 3H).
15	4-(1-(8-chloroquinolin-4-yl)-2-(pyridin-4-yl)-4-(4H-1,2,4-triazol-3-yl)-1H-	509.26	1H NMR (400 MHz, DMSO-d6) δ 9.30 (d, J = 4.5 Hz, 1H), 8.50 (d, J = 5.9 Hz, 2H), 8.19 (s, 1H), 8.08 (d, J = 7.6 Hz, 1H), 8.02 (d, J = 4.6 Hz, 1H), 7.77 (s,

	benzo[d]imidazol-6-yl)morpholine		1H), 7.62 (s, 2H), 7.59 - 7.52 (m, 1H), 7.31 (d, J = 8.5 Hz, 1H), 6.60 (s, 1H), 3.67 (t, J = 4.6 Hz, 4H), 3.13 - 3.01 (m, 4H).
16	4-(1-(8-chloroquinolin-4-yl)-4-(5-methyl-4H-1,2,4-triazol-3-yl)-2-(tetrahydrofuran-2-yl)-1H-benzo[d]imidazol-6-yl)morpholine	516.4	1H NMR (400 MHz, DMSO-d6) δ 9.29 (dd, J = 6.4, 4.5 Hz, 1H), 8.08 (ddd, J = 7.5, 2.6, 1.2 Hz, 1H), 7.98 (d, J = 4.5 Hz, 1H), 7.64 (dd, J = 9.0, 2.2 Hz, 1H), 7.58 (ddd, J = 8.5, 7.4, 1.3 Hz, 1H), 7.23 (td, J = 8.4, 7.9, 1.2 Hz, 1H), 6.52 (d, J = 2.3 Hz, 1H), 5.07 (dd, J = 7.6, 5.8 Hz, 1H), 4.92 (t, J = 7.1 Hz, 1H), 3.65 (q, J = 4.3 Hz, 4H), 3.59 - 3.29 (m, 3H), 3.02 (dd, J = 10.6, 3.9 Hz, 4H), 2.72 (ddd, J = 22.0, 11.7, 5.6 Hz, 2H), 2.20 - 2.08 (m, 1H), 1.99 - 1.72 (m, 2H).
17	4-(2-cyclopropyl-1-(quinolin-4-yl)-4-(4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	438.26	1H NMR (400 MHz, DMSO-d6) δ 9.24 (d, J = 4.5 Hz, 1H), 8.39 (s, 1H), 8.30 - 8.26 (m, 1H), 7.96 - 7.90 (m, 2H), 7.71 - 7.64 (m, 2H), 7.45 - 7.40 (m, 1H), 6.61 (d, J = 2.2 Hz, 1H), 3.66 (t, J = 4.7 Hz, 4H), 3.03 (q, J = 4.0 Hz, 4H), 1.63 (td, J = 8.4, 4.3 Hz, 1H), 1.39 (dt, J = 23.4, 4.8 Hz, 2H), 1.00 - 0.81 (m, 2H).
18	4-(1-(8-chloro-6-fluoroquinolin-4-yl)-2-methyl-4-(5-methyl-4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	478.3	1H NMR (400 MHz, DMSO-d6) δ 9.34 (d, J = 4.5 Hz, 1H), 8.30 - 8.24 (m, 1H), 8.13 (d, J = 4.5 Hz, 1H), 7.82 - 7.78 (m, 1H), 7.59 (d, J = 9.1 Hz, 1H), 6.75 - 6.72 (m, 1H), 3.72 - 3.63 (m, 4H), 3.14 - 3.04 (m, 4H), 2.60 (s, 3H), 2.54 (dd, J = 1.5, 0.8 Hz, 3H).
19	4-(2-methyl-4-(5-methyl-4H-1,2,4-triazol-3-yl)-1-(quinolin-4-yl)-1H-benzo[d]imidazol-6-yl)morpholine	426.1	1H NMR (400 MHz, DMSO-d6) δ 9.27 (d, J = 4.5 Hz, 1H), 8.31 (d, J = 8.5 Hz, 1H), 7.99 (d, J = 4.6 Hz, 1H), 7.97 - 7.93 (m, 1H), 7.81 (d, J = 2.2 Hz, 1H), 7.71 - 7.66 (m, 1H), 7.60 (d, J = 8.4 Hz, 1H), 6.65 - 6.62 (m, 1H), 3.65 (t, J = 4.7 Hz, 4H), 3.11 - 2.99 (m, 4H), 2.59 (s, 3H), 2.55 (s, 3H).
20	4-(2-(tert-butyl)-1-(8-chloroquinolin-4-yl)-4-(4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	488.2	1H NMR (400 MHz, DMSO-d6) δ 9.32 (d, J = 4.5 Hz, 1H), 8.40 - 8.34 (m, 1H), 8.11 - 8.06 (m, 2H), 7.62 (d, J = 2.3 Hz, 1H), 7.58 (dd, J = 8.5, 7.5 Hz, 1H), 7.12 (dd, J = 8.5, 1.3 Hz, 1H), 6.33 (d, J = 2.3 Hz, 1H), 3.63 (t, J = 4.8 Hz, 4H), 3.00 -

			2.94 (m, 4H), 1.24 (s, 9H).
21	4-(1-(7-fluoroquinolin-4-yl)-4-(5-methyl-4H-1,2,4-triazol-3-yl)-2-propyl-1H-benzo[d]imidazol-6-yl)morpholine	472.3	1H NMR (400 MHz, DMSO-d6) δ 9.29 (dd, J = 4.5, 2.0 Hz, 1H), 8.09 (dt, J = 10.1, 2.3 Hz, 1H), 8.02 (dd, J = 4.6, 2.0 Hz, 1H), 7.80 (d, J = 2.2 Hz, 1H), 7.72 - 7.58 (m, 2H), 6.63 (t, J = 2.1 Hz, 1H), 3.66 (q, J = 3.3, 1.9 Hz, 4H), 3.14 - 3.03 (m, 4H), 2.96 - 2.84 (m, 2H), 2.55 (dt, J = 2.0, 1.1 Hz, 3H), 1.50 (dd, J = 18.3, 8.3 Hz, 2H), 0.76 (td, J = 7.4, 2.2 Hz, 3H).
22	4-(1-(7-fluoroquinolin-4-yl)-4-(5-methyl-4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	430.34	1H NMR (400 MHz, DMSO-d6) δ 11.27 (s, 0.5H), 9.31 - 9.30 (m, 0.5H), 9.22 (dd, J = 4.6, 1.6 Hz, 0.5H), 8.93 (dd, J = 9.5, 5.5 Hz, 0.5H), 8.44 (d, J = 7.0 Hz, 0.5H), 8.07 (d, J = 2.5 Hz, 0.5H), 8.04 (d, J = 2.5 Hz, 0.5H), 7.95 - 7.92 (m, 0.5H), 7.87 (d, J = 8.7 Hz, 0.5H), 7.83 (d, J = 2.8 Hz, 0.5H), 7.78 (dt, J = 7.4, 3.4 Hz, 1.5H), 7.76 - 7.72 (m, 1H), 7.65 (td, J = 8.9, 2.5 Hz, 0.5H), 6.85 (d, J = 2.1 Hz, 0.5H), 6.46 (dd, J = 7.4, 1.4 Hz, 0.5H), 3.80 (d, J = 5.0 Hz, 2H), 3.69 (t, J = 4.9 Hz, 2H), 3.44 (d, J = 5.2 Hz, 2H), 3.11 (s, 2H), 2.59 (t, J = 1.0 Hz, 1.5H), 2.54 (d, J = 0.7 Hz, 1.5H).
23	4-(1-(8-chloroquinolin-4-yl)-4-(5-methyl-4H-1,2,4-triazol-3-yl)-2-(pyridin-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	523.4	1H NMR (400 MHz, DMSO-d6) δ 9.28 (d, J = 4.5 Hz, 1H), 8.92 (s, 1H), 8.54 (d, J = 4.9 Hz, 1H), 8.07 (d, J = 7.5 Hz, 1H), 8.02 (d, J = 4.5 Hz, 1H), 7.89 (d, J = 8.0 Hz, 1H), 7.72 (d, J = 2.2 Hz, 1H), 7.60 - 7.53 (m, 1H), 7.42 - 7.31 (m, 2H), 6.66 (s, 1H), 3.68 (s, 4H), 3.08 (s, 4H), 2.50 (s, 3H).
24	4-(2-(oxetan-3-yl)-1-(quinolin-4-yl)-4-(4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	454.23	1H NMR (400 MHz, DMSO-d6) δ 9.19 (d, J = 4.5 Hz, 1H), 8.40 (s, 1H), 8.29 - 8.24 (m, 1H), 7.92 (ddd, J = 8.5, 6.9, 1.4 Hz, 1H), 7.79 (d, J = 4.5 Hz, 1H), 7.71 (d, J = 2.2 Hz, 1H), 7.64 (ddd, J = 8.1, 6.9, 1.2 Hz, 1H), 7.28 - 7.24 (m, 1H), 6.58 (d, J = 2.3 Hz, 1H), 5.14 (dd, J = 6.9, 5.6 Hz, 1H), 5.07 (dd, J = 6.9, 5.6 Hz, 1H), 4.64 (dd, J = 8.7, 5.5 Hz, 1H), 4.46 (dd, J = 8.6, 5.5 Hz, 1H), 4.25 - 4.13 (m, 1H), 3.66 (t, J = 4.7 Hz, 4H),

			3.03 (q, J = 4.3 Hz, 4H).
25	4-(1-(8-chloroquinolin-4-yl)-4-(5-methyl-4H-1,2,4-triazol-3-yl)-2-(pyridin-4-yl)-1H-benzo[d]imidazol-6-yl)morpholine	523.25	1H NMR (400 MHz, DMSO-d6) δ 9.32 (d, J = 4.5 Hz, 1H), 8.64 (d, J = 6.5 Hz, 2H), 8.10 (d, J = 3.4 Hz, 1H), 8.04 (d, J = 4.6 Hz, 1H), 7.84 (t, J = 4.9 Hz, 2H), 7.81 - 7.76 (m, 1H), 7.57 (s, 1H), 7.35 (d, J = 1.5 Hz, 1H), 6.62 (s, 1H), 3.68 (s, 4H), 3.11 (s, 4H) 2.50 (s, 3H).
26	4-[3-(3,8-dichloroquinolin-4-yl)-2-ethyl-7-(5-methyl-4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	508.2	1H NMR (400 MHz, DMSO-d6) δ 9.40 (s, 1H), 8.13 (dd, J = 7.5, 1.2 Hz, 1H), 7.70 – 7.57 (m, 2H), 7.29 (d, J = 8.4 Hz, 1H), 6.73 (d, J = 2.2 Hz, 1H), 3.64 (t, J = 4.8 Hz, 4H), 3.03 (t, J = 4.9 Hz, 4H), 2.73 – 2.50 (m, 2H), 1.15 (t, J = 7.5 Hz, 3H).
27	4-[3-(3-chloro-8-fluoroquinolin-4-yl)-2-methyl-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	464.2	1H NMR (400 MHz, DMSO-d6) δ 9.36 (s, 1H), 8.59 (s, 1H), 7.80 (ddd, J = 10.7, 7.8, 1.2 Hz, 1H), 7.77 – 7.60 (m, 1H), 7.34 – 7.18 (m, 1H), 6.80 (d, J = 2.2 Hz, 1H), 3.65 (dd, J = 5.8, 3.9 Hz, 4H), 3.07 (dd, J = 6.2, 3.7 Hz, 4H), 2.48 (s, 3H).
28	4-(1-(5,8-difluoroquinolin-4-yl)-4-(4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	434.2	1H NMR (400 MHz, DMSO-d6) δ 9.29 (d, J = 4.5 Hz, 1H), 9.13 (s, 1H), 8.51 (s, 1H), 8.06 (s, 1H), 7.82 (dt, J = 9.5, 4.6 Hz, 1H), 7.78 (d, J = 2.2 Hz, 1H), 7.52 (ddd, J = 12.4, 8.9, 3.9 Hz, 1H), 6.98 (d, J = 2.0 Hz, 1H), 3.70 (t, J = 4.6 Hz, 4H), 3.15 - 3.11 (m, 4H).
29	4-(1-(8-chloro-7-fluoroquinolin-4-yl)-4-(4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	450.2	1H NMR (400 MHz, DMSO-d6) δ 9.33 (dd, J = 4.6, 0.6 Hz, 1H), 9.03 (s, 1H), 8.45 (s, 1H), 8.02 (d, J = 4.6 Hz, 1H), 7.83 - 7.76 (m, 2H), 7.68 (dd, J = 9.4, 5.7 Hz, 1H), 6.88 (d, J = 2.2 Hz, 1H), 3.69 (t, J = 4.8 Hz, 4H), 3.10 (s, 4H).
30	4-(1-(8-chloroquinolin-4-yl)-2-cyclobutyl-4-(4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	486.27	1H NMR (400 MHz, DMSO-d6) δ 9.31 (d, J = 4.5 Hz, 1H), 8.47 (s, 1H), 8.11 (dd, J = 7.5, 1.2 Hz, 1H), 7.96 (d, J = 4.5 Hz, 1H), 7.68 (d, J = 2.2 Hz, 1H), 7.63 - 7.56 (m, 1H), 7.27 (d, J = 8.5 Hz, 1H), 6.63 (d, J = 2.3 Hz, 1H), 3.69 - 3.58 (m, 4H), 3.53 - 3.36 (m, 2H), 3.08 - 2.96 (m, 4H), 2.12 - 2.01 (m, 1H), 1.90 - 1.67 (m, 4H).

31	4-(1-(8-chloro-7-fluoroquinolin-4-yl)-2-(cyclopropylmethyl)-4-(4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	504.2	1H NMR (400 MHz, DMSO-d6) δ 9.38 (d, J = 4.5 Hz, 1H), 8.57 (s, 1H), 8.08 (d, J = 4.6 Hz, 1H), 7.79 - 7.71 (m, 2H), 7.52 (s, 1H), 6.66 (d, 1H), 3.66 (t, J = 4.8 Hz, 4H), 3.09 - 3.02 (m, 4H), 2.91 - 2.74 (m, 2H), 0.92 - 0.76 (m, 1H), 0.35 - 0.23 (m, 1H), 0.19 - 0.11 (m, 1H), 0.10 - 0.02 (m, 1H), -0.12 - -0.24 (m, 1H).
32	4-(1-(8-chloroquinolin-4-yl)-2-(cyclopropylmethyl)-4-(4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	486.2	1H NMR (400 MHz, DMSO-d6) δ 9.36 (d, J = 4.5 Hz, 1H), 8.68 (s, 1H), 8.16 - 8.10 (m, 2H), 7.80 (d, J = 2.2 Hz, 1H), 7.67 - 7.58 (m, 1H), 7.45 (d, J = 8.5 Hz, 1H), 6.69 (d, J = 2.2 Hz, 1H), 3.66 (t, J = 4.7 Hz, 4H), 3.10 - 3.04 (m, 4H), 2.96 - 2.78 (m, 2H), 0.87 - 0.74 (m, 1H), 0.34 - 0.22 (m, 1H), 0.18 - 0.01 (m, 2H), -0.14 - -0.25 (m, 1H).
33	4-(1-(8-chloro-6-fluoroquinolin-4-yl)-2-propyl-4-(4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	492.2	1H NMR (400 MHz, DMSO-d6) δ 9.31 (d, J = 4.5 Hz, 1H), 8.64 (s, 1H), 8.27 – 8.19 (m, 1H), 8.15 – 8.09 (m, 1H), 7.79 – 7.74 (m, 1H), 7.39 (s, 1H), 6.70 – 6.65 (m, 1H), 3.65 (t, J = 4.8 Hz, 4H), 3.09 – 3.01 (m, 4H), 2.93 – 2.72 (m, 2H), 1.64 – 1.47 (m, 2H), 0.77 (t, J = 7.3 Hz, 3H).
34	4-(1-(8-chloro-7-fluoroquinolin-4-yl)-2-propyl-4-(4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	492.2	1H NMR (400 MHz, DMSO-d6) δ 9.39 (d, J = 4.6 Hz, 1H), 8.60 (s, 1H), 8.08 (d, J = 4.5 Hz, 1H), 7.80 - 7.74 (m, 2H), 7.58 - 7.52 (m, 1H), 6.66 (d, J = 2.3 Hz, 1H), 3.66 (t, J = 4.8 Hz, 4H), 3.05 (dd, J = 6.4, 3.8 Hz, 4H), 2.81 (t, J = 7.7 Hz, 2H), 1.57 (dq, J = 13.9, 7.0 Hz, 2H), 0.79 (t, J = 7.4 Hz, 3H).
35	4-(1-(8-chloro-6-fluoroquinolin-4-yl)-2-methyl-4-(4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	464.24	1H NMR (400 MHz, DMSO-d6) δ 9.34 (d, J = 4.5 Hz, 1H), 8.80 (s, 1H), 8.27 (ddd, J = 8.5, 2.7, 0.8 Hz, 1H), 8.13 (d, J = 4.5 Hz, 1H), 7.84 (d, J = 2.2 Hz, 1H), 7.58 (d, J = 9.1 Hz, 1H), 6.76 (d, J = 2.2 Hz, 1H), 3.67 (t, J = 4.8 Hz, 4H), 3.14 - 3.07 (m, 4H), 2.60 (s, 3H).
36	4-(1-(8-chloroquinolin-4-yl)-2-isopropyl-4-(4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	474.2	1H NMR (400 MHz, DMSO-d6) δ 9.32 (dd, J = 4.5, 0.8 Hz, 1H), 8.33 (s, 1H), 8.11 (dd, J = 7.5, 1.1 Hz, 1H), 8.04 (d, J = 4.5 Hz, 1H), 7.64 (d, J = 2.7 Hz, 1H), 7.60 (d, J = 8.0 Hz, 1H), 7.23 (d, J = 8.4 Hz, 1H), 6.58 (s, 1H), 3.65 (t, J = 4.7 Hz,

			4H), 3.01 (s, 4H), 2.85 - 2.78 (m, 1H), 1.33 (d, J = 6.8 Hz, 3H), 1.19 (d, J = 6.8 Hz, 3H).
37	4-(1-(5-fluoro-8-methylquinolin-4-yl)-2-propyl-4-(4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	472.25	1H NMR (400 MHz, DMSO-d6) δ 9.34 (d, J = 4.5 Hz, 1H), 8.72 (s, 1H), 8.08 (d, J = 4.5 Hz, 1H), 7.84 - 7.77 (m, 2H), 7.42 (dd, J = 12.5, 8.1 Hz, 1H), 6.76 (d, J = 2.3 Hz, 1H), 3.67 (t, J = 4.8 Hz, 4H), 3.10 (t, J = 4.9 Hz, 4H), 2.88 (q, J = 6.8 Hz, 2H), 2.82 (s, 3H), 1.55 (d, J = 8.2 Hz, 2H), 0.80 (t, J = 7.3 Hz, 3H).
38	4-(1-(8-chloro-7-fluoroquinolin-4-yl)-2-cyclopropyl-4-(4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	490.28	1H NMR (400 MHz, DMSO-d6) δ 9.36 (dd, J = 4.6, 3.3 Hz, 1H), 8.31 (s, 1H), 8.02 (d, J = 4.6 Hz, 1H), 7.79 - 7.72 (m, 1H), 7.63 (d, J = 2.3 Hz, 1H), 7.46 (dd, J = 9.4, 5.6 Hz, 1H), 6.66 (d, J = 2.2 Hz, 1H), 3.69 - 3.64 (m, 4H), 3.03 (dd, J = 6.2, 3.6 Hz, 4H), 1.64 (tt, J = 8.5, 4.8 Hz, 1H), 1.48 - 1.30 (m, 2H), 1.00 - 0.80 (m, 2H).
39	4-(1-(8-chloro-7-fluoroquinolin-4-yl)-2-methyl-4-(4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	464.2	1H NMR (400 MHz, DMSO-d6) δ 9.41 (t, J = 4.2 Hz, 1H), 8.73 (s, 1H), 8.09 (t, J = 4.2 Hz, 1H), 7.84 - 7.77 (m, 2H), 7.70 (s, 1H), 6.73 (d, J = 2.4 Hz, 1H), 3.67 (d, J = 4.6 Hz, 4H), 3.08 (s, 4H), 2.58 (d, J = 3.6 Hz, 3H).
40	4-(1-(8-chloro-7-fluoroquinolin-4-yl)-4-(5-methyl-4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	464.2	1H NMR (400 MHz, DMSO-d6) δ 9.33 (d, J = 4.6 Hz, 1H), 9.05 (s, 1H), 8.02 (d, J = 4.6 Hz, 1H), 7.80 (t, J = 9.1 Hz, 1H), 7.74 (d, J = 2.1 Hz, 1H), 7.68 (dd, J = 9.4, 5.6 Hz, 1H), 6.86 (d, J = 2.3 Hz, 1H), 3.69 (t, J = 4.8 Hz, 4H), 3.09 (s, 4H), 2.48 (s, 3H).
41	4-(2-propyl-1-(quinolin-4-yl)-4-(4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	440.3	1H NMR (400 MHz, DMSO-d6) δ 9.25 (d, J = 4.5 Hz, 1H), 8.64 (s, 1H), 8.30 (ddd, J = 8.5, 1.2, 0.6 Hz, 1H), 7.99 (d, J = 4.5 Hz, 1H), 7.95 (ddd, J = 8.5, 6.9, 1.4 Hz, 1H), 7.79 (d, J = 2.2 Hz, 1H), 7.67 (ddd, J = 8.2, 6.9, 1.2 Hz, 1H), 7.46 (d, J = 8.3 Hz, 1H), 6.59 (d, J = 2.3 Hz, 1H), 3.66 (t, J = 4.8 Hz, 4H), 3.05 (q, J = 4.3 Hz, 4H), 2.81 (tq, J = 14.9, 7.4 Hz, 2H), 1.55 (dt, J = 16.7, 7.5 Hz, 2H), 0.77 (t, J = 7.4 Hz, 3H).

42	4-(1-(8-fluoroquinolin-4-yl)-2-(2-methoxyethyl)-4-(4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	474.2	1H NMR (400 MHz, DMSO-d6) δ 9.28 (d, J = 4.5 Hz, 1H), 8.58 (s, 1H), 8.03 (d, J = 4.5 Hz, 1H), 7.82 - 7.72 (m, 2H), 7.64 (td, J = 8.2, 5.0 Hz, 1H), 7.20 (d, J = 8.5 Hz, 1H), 6.64 (d, J = 2.3 Hz, 1H), 3.66 (t, J = 4.8 Hz, 4H), 3.57 (ddd, J = 16.0, 10.4, 6.4 Hz, 2H), 3.09 (d, J = 5.3 Hz, 2H), 3.05 (q, J = 4.4 Hz, 4H), 2.98 (s, 3H).
43	4-(1-(5-fluoro-8-methylquinolin-4-yl)-4-(5-methyl-4H-1,2,4-triazol-3-yl)-2-propyl-1H-benzo[d]imidazol-6-yl)morpholine	486.31	1H NMR (400 MHz, DMSO-d6) δ 9.35 (dd, J = 4.4, 0.9 Hz, 1H), 8.11 (dd, J = 4.5, 0.9 Hz, 1H), 7.84 - 7.76 (m, 2H), 7.46 - 7.39 (m, 1H), 6.76 (dd, J = 2.3, 0.9 Hz, 1H), 3.66 (t, J = 4.8 Hz, 4H), 3.09 (t, J = 5.0 Hz, 4H), 2.92 (q, J = 8.1 Hz, 2H), 2.85 - 2.79 (m, 3H), 2.55 (d, J = 0.9 Hz, 3H), 1.52 (dt, J = 13.7, 6.9 Hz, 2H), 0.85 - 0.75 (m, 3H).
44	4-(1-(5,8-difluoroquinolin-4-yl)-4-(5-methyl-4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	448.2	1H NMR (400 MHz, DMSO-d6) δ 9.27 (d, J = 4.7 Hz, 1H), 8.05 (d, J = 5.4 Hz, 1H), 7.85 - 7.77 (m, 2H), 7.71 (d, J = 2.6 Hz, 1H), 7.56 - 7.46 (m, 1H), 6.95 (d, J = 2.8 Hz, 1H), 3.72 - 3.68 (m, 4H), 3.11 (s, 4H), 2.47 (s, 3H).
45	4-(1-(5,8-difluoroquinolin-4-yl)-2-propyl-4-(4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	476.3	1H NMR (400 MHz, DMSO-d6) δ 9.37 (t, J = 4.0 Hz, 1H), 8.70 (s, 1H), 8.17 (t, J = 4.0 Hz, 1H), 7.88 - 7.77 (m, 2H), 7.58 - 7.48 (m, 1H), 6.85 - 6.82 (m, 1H), 3.73 - 3.63 (m, 4H), 3.10 (d, J = 3.9 Hz, 4H), 2.90 (s, 2H), 1.64 - 1.52 (m, 2H), 0.82 (td, J = 7.3, 3.4 Hz, 3H).
46	4-(1-(8-chloroquinolin-4-yl)-4-(5-methyl-4H-1,2,4-triazol-3-yl)-2-propyl-1H-benzo[d]imidazol-6-yl)morpholine	488.2	1H NMR (400 MHz, DMSO-d6) δ 9.37 (dd, J = 4.6, 0.8 Hz, 1H), 8.16 - 8.11 (m, 2H), 7.77 (d, J = 2.4 Hz, 1H), 7.63 (ddd, J = 8.3, 7.4, 0.7 Hz, 1H), 7.49 (d, J = 8.4 Hz, 1H), 6.69 - 6.64 (m, 1H), 3.65 (t, J = 4.8 Hz, 4H), 3.05 (d, J = 3.0 Hz, 4H), 2.93 - 2.81 (m, 2H), 2.54 (s, 3H), 1.60 - 1.43 (m, 2H), 0.80 - 0.73 (m, 3H).
47	4-(1-(8-chloroquinolin-4-yl)-2-cyclopropyl-4-(5-methyl-4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	486.2	1H NMR (400 MHz, DMSO-d6) δ 9.34 (dd, J = 7.9, 4.5 Hz, 1H), 8.13 (s, 1H), 8.04 (s, 1H), 7.69 - 7.57 (m, 2H), 7.37 (d, J = 9.0 Hz, 1H), 6.67 (s, 1H), 3.67 (d, J = 7.7 Hz, 4H), 3.04 (s, 4H), 2.47 (s, 3H), 1.66 (s, 1H), 1.37 (d, J = 33.2 Hz,

			2H), 0.91 (d, J = 42.9 Hz, 2H).
48	4-(1-(8-chloro-5-fluoroquinolin-4-yl)-2-propyl-4-(4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	492.2	1H NMR (400 MHz, DMSO-d6) δ 9.42 (d, J = 4.5 Hz, 1H), 8.63 (s, 1H), 8.15 (td, J = 5.5, 3.8 Hz, 2H), 7.75 (s, 1H), 7.53 (dd, J = 11.9, 8.5 Hz, 1H), 6.82 (d, J = 2.2 Hz, 1H), 3.67 (t, J = 4.9 Hz, 4H), 3.09 (t, J = 4.9 Hz, 4H), 2.84 (d, J = 10.0 Hz, 2H), 1.64 - 1.53 (m, 2H), 0.81 (t, J = 7.3 Hz, 3H).
49	4-(1-(7,8-difluoroquinolin-4-yl)-2-propyl-4-(4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	476.2	1H NMR (400 MHz, DMSO-d6) δ 9.33 (d, J = 4.5 Hz, 1H), 8.62 (s, 1H), 8.08 (d, J = 4.5 Hz, 1H), 7.85 - 7.73 (m, 2H), 7.44 - 7.36 (m, 1H), 6.65 (d, J = 2.3 Hz, 1H), 3.66 (t, J = 4.8 Hz, 4H), 3.10 - 3.02 (m, 4H), 2.83 (t, J = 7.7 Hz, 2H), 1.65 - 1.48 (m, 2H), 0.79 (t, J = 7.4 Hz, 3H).
50	4-(1-(8-chloroquinolin-4-yl)-2-isobutyl-4-(4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	488.2	1H NMR (400 MHz, DMSO-d6) δ 9.35 (d, J = 4.5 Hz, 1H), 8.55 (s, 1H), 8.13 (dd, J = 7.5, 1.3 Hz, 1H), 8.07 (d, J = 4.5 Hz, 1H), 7.74 (s, 1H), 7.62 (dd, J = 8.5, 7.5 Hz, 1H), 7.38 (d, J = 8.0 Hz, 1H), 6.64 (s, 1H), 3.65 (t, J = 4.7 Hz, 4H), 3.04 (d, J = 5.7 Hz, 4H), 2.67 (s, 2H), 2.54 (s, 1H), 0.79 (d, J = 6.6 Hz, 3H), 0.75 (d, J = 6.6 Hz, 3H).
51	4-(1-(5,8-difluoroquinolin-4-yl)-2-methyl-4-(5-methyl-4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	462.2	1H NMR (400 MHz, DMSO-d6) δ 9.38 (d, J = 4.5 Hz, 1H), 8.14 (d, J = 4.5 Hz, 1H), 7.90 - 7.74 (m, 2H), 7.62 - 7.49 (m, 1H), 6.87 - 6.83 (m, 1H), 3.70 - 3.64 (m, 4H), 3.11 (t, J = 4.9 Hz, 4H), 2.63 (s, 3H), 2.55 - 2.53 (m, 3H).
52	4-(1-(8-chloro-7-fluoroquinolin-4-yl)-2-methyl-4-(5-methyl-4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	478.2	1H NMR (400 MHz, DMSO-d6) δ 9.40 (d, J = 4.5 Hz, 1H), 8.08 (d, J = 4.6 Hz, 1H), 7.83 - 7.75 (m, 2H), 7.70 (d, J = 6.7 Hz, 1H), 6.70 (d, J = 2.2 Hz, 1H), 3.65 (d, J = 4.8 Hz, 4H), 3.06 (s, 4H), 2.58 (s, 3H), 2.53 (s, 3H).
53	4-(1-(7-fluoroquinolin-4-yl)-4-(4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	416.32	1H NMR (400 MHz, DMSO-d6) δ 9.22 (dd, J = 4.6, 1.6 Hz, 1H), 9.17 (s, 1H), 8.53 (s, 1H), 8.05 (dd, J = 10.1, 2.4 Hz, 1H), 7.92 (dd, J = 4.6, 1.6 Hz, 1H), 7.82 (d, J = 2.2 Hz, 1H), 7.74 (dd, J = 9.3, 6.0 Hz, 1H), 7.69 - 7.62 (m, 1H), 6.85 (s, 1H), 3.70 (t, J = 4.9 Hz, 4H), 3.11 (s,

			4H).
54	4-(1-(8-chloroquinolin-4-yl)-2-(1-fluorocyclopropyl)-4-(4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	490.2	1H NMR (400 MHz, DMSO-d6) δ 9.30 (d, J = 4.5 Hz, 1H), 8.36 (s, 1H), 8.09 (dd, J = 7.5, 1.2 Hz, 1H), 8.04 (d, J = 4.5 Hz, 1H), 7.70 (d, J = 2.3 Hz, 1H), 7.60 (dd, J = 8.5, 7.5 Hz, 1H), 7.32 (dd, J = 8.5, 1.3 Hz, 1H), 6.61 (d, J = 2.3 Hz, 1H), 3.66 (t, J = 4.7 Hz, 4H), 3.04 (td, J = 4.3, 2.2 Hz, 4H), 1.70 (dddd, J = 14.5, 11.2, 8.5, 3.3 Hz, 2H), 1.43 - 1.17 (m, 2H).
55	4-[3-(2-ethyl-3-methylquinolin-4-yl)-2-methyl-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	454.2	1H NMR (400 MHz, DMSO-d6) δ 8.77 (s, 1H), 8.14 (dt, J = 8.2, 0.9 Hz, 1H), 7.83 (d, J = 2.2 Hz, 1H), 7.79 (ddd, J = 8.4, 7.0, 1.4 Hz, 1H), 7.51 (ddd, J = 8.3, 6.9, 1.2 Hz, 1H), 7.25 – 7.18 (m, 1H), 6.62 (d, J = 2.2 Hz, 1H), 3.63 (t, J = 4.8 Hz, 4H), 3.17 – 3.00 (m, 6H), 2.48 (s, 3H), 2.10 (s, 3H), 1.41 (t, J = 7.4 Hz, 3H).
56	4-[3-(2-cyclopropyl-3-methylquinolin-4-yl)-2-methyl-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	466.2	1H NMR (400 MHz, DMSO-d6) δ 8.81 (s, 1H), 8.01 (dt, J = 8.4, 0.9 Hz, 1H), 7.85 (d, J = 2.2 Hz, 1H), 7.74 (ddd, J = 8.4, 6.9, 1.4 Hz, 1H), 7.45 (ddd, J = 8.2, 6.9, 1.2 Hz, 1H), 7.22 – 7.15 (m, 1H), 6.67 (d, J = 2.2 Hz, 1H), 3.64 (t, J = 4.8 Hz, 4H), 3.09 (td, J = 4.2, 2.0 Hz, 4H), 2.55 - 2.49 (m, 1H), 2.51 (s, 3H), 2.23 (s, 3H), 1.40 – 1.06 (m, 4H).
57	4-[2-methyl-7-(4H-1,2,4-triazol-3-yl)-3-[2-(4H-1,2,4-triazol-3-yl)quinolin-4-yl]benzimidazol-5-yl]morpholine	479.2	1H NMR (400 MHz, DMSO-d6) δ 8.80 (br s, 1H), 8.65 (s, 1H), 8.57 (br s, 2H), 8.33 (dt, J = 8.5, 0.9 Hz, 1H), 7.97 (ddd, J = 8.4, 6.8, 1.5 Hz, 1H), 7.83 (d, J = 2.2 Hz, 1H), 7.67 (ddd, J = 8.2, 6.9, 1.2 Hz, 1H), 7.62 – 7.56 (m, 1H), 6.77 (d, J = 2.2 Hz, 1H), 3.61 (t, J = 4.8 Hz, 4H), 3.05 (q, J = 4.5 Hz, 4H), 2.60 (s, 3H).
58	4-[3-[8-chloro-2-(trifluoromethyl)quinolin-4-yl]-2-methyl-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	514.1	1H NMR (400 MHz, DMSO-d6) δ 8.75 (br s, 1H), 8.61 (s, 1H), 8.27 (dd, J = 7.5, 1.2 Hz, 1H), 7.83 – 7.72 (m, 2H), 7.72 – 7.63 (m, 1H), 6.82 (d, J = 2.2 Hz, 1H), 3.63 (t, J = 4.8 Hz, 4H), 3.04 (q, J = 4.4 Hz, 4H), 2.59 (s, 3H).
59	4-[2-methyl-3-(2-phenylquinolin-4-yl)-7-	488.2	1H NMR (400 MHz, DMSO-d6) δ 8.81 (br s, 1H), 8.65 (s, 1H), 8.36 – 8.27 (m,

	(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine		3H), 7.93 (ddd, J = 8.4, 6.5, 1.8 Hz, 1H), 7.85 (d, J = 2.2 Hz, 1H), 7.67 – 7.49 (m, 6H), 6.75 (d, J = 2.2 Hz, 1H), 3.62 (t, J = 4.9 Hz, 4H), 3.13 – 2.98 (m, 4H), 2.65 (s, 3H).
60	4-[2-methyl-3-[2-methyl-8-(trifluoromethyl)quinolin-4-yl]-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	494.2	1H NMR (400 MHz, DMSO-d6) δ 8.68 (s, 1H), 8.30 – 8.23 (m, 1H), 7.98 (s, 1H), 7.83 – 7.72 (m, 2H), 7.67 (t, J = 7.9 Hz, 1H), 6.73 (d, J = 2.2 Hz, 1H), 3.63 (t, J = 4.8 Hz, 4H), 3.13 – 2.96 (m, 4H), 2.82 (s, 3H), 2.54 (s, 3H).
61	4-[3-(8-fluoro-2,3-dimethylquinolin-4-yl)-2-methyl-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	458.2	1H NMR (400 MHz, DMSO-d6) δ 8.71 (s, 1H), 7.85 – 7.77 (m, 1H), 7.70 – 7.59 (m, 1H), 7.50 (td, J = 8.1, 4.9 Hz, 1H), 7.03 (d, J = 8.2 Hz, 1H), 6.69 (d, J = 2.2 Hz, 1H), 3.67 (t, J = 4.8 Hz, 4H), 3.09 (dt, J = 4.4, 2.5 Hz, 4H), 2.84 (s, 3H), 2.49 (s, 3H), 2.13 (s, 3H).
62	4-[3-(3-ethyl-2-methylquinolin-4-yl)-2-methyl-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	454.26	1H NMR (400 MHz, DMSO-d6) δ 8.74 (br s, 1H), 8.18 – 8.09 (m, 1H), 7.88 – 7.75 (m, 2H), 7.53 (ddd, J = 8.2, 6.9, 1.2 Hz, 1H), 7.12 (d, J = 8.3 Hz, 1H), 6.70 (d, J = 2.2 Hz, 1H), 3.66 (t, J = 4.8 Hz, 4H), 3.09 (q, J = 4.1 Hz, 4H), 2.88 (s, 3H), 2.63 – 2.52 (m, 2H), 2.48 (s, 3H), 1.01 (t, J = 7.5 Hz, 3H).
63	4-[3-(7-fluoro-2-methylquinolin-4-yl)-2-methyl-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	444.2	1H NMR (400 MHz, DMSO-d6) δ 8.75 (br s, 1H), 7.96 (dd, J = 10.2, 2.6 Hz, 1H), 7.88 – 7.79 (m, 2H), 7.69 – 7.57 (m, 1H), 7.53 (td, J = 8.8, 2.6 Hz, 1H), 6.67 (d, J = 2.2 Hz, 1H), 3.67 (t, J = 4.8 Hz, 4H), 3.08 (q, J = 4.7 Hz, 4H), 2.80 (s, 3H), 2.58 (s, 3H).
64	4-[3-(8-chloro-2-methylquinolin-4-yl)-2-methyl-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	460.2	1H NMR (400 MHz, DMSO-d6) δ 8.78 (s, 1H), 8.11 – 8.03 (m, 1H), 7.98 (s, 1H), 7.83 (d, J = 2.2 Hz, 1H), 7.55 (dd, J = 8.4, 7.3 Hz, 1H), 7.52 – 7.44 (m, 1H), 6.74 (d, J = 2.2 Hz, 1H), 3.66 (t, J = 4.8 Hz, 4H), 3.16 – 3.00 (m, 4H), 2.85 (s, 3H), 2.60 (s, 3H).
65	4-[2-methyl-3-(3-methylquinolin-4-yl)-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-	426.2	1H NMR (400 MHz, DMSO-d6) δ 9.20 (s, 1H), 8.78 (s, 1H), 8.29 – 8.21 (m, 1H), 7.92 – 7.81 (m, 2H), 7.63 (ddd, J = 8.2, 6.9, 1.2 Hz, 1H), 7.43 – 7.35 (m,

	yl]morpholine		1H), 6.68 (d, J = 2.2 Hz, 1H), 3.67 (t, J = 4.9 Hz, 4H), 3.17 – 3.05 (m, 4H), 2.52 (s, 3H), 2.23 (s, 3H).
66	4-[3-(3-cyclopropylquinolin-4-yl)-2-methyl-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	452.2	1H NMR (400 MHz, DMSO-d6) δ 8.88 (s, 1H), 8.76 (br s, 1H), 8.26 – 8.19 (m, 1H), 7.89 – 7.80 (m, 2H), 7.62 (ddd, J = 8.2, 6.9, 1.2 Hz, 1H), 7.35 (d, J = 8.3 Hz, 1H), 6.70 (d, J = 2.2 Hz, 1H), 3.74 – 3.55 (m, 4H), 3.10 (t, J = 4.8 Hz, 4H), 2.56 (s, 3H), 1.65 – 1.56 (m, 1H), 1.11 – 1.03 (m, 2H), 1.00 – 0.81 (m, 2H).
67	4-[2-methyl-6-morpholin-4-yl-4-(4H-1,2,4-triazol-3-yl)benzimidazol-1-yl]quinoline-2-carbonitrile	437.1	1H NMR (400 MHz, DMSO-d6) δ 8.63 (br s, 1H), 8.51 (s, 1H), 8.45 – 8.38 (m, 1H), 8.10 (ddd, J = 8.5, 6.9, 1.3 Hz, 1H), 7.85 (ddd, J = 8.4, 6.8, 1.1 Hz, 1H), 7.77 (s, 1H), 7.63 (d, J = 8.4 Hz, 1H), 6.76 (d, J = 2.2 Hz, 1H), 3.67 (t, J = 4.9 Hz, 4H), 3.07 (q, J = 5.0 Hz, 4H), 2.53 (d, J = 17.6 Hz, 3H).
68	4-[3-(8-chloro-3-methylquinolin-4-yl)-2-methyl-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	460.1	1H NMR (400 MHz, DMSO-d6) δ 9.29 (s, 1H), 8.69 (br s, 1H), 8.05 (dd, J = 7.5, 1.2 Hz, 1H), 7.80 (d, J = 2.2 Hz, 1H), 7.58 (dd, J = 8.4, 7.6 Hz, 1H), 7.32 (d, J = 8.2 Hz, 1H), 6.70 (d, J = 2.2 Hz, 1H), 3.71 – 3.61 (m, 4H), 3.13 – 3.06 (m, 4H), 2.49 (s, 3H), 2.23 (s, 3H).
69	4-[2-methyl-3-(2-methylquinolin-4-yl)-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	426.2	1H NMR (400 MHz, DMSO-d6) δ 13.94 (s, 1H), 11.95 (s, 1H), 8.18 – 8.09 (m, 2H), 7.84 (ddd, J = 8.4, 7.0, 1.4 Hz, 1H), 7.78 – 7.73 (m, 1H), 7.62 – 7.51 (m, 2H), 7.19 (dd, J = 8.2, 1.3 Hz, 1H), 6.54 (s, 1H), 3.66 (t, J = 4.8 Hz, 4H), 3.07 – 2.94 (m, 4H), 2.80 (s, 3H), 2.37 (s, 3H), 1.91 (s, 3H).
70	4-[3-(8-chloro-2,3-dimethylquinolin-4-yl)-2-methyl-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	474.16	1H NMR (400 MHz, DMSO-d6) δ 8.75 (s, 1H), 7.99 (dd, J = 7.6, 1.2 Hz, 1H), 7.84 (d, J = 2.2 Hz, 1H), 7.49 (dd, J = 8.3, 7.6 Hz, 1H), 7.21 (dd, J = 8.4, 1.2 Hz, 1H), 6.70 (d, J = 2.2 Hz, 1H), 3.67 (t, J = 4.8 Hz, 4H), 3.16 – 3.04 (m, 4H), 2.86 (s, 3H), 2.51 (s, 3H), 2.13 (s, 3H).
71	4-[3-(3-ethyl-2-methylquinolin-4-yl)-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-	440.2	1H NMR (400 MHz, DMSO-d6) δ 9.10 (s, 1H), 8.51 (s, 1H), 8.16 – 8.09 (m, 1H), 7.85 – 7.76 (m, 2H), 7.52 (ddd, J = 8.2, 6.7, 1.2 Hz, 1H), 7.02 (dd, J = 8.3,

	yl]morpholine		0.9 Hz, 1H), 6.67 (d, J = 2.2 Hz, 1H), 3.67 (dd, J = 6.0, 3.6 Hz, 4H), 3.08 (t, J = 4.8 Hz, 4H), 2.87 (s, 3H), 2.67 – 2.55 (m, 1H), 2.48 – 2.34 (m, 1H), 1.04 (t, J = 7.5 Hz, 3H).
72	4-[3-(2-ethyl-3-methylquinolin-4-yl)-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	440.2	1H NMR (400 MHz, DMSO-d6) δ 9.36 (s, 1H), 8.67 (s, 1H), 8.20 – 8.13 (m, 1H), 7.88 (d, J = 2.3 Hz, 1H), 7.81 (ddd, J = 8.4, 6.9, 1.4 Hz, 1H), 7.54 (ddd, J = 8.2, 6.9, 1.2 Hz, 1H), 7.22 – 7.15 (m, 1H), 6.72 (d, J = 2.2 Hz, 1H), 3.68 (t, J = 4.8 Hz, 4H), 3.22 – 3.06 (m, 6H), 2.16 (s, 3H), 1.43 (t, J = 7.4 Hz, 3H).
73	4-[2-methyl-3-(2-methylquinolin-4-yl)-7-(3-methyl-1H-1,2,4-triazol-5-yl)benzimidazol-5-yl]morpholine	440.2	1H NMR (400 MHz, DMSO-d6) δ 8.20 (d, J = 8.5 Hz, 1H), 7.95 – 7.86 (m, 2H), 7.82 (d, J = 2.0 Hz, 1H), 7.65 – 7.57 (m, 1H), 7.56 – 7.50 (m, 1H), 6.69 – 6.63 (m, 1H), 3.66 (t, J = 4.8 Hz, 4H), 3.15 – 3.00 (m, 4H), 2.81 (s, 3H), 2.62 (s, 3H), 2.56 (s, 3H).
74	4-[2-methyl-3-(3-methylquinolin-4-yl)-7-(3-methyl-1H-1,2,4-triazol-5-yl)benzimidazol-5-yl]morpholine	440.2	1H NMR (400 MHz, DMSO-d6) δ 9.20 (s, 1H), 8.26 (d, J = 8.7 Hz, 1H), 7.92 – 7.84 (m, 1H), 7.84 – 7.79 (m, 1H), 7.70 – 7.58 (m, 1H), 7.44 – 7.36 (m, 1H), 6.67 (d, J = 2.4 Hz, 1H), 3.66 (t, J = 4.7 Hz, 4H), 3.10 (dd, J = 6.3, 3.7 Hz, 4H), 2.56 (s, 3H), 2.54 (s, 3H), 2.23 (s, 3H).
75	4-[3-(3-ethyl-2-methylquinolin-4-yl)-7-(3-methyl-1H-1,2,4-triazol-5-yl)benzimidazol-5-yl]morpholine	454.29	1H NMR (400 MHz, DMSO-d6) δ 9.15 (s, 1H), 8.12 (d, J = 8.0 Hz, 1H), 7.80 (t, J = 7.8 Hz, 1H), 7.76 (d, J = 2.2 Hz, 1H), 7.56 – 7.47 (m, 1H), 7.02 (d, J = 8.4 Hz, 1H), 6.68 (d, J = 2.2 Hz, 1H), 3.70 – 3.63 (m, 4H), 3.09 – 3.03 (m, 4H), 2.87 (s, 3H), 2.65 – 2.57 (m, 1H), 2.45 – 2.35 (m, 1H), 1.04 (t, J = 7.5 Hz, 3H).
76	4-[3-(2-ethyl-3-methylquinolin-4-yl)-2-methyl-7-(3-methyl-1H-1,2,4-triazol-5-yl)benzimidazol-5-yl]morpholine	468.3	1H NMR (400 MHz, DMSO-d6) δ 8.17 (d, J = 8.4 Hz, 1H), 7.86 – 7.76 (m, 2H), 7.58 – 7.49 (m, 1H), 7.21 (d, J = 8.3 Hz, 1H), 6.61 (s, 1H), 3.66 (t, J = 4.8 Hz, 4H), 3.18 – 3.10 (m, 2H), 3.10 – 3.03 (m, 4H), 2.54 (s, 3H), 2.13 (s, 3H), 1.45 (t, J = 7.4 Hz, 3H).
77	4-[2-methyl-7-(3-methyl-1H-1,2,4-triazol-5-yl)-3-[2-	508.33	1H NMR (400 MHz, DMSO-d6) δ 8.31 (d, J = 7.3 Hz, 1H), 8.02 (s, 1H), 7.82 (d, J = 8.5 Hz, 1H), 7.78 (d, J = 2.2 Hz, 1H),

	methyl-8-(trifluoromethyl)quinolin-4-yl]benzimidazol-5-yl]morpholine		7.70 (t, J = 7.9 Hz, 1H), 6.75 (d, J = 2.2 Hz, 1H), 3.66 (t, J = 4.8 Hz, 4H), 3.15 – 3.00 (m, 4H), 2.85 (s, 3H), 2.59 (s, 3H), 2.54 (s, 3H).
78	4-[3-(8-chloro-3-methylquinolin-4-yl)-2-methyl-7-(3-methyl-1H-1,2,4-triazol-5-yl)benzimidazol-5-yl]morpholine	474.25	1H NMR (400 MHz, DMSO-d6) δ 9.29 (s, 1H), 8.05 (d, J = 7.6 Hz, 1H), 7.76 (s, 1H), 7.58 (t, J = 8.0 Hz, 1H), 7.32 (d, J = 8.4 Hz, 1H), 6.69 (d, J = 2.2 Hz, 1H), 3.66 (t, J = 4.9 Hz, 4H), 3.08 (t, J = 4.9 Hz, 4H), 2.53 (s, 3H), 2.23 (s, 3H).
79	4-[3-(7-fluoro-2-methylquinolin-4-yl)-2-methyl-7-(3-methyl-1H-1,2,4-triazol-5-yl)benzimidazol-5-yl]morpholine	458.29	1H NMR (400 MHz, DMSO-d6) δ 7.97 (dd, J = 10.2, 2.5 Hz, 1H), 7.86 (s, 1H), 7.80 (d, J = 2.3 Hz, 1H), 7.69 – 7.61 (m, 1H), 7.53 (td, J = 8.8, 2.6 Hz, 1H), 6.66 (d, J = 2.3 Hz, 1H), 3.66 (t, J = 4.8 Hz, 4H), 3.15 – 2.98 (m, 4H), 2.80 (s, 3H), 2.61 (s, 3H), 2.54 (s, 3H).
80	4-[3-(2-ethyl-8-fluoro-3-methylquinolin-4-yl)-2-methyl-7-(3-methyl-1H-1,2,4-triazol-5-yl)benzimidazol-5-yl]morpholine	486.3	1H NMR (400 MHz, DMSO-d6) δ 7.75 (s, 1H), 7.69 – 7.60 (m, 1H), 7.50 (td, J = 8.0, 4.8 Hz, 1H), 7.00 (d, J = 8.5 Hz, 1H), 6.65 (s, 1H), 3.66 (t, J = 4.8 Hz, 4H), 3.15 (q, J = 15.0, 7.8 Hz, 2H), 3.10 – 3.04 (m, 4H), 2.52 (s, 3H), 2.47 (s, 3H), 2.13 (s, 3H), 1.45 (t, J = 7.3 Hz, 3H).
81	4-[3-(5-fluoroquinolin-4-yl)-2-methyl-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	430.2	1H NMR (400 MHz, DMSO-d6) δ 9.31 (d, J = 4.5 Hz, 1H), 8.20 – 8.16 (m, 1H), 8.00 (d, J = 4.5 Hz, 1H), 7.94 (td, J = 8.3, 5.8 Hz, 1H), 7.78 (s, 1H), 7.52 (dd, J = 12.4, 7.9 Hz, 1H), 6.80 (d, J = 2.2 Hz, 1H), 3.67 (t, J = 4.8 Hz, 4H), 3.10 (t, J = 5.0 Hz, 4H), 2.57 (s, 3H).
82	4-[3-[8-(difluoromethyl)quinolin-4-yl]-2-methyl-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	462.1	1H NMR (400 MHz, DMSO-d6) δ 9.34 (d, J = 4.5 Hz, 1H), 8.20 (d, J = 7.0 Hz, 1H), 8.14 – 7.82 (m, 2H), 7.82 – 7.71 (m, 3H), 6.68 (d, J = 2.2 Hz, 1H), 3.64 (t, J = 4.7 Hz, 4H), 3.05 (q, J = 4.2 Hz, 4H), 2.53 (d, J = 6.2 Hz, 3H).
83	4-[2-methyl-3-(5-methylquinolin-4-yl)-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	426.2	1H NMR (400 MHz, DMSO-d6) δ 9.21 (d, J = 4.4 Hz, 1H), 8.73 (s, 1H), 8.21 – 8.15 (m, 1H), 7.90 – 7.80 (m, 3H), 7.57 – 7.50 (m, 1H), 6.69 (d, J = 2.2 Hz, 1H), 3.67 (t, J = 4.8 Hz, 4H), 3.15 – 3.07 (m, 4H), 2.55 (s, 3H), 1.82 (s, 3H).

84	4-[3-(5-chloroquinolin-4-yl)-2-methyl-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	446.1	1H NMR (400 MHz, DMSO-d6) δ 9.32 (d, J = 4.5 Hz, 1H), 8.83 – 8.53 (m, 1H), 8.33 (dd, J = 8.5, 1.2 Hz, 1H), 8.01 (d, J = 4.5 Hz, 1H), 7.96 – 7.90 (m, 1H), 7.84 (dd, J = 7.7, 1.2 Hz, 1H), 7.81 – 7.77 (m, 1H), 6.77 – 6.75 (m, 1H), 3.67 (t, J = 4.9 Hz, 4H), 3.11 (t, J = 4.9 Hz, 4H), 2.54 (s, 3H).
85	4-[3-[5-(difluoromethyl)quinolin-4-yl]-2-methyl-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	462.1	1H NMR (400 MHz, DMSO-d6) δ 9.29 (d, J = 4.5 Hz, 1H), 8.64 (s, 1H), 8.54 – 8.48 (m, 1H), 8.13 – 8.02 (m, 2H), 7.96 (d, J = 4.5 Hz, 1H), 7.77 (d, J = 2.2 Hz, 1H), 6.71 (d, J = 2.2 Hz, 1H), 6.30 (t, J = 54.8 Hz, 1H), 3.65 (t, J = 4.7 Hz, 4H), 3.07 (q, J = 4.0 Hz, 4H), 2.45 (s, 3H).
86	4-[3-(8-chloroquinolin-4-yl)-6-fluoro-2-methyl-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	464.1	1H NMR (400 MHz, DMSO-d6) δ 9.33 (d, J = 4.5 Hz, 1H), 8.63 (s, 1H), 8.11 (dd, J = 7.5, 1.2 Hz, 1H), 8.01 (d, J = 4.5 Hz, 1H), 7.61 (dd, J = 8.5, 7.5 Hz, 1H), 7.40 (d, J = 8.4 Hz, 1H), 6.82 (d, J = 6.9 Hz, 1H), 3.65 (t, J = 4.6 Hz, 4H), 2.93 – 2.76 (m, 4H), 2.42 (s, 3H).
87	4-[3-(8-chloro-5-fluoroquinolin-4-yl)-2-methyl-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	464.1	1H NMR (400 MHz, DMSO-d6) δ 9.42 (d, J = 4.5 Hz, 1H), 8.74 (s, 1H), 8.18 – 8.10 (m, 2H), 7.80 (d, J = 2.2 Hz, 1H), 7.52 (dd, J = 11.9, 8.6 Hz, 1H), 6.87 (d, J = 2.2 Hz, 1H), 3.65 (dd, J = 5.9, 3.7 Hz, 5H), 3.10 (dd, J = 6.1, 3.7 Hz, 4H), 2.61 (s, 3H).
88	4-[3-[8-chloro-2-(difluoromethyl)quinolin-4-yl]-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	482.1	1H NMR (400 MHz, DMSO-d6) δ 8.94 (s, 1H), 8.39 (s, 1H), 8.29 (s, 1H), 8.21 (dt, J = 7.5, 1.0 Hz, 1H), 7.75 (s, 1H), 7.72 (d, J = 7.9 Hz, 1H), 7.57 (d, J = 8.5 Hz, 1H), 7.31 (t, J = 54.0 Hz, 1H), 6.86 (d, J = 2.3 Hz, 1H), 3.70 - 3.64 (m, 4H), 3.10 - 3.02 (m, 4H).
89	4-[2-methyl-6-morpholin-4-yl-4-(4H-1,2,4-triazol-3-yl)benzimidazol-1-yl]quinoline-8-carbonitrile	437.2	1H NMR (400 MHz, DMSO-d6) δ 9.42 (d, J = 4.6 Hz, 1H), 8.56 – 8.51 (m, 1H), 8.12 (d, J = 4.5 Hz, 1H), 7.86 (s, 1H), 7.82 – 7.73 (m, 2H), 6.69 (s, 1H), 3.70 - 3.60 (m, 4H), 3.08 – 3.00 (m, 4H), 2.48 (s, 3H).
90	4-[3-(7-fluoroquinolin-4-yl)-2-methyl-7-(4H-1,2,4-triazol-3-	430.2	1H NMR (400 MHz, DMSO-d6) δ 9.27 (d, J = 4.5 Hz, 1H), 8.77 (s, 1H), 8.07 (dd, J = 10.0, 2.5 Hz, 1H), 7.95 (d, J =

	yl)benzimidazol-5-yl]morpholine		4.6 Hz, 1H), 7.83 (d, J = 2.2 Hz, 1H), 7.76 – 7.69 (m, 1H), 7.61 (td, J = 8.7, 2.5 Hz, 1H), 6.66 (d, J = 2.2 Hz, 1H), 3.65 (t, J = 4.7 Hz, 4H), 3.07 (d, J = 3.5 Hz, 4H), 2.58 (s, 3H).
91	4-[3-(8-chloroquinolin-4-yl)-4-fluoro-2-methyl-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	464.2	1H NMR (400 MHz, DMSO-d6) δ 9.29 (dd, J = 4.5, 1.6 Hz, 1H), 8.38 (s, 1H), 8.14 – 8.07 (m, 2H), 7.70 – 7.59 (m, 3H), 7.41 (dd, J = 8.4, 1.6 Hz, 1H), 3.63 (t, J = 4.3 Hz, 4H), 3.02 – 2.84 (m, 4H), 2.45 (s, 3H).
92	4-[3-[8-(difluoromethyl)quinolin-4-yl]-2-methyl-7-(5-methyl-4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	476.3	1H NMR (400 MHz, DMSO-d6) δ 9.35 (dd, J = 4.5, 1.3 Hz, 1H), 8.22 - 8.18 (d, J = 4.7 Hz, 1H), 8.14 – 7.83 (m, 2H), 7.83 - 7.75 (m, 4H), 6.68 (d, J = 2.1 Hz, 1H), 3.64 (t, J = 4.7 Hz, 4H), 3.09 - 3.00 (m, 4H), 2.57 (d, J = 1.3 Hz, 3H), 2.52 (d, J = 1.4 Hz, 3H).
93	4-[2-methyl-3-(5-methylquinolin-4-yl)-7-(5-methyl-4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	440.5	1H NMR (400 MHz, DMSO-d6) δ 9.19 (d, J = 4.4 Hz, 1H), 8.16 (d, J = 8.4 Hz, 1H), 7.84 (d, J = 4.4 Hz, 1H), 7.81 (dd, J = 8.5, 7.1 Hz, 1H), 7.75 (s, 1H), 7.51 (d, J = 7.2 Hz, 1H), 6.65 (d, J = 2.3 Hz, 1H), 3.64 (t, J = 4.8 Hz, 5H), 3.13 – 3.02 (m, 4H), 2.52 (s, 3H), 2.51 (s, 2H), 1.79 (s, 3H).
94	4-[3-(8-chloro-5-fluoroquinolin-4-yl)-2-methyl-7-(5-methyl-4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	478.4	1H NMR (400 MHz, DMSO-d6) δ 9.40 (d, J = 4.5 Hz, 1H), 8.17 – 8.07 (m, 2H), 7.71 (s, 1H), 7.51 (dd, J = 11.9, 8.5 Hz, 1H), 6.81 (s, 1H), 3.70 - 3.60 (m, 4H), 3.11 - 3.01 (m, 4H), 2.57 (s, 3H).
95	4-[3-(8-fluoroquinolin-4-yl)-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	416.2	1H NMR (400 MHz, DMSO-d6) δ 9.21 (d, J = 4.5 Hz, 1H), 9.06 (s, 1H), 8.46 (s, 1H), 8.00 (d, J = 4.6 Hz, 1H), 7.81 – 7.70 (m, 2H), 7.66 (td, J = 8.1, 5.1 Hz, 1H), 7.42 (dt, J = 8.4, 1.0 Hz, 1H), 6.85 (d, J = 2.3 Hz, 1H), 3.68 (t, J = 4.8 Hz, 4H), 3.09 (d, J = 5.2 Hz, 4H).
96	4-[3-(5-chloro-8-fluoroquinolin-4-yl)-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	450.1	1H NMR (400 MHz, DMSO-d6) δ 9.29 (d, J = 4.5 Hz, 1H), 9.19 (s, 1H), 8.54 (d, J = 6.7 Hz, 1H), 8.10 – 8.00 (m, 1H), 7.85 – 7.76 (m, 3H), 6.89 (d, J = 2.3 Hz, 1H), 3.67 (t, J = 4.8 Hz, 4H), 3.11 (t, J =

			5.0 Hz, 4H).
97	4-[3-(3,8-dichloroquinolin-4-yl)-2-methyl-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	480.1	1H NMR (400 MHz, DMSO-d6) δ 9.42 (s, 1H), 8.51 (s, 1H), 8.14 (dd, J = 7.6, 1.2 Hz, 1H), 7.66 (dd, J = 8.5, 7.6 Hz, 2H), 7.38 (d, J = 8.4 Hz, 1H), 6.78 (d, J = 2.2 Hz, 1H), 3.72 – 3.51 (m, 4H), 3.05 (t, J = 5.0 Hz, 4H), 2.43 (s, 3H).
98	4-[3-(3,8-dichloroquinolin-4-yl)-2-ethyl-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	494.1	1H NMR (400 MHz, DMSO-d6) δ 9.40 (s, 1H), 8.45 (s, 1H), 8.13 (dd, J = 7.6, 1.2 Hz, 1H), 7.70 – 7.61 (m, 2H), 7.30 (d, J = 8.5 Hz, 1H), 6.75 (d, J = 2.3 Hz, 1H), 3.64 (t, J = 4.9 Hz, 4H), 3.17 – 2.92 (m, 4H), 2.64 (q, J = 7.5 Hz, 2H), 1.17 (t, J = 7.5 Hz, 3H).
99	(3S)-4-[3-(8-chloroquinolin-4-yl)-2-methyl-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]-3-methylmorpholine	460.3	1H NMR (400 MHz, DMSO-d6) δ 9.35 (dd, J = 4.5, 1.9 Hz, 0.5H), 8.71 (s, 0.5H), 8.16 – 8.03 (m, 1H), 7.80 - 7.70 (m , 1H), 7.67 – 7.49 (m, 1H), 6.70 - 6.55 (m, 1H), 3.89 - 3.75 (m, 2H), 3.62 - 3.40 (m, 3H), 3.15 – 2.84 (m, 2H), 2.60 - 2.51 (mz, 3H), 0.96 – 0.82 (m, 3H).
100	(3R)-4-[3-(8-chloroquinolin-4-yl)-2-methyl-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]-3-methylmorpholine	460.3	1H NMR (400 MHz, DMSO-d6) δ 9.35 (dd, J = 4.5, 1.9 Hz, 0.5H), 8.71 (s, 0.5H), 8.16 – 8.03 (m, 1H), 7.80 - 7.70 (m , 1H), 7.67 – 7.49 (m, 1H), 6.70 - 6.55 (m, 1H), 3.89 - 3.75 (m, 2H), 3.62 - 3.40 (m, 3H), 3.15 – 2.84 (m, 2H), 2.60 - 2.51 (mz, 3H), 0.96 – 0.82 (m, 3H).
101	4-[3-(8-chloroquinolin-4-yl)-2-methyl-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	446.1	1H NMR (400 MHz, DMSO-d6) δ 9.37 (dd, J = 4.5, 0.6 Hz, 1H), 8.77 (s, 1H), 8.15 (dd, J = 7.4, 1.3 Hz, 1H), 8.09 (d, J = 4.5 Hz, 1H), 7.83 (d, J = 2.3 Hz, 1H), 7.64 (dd, J = 8.4, 7.5 Hz, 1H), 7.57 (d, J = 8.4 Hz, 1H), 6.73 (d, J = 2.3 Hz, 1H), 3.66 (t, J = 4.8 Hz, 4H), 3.08 (q, J = 3.9 Hz, 4H), 2.59 (s, 3H).
102	4-[3-(8-chloroquinolin-4-yl)-2-(oxolan-2-yl)-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	502.2	1H NMR (400 MHz, DMSO-d6) δ 9.30 (d, J = 4.5 Hz, 0.5H), 9.28 (d, J = 4.5 Hz, 0.5H), 8.46 (s, 0.5H), 8.41 (s, 0.5H), 8.09 (dd, J = 3.7, 1.2 Hz, 0.5H), 8.08 – 8.06 (m, 0.5H), 8.00 – 7.96 (m, 1H), 7.71 – 7.67 (m, 1H), 7.60 – 7.54 (m, 1H), 7.27 – 7.21 (m, 1H), 6.61 (d, J = 2.3 Hz, 0.5H), 6.52 (d, J = 2.3 Hz,1H), 5.07 (dd, J = 7.6, 5.7 Hz, 0.5H), 4.90 (t,

			J = 7.0 Hz, 0.5H), 3.65 (q, J = 4.5 Hz, 4H), 3.55 (td, J = 7.7, 5.2 Hz, 0.5H), 3.52 – 3.32 (m, 1.5H), 3.03 (dq, J = 12.1, 4.2 Hz, 4H), 2.89 – 2.68 (m, 1H), 2.20 – 2.06 (m, 1H), 2.04 – 1.85 (m, 1H), 1.85 – 1.70 (m, 1H).
103	4-(2-methyl-1-(2-(thiazol-4-yl)quinolin-4-yl)-4-(4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	495.20	1H NMR (400 MHz, DMSO-d6) δ 9.34 – 9.32 (m, 1H), 8.74 – 8.73 (m, 1H), 8.71 (s, 1H), 8.33 – 8.28 (m, 1H), 7.99 – 7.92 (m, 1H), 7.86 – 7.84 (m, 1H), 7.69 – 7.62 (m, 1H), 7.60 – 7.53 (m, 1H), 6.79 – 6.76 (m, 1H), 3.67 – 3.61 (m, 4H), 3.11 – 3.04 (m, 4H), 2.62 (s, 3H).
104	4-(2-methyl-4-(5-methyl-4H-1,2,4-triazol-3-yl)-1-(2-(thiazol-4-yl)quinolin-4-yl)-1H-benzo[d]imidazol-6-yl)morpholine	509.2	1H NMR (400 MHz, DMSO-d6) δ 9.33 (d, J = 2.0 Hz, 1H), 8.73 (d, J = 2.0 Hz, 1H), 8.69 (s, 1H), 8.33 - 8.29 (m, 1H), 7.98 - 7.93 (m, 1H), 7.78 (s, 1H), 7.68 - 7.62 (m, 1H), 7.53 (s, 1H), 6.74 (s, 1H), 3.64 (t, J = 4.8 Hz, 4H), 3.09 - 3.03 (m, 4H), 2.60 (s, 3H), 2.53 (s, 3H).
105	4-[3-(8-chloroquinolin-4-yl)-2-ethyl-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	460.2	1H NMR (400 MHz, DMSO-d6) δ 9.36 (d, J = 4.5 Hz, 1H), 8.70 – 8.60 (m, 1H), 8.17 – 8.07 (m, 2H), 7.78 (d, J = 2.2 Hz, 1H), 7.67 – 7.59 (m, 1H), 7.51 – 7.41 (m, 1H), 6.68 (d, J = 2.3 Hz, 1H), 3.66 (t, J = 4.8 Hz, 4H), 3.11 – 3.00 (m, 4H), 2.90 – 2.80 (m, 2H), 1.11 (t, J = 7.5 Hz, 3H).
106	4-[2-methyl-3-quinolin-4-yl-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	412.2	1H NMR (400 MHz, DMSO-d6) δ 9.29 – 9.24 (m, 1H), 8.79 (s, 1H), 8.34 – 8.27 (m, 1H), 8.00 – 7.93 (m, 2H), 7.87 – 7.84 (m, 1H), 7.71 – 7.66 (m, 1H), 7.62 – 7.58 (m, 1H), 6.66 (d, J = 2.2 Hz, 1H), 3.66 (t, J = 4.8 Hz, 4H), 3.12 – 3.05 (m, 4H), 2.59 (s, 3H).
107	4-[2-ethyl-3-quinolin-4-yl-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	426.2	1H NMR (400 MHz, DMSO-d6) δ 9.26 (d, J = 4.5 Hz, 1H), 8.68 (s, 1H), 8.30 (dd, J = 8.4, 1.0 Hz, 1H), 8.01 (d, J = 4.5 Hz, 1H), 7.98 – 7.91 (m, 1H), 7.80 (d, J = 2.2 Hz, 1H), 7.71 – 7.64 (m, 1H), 7.50 (d, J = 8.4 Hz, 1H), 6.62 (d, J = 2.2 Hz, 1H), 3.66 (t, J = 4.8 Hz, 4H), 3.12 – 3.00 (m, 4H), 2.86 (q, J = 7.4 Hz, 2H), 1.10 (t, J = 7.5 Hz, 3H).

108	4-[2-methyl-7-(4H-1,2,4-triazol-3-yl)-3-[8-(trifluoromethyl)quinolin-4-yl]benzimidazol-5-yl]morpholine	480.2	1H NMR (400 MHz, DMSO-d6) δ 9.42 (d, J = 4.6 Hz, 1H), 8.82 – 8.69 (m, 1H), 8.38 (d, J = 7.3 Hz, 1H), 8.14 (d, J = 4.5 Hz, 1H), 7.97 – 7.87 (m, 1H), 7.87 – 7.76 (m, 2H), 6.81 – 6.74 (m, 1H), 3.66 (t, J = 4.8 Hz, 4H), 3.14 – 3.04 (m, 4H), 2.58 (s, 3H).
109	4-[2-methyl-3-(8-methylquinolin-4-yl)-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	426.2	1H NMR (400 MHz, DMSO-d6) δ 9.30 – 9.26 (m, 1H), 8.86 – 8.75 (m, 1H), 7.99 (d, J = 4.5 Hz, 1H), 7.86 (d, J = 2.2 Hz, 1H), 7.82 (d, J = 7.1 Hz, 1H), 7.61 – 7.52 (m, 1H), 7.44 – 7.38 (m, 1H), 6.65 (d, J = 2.2 Hz, 1H), 3.66 (t, J = 4.8 Hz, 4H), 3.12 – 3.04 (m, 4H), 2.86 (s, 3H), 2.58 (s, 3H).
110	4-[3-(8-chloroquinolin-4-yl)-2-cyclopropyl-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	472.1	1H NMR (400 MHz, DMSO-d6) δ 9.34 (d, J = 4.5 Hz, 1H), 8.40 (s, 1H), 8.15 – 8.10 (m, 1H), 8.05 (d, J = 4.5 Hz, 1H), 7.67 – 7.60 (m, 2H), 7.39 (dd, J = 8.4, 1.2 Hz, 1H), 6.67 (d, J = 2.2 Hz, 1H), 3.66 (t, J = 4.8 Hz, 4H), 3.09 – 2.98 (m, 4H), 1.70 – 1.61 (m, 1H), 1.49 – 1.30 (m, 2H), 1.02 – 0.80 (m, 2H).
111	4-[3-(8-chloroquinolin-4-yl)-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	432.1	1H NMR (400 MHz, DMSO-d6) δ 9.30 (d, J = 4.6 Hz, 1H), 9.12 (s, 1H), 8.50 (s, 1H), 8.14 (dd, J = 7.4, 1.3 Hz, 1H), 8.04 (d, J = 4.6 Hz, 1H), 7.81 (d, J = 2.3 Hz, 1H), 7.69 – 7.62 (m, 1H), 7.61 – 7.56 (m, 1H), 6.87 (d, J = 2.3 Hz, 1H), 3.69 (t, J = 4.8 Hz, 4H), 3.13 – 3.07 (m, 4H).
112	4-[3-(8-chloroquinolin-4-yl)-2-(1,3-oxazol-5-yl)-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	499.1	1H NMR (400 MHz, DMSO-d6) δ 9.26 (d, J = 4.5 Hz, 1H), 9.07 (s, 1H), 8.30 (s, 1H), 8.20 – 8.16 (m, 1H), 8.04 (dd, J = 7.5, 1.2 Hz, 1H), 7.93 (d, J = 4.5 Hz, 1H), 7.72 (d, J = 2.3 Hz, 1H), 7.54 – 7.48 (m, 1H), 7.24 (dd, J = 8.5, 1.2 Hz, 1H), 6.60 (d, J = 2.3 Hz, 1H), 3.67 (t, J = 4.7 Hz, 4H), 3.09 – 3.02 (m, 4H).
113	4-[3-(8-chloroquinolin-4-yl)-2-(oxetan-3-yl)-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	488.1	1H NMR (400 MHz, DMSO-d6) δ 9.28 (d, J = 4.4 Hz, 1H), 8.33 (s, 1H), 8.10 (dd, J = 7.5, 1.2 Hz, 1H), 7.88 (d, J = 4.5 Hz, 1H), 7.68 (d, J = 2.2 Hz, 1H), 7.63 – 7.55 (m, 1H), 7.20 (dd, J = 8.5, 1.2 Hz, 1H), 6.61 (d, J = 2.3 Hz, 1H), 5.19 – 5.12 (m, 1H), 5.10 – 5.03 (m, 1H), 4.66

			(dd, J = 8.6, 5.5 Hz, 1H), 4.47 (dd, J = 8.6, 5.5 Hz, 1H), 4.24 – 4.14 (m, 1H), 3.66 (t, J = 4.7 Hz, 4H), 3.06 – 3.00 (m, 4H).
114	4-[3-(5,8-difluoroquinolin-4-yl)-2-methyl-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	448.1	1H NMR (400 MHz, DMSO-d6) δ 9.36 (d, J = 4.5 Hz, 1H), 8.79 – 8.61 (m, 1H), 8.12 (d, J = 4.5 Hz, 1H), 7.88 – 7.76 (m, 2H), 7.57 – 7.48 (m, 1H), 6.85 (d, J = 2.2 Hz, 1H), 3.68 (t, J = 4.8 Hz, 4H), 3.11 (t, J = 4.9 Hz, 4H), 2.60 (s, 3H).
115	4-[3-(8-chloroquinolin-4-yl)-2-pyridin-2-yl-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	509.1	1H NMR (400 MHz, DMSO-d6) δ 9.22 (d, J = 4.5 Hz, 1H), 8.95 – 8.88 (m, 1H), 8.30 (s, 1H), 7.99 (dd, J = 7.5, 1.3 Hz, 1H), 7.97 – 7.90 (m, 2H), 7.85 (d, J = 4.6 Hz, 1H), 7.77 (d, J = 2.2 Hz, 1H), 7.44 (dd, J = 8.4, 7.5 Hz, 1H), 7.27 – 7.20 (m, 2H), 6.52 (d, J = 2.3 Hz, 1H), 3.67 (t, J = 4.7 Hz, 4H), 3.10 – 3.02 (m, 4H).
116	4-[3-(8-chloroquinolin-4-yl)-2-(2-methoxyethyl)-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	490.1	1H NMR (400 MHz, DMSO-d6) δ 9.34 (d, J = 4.5 Hz, 1H), 8.66 – 8.47 (m, 1H), 8.12 (dd, J = 7.5, 1.2 Hz, 1H), 8.04 (d, J = 4.5 Hz, 1H), 7.78 – 7.73 (m, 1H), 7.62 (dd, J = 8.5, 7.5 Hz, 1H), 7.34 (d, J = 8.4 Hz, 1H), 6.64 (d, J = 2.3 Hz, 1H), 3.69 – 3.50 (m, 6H), 3.13 – 3.00 (m, 6H), 2.98 (s, 3H).
117	4-[3-(8-chloroquinolin-4-yl)-2-(1H-pyrazol-5-yl)-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	498.1	1H NMR (400 MHz, DMSO-d6) δ 9.29 (d, J = 4.5 Hz, 1H), 8.33 (s, 1H), 8.04 (dd, J = 7.6, 1.3 Hz, 1H), 7.95 (d, J = 4.6 Hz, 1H), 7.73 (d, J = 2.2 Hz, 1H), 7.68 – 7.62 (m, 1H), 7.53 – 7.46 (m, 1H), 7.26 (s, 1H), 7.22 (dd, J = 8.4, 1.2 Hz, 1H), 7.13 (s, 1H), 7.00 (s, 1H), 6.61 (d, J = 2.2 Hz, 1H), 3.67 (t, J = 4.8 Hz, 4H), 3.09 – 3.03 (m, 4H).
118	4-[3-(8-chloroquinolin-4-yl)-2-(1,2-thiazol-4-yl)-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	515.1	1H NMR (400 MHz, DMSO-d6) δ 9.40 – 9.33 (m, 2H), 8.42 – 8.38 (m, 1H), 8.34 – 8.27 (m, 1H), 8.11 – 8.04 (m, 2H), 7.78 – 7.75 (m, 1H), 7.58 – 7.52 (m, 1H), 7.28 – 7.22 (m, 1H), 6.65 – 6.62 (m, 1H), 3.67 (t, J = 4.7 Hz, 4H), 3.11 – 3.04 (m, 4H).
119	4-[3-(8-chloroquinolin-4-yl)-2-(1,3-thiazol-5-	515.1	1H NMR (400 MHz, DMSO-d6) δ 9.38 – 9.35 (m, 1H), 9.01 – 8.97 (m, 1H),

	yl)-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine		8.37 – 8.30 (m, 1H), 8.29 – 8.20 (m, 1H), 8.13 – 8.07 (m, 2H), 7.72 (d, J = 2.3 Hz, 1H), 7.59 – 7.52 (m, 1H), 7.24 – 7.18 (m, 1H), 6.65 (d, J = 2.3 Hz, 1H), 3.67 (t, J = 4.8 Hz, 4H), 3.11 – 3.04 (m, 4H).
120	4-[3-(8-chloroquinolin-4-yl)-2-(1H-pyrazol-4-yl)-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	498.1	1H NMR (400 MHz, DMSO-d6) δ 9.35 (d, J = 4.5 Hz, 1H), 8.37 (s, 1H), 8.09 (dd, J = 7.5, 1.2 Hz, 1H), 8.06 (d, J = 4.5 Hz, 1H), 7.70 (d, J = 2.3 Hz, 1H), 7.66 (s, 2H), 7.57 – 7.51 (m, 1H), 7.25 – 7.21 (m, 1H), 6.64 (d, J = 2.3 Hz, 1H), 3.67 (t, J = 4.8 Hz, 4H), 3.08 – 3.03 (m, 4H).
121	4-[3-(8-chloroquinolin-4-yl)-2-(1-methylpyrazol-4-yl)-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	512	1H NMR (400 MHz, DMSO-d6) δ 9.35 (d, J = 4.5 Hz, 1H), 8.38 (s, 1H), 8.09 (dd, J = 7.5, 1.2 Hz, 1H), 8.04 (d, J = 4.5 Hz, 1H), 7.84 – 7.83 (m, 1H), 7.70 (d, J = 2.2 Hz, 1H), 7.57 – 7.52 (m, 1H), 7.51 – 7.50 (m, 1H), 7.23 (dd, J = 8.6, 1.2 Hz, 1H), 6.60 (d, J = 2.3 Hz, 1H), 3.73 (s, 3H), 3.66 (t, J = 4.8 Hz, 4H), 3.07 – 3.01 (m, 4H).
122	4-[3-(5,8-dichloroquinolin-4-yl)-2-methyl-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	481.1	1H NMR (400 MHz, DMSO-d6) δ 9.43 (d, J = 4.4 Hz, 1H), 8.77 – 8.60 (m, 1H), 8.17 – 8.12 (m, 2H), 7.84 – 7.76 (m, 2H), 6.83 – 6.79 (m, 1H), 3.67 (t, J = 4.9 Hz, 4H), 3.11 (t, J = 4.9 Hz, 4H), 2.56 (s, 3H).
123	4-[3-(5,8-difluoroquinolin-4-yl)-2-(oxetan-3-yl)-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	490.1	1H NMR (400 MHz, DMSO-d6) δ 9.25 (d, J = 4.5 Hz, 1H), 8.32 – 8.27 (m, 1H), 7.91 (d, J = 4.6 Hz, 1H), 7.82 – 7.73 (m, 1H), 7.64 (d, J = 2.3 Hz, 1H), 7.44 (ddd, J = 12.3, 8.8, 3.8 Hz, 1H), 6.72 (d, J = 2.3 Hz, 1H), 5.16 – 5.09 (m, 2H), 4.59 (ddd, J = 13.5, 8.6, 5.5 Hz, 2H), 4.29 – 4.19 (m, 1H), 3.71 – 3.63 (m, 4H), 3.05 (t, J = 4.9 Hz, 4H).
124	4-[3-(5-fluoro-8-methylquinolin-4-yl)-2-methyl-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	444.2	1H NMR (400 MHz, DMSO-d6) δ 9.35 (d, J = 4.5 Hz, 1H), 8.81 – 8.69 (m, 1H), 8.03 (d, J = 4.5 Hz, 1H), 7.85 – 7.77 (m, 2H), 7.42 (dd, J = 12.5, 8.1 Hz, 1H), 6.80 (d, J = 2.2 Hz, 1H), 3.67 (t, J = 4.8 Hz, 4H), 3.11 (t, J = 4.9 Hz, 4H), 2.81 (s, 3H), 2.59 (s, 3H).

125	4-[3-(5,8-difluoroquinolin-4-yl)-2-ethyl-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	462.2	1H NMR (400 MHz, DMSO-d6) δ 9.35 (d, J = 4.5 Hz, 1H), 8.67 – 8.59 (m, 1H), 8.14 (d, J = 4.5 Hz, 1H), 7.86 – 7.78 (m, 1H), 7.75 (d, J = 2.2 Hz, 1H), 7.52 (ddd, J = 12.3, 8.7, 3.8 Hz, 1H), 6.81 (d, J = 2.2 Hz, 1H), 3.67 (t, J = 4.8 Hz, 4H), 3.10 (t, J = 4.9 Hz, 4H), 2.94 – 2.81 (m, 2H), 1.16 (t, J = 7.5 Hz, 3H).
126	4-[3-(5-chloro-8-fluoroquinolin-4-yl)-2-methyl-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	464.1	1H NMR (400 MHz, DMSO-d6) δ 9.37 (d, J = 4.4 Hz, 1H), 8.78 – 8.67 (m, 1H), 8.14 (d, J = 4.4 Hz, 1H), 7.87 – 7.82 (m, 2H), 7.83 – 7.79 (m, 1H), 6.81 (d, J = 2.2 Hz, 1H), 3.70 – 3.65 (m, 4H), 3.15 – 3.09 (m, 4H), 2.58 (s, 3H).
127	4-[3-(5-methylquinolin-4-yl)-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	412.1	1H NMR (400 MHz, DMSO-d6) δ 9.15 – 9.08 (m, 1H), 9.07 – 8.99 (m, 1H), 8.50 – 8.45 (m, 1H), 8.17 – 8.11 (m, 1H), 7.84 – 7.73 (m, 3H), 7.52 – 7.46 (m, 1H), 6.75 – 6.72 (m, 1H), 3.71 – 3.66 (m, 4H), 3.13 – 3.08 (m, 4H), 1.84 (s, 3H).
128	4-[3-(3-chloroquinolin-4-yl)-2-methyl-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	446.1	1H NMR (400 MHz, DMSO-d6) δ 9.38 – 9.29 (m, 1H), 8.67 – 8.56 (m, 1H), 8.38 – 8.27 (m, 1H), 8.02 – 7.92 (m, 1H), 7.79 – 7.68 (m, 2H), 7.54 – 7.44 (m, 1H), 6.82 – 6.72 (m, 1H), 3.74 – 3.61 (m, 4H), 3.14 – 3.04 (m, 4H), 2.78 – 2.63 (m, 3H).
129	4-[3-(8-chloroquinolin-4-yl)-2-methyl-7-(5-methyl-4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	460.1	1H NMR (400 MHz, DMSO-d6) δ 9.35 (dd, J = 4.5, 0.6 Hz, 1H), 8.16 - 8.10 (m, 1H), 8.07 (d, J = 4.5 Hz, 1H), 7.77 (d, J = 2.2 Hz, 1H), 7.62 (ddd, J = 8.1, 7.4, 0.6 Hz, 1H), 7.58 - 7.48 (m, 1H), 6.69 (d, J = 2.2 Hz, 1H), 3.64 (t, J = 4.8 Hz, 4H), 3.05 (t, J = 4.1 Hz, 4H), 2.60 - 2.56 (m, 2H), 2.52 (d, J = 0.6 Hz, 2H).
130	4-[3-(8-fluoroquinolin-4-yl)-2-methyl-7-(5-methyl-4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	444.1	1H NMR (400 MHz, DMSO-d6) δ 9.32 - 9.20 (m, 1H), 8.07 (d, J = 4.5 Hz, 1H), 7.83 - 7.71 (m, 2H), 7.64 (td, J = 8.1, 4.9 Hz, 1H), 7.40 (d, J = 8.5 Hz, 1H), 6.68 (d, J = 2.3 Hz, 1H), 3.64 (t, J = 4.8 Hz, 4H), 3.11 - 2.96 (m, 4H), 2.58 (s, 3H), 2.52 (d, J = 0.7 Hz, 3H).
131	4-[3-(5,7-difluoroquinolin-4-yl)-	448.1	1H NMR (400 MHz, DMSO-d6) δ 9.25 (d, J = 4.5 Hz, 1H), 8.72 (s, 1H), 8.09 (d,

	2-methyl-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine		J = 4.5 Hz, 1H), 7.95 (ddd, J = 11.3, 9.0, 2.7 Hz, 1H), 7.80 (d, J = 2.2 Hz, 1H), 7.36 (s, 1H), 6.71 (d, J = 2.2 Hz, 1H), 3.66 (s, 4H), 3.13 - 3.02 (m, 4H), 2.56 (s, 3H).
132	4-[2-(azetidin-3-yl)-3-(8-chloroquinolin-4-yl)-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	487.2	1H NMR (400 MHz, DMSO-d6) δ 9.29 (dd, J = 4.5, 0.7 Hz, 1H), 9.10 (s, 1H), 8.70 (s, 1H), 8.25 (s, 1H), 8.10 (dt, J = 7.5, 1.0 Hz, 1H), 7.89 (dd, J = 4.6, 0.7 Hz, 1H), 7.74 - 7.69 (m, 1H), 7.62 - 7.53 (m, 1H), 7.26 (dt, J = 8.5, 1.0 Hz, 1H), 6.67 - 6.62 (m, 1H), 4.47 (d, J = 8.1 Hz, 1H), 4.21 (s, 4H), 3.76 (p, J = 7.8 Hz, 1H), 3.65 (t, J = 4.8 Hz, 4H), 3.01 (q, J = 3.9 Hz, 4H).
133	4-[3-(8-chloroquinolin-4-yl)-2-ethyl-7-(5-methyl-4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	474.2	1H NMR (400 MHz, DMSO-d6) δ 9.50 - 9.25 (m, 1H), 8.11 (s, 2H), 7.73 (s, 1H), 7.61 (s, 1H), 7.54 - 7.39 (m, 1H), 6.65 (d, J = 3.1 Hz, 1H), 3.63 (d, J = 4.9 Hz, 4H), 3.12 - 2.95 (m, 4H), 2.86 (d, J = 7.6 Hz, 2H), 2.53 - 2.49 (m, 3H), 1.06 (s, 3H).
134	4-[3-(8-chloroquinolin-4-yl)-7-(5-methyl-4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	446.2	1H NMR (400 MHz, DMSO-d6) δ 9.32 – 9.27 (m, 1H), 9.07 – 8.95 (m, 1H), 8.16 – 8.11 (m, 1H), 8.05 – 8.01 (m, 1H), 7.76 – 7.72 (m, 1H), 7.70 – 7.63 (m, 1H), 7.59 – 7.54 (m, 1H), 6.87 – 6.83 (m, 1H), 3.72 – 3.66 (m, 4H), 3.14 – 3.04 (m, 4H), 2.48 – 2.47 (m, 3H).
135	4-[3-(8-chloroquinolin-4-yl)-7-(5-cyclopropyl-4H-1,2,4-triazol-3-yl)-2-methylbenzimidazol-5-yl]morpholine	486.2	1H NMR (400 MHz, DMSO-d6) δ 9.40 – 9.35 (m, 1H), 8.18 – 8.13 (m, 1H), 8.11 – 8.06 (m, 1H), 7.75 – 7.69 (m, 1H), 7.68 – 7.61 (m, 1H), 7.59 – 7.53 (m, 1H), 6.71 – 6.67 (m, 1H), 3.72 – 3.59 (m, 4H), 3.11 – 3.01 (m, 4H), 2.62 – 2.56 (m, 3H), 2.26 – 2.16 (m, 1H), 1.17 – 1.05 (m, 4H).
136	4-[3-(8-chloroquinolin-4-yl)-2-methyl-7-[5-(trifluoromethyl)-4H-1,2,4-triazol-3-yl]benzimidazol-5-yl]morpholine	514.2	1H NMR (400 MHz, DMSO-d6) δ 9.33 – 9.30 (m, 1H), 8.14 – 8.09 (m, 1H), 8.00 (d, J = 4.5 Hz, 1H), 7.65 – 7.57 (m, 2H), 7.30 – 7.25 (m, 1H), 6.71 (d, J = 2.2 Hz, 1H), 3.65 (t, J = 4.7 Hz, 4H), 3.07 – 3.00 (m, 4H), 2.41 (s, 3H).
137	4-[3-(8-chloroquinolin-4-yl)-7-(5-ethyl-4H-	474.2	1H NMR (400 MHz, DMSO-d6) δ 9.38 (d, J = 4.5 Hz, 1H), 8.17 – 8.07 (m, 2H),

	1,2,4-triazol-3-yl)-2-methylbenzimidazol-5-yl]morpholine		7.78 (d, J = 2.2 Hz, 1H), 7.68 – 7.54 (m, 2H), 6.71 (d, J = 2.2 Hz, 1H), 3.66 (t, J = 4.8 Hz, 4H), 3.13 – 3.03 (m, 4H), 2.91 (q, J = 7.6 Hz, 2H), 2.60 (s, 3H), 1.37 (t, J = 7.6 Hz, 3H).
138	4-[3-(8-chloroquinolin-4-yl)-2-methyl-7-(5-propan-2-yl-4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	488.2	1H NMR (400 MHz, DMSO-d6) δ 9.36 (d, J = 4.5 Hz, 1H), 8.16 – 8.12 (m, 1H), 8.08 (d, J = 4.5 Hz, 1H), 7.74 (d, J = 2.2 Hz, 1H), 7.67 – 7.61 (m, 1H), 7.52 (d, J = 8.5 Hz, 1H), 6.68 (d, J = 2.3 Hz, 1H), 3.66 (t, J = 4.8 Hz, 4H), 3.29 – 3.19 (m, 1H), 3.12 – 2.99 (m, 4H), 2.56 (s, 3H), 1.40 (d, J = 7.0 Hz, 6H).
139	4-[2-ethyl-3-(8-fluoroquinolin-4-yl)-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	444.2	1H NMR (400 MHz, DMSO-d6) δ 9.30 (d, J = 4.5 Hz, 1H), 8.65 (s, 1H), 8.10 (d, J = 4.5 Hz, 1H), 7.82 – 7.75 (m, 2H), 7.69 – 7.61 (m, 1H), 7.32 (d, J = 8.5 Hz, 1H), 6.67 (d, J = 2.3 Hz, 1H), 3.66 (t, J = 4.7 Hz, 4H), 3.11 – 3.02 (m, 4H), 2.86 (q, J = 7.5 Hz, 2H), 1.12 (t, J = 7.5 Hz, 3H).
140	4-[3-(8-fluoroquinolin-4-yl)-2-methyl-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	430.2	1H NMR (400 MHz, DMSO-d6) δ 9.30 (d, J = 4.5 Hz, 1H), 8.79 – 8.65 (m, 1H), 8.07 (d, J = 4.5 Hz, 1H), 7.84 – 7.75 (m, 2H), 7.69 – 7.62 (m, 1H), 7.39 (d, J = 8.4 Hz, 1H), 6.71 (d, J = 2.3 Hz, 1H), 3.66 (t, J = 4.8 Hz, 4H), 3.11 – 3.03 (m, 4H), 2.58 (s, 3H).
141	4-[3-(8-fluoroquinolin-4-yl)-2-propyl-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	458.2	1H NMR (400 MHz, DMSO-d6) δ 9.29 (d, J = 4.4 Hz, 1H), 8.62 (s, 1H), 8.09 (d, J = 4.5 Hz, 1H), 7.83 – 7.73 (m, 2H), 7.64 (td, J = 8.1, 5.0 Hz, 1H), 7.28 (d, J = 8.5 Hz, 1H), 6.65 (d, J = 2.3 Hz, 1H), 3.66 (t, J = 4.8 Hz, 4H), 3.12 – 2.98 (m, 4H), 2.91 – 2.74 (m, 2H), 1.66 – 1.46 (m, 2H), 0.78 (t, J = 7.4 Hz, 3H).
142	4-[3-(7,8-difluoroquinolin-4-yl)-2-methyl-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	448.2	1H NMR (400 MHz, Methanol-d4) δ 9.34 (d, J = 4.5 Hz, 1H), 8.75 – 8.59 (m, 1H), 8.06 (d, J = 4.5 Hz, 1H), 7.85 – 7.75 (m, 2H), 7.53 – 7.44 (m, 1H), 6.69 (d, J = 2.2 Hz, 1H), 3.67 (t, J = 4.8 Hz, 4H), 3.10 – 3.04 (m, 4H), 2.57 (s, 3H).
143	4-[2-cyclopropyl-3-(7,8-difluoroquinolin-4-yl)-7-(4H-1,2,4-	474.2	1H NMR (400 MHz, Methanol-d4) δ 9.30 (d, J = 4.6 Hz, 1H), 8.38 – 8.30 (m, 1H), 8.01 (d, J = 4.5 Hz, 1H), 7.85 –

	triazol-3-yl)benzimidazol-5-yl]morpholine		7.74 (m, 1H), 7.66 – 7.60 (m, 1H), 7.36 – 7.26 (m, 1H), 6.68 – 6.64 (m, 1H), 3.67 (t, J = 4.7 Hz, 4H), 3.10 – 2.97 (m, 4H), 1.70 – 1.60 (m, 1H), 1.49 – 1.30 (m, 2H), 1.02 – 0.80 (m, 2H).
144	4-[2-cyclopropyl-3-(8-fluoroquinolin-4-yl)-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	456.2	1H NMR (400 MHz, Methanol-d4) δ 9.27 (d, J = 4.5 Hz, 1H), 8.41 (s, 1H), 8.03 (d, J = 4.5 Hz, 1H), 7.80 – 7.72 (m, 1H), 7.68 – 7.61 (m, 2H), 7.27 – 7.21 (m, 1H), 6.67 (d, J = 2.3 Hz, 1H), 3.67 (t, J = 4.8 Hz, 4H), 3.09 – 2.99 (m, 4H), 1.71 – 1.61 (m, 1H), 1.48 – 1.30 (m, 2H), 1.02 – 0.82 (m, 2H).
145	4-[3-(6,8-difluoroquinolin-4-yl)-2-methyl-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	448.2	1H NMR (400 MHz, DMSO-d6) δ 9.28 (d, J = 4.5 Hz, 1H), 8.79 (s, 1H), 8.12 (d, J = 4.5 Hz, 1H), 7.97 (ddd, J = 10.7, 9.0, 2.7 Hz, 1H), 7.86 – 7.81 (m, 1H), 7.48 – 7.37 (m, 1H), 6.74 (d, J = 2.3 Hz, 1H), 3.68 (t, J = 4.8 Hz, 4H), 3.14 – 3.07 (m, 4H), 2.61 (s, 3H).
146	4-[3-(6,8-difluoroquinolin-4-yl)-2-propyl-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	476.2	1H NMR (400 MHz, DMSO-d6) δ 9.26 (d, J = 4.5 Hz, 1H), 8.72 – 8.61 (m, 1H), 8.17 – 8.11 (m, 1H), 8.01 – 7.90 (m, 1H), 7.84 – 7.76 (m, 1H), 7.34 – 7.20 (m, 1H), 6.72 – 6.66 (m, 1H), 3.67 (t, J = 4.8 Hz, 4H), 3.10 – 3.05 (m, 4H), 2.95 – 2.74 (m, 2H), 1.68 – 1.45 (m, 2H), 0.80 (t, J = 7.3 Hz, 3H).
147	4-(2-methyl-4-(4H-1,2,4-triazol-3-yl)-1-(2-(1-trityl-1H-pyrazol-4-yl)quinolin-4-yl)-1H-benzo[d]imidazol-6-yl)morpholine	720.4	
148	tert-butyl 4-(4-(2-methyl-6-morpholino-4-(4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-1-yl)quinolin-2-yl)piperazine-1-carboxylate	596.4	
149	4-(1-(8-chloroquinolin-4-yl)-7-fluoro-4-(4H-1,2,4-triazol-3-yl)-1H-	450.1	1H NMR (400 MHz, DMSO-d6) δ 9.26 (d, J = 4.5 Hz, 1H), 8.73 (s, 1H), 8.28 (s, 1H), 8.12 (dd, J = 7.5, 1.2 Hz, 1H), 8.07

	benzo[d]imidazol-6-yl)morpholine		(d, J = 4.6 Hz, 1H), 7.75 (d, J = 7.6 Hz, 1H), 7.69 – 7.63 (m, 1H), 7.57 – 7.52 (m, 1H), 3.68 (t, J = 4.6 Hz, 4H), 3.08 – 2.93 (m, 4H).
150	4-(1-(8-chloro-5-fluoroquinolin-4-yl)-7-fluoro-2-methyl-4-(4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	482.1	1H NMR (400 MHz, DMSO-d6) δ 9.35 (d, J = 4.5 Hz, 1H), 8.36 (s, 1H), 8.18 – 8.13 (m, 2H), 7.64 (d, J = 7.7 Hz, 1H), 7.55 (dd, J = 11.9, 8.5 Hz, 1H), 3.69 – 3.63 (m, 4H), 3.05 – 2.90 (m, 4H), 2.43 (s, 3H).
151	4-(1-(5,8-dichloroquinolin-4-yl)-2-methyl-4-(5-methyl-4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	494.1	1H NMR (400 MHz, DMSO-d6) δ 9.42 (d, J = 4.4 Hz, 1H), 8.18 – 8.08 (m, 2H), 7.81 (d, J = 8.3 Hz, 1H), 7.74 (d, J = 2.2 Hz, 1H), 6.79 (d, J = 2.2 Hz, 1H), 3.70 – 3.49 (m, 4H), 3.08 (t, J = 4.9 Hz, 4H), 2.56 (s, 3H), 2.51 (s, 3H).
152	4-(1-(5,8-difluoroquinolin-4-yl)-2-ethyl-4-(5-methyl-4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	476.2	1H NMR (400 MHz, DMSO-d6) δ 9.35 (d, J = 4.5 Hz, 1H), 8.15 (d, J = 4.5 Hz, 1H), 7.86 – 7.75 (m, 1H), 7.71 (d, J = 2.3 Hz, 1H), 7.51 (ddd, J = 12.3, 8.8, 3.7 Hz, 1H), 6.79 (d, J = 2.2 Hz, 1H), 3.65 (t, J = 4.8 Hz, 4H), 3.07 (dd, J = 6.0, 3.8 Hz, 4H), 2.90 (dd, J = 7.5, 3.4 Hz, 2H), 2.51 (s, 3H), 1.11 (t, J = 7.5 Hz, 3H).
153	4-(1-(3-fluoroquinolin-4-yl)-2-methyl-4-(4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	430.2	1H NMR (400 MHz, DMSO-d6) δ 9.35 (d, J = 4.6 Hz, 1H), 8.53 (s, 1H), 8.29 (d, J = 8.4 Hz, 1H), 7.91 (ddd, J = 8.5, 6.9, 1.4 Hz, 1H), 7.71 (t, J = 7.6 Hz, 2H), 7.49 (d, J = 8.2 Hz, 1H), 6.79 (s, 1H), 3.65 (t, J = 4.8 Hz, 4H), 3.06 (d, J = 3.3 Hz, 4H), 2.49 (s, 3H).
154	4-(1-(3-fluoroquinolin-4-yl)-2-methyl-4-(5-methyl-4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	444.2	1H NMR (400 MHz, DMSO-d6) δ 9.35 (d, J = 0.9 Hz, 1H), 8.33 – 8.26 (m, 1H), 7.91 (ddd, J = 8.5, 6.9, 1.3 Hz, 1H), 7.76 – 7.65 (m, 2H), 7.50 (d, J = 8.4 Hz, 1H), 6.78 (d, J = 2.2 Hz, 1H), 3.64 (t, J = 4.8 Hz, 4H), 3.05 (q, J = 3.9 Hz, 4H), 2.49 (d, J = 1.9 Hz, 6H).
155	4-(2-ethyl-6-morpholino-4-(4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-1-yl)-3-methylquinoline-8-carbonitrile	465.2	1H NMR (400 MHz, DMSO-d6) δ 9.34 (d, J = 0.5 Hz, 1H), 8.54 (s, 1H), 8.43 (dd, J = 7.2, 1.3 Hz, 1H), 7.76 – 7.67 (m, 2H), 7.60 (d, J = 8.4 Hz, 1H), 6.64 (d, J = 2.3 Hz, 1H), 3.64 (t, J = 4.8 Hz, 4H), 3.05 (dd, J = 6.3, 3.8 Hz, 4H), 2.67 (d, J = 8.1 Hz, 2H), 2.21 (s, 3H), 1.11 (t, J =

			7.5 Hz, 3H).
156	3-methyl-4-(2-methyl-6-morpholino-4-(4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-1-yl)quinoline-8-carbonitrile	451.2	1H NMR (400 MHz, DMSO-d6) δ 9.35 (d, J = 0.5 Hz, 1H), 8.61 (s, 1H), 8.44 (dd, J = 7.1, 1.4 Hz, 1H), 7.87 – 7.60 (m, 3H), 6.68 (d, J = 2.3 Hz, 1H), 3.64 (t, J = 4.7 Hz, 4H), 3.06 (dd, J = 6.2, 3.7 Hz, 4H), 2.44 (s, 3H), 2.23 (s, 3H).
157	4-(1-(3,8-dichloroquinolin-4-yl)-2-methyl-4-(5-methyl-4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	494.1	1H NMR (400 MHz, DMSO-d6) δ 9.42 (s, 1H), 8.14 (dd, J = 7.6, 1.2 Hz, 1H), 7.71 – 7.62 (m, 2H), 7.38 (d, J = 8.5 Hz, 1H), 6.76 (d, J = 2.3 Hz, 1H), 3.72 – 3.58 (m, 4H), 3.04 (dd, J = 6.1, 3.8 Hz, 4H), 2.48 (s, 3H), 2.44 (s, 3H).
158	tert-butyl 4-(4-(6-morpholino-4-(4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-1-yl)quinolin-2-yl)piperazine-1-carboxylate		
159	4-(4-(5-methyl-4H-1,2,4-triazol-3-yl)-1-(2-(1-trityl-1H-pyrazol-3-yl)quinolin-4-yl)-1H-benzo[d]imidazol-6-yl)morpholine		
384	4-(4-(4H-1,2,4-triazol-3-yl)-1-(2-(1-trityl-1H-pyrazol-3-yl)quinolin-4-yl)-1H-benzo[d]imidazol-6-yl)morpholine		
385	4-(4-(5-methyl-4H-1,2,4-triazol-3-yl)-1-(2-(1-trityl-1H-pyrazol-4-yl)quinolin-4-yl)-1H-benzo[d]imidazol-6-yl)morpholine		
386	4-(4-(4H-1,2,4-triazol-3-yl)-1-(2-(1-trityl-1H-pyrazol-4-yl)quinolin-4-yl)-1H-benzo[d]imidazol-6-		

	yl)morpholine		
391	4-(1-(3-(4H-1,2,4-triazol-3-yl)quinolin-4-yl)-2-ethyl-4-(4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	493.2	1H NMR (400 MHz, DMSO-d6) δ 9.91 (s, 1H), 8.72 (s, 1H), 8.60 (s, 1H), 8.35 – 8.28 (m, 1H), 7.96 (ddd, J = 8.4, 6.9, 1.4 Hz, 1H), 7.77 – 7.65 (m, 2H), 7.57 (s, 1H), 6.57 (d, J = 2.2 Hz, 1H), 3.81 – 3.43 (m, 4H), 2.98 (t, J = 4.9 Hz, 4H), 2.84 – 2.57 (m, 2H), 0.95 (t, J = 7.5 Hz, 3H).
392	4-(1-(3-(4H-1,2,4-triazol-3-yl)quinolin-4-yl)-2-methyl-4-(4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	479.2	1H NMR (400 MHz, DMSO-d6) δ 9.91 (s, 1H), 8.83 (s, 1H), 8.60 (s, 1H), 8.32 (dt, J = 8.5, 0.9 Hz, 1H), 7.97 (ddd, J = 8.4, 6.8, 1.5 Hz, 1H), 7.89 – 7.53 (m, 4H), 6.60 (d, J = 2.2 Hz, 1H), 3.59 (t, J = 4.8 Hz, 4H), 2.99 (t, J = 5.0 Hz, 4H), 2.49 (s, 3H).

Step 5a: 4-(2-methyl-1-(2-methylquinolin-4-yl)-4-(1H-tetrazol-5-yl)-1H-benzo[d]imidazol-6-yl)morpholine



To a suspension of ammonium chloride (193 mg, 3.6 mmol) in dichloroethane (2 mL) at 0°C under N_2 was added trimethylaluminum (1.8 mL of a 2.0M heptane solution, 3.6 mmol). The mixture was stirred at 0°C for 5 minutes, then at ambient temperature for 20 minutes. The reaction was cooled back to 0°C, and a suspension of methyl 2-methyl-1-(2-methylquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carboxylate (300 mg, 0.72 mmol) in dichloroethane (1 mL) was added. The reaction was allowed to warm to ambient temperature and stir for 3 days. After heating to 60°C for 3 hours the reaction was allowed to cool, then treated with aq. citric acid. The product was extracted 3x into dichloromethane and was purified on silica (0 – 100% EtOAc in DCM) to give 2-methyl-

1-(2-methylquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carbonitrile. 2-Methyl-1-(2-methylquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazole-4-carbonitrile (50 mg, 0.13 mmol) was combined with sodium azide (85 mg, 1.3 mmol) and ammonium chloride (70 mg, 1.3 mmol) in DMF (1 mL) and heated in a microwave at 100°C for 14 hours. The crude reaction was purified by preparatory LC to provide 4-(2-methyl-1-(2-methylquinolin-4-yl)-4-(1H-tetrazol-5-yl)-1H-benzo[d]imidazol-6-yl)morpholine (Compound 160). 1H NMR (400 MHz, DMSO-d6) δ 8.21 – 8.14 (m, 1H), 7.88 (ddd, J = 8.5, 6.9, 1.4 Hz, 1H), 7.83 (s, 1H), 7.71 (d, J = 2.2 Hz, 1H), 7.58 (ddd, J = 8.2, 6.9, 1.2 Hz, 1H), 7.31 (d, J = 8.2 Hz, 1H), 6.71 (d, J = 2.2 Hz, 1H), 3.67 (t, J = 4.8 Hz, 4H), 3.14 – 2.99 (m, 4H), 2.82 (s, 3H), 2.45 (s, 3H). ES/MS *m/z* = 427.2 $(M+H)^+$.

The compounds listed in the table below were prepared in a manner similar to that described above using appropriate intermediates and chemistry.

Compound	Compound Name	MS	NMR
161	4-(1-(8-chloroquinolin-4-yl)-2-methyl-4-(1H-tetrazol-5-yl)-1H-benzo[d]imidazol-6-yl)morpholine	447.1	1H NMR (400 MHz, DMSO-d6) δ 9.34 (d, J = 4.5 Hz, 1H), 8.12 (dd, J = 7.6, 1.2 Hz, 1H), 8.02 (d, J = 4.5 Hz, 1H), 7.70 (d, J = 2.2 Hz, 1H), 7.62 (dd, J = 8.5, 7.5 Hz, 1H), 7.36 (dd, J = 8.5, 1.2 Hz, 1H), 6.76 (d, J = 2.2 Hz, 1H), 3.67 (t, J = 4.7 Hz, 4H), 3.07 (q, J = 4.1 Hz, 4H), 2.45 (s, 3H).

Step 5b: 4-(1-(8-chloroquinolin-4-yl)-2-methyl-4-(1,3,4-oxadiazol-2-yl)-1H-benzo[d]imidazol-6-yl)morpholine



A solution of methyl 1-(8-chloroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylate (210 mg, 0.48 mmol) and hydrazine hydrate (0.46 mL, 9.6 mmol) in ethanol was refluxed for 2h. Upon cooling, the reaction mixture was concentrated. Ethyl acetate and water were added followed by two extractions of the aqueous phase with ethyl acetate. The combined organic phases were dried over MgSO4, filtrated and concentrated under reduce pressure to afford 1-(8-chloroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carbohydrazide (ES/MS m/z = 437.1 $(M+H)^+$) which was dissolved in trimethylorthoformate (2.6 mL) and trifluoroacetic acid (0.5 mL) and heated to 100 °C for 45 minutes. After cooling and concentration under reduced pressure, the resultant was purified by HPLC eluting with 5-95% water/ acetonitrile (0.1%v/v trifluoroacetic acid). The appropriate fractions were pooled and lyophilized to afford 4-(1-(8-chloroquinolin-4-yl)-2-methyl-4-(1,3,4-oxadiazol-2-yl)-1H-benzo[d]imidazol-6-yl)morpholine as a 2,2,2-trifluoroacetic acid salt (Compound 162). 1H NMR (400 MHz, DMSO-d6) δ 9.50 (s, 1H), 9.31 (d, J = 4.5 Hz, 1H), 8.10 (dd, J = 7.5, 1.2 Hz, 1H), 7.98 (d, J = 4.5 Hz, 1H), 7.63 – 7.56 (m, 2H), 7.32 (dd, J = 8.5, 1.2 Hz, 1H), 6.77 (d, J = 2.2 Hz, 1H), 3.64 (t, J = 4.8 Hz, 4H), 3.04 (q, J = 4.3 Hz, 4H), 2.39 (s, 3H). ES/MS m/z = 447.1 $(M+H)^+$.

Step 5c: 5-(1-(7-fluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazol-4-yl)-1,3,4-oxadiazol-2-amine



1-(7-fluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carbohydrazide was prepared in a manner similar to 1-(8-chloroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carbohydrazide. A mixture of 1-(7-fluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carbohydrazide (50 mg, 0.119 mmol), sodium bicarbonate (15 mg, 0.178 mmol) and BrCN (14.5 mg, 0.137 mmol) was stirred at room temperature for 4 hours. After concentration under reduced pressure, the resultant was purified by HPLC eluting with 5-95% water/ acetonitrile (0.1%v/v trifluoroacetic acid). The appropriate fractions were pooled and lyophilized to afford 5-(1-(7-fluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazol-4-yl)-1,3,4-oxadiazol-2-amine as a 2,2,2-trifluoroacetic acid salt(Compound 163). 1H NMR (400 MHz, DMSO-d6) δ 9.23 (d, J = 4.6 Hz, 1H), 8.09 – 8.00 (m, 1H), 7.88 (d, J = 4.6 Hz, 1H), 7.63 – 7.45 (m, 5H), 7.39 (d, J = 2.2 Hz, 1H), 6.66 (s, 1H), 3.63 (t, J = 4.8 Hz, 4H), 3.06 - 2.98 (m, 4H), 2.44 (s, 3H). ES/MS m/z = 446.2 $(M+H)^+$.

Step 5d: 5-(1-(7-fluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazol-4-yl)-1,3,4-oxadiazole-2(3H)-thione



1-(7-fluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carbohydrazide was prepared in a manner similar to 1-(8-chloroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carbohydrazide. A mixture of 1-(7-fluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carbohydrazide (50 mg, 0.119 mmol), potassium hydroxide (13.3 mg, 0.238 mmol) and CS_2 (14.3 □L, 0.238 mmol) was refluxed for 20 hours. After concentration under reduced pressure, the resultant was purified by HPLC eluting with 5-95% water/ acetonitrile (0.1%v/v trifluoroacetic acid). The appropriate fractions were pooled and lyophilized to afford 5-(1-(7-fluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazol-4-yl)-1,3,4-oxadiazole-2(3H)-thione as a 2,2,2-trifluoroacetic acid salt (Compound 164). H NMR (400 MHz, DMSO-d6) δ 9.21 (d, J = 4.6 Hz, 1H), 8.02 (dd, J = 10.1, 2.6 Hz, 1H), 7.83 (d, J = 4.7 Hz, 1H), 7.57 (td, J = 8.9, 2.7 Hz, 1H), 7.43 – 7.35 (m, 2H), 6.71 (d, J = 2.2 Hz, 1H), 3.63 (t, J = 4.7 Hz, 4H), 3.08 – 2.94 (m, 4H), 2.35 (d, J = 1.3 Hz, 3H). ES/MS m/z = 463.2 $(M+H)^+$.

Step 5e: 5-(1-(7-fluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazol-4-yl)-1,3,4-thiadiazol-2-amine



1-(7-fluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carbohydrazide was prepared in a manner similar to 1-(8-chloroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carbohydrazide. A mixture of 1-(7-fluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carbohydrazide (100 mg, 0.238 mmol) and trimethylsilyl isothiocyanate (33 □L, 0.238 mmol) in ethanol (2.3 mL) was refluxed for 4 h, and then the reaction mixture was concentrated. After adding conc. H_2SO_4 (2.3 mL), the solution was stirred at 30 °C for 6 h. The mixture was slowly neutralized by adding potassium carbonate. The aqueous phase was extracted twice with dichloromethane. After concentration under reduced pressure, the resultant

was purified by HPLC eluting with 5-95% water/ acetonitrile (0.1%v/v trifluoroacetic acid). The appropriate fractions were pooled and lyophilized to 5-(1-(7-fluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazol-4-yl)-1,3,4-thiadiazol-2-amine as a 2,2,2-trifluoroacetic acid salt (Compound 165). 1H NMR (400 MHz, DMSO-d6) δ 9.22 - 9.19 (m, 1H), 8.03 - 7.98 (m, 1H), 7.85 - 7.82 (m, 1H), 7.73 – 7.51 (m, 4H), 7.48 - 7.41 (m, 1H), 6.55 - 6.52 (m, 1H), 3.68 - 3.60 (m, 4H), 3.05 - 2.95 (m, 4H), 2.35 (s, 3H). ES/MS m/z = 462.2 $(M+H)^+$.

Step 5f: 5-(1-(7-fluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazol-4-yl)-1,3,4-oxadiazol-2(3H)-one



1-(7-fluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carbohydrazide was prepared in a manner similar to 1-(8-chloroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carbohydrazide. A mixture of 1-(7-fluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carbohydrazide (50 mg, 0.119 mmol) and carbonyl diimidazole (21 mg, 0.131 mmol) in THF (2.0 mL) was stirred at room temperature for 16 h. After concentration under reduced pressure, the resultant was purified by HPLC eluting with 5-95% water/ acetonitrile (0.1%v/v trifluoroacetic acid). The appropriate fractions were pooled and lyophilized to afford 5-(1-(7-fluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazol-4-yl)-1,3,4-oxadiazol-2(3H)-one as a 2,2,2-trifluoroacetic acid salt (Compound 166). 1H NMR (400 MHz, DMSO-d6) δ 12.75 (s, 1H), 9.20 (d, J = 4.6 Hz, 1H), 8.02 (dd, J = 10.1, 2.6 Hz, 1H), 7.83 (d, J = 4.6 Hz, 1H), 7.57 (td, J = 8.8, 2.7 Hz, 1H), 7.42 (dd, J = 9.2, 6.0 Hz, 1H), 7.35 (d, J = 2.2 Hz, 1H), 6.65 (d, J = 2.2 Hz, 1H), 3.62 (t, J = 4.8 Hz, 4H), 3.08 – 2.93 (m, 4H), 2.36 (s, 3H). ES/MS *m/z* = 447.2 $(M+H)^+$.

Step 5g: 4-(1-(2-(1H-pyrazol-4-yl)quinolin-4-yl)-2-methyl-4-(4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine.



Trifluoroacetic acid (0.50 mL, 6.53 mmol) was added to 4-(2-methyl-4-(4H-1,2,4-triazol-3-yl)-1-(2-(1-trityl-1H-pyrazol-4-yl)quinolin-4-yl)-1H-benzo[d]imidazol-6-yl)morpholine (180 mg, 0.25 mmol) in DCM (6 mL). The reaction mixture was stirred for 2 hours at ambient temperature. The resultant was purified by HPLC eluting with 5-95% water/ acetonitrile (0.1%v/v trifluoroacetic acid). The appropriate fractions were pooled and lyophilized to afford 4-(1-(2-(1H-pyrazol-4-yl)quinolin-4-yl)-2-methyl-4-(4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine 2,2,2-trifluoroacetate (Compound 167). ^{1}H NMR (400 MHz, DMSO-d6) δ 8.81 (s, 1H), 8.40 (s, 2H), 8.35 (s, 1H), 8.23 - 8.13 (m, 1H), 7.93 - 7.83 (m, 2H), 7.60 - 7.48 (m, 2H), 6.79 - 6.73 (m, 1H), 3.65 (t, J = 4.8 Hz, 4H), 3.13 - 3.04 (m, 4H), 2.66 (s, 3H). ES/MS *m/z* = 478.20 $(M+H)^{+}$.

The compounds listed in the table below were prepared in a manner similar to that described above using appropriate intermediates and chemistry known to those skilled in the art.

Compound	name	MS	NMR
380	4-(1-(2-(1H-pyrazol-4-yl)quinolin-4-yl)-4-(5-methyl-4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	478.2	1H NMR (400 MHz, DMSO-d6) δ 9.23 (s, 1H), 8.44 (s, 2H), 8.30 (s, 1H), 8.18 – 8.12 (m, 1H), 7.85 (ddd, J = 8.4, 6.8, 1.5 Hz, 1H), 7.77 (d, J = 2.2 Hz, 1H), 7.55 (ddd, J = 8.1, 6.8, 1.2 Hz, 1H), 7.47 (d, J = 8.1 Hz, 1H), 6.84 (d, J = 2.3 Hz, 1H), 3.66 (t,

			J = 4.8 Hz, 4H), 3.08 (d, J = 5.2 Hz, 5H), 2.49 (s, 3H).
381	4-(1-(2-(1H-pyrazol-4-yl)quinolin-4-yl)-4-(4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	464.2	1H NMR (400 MHz, DMSO-d6) δ 9.19 (s, 1H), 8.50 (s, 1H), 8.45 (s, 2H), 8.30 (s, 1H), 8.15 (ddd, J = 8.5, 1.2, 0.6 Hz, 1H), 7.85 (ddd, J = 8.4, 6.8, 1.4 Hz, 1H), 7.82 (d, J = 2.2 Hz, 1H), 7.55 (ddd, J = 8.1, 6.8, 1.2 Hz, 1H), 7.49 – 7.44 (m, 1H), 6.85 (d, J = 2.3 Hz, 1H), 3.67 (t, J = 4.8 Hz, 4H), 3.15 - 3.02 (m, 4H).
382	4-(1-(2-(1H-pyrazol-3-yl)quinolin-4-yl)-4-(5-methyl-4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	478.2	1H NMR (400 MHz, DMSO-d6) δ 8.42 (s, 1H), 8.23 (d, J = 8.6 Hz, 1H), 7.94 – 7.86 (m, 1H), 7.77 (d, J = 2.2 Hz, 1H), 7.61 (ddd, J = 8.2, 6.9, 1.2 Hz, 1H), 7.51 (d, J = 8.3 Hz, 1H), 7.12 (d, J = 2.3 Hz, 1H), 6.84 (d, J = 2.2 Hz, 1H), 3.66 (t, J = 4.8 Hz, 5H), 3.08 (d, J = 7.2 Hz, 5H), 2.49 (s, 3H).
383	4-(1-(2-(1H-pyrazol-3-yl)quinolin-4-yl)-4-(4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	464.2	1H NMR (400 MHz, DMSO-d6) δ 9.20 (s, 1H), 8.50 (s, 1H), 8.42 (s, 1H), 8.23 (ddd, J = 8.5, 1.1, 0.6 Hz, 1H), 7.90 (ddd, J = 8.4, 6.9, 1.4 Hz, 2H), 7.81 (d, J = 2.2 Hz, 1H), 7.61 (ddd, J = 8.2, 6.8, 1.2 Hz, 1H), 7.51 (ddd, J = 8.4, 1.5, 0.7 Hz, 1H), 7.12 (d, J = 2.3 Hz, 1H), 6.85 (d, J = 2.3 Hz,

			1H), 3.66 (t, J = 4.8 Hz, 4H), 3.08 (d, J = 5.1 Hz, 4H).

Step 5h: 4-(2-methyl-1-(2-(piperazin-1-yl)quinolin-4-yl)-4-(4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine 2,2,2-trifluoroacetate.



To a solution of tert-butyl 4-(4-(2-methyl-6-morpholino-4-(4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-1-yl)quinolin-2-yl)piperazine-1-carboxylate (319 mg, 0.54 mmol) in DCM (3.0 mL) was added TFA (0.8 mL). After concentration under reduced pressure, the resultant was purified by HPLC eluting with 5-95% water/ acetonitrile (0.1%v/v trifluoroacetic acid). The appropriate fractions were pooled and lyophilized to afford the parent compound as a 2,2,2-trifluoroacetic acid salt. ES/MS m/z = 482.2 (M+H)+. (Compound 168). ^{1}H NMR (400 MHz, DMSO-d6) δ 8.96 (s, 2H), 8.71 (s, 1H), 7.87 - 7.67 (m, 4H), 7.34 - 7.21 (m, 2H), 6.71 - 6.64 (m, 1H), 4.03 - 3.90 (m, 4H), 3.72 - 3.64 (m, 4H), 3.31 - 3.26 (m, 4H), 3.14 - 3.04 (m, 4H), 2.59 (s, 3H). ES/MS *m/z* 496.30 $(M+H)^+$.

The compounds listed in the table below were prepared in a manner similar to that described above using appropriate intermediates and chemistry known to those skilled in the art.

Compound	name	MS	NMR
169	4-(2-methyl-4-(5-methyl-4H-1,2,4-triazol-3-yl)-1-(2-(piperazin-1-yl)quinolin-4-yl)-1H-benzo[d]imidazol-6-	510.3	1H NMR (400 MHz, DMSO-d6) δ 8.87 (s, 1H), 7.82 (dt, J = 8.6, 0.9 Hz, 1H), 7.76 (s, 1H), 7.73 (dddd, J = 8.4, 6.7, 1.4, 0.0 Hz,

	yl)morpholine		1H), 7.30 (ddd, J = 8.1, 6.8, 1.2 Hz, 1H), 7.25 - 7.19 (m, 1H), 6.63 (d, J = 1.9 Hz, 1H), 3.96 (dd, J = 6.2, 4.0 Hz, 4H), 3.67 (t, J = 4.8 Hz, 4H), 3.33 - 3.24 (m, 4H), 3.07 (q, J = 4.6 Hz, 4H), 2.56 (s, 3H), 2.51 (s, 3H).
379	4-(1-(2-(piperazin-1-yl)quinolin-4-yl)-4-(4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	482.3	1H NMR (400 MHz, DMSO-d6) δ 8.89 (s, 3H), 8.40 (s, 1H), 7.82 – 7.75 (m, 2H), 7.74 – 7.67 (m, 2H), 7.34 – 7.25 (m, 2H), 6.79 (d, J = 2.3 Hz, 1H), 3.97 (s, 4H), 3.69 (t, J = 4.8 Hz, 4H), 3.25 (s, 4H), 3.08 (d, J = 5.1 Hz, 4H).

Step 5i: 5-(1-(5,8-difluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazol-4-yl)-4H-1,2,4-triazol-3-amine



Anhydrous hydrazine (0.36 mL, 11.4 mmol) was added to a suspension of methyl 1-(5,8-difluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carboxylate (500 mg, 1.14 mmol) in MeOH (4 mL) and heated to 65C. After several hours, the reaction was cooled and filtered. The yellow solid was washed with MeOH and dried to give 1-(5,8-difluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-

carbohydrazide. 1-(5,8-difluoroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazole-4-carbohydrazide (99 mg, 0.226 mmol) and cyanamide (80 mg, 1.90 mmol) were combined in DMF (0.5 mL) and heated to 120°C for 4 days. The mixture was purified by HPLC eluting with 5-95% water/ acetonitrile (0.1%v/v trifluoroacetic acid) to give the title compound (Compound 393). 1H NMR (400 MHz, DMSO-d6) δ 9.33 (d, J = 4.5 Hz, 1H), 8.05 (d, J = 4.5 Hz, 1H), 7.81 (ddd, J = 10.0, 9.0, 4.2 Hz, 1H), 7.53 (d, J = 2.3 Hz, 1H), 7.54 - 7.44 (m, 1H), 6.83 (d, J = 2.3 Hz, 1H), 3.70 - 3.63 (m, 4H), 3.09 - 3.02 (m, 4H), 2.48 (s, 3H). ES/MS m/z = 463.2 $(M+H)^+$.

Step 6: 4-(4-(5-chloro-4H-1,2,4-triazol-3-yl)-1-(8-chloro-5-fluoroquinolin-4-yl)-2-methyl-1H-benzo[d]imidazol-6-yl)morpholine



[1,1′-Bis(diphenylphosphino)ferrocene] dichloropalladium(II), complex with dichloromethane (50.29 mg, 0.06 mmol) was added to a mixture of 4-(4-bromo-1-(8-chloro-5-fluoroquinolin-4-yl)-2-methyl-1H-benzo[d]imidazol-6-yl)morpholine (293 mg, 0.62 mmol), Bis-(Pinacolato) Diboron (187.67 mg, 0.74 mmol), and potassium acetate (181.33 mg, 1.85 mmol) in dioxane (1.2 mL). The reaction mixture was degassed and stirred at 125 °C for 5 hours. The resultant was filtered through a pad of celite and washed with ethyl acetate (25 mL). The filtrate was concentrated to afford 4-(1-(8-chloro-5-fluoroquinolin-4-yl)-2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-benzo[d]imidazol-6-yl)morpholine, which was dissolved in THF (10 mL) and water (2 mL) with 3,5-dichloro-4-(tetrahydro-2H-pyran-2-yl)-4H-1,2,4-triazole (205.16 mg, 0.92 mmol) and tripotassium phosphate (39 mg, 2 mmol). Tetrakis(triphenylphosphine)palladium(0) (71 mg, 0.06 mmol) was added and the reagents were stirred at 90 °C for 16 hours, after which time the reaction mixture was cooled to ambient temperature and partitioned between ethyl acetate (50 mL) and water (50 mL). The aqueous layer was extracted 3 times with ethyl acetate. The combined

organic phases were dried with sodium sulfate and filtered. The resultant residue was purified on silica gel with 0 to 100% ethyl acetate in hexanes to afford 4-(4-(5-chloro-4-(tetrahydro-2H-pyran-2-yl)-4H-1,2,4-triazol-3-yl)-1-(8-chloro-5-fluoroquinolin-4-yl)-2-methyl-1H-benzo[d]imidazol-6-yl)morpholine which was dissolved in DCM (2 mL). Trifluoroacetic acid (2 mL) was added and the reaction mixture was stirred at 40 °C for 2 hour, after which the reaction was cooled to ambient temperature. The resultant was purified by HPLC eluting with 5-95% water/ acetonitrile (0.1%v/v trifluoroacetic acid). The appropriate fractions were pooled and lyophilized to afford 4-(4-(5-chloro-4H-1,2,4-triazol-3-yl)-1-(8-chloro-5-fluoroquinolin-4-yl)-2-methyl-1H-benzo[d]imidazol-6-yl)morpholine (Compound 170). ^{1}H NMR (400 MHz, DMSO-d6) δ 9.35 (d, J = 4.5 Hz, 1H), 8.15 - 8.07 (m, 1H), 8.00 (d, J = 4.5 Hz, 1H), 7.53 - 7.43 (m, 2H), 6.79 (d, J = 2.2 Hz, 1H), 3.67 - 3.61 (m, 4H), 3.04 (t, J = 4.9 Hz, 4H), 2.39 (s, 3H). ES/MS *m/z* = 498.1 $(M+H)^{+}$.

The compounds listed in the table below were prepared in a manner similar to that described above using appropriate intermediates and chemistry known to those skilled in the art.

Compound	name	MS	NMR
171	4-(4-(5-chloro-4H-1,2,4-triazol-3-yl)-1-(8-chloro-7-fluoroquinolin-4-yl)-2-methyl-1H-benzo[d]imidazol-6-yl)morpholine	498.1	1H NMR (400 MHz, DMSO-d6) δ 9.36 (d, J = 4.5 Hz, 1H), 7.99 (d, J = 4.6 Hz, 1H), 7.75 (t, J = 9.1 Hz, 1H), 7.59 – 7.54 (m, 1H), 7.44 – 7.36 (m, 1H), 6.73 – 6.65 (m, 1H), 3.66 (t, J = 4.8 Hz, 4H), 3.05 – 3.01 (m, 4H), 2.43 (s, 3H).
172	4-(4-(5-chloro-4H-1,2,4-triazol-3-yl)-1-(8-chloro-7-fluoroquinolin-4-yl)-2-ethyl-1H-benzo[d]imidazol-6-yl)morpholine	512.1	1H NMR (400 MHz, DMSO-d6) δ 9.35 (d, J = 4.5 Hz, 1H), 8.00 (d, J = 4.6 Hz, 1H), 7.74 (t, J = 9.1 Hz, 1H), 7.57 – 7.52 (m, 1H), 7.38 – 7.30 (m, 1H), 6.69 – 6.65 (m, 1H), 3.65 (t, J = 4.8 Hz, 4H), 3.06 – 2.98 (m, 4H), 2.77 – 2.57 (m, 2H), 1.21 (t, J = 7.5 Hz, 3H).
173	4-(4-(5-chloro-4H-1,2,4-triazol-3-yl)-1-(8-chloro-7-fluoroquinolin-4-yl)-2-cyclopropyl-1H-benzo[d]imidazol-6-	524.1	1H NMR (400 MHz, DMSO-d6) δ 9.35 (d, J = 4.6 Hz, 1H), 8.00 (d, J = 4.6 Hz, 1H), 7.79 – 7.72 (m, 1H), 7.53 – 7.51 (m, 1H), 7.45 – 7.37 (m, 1H), 6.71 – 6.68 (m, 1H), 3.65 (t, J

	yl)morpholine		= 4.8 Hz, 4H), 3.05 – 2.97 (m, 4H), 1.63 – 1.53 (m, 1H), 1.52 – 1.42 (m, 1H), 1.43 – 1.33 (m, 1H), 0.98 – 0.89 (m, 1H), 0.87 – 0.77 (m, 1H), .
174	4-(4-(5-chloro-4H-1,2,4-triazol-3-yl)-1-(8-chloro-5-fluoroquinolin-4-yl)-2-cyclopropyl-1H-benzo[d]imidazol-6-yl)morpholine	524.1	1H NMR (400 MHz, DMSO-d6) δ 9.36 (d, J = 4.5 Hz, 1H), 8.15 – 8.09 (m, 1H), 8.03 (d, J = 4.5 Hz, 1H), 7.53 – 7.45 (m, 2H), 6.81 – 6.78 (m, 1H), 3.66 (t, J = 4.8 Hz, 4H), 3.04 (t, J = 4.8 Hz, 4H), 1.66 – 1.55 (m, 1H), 1.48 – 1.38 (m, 1H), 1.33 – 1.25 (m, 1H), 0.93 – 0.78 (m, 2H).
175	4-[3-(8-chloroquinolin-4-yl)-7-(1H-imidazol-2-yl)-2-methylbenzimidazol-5-yl]morpholine	445.1	1H NMR (400 MHz, DMSO-d6) δ 9.33 (d, J = 4.6 Hz, 1H), 8.16 – 8.09 (m, 1H), 7.99 (d, J = 4.5 Hz, 1H), 7.87 (d, J = 0.6 Hz, 2H), 7.72 (d, J = 2.1 Hz, 1H), 7.62 (dd, J = 8.4, 7.6 Hz, 1H), 7.26 – 7.18 (m, 1H), 6.78 (d, J = 2.1 Hz, 1H), 3.70 – 3.60 (m, 4H), 3.06 (dd, J = 6.6, 3.7 Hz, 4H), 2.44 – 2.39 (m, 3H).
176	4-[3-(8-chloroquinolin-4-yl)-2-methyl-7-(4-methyl-1H-imidazol-2-yl)benzimidazol-5-yl]morpholine	459.1	1H NMR (400 MHz, DMSO-d6) δ 9.31 (d, J = 4.5 Hz, 1H), 9.16 (s, 1H), 8.12 (dd, J = 7.6, 1.2 Hz, 1H), 7.95 (d, J = 4.5 Hz, 1H), 7.67 – 7.59 (m, 1H), 7.21 (dd, J = 8.4, 1.2 Hz, 1H), 7.10 (d, J = 2.2 Hz, 1H), 6.57 (d, J = 2.2 Hz, 1H), 3.65 (t, J = 4.7 Hz, 4H), 3.07 – 2.95 (m, 4H), 2.54 (s, 3H), 2.32 (s, 3H).
177	4-[3-(8-chloroquinolin-4-yl)-2-methyl-7-(4-methyl-1H-imidazol-5-yl)benzimidazol-5-yl]morpholine	459.1	1H NMR (400 MHz, DMSO-d6) δ 9.32 (d, J = 4.5, 0.7 Hz, 1H), 9.16 (s, 1H), 8.12 (d, J = 7.5, 1.0 Hz, 1H), 7.95 (d, J = 4.6, 0.7 Hz, 1H), 7.63 (dd, J = 8.3, 7.5 Hz, 1H), 7.21 (d, J = 8.5 Hz, 1H), 7.10 (d, J = 2.2 Hz, 1H), 6.60 – 6.54 (m, 1H), 3.65 (t, J = 4.7 Hz, 4H), 3.01 (q, J = 4.1 Hz, 4H), 2.53 (s, 3H), 2.33 (s, 3H).
178	4-[3-(8-chloroquinolin-4-yl)-7-(5-chloro-4H-1,2,4-triazol-3-yl)-2-methylbenzimidazol-5-yl]morpholine	480.1	1H NMR (400 MHz, DMSO-d6) δ 9.30 (d, J = 4.5 Hz, 1H), 8.10 (d, J = 7.5 Hz, 1H), 7.99 (d, J = 4.5 Hz, 1H), 7.59 (m, 2H), 7.30 (s, 1H), 6.67 (s, 1H), 3.63 (m, 4H), 3.02 (bs, 4H), 2.41 (s, 3H).

179	4-[7-(5-chloro-4H-1,2,4-triazol-3-yl)-3-(5,8-difluoroquinolin-4-yl)-2-ethylbenzimidazol-5-yl]morpholine	496.2	1H NMR (400 MHz, DMSO-d6) δ 9.27 (d, J = 4.6 Hz, 1H), 8.00 (d, J = 4.5 Hz, 1H), 7.82 – 7.71 (m, 1H), 7.54 – 7.40 (m, 2H), 6.76 (d, J = 2.0 Hz, 1H), 3.70 – 3.58 (m, 4H), 3.09 – 3.00 (m, 4H), 2.73 – 2.61 (m, 2H), 1.20 (t, J = 7.9, 7.1 Hz, 3H).
180	4-[7-(5-chloro-4H-1,2,4-triazol-3-yl)-3-(5,8-difluoroquinolin-4-yl)-2-methylbenzimidazol-5-yl]morpholine	482.2	1H NMR (400 MHz, DMSO-d6) δ 9.29 (d, J = 4.5 Hz, 1H), 8.00 (d, J = 4.4 Hz, 1H), 7.78 (td, J = 9.4, 4.2 Hz, 1H), 7.57 – 7.41 (m, 2H), 6.80 (d, J = 2.1 Hz, 1H), 3.75 – 3.55 (m, 4H), 3.05 (t, J = 4.8 Hz, 4H), 2.42 (s, 3H).
181	4-[7-(5-chloro-4H-1,2,4-triazol-3-yl)-2-cyclopropyl-3-(5,8-difluoroquinolin-4-yl)benzimidazol-5-yl]morpholine	508.2	1H NMR (400 MHz, DMSO-d6) δ 9.27 (d, J = 4.5 Hz, 1H), 8.00 (d, J = 4.5 Hz, 1H), 7.76 (ddd, J = 10.1, 8.7, 4.1 Hz, 1H), 7.49 – 7.41 (m, 2H), 6.77 (d, J = 2.2 Hz, 1H), 3.65 (dd, J = 6.0, 3.5 Hz, 4H), 3.11 – 2.90 (m, 4H), 1.59 (td, J = 8.2, 4.1 Hz, 1H), 1.47 – 1.18 (m, 2H), 0.85 (dddd, J = 12.2, 8.5, 6.3, 3.1 Hz, 2H).
182	4-[7-(5-chloro-4H-1,2,4-triazol-3-yl)-3-(5,8-difluoroquinolin-4-yl)-2-propylbenzimidazol-5-yl]morpholine	510.2	1H NMR (400 MHz, DMSO-d6) δ 9.28 (d, J = 4.5 Hz, 1H), 8.00 (d, J = 4.5 Hz, 1H), 7.77 (ddd, J = 9.9, 8.7, 4.2 Hz, 1H), 7.56 – 7.40 (m, 2H), 6.77 (d, J = 2.2 Hz, 1H), 3.64 (dd, J = 5.9, 3.7 Hz, 4H), 3.13 – 2.92 (m, 4H), 2.65 (td, J = 7.3, 2.8 Hz, 2H), 1.68 (h, J = 7.4 Hz, 2H), 0.80 (t, J = 7.4 Hz, 3H).
183	4-(1-(8-chloroquinolin-4-yl)-2-methyl-4-(1H-pyrazol-4-yl)-1H-benzo[d]imidazol-6-yl)morpholine	445.2	1H NMR (400 MHz, DMSO-d6) δ 9.32 (d, J = 4.5 Hz, 1H), 8.48 (s,2H),8.12 (dd, J=7.5, 1.2 Hz, 1H), 7.98 (d, J = 4.5 Hz, 1H), 7.62 (dd, J = 8., 7.6 Hz, 1H), 7.41 – 7.28 (m, 2H), 6.33 (s, 1H), 3.66 (m, 4H), 3.04 (m,4H), 2.39 (s, 3H).

Step 6a: 4-(1-(8-fluoroquinolin-4-yl)-2-methyl-4-(oxazol-2-yl)-1H-benzo[d]imidazol-6-yl)morpholine



To a solution of 4-(4-bromo-1-(8-fluoroquinolin-4-yl)-2-methyl-1H-benzo[d]imidazol-6-yl)morpholine (290 mg, 0.66 mmol) in dioxane (3.5 mL) were added 2-(tri-n-butylstannyl)oxazole (0.21 mL, 0.99 mmol), copper iodide (13 mg, 0.07 mmol), and Pd(II)Cl_2dppf (42 mg, 0.07 mmol). The resulting mixture was degassed under Argon and heated to 80°C for 6 days. The reaction was purified directly on silica (0 – 30% MeOH/DCM), then by prep LC to give 4-(1-(8-fluoroquinolin-4-yl)-2-methyl-4-(oxazol-2-yl)-1H-benzo[d]imidazol-6-yl)morpholine (Compound 200). 1H NMR (400 MHz, DMSO-d6) δ 9.29 (d, J = 4.5 Hz, 1H), 8.45 (d, J = 0.8 Hz, 1H), 8.04 (d, J = 4.5 Hz, 1H), 7.78 (ddd, J = 10.8, 7.8, 1.2 Hz, 1H), 7.69 (d, J = 2.3 Hz, 1H), 7.68 – 7.62 (m, 1H), 7.61 (d, J = 0.8 Hz, 1H), 7.34 (d, J = 8.4 Hz, 1H), 6.76 (d, J = 2.2 Hz, 1H), 3.66 (t, J = 4.8 Hz, 4H), 3.08 (td, J = 4.5, 2.8 Hz, 4H), 2.52 (s, 3H). ES/MS *m/z* 430.2 $(M+H)^+$.

The compounds listed in the table below were prepared in a manner similar to that described above using appropriate intermediates and chemistry.

Compound	Name	MS	NMR
201	4-[3-(8-chloroquinolin-4-yl)-2-methyl-7-(2-methyl-1H-imidazol-5-yl)benzimidazol-5-yl]morpholine	459.15	1H NMR (400 MHz, DMSO-d6) δ 9.31 (d, J = 4.5 Hz, 1H), 8.40 (s, 1H), 8.11 (dd, J = 7.5, 1.2 Hz, 1H), 7.95 (d, J = 4.5 Hz, 1H), 7.61 (dd, J = 8.5, 7.5 Hz, 1H), 7.43 (d, J = 2.1 Hz, 1H), 7.21 (dd, J = 8.4, 1.2 Hz, 1H), 6.49 (d, J = 2.1 Hz, 1H), 3.68 (t, J = 4.8 Hz, 4H), 3.10 – 2.95 (m, 4H), 2.72 (s, 3H), 2.35 (s, 3H).
202	4-[3-(8-chloroquinolin-	459.1	1H NMR (400 MHz, DMSO-d6) δ

	4-yl)-2-methyl-7-(3-methylimidazol-4-yl)benzimidazol-5-yl]morpholine		9.32 (d, J = 4.5 Hz, 1H), 9.29 (s, 1H), 8.12 (dd, J = 7.5, 1.2 Hz, 1H), 7.99 (s, 1H), 7.96 (d, J = 4.5 Hz, 1H), 7.63 (dd, J = 8.5, 7.5 Hz, 1H), 7.25 (dd, J = 8.5, 1.2 Hz, 1H), 7.14 (d, J = 2.2 Hz, 1H), 6.64 (d, J = 2.2 Hz, 1H), 3.97 (s, 3H), 3.65 (t, J = 4.8 Hz, 4H), 3.09 – 2.95 (m, 4H), 2.31 (s, 3H).
203	4-[3-(8-chloroquinolin-4-yl)-2-methyl-7-(1-methylimidazol-4-yl)benzimidazol-5-yl]morpholine	459.1	1H NMR (400 MHz, DMSO-d6) δ 9.31 (d, J = 4.5 Hz, 1H), 9.22 (s, 1H), 8.55 (d, J = 1.5 Hz, 1H), 8.11 (dd, J = 7.6, 1.2 Hz, 1H), 7.96 (d, J = 4.5 Hz, 1H), 7.65 – 7.56 (m, 1H), 7.50 (d, J = 2.1 Hz, 1H), 7.21 (dd, J = 8.4, 1.2 Hz, 1H), 6.51 (d, J = 2.1 Hz, 1H), 4.01 (s, 3H), 3.67 (t, J = 4.7 Hz, 4H), 3.10 – 2.96 (m, 4H), 2.37 (s, 3H).
204	4-[3-(8-chloroquinolin-4-yl)-2-methyl-7-(1,3-oxazol-2-yl)benzimidazol-5-yl]morpholine	446.1	1H NMR (400 MHz, DMSO-d6) δ 9.34 (d, J = 4.5 Hz, 1H), 8.43 (s, 1H), 8.13 (dd, J = 7.5, 1.2 Hz, 1H), 8.03 (d, J = 4.5 Hz, 1H), 7.66 (d, J = 2.3 Hz, 1H), 7.65 – 7.56 (m, 2H), 7.44 (d, J = 8.5 Hz, 1H), 6.74 (d, J = 2.3 Hz, 1H), 3.65 (t, J = 4.8 Hz, 4H), 3.13 – 3.00 (m, 4H), 2.48 (s, 3H).
205	4-[3-(8-chloroquinolin-4-yl)-2-methyl-7-(4-methyl-1,3-thiazol-2-yl)benzimidazol-5-yl]morpholine	476.1	1H NMR (400 MHz, DMSO-d6) δ 9.32 (d, J = 4.5 Hz, 1H), 8.11 (dd, J = 7.5, 1.2 Hz, 1H), 7.99 (d, J = 4.5 Hz, 1H), 7.78 (d, J = 2.2 Hz, 1H), 7.61 (dd, J = 8.4, 7.6 Hz, 1H), 7.49 – 7.43 (m, 1H), 7.34 (dd, J = 8.5, 1.2 Hz, 1H), 6.63 (d, J = 2.2 Hz, 1H), 3.67 (t, J = 4.7 Hz, 4H), 3.10 – 2.99 (m, 4H), 2.51 (s, 3H), 2.40 (s, 3H).
206	4-[3-(5,8-difluoroquinolin-4-yl)-2-ethyl-7-(2-methyl-1H-imidazol-5-yl)benzimidazol-5-yl]morpholine	475.2	1H NMR (400 MHz, DMSO-d6) δ 9.28 (d, J = 4.5 Hz, 1H), 8.40 (s, 1H), 7.97 (d, J = 4.5 Hz, 1H), 7.84 – 7.72 (m, 1H), 7.51 – 7.39 (m, 2H), 6.61 – 6.55 (m, 1H), 3.69 (t, J = 4.7 Hz, 4H), 3.12 – 2.99 (m, 4H), 2.73 (s, 3H), 2.70 – 2.54 (m, 2H),

			1.22 (t, J = 7.5 Hz, 3H).
207	4-[3-(8-chloroquinolin-4-yl)-7-(1H-imidazol-5-yl)-2-propylbenzimidazol-5-yl]morpholine	473.21	1H NMR (400 MHz, DMSO-d6) δ 9.31 (d, J = 4.5 Hz, 1H), 9.30 (s, 1H), 8.56 (s, 1H), 8.11 (dd, J = 7.5, 1.1 Hz, 1H), 7.97 (d, J = 4.5 Hz, 1H), 7.60 (t, J = 8.0 Hz, 1H), 7.56 (d, J = 2.1 Hz, 1H), 7.18 (dd, J = 8.4, 1.2 Hz, 1H), 6.49 (d, J = 2.0 Hz, 1H), 3.67 (t, J = 4.8 Hz, 4H), 3.10 – 2.96 (m, 4H), 2.59 (td, J = 7.4, 2.4 Hz, 2H), 1.75 – 1.59 (m, 2H), 0.83 (t, J = 7.4 Hz, 3H).
208	4-[3-(8-fluoroquinolin-4-yl)-7-(1H-imidazol-5-yl)-2-methylbenzimidazol-5-yl]morpholine	429.2	1H NMR (400 MHz, DMSO-d6) δ 9.28 (s, 1H), 9.25 (d, J = 4.5 Hz, 1H), 8.54 (s, 1H), 7.96 (d, J = 4.5 Hz, 1H), 7.76 (dd, J = 10.8, 7.7 Hz, 1H), 7.63 (td, J = 8.1, 4.9 Hz, 1H), 7.55 (d, J = 2.0 Hz, 1H), 7.09 (d, J = 8.4 Hz, 1H), 6.51 (d, J = 2.0 Hz, 1H), 3.68 (t, J = 4.8 Hz, 4H), 3.11 – 2.97 (m, 4H), 2.37 (s, 3H).
209	4-[2-ethyl-3-(8-fluoroquinolin-4-yl)-7-(1H-imidazol-5-yl)benzimidazol-5-yl]morpholine	443.2	1H NMR (400 MHz, DMSO-d6) δ 9.31 (s, 1H), 9.25 (d, J = 4.5 Hz, 1H), 8.57 (s, 1H), 7.97 (d, J = 4.5 Hz, 1H), 7.75 (dd, J = 10.8, 7.7 Hz, 1H), 7.62 (td, J = 8.1, 4.9 Hz, 1H), 7.57 (d, J = 2.1 Hz, 1H), 7.05 (d, J = 8.4 Hz, 1H), 6.50 (d, J = 2.0 Hz, 1H), 3.68 (t, J = 4.8 Hz, 4H), 3.11 – 2.97 (m, 4H), 2.64 (ddt, J = 28.6, 16.0, 7.9 Hz, 2H), 1.22 (t, J = 7.4 Hz, 3H).
210	4-[3-(8-fluoro-2-methylquinolin-4-yl)-7-(1H-imidazol-5-yl)-2-methylbenzimidazol-5-yl]morpholine	443.2	1H NMR (400 MHz, DMSO-d6) δ 9.28 (d, J = 1.4 Hz, 1H), 8.54 (d, J = 1.3 Hz, 1H), 7.85 (s, 1H), 7.74 – 7.64 (m, 1H), 7.56 (d, J = 2.2 Hz, 1H), 7.52 (dt, J = 7.9, 4.0 Hz, 1H), 7.00 (d, J = 8.4 Hz, 1H), 6.52 (d, J = 2.1 Hz, 1H), 3.68 (t, J = 4.8 Hz, 4H), 3.12 – 2.97 (m, 4H), 2.82 (s, 3H), 2.38 (s, 3H).
211	4-[2-ethyl-3-(8-fluoro-2-methylquinolin-4-yl)-7-(1H-imidazol-5-yl)benzimidazol-5-	457.27	1H NMR (400 MHz, DMSO-d6) δ 9.30 (s, 1H), 8.57 (s, 1H), 7.86 (s, 1H), 7.68 (m, 1H), 7.57 (d, J = 2.1 Hz, 1H), 7.52 (m, 1H), 6.95 (d, J =

	yl]morpholine		8.4 Hz, 1H), 6.50 (d, J = 2.1 Hz, 1H), 3.68 (t, J = 4.8 Hz, 4H), 3.12 – 2.93 (m, 4H), 2.82 (s, 3H), 2.64 (m, 2H), 1.22 (t, J = 7.4 Hz, 3H).
212	4-[3-(8-chloroquinolin-4-yl)-7-(2-methyl-1H-imidazol-5-yl)-2-propylbenzimidazol-5-yl]morpholine	487.2	1H NMR (400 MHz, DMSO-d6) δ 9.31 (d, J = 4.5 Hz, 1H), 8.41 (s, 1H), 8.11 (d, J = 7.6 Hz, 1H), 7.95 (d, J = 4.6 Hz, 1H), 7.60 (app. t, 1H), 7.44 (d, J = 2.1 Hz, 1H), 7.16 (d, J = 8.4 Hz, 1H), 6.46 (d, J = 2.0 Hz, 1H), 3.67 (t, J = 4.8 Hz, 4H), 3.08 – 2.95 (m, 4H), 2.72 (s, 3H), 2.58 (t, J = 7.5 Hz, 2H), 1.71 – 1.59 (m, 2H), 0.82 (t, J = 7.3 Hz, 3H).
213	4-[2-ethyl-3-(8-fluoroquinolin-4-yl)-7-(1,3-oxazol-2-yl)benzimidazol-5-yl]morpholine	444.2	1H NMR (400 MHz, DMSO-d6) δ 9.28 (d, J = 4.5 Hz, 1H), 8.43 (d, J = 0.8 Hz, 1H), 8.05 (d, J = 4.5 Hz, 1H), 7.77 (ddd, J = 10.8, 7.8, 1.2 Hz, 1H), 7.66 (d, J = 2.3 Hz, 1H), 7.65 – 7.59 (m, 1H), 7.57 (d, J = 0.8 Hz, 1H), 7.23 (d, J = 8.4 Hz, 1H), 6.70 (d, J = 2.3 Hz, 1H), 3.65 (t, J = 4.8 Hz, 4H), 3.05 (td, J = 4.3, 2.3 Hz, 4H), 2.78 (q, J = 7.5 Hz, 2H), 1.10 (t, J = 7.5 Hz, 3H).
214	4-[2-cyclopropyl-3-(8-fluoroquinolin-4-yl)-7-(1,3-oxazol-2-yl)benzimidazol-5-yl]morpholine	456.2	1H NMR (400 MHz, DMSO-d6) δ 9.26 (d, J = 4.5 Hz, 1H), 8.36 (d, J = 0.8 Hz, 1H), 8.00 (d, J = 4.5 Hz, 1H), 7.75 (ddd, J = 10.8, 7.8, 1.2 Hz, 1H), 7.64 (td, J = 8.1, 5.1 Hz, 1H), 7.57 (d, J = 2.3 Hz, 1H), 7.47 (d, J = 0.8 Hz, 1H), 7.24 – 7.17 (m, 1H), 6.66 (d, J = 2.3 Hz, 1H), 3.66 (t, J = 4.7 Hz, 4H), 3.03 (td, J = 4.3, 1.9 Hz, 4H), 1.70 – 1.58 (m, 1H), 1.26 – 1.08 (m, 2H), 0.95 (tdd, J = 8.9, 6.2, 3.2 Hz, 1H), 0.89 – 0.78 (m, 1H).
215	4-[3-(8-chloroquinolin-4-yl)-2-methyl-7-(5-methyl-1,3-thiazol-2-yl)benzimidazol-5-yl]morpholine	476.19	1H NMR (400 MHz, DMSO-d6) δ 9.32 (d, J = 4.5 Hz, 1H), 8.12 (dd, J = 7.5, 1.2 Hz, 1H), 8.00 (d, J = 4.5 Hz, 1H), 7.76 – 7.70 (m, 2H), 7.61 (dd, J = 8.5, 7.5 Hz, 1H), 7.36 (dd, J = 8.5, 1.2 Hz, 1H), 6.62 (d, J = 2.2 Hz, 1H), 3.66 (t, J = 4.7 Hz, 4H), 3.10 – 2.98 (m, 4H), 2.58 (d, J = 1.2

			Hz, 3H), 2.42 (s, 3H).
216	4-[3-(8-chloroquinolin-4-yl)-7-(4,5-dimethyl-1,3-thiazol-2-yl)-2-methylbenzimidazol-5-yl]morpholine	490.2	1H NMR (400 MHz, DMSO-d6) δ 9.31 (d, J = 4.5 Hz, 1H), 8.11 (dd, J = 7.5, 1.2 Hz, 1H), 7.98 (d, J = 4.5 Hz, 1H), 7.72 (d, J = 2.3 Hz, 1H), 7.61 (dd, J = 8.5, 7.5 Hz, 1H), 7.33 (dd, J = 8.5, 1.2 Hz, 1H), 6.59 (d, J = 2.2 Hz, 1H), 3.66 (t, J = 4.7 Hz, 4H), 3.09 – 2.97 (m, 4H), 2.46 (d, J = 0.9 Hz, 3H), 2.40 (d, J = 0.9 Hz, 3H), 2.39 (s, 3H).
217	4-[3-(5,8-difluoroquinolin-4-yl)-2-ethyl-7-(1,3-oxazol-2-yl)benzimidazol-5-yl]morpholine	462.2	1H NMR (400 MHz, DMSO-d6) δ 9.33 (d, J = 4.5 Hz, 1H), 8.42 (d, J = 0.8 Hz, 1H), 8.09 (d, J = 4.5 Hz, 1H), 7.81 (ddd, J = 10.1, 8.8, 4.2 Hz, 1H), 7.63 (d, J = 2.3 Hz, 1H), 7.56 (d, J = 0.8 Hz, 1H), 7.54 - 7.45 (m, 1H), 6.83 (d, J = 2.2 Hz, 1H), 3.70 - 3.56 (m, 4H), 3.12 - 3.05 (m, 4H), 2.79 (q, J = 7.6 Hz, 2H), 1.13 (t, J = 7.5 Hz, 3H).
218	4-[3-(8-chloro-7-fluoroquinolin-4-yl)-2-ethyl-7-(1,3-oxazol-2-yl)benzimidazol-5-yl]morpholine	478.2	1H NMR (400 MHz, DMSO-d6) δ 9.37 (d, J = 4.6 Hz, 1H), 8.43 (d, J = 0.8 Hz, 1H), 8.05 (d, J = 4.6 Hz, 1H), 7.76 (t, J = 9.1 Hz, 1H), 7.64 (d, J = 2.3 Hz, 1H), 7.56 (d, J = 0.9 Hz, 1H), 7.49 (dd, J = 9.3, 5.6 Hz, 1H), 6.70 (d, J = 2.3 Hz, 1H), 3.65 (t, J = 4.8 Hz, 4H), 3.11 - 2.99 (m, 4H), 2.77 (q, J = 7.6 Hz, 2H), 1.10 (t, J = 7.5 Hz, 3H).
219	4-[3-(5,8-difluoroquinolin-4-yl)-2-(2-methylpropyl)-7-(1,3-oxazol-2-yl)benzimidazol-5-yl]morpholine	490.2	1H NMR (400 MHz, DMSO-d6) δ 9.33 (d, J = 4.5 Hz, 1H), 8.42 (d, J = 0.8 Hz, 1H), 8.09 (d, J = 4.5 Hz, 1H), 7.81 (ddd, J = 10.0, 8.8, 4.2 Hz, 1H), 7.64 (d, J = 2.3 Hz, 1H), 7.56 (d, J = 0.8 Hz, 1H), 7.55 – 7.45 (m, 1H), 6.83 (d, J = 2.3 Hz, 1H), 3.67 (t, J = 4.8 Hz, 4H), 3.12 – 3.05 (m, 4H), 2.77 (dd, J = 14.6, 6.8 Hz, 1H), 2.66 (dd, J = 14.5, 7.9 Hz, 1H), 1.99 – 1.84 (m, 1H), 0.80 (dd, J = 6.6, 3.3 Hz, 6H).
220	4-[3-(8-chloroquinolin-4-yl)-2-	486.2	1H NMR (400 MHz, DMSO-d6) δ 9.35 (d, J = 4.5 Hz, 1H), 8.44 (d, J =

	(cyclopropylmethyl)-7-(1,3-oxazol-2-yl)benzimidazol-5-yl]morpholine		0.8 Hz, 1H), 8.12 (dd, J = 7.5, 1.2 Hz, 1H), 8.08 (d, J = 4.5 Hz, 1H), 7.68 (d, J = 2.3 Hz, 1H), 7.66 - 7.57 (m, 2H), 7.38 (dd, J = 8.6, 1.2 Hz, 1H), 6.72 (d, J = 2.3 Hz, 1H), 3.65 (t, J = 4.8 Hz, 4H), 3.06 (td, J = 4.3, 1.9 Hz, 4H), 2.80 (d, J = 6.9 Hz, 2H), 0.83 - 0.68 (m, 1H), 0.33 - 0.21 (m, 1H), 0.18 - 0.08 (m, 1H), 0.08 - -0.03 (m, 1H), -0.16 - -0.27 (m, 1H).
221	4-[2-(cyclopropylmethyl)-3-(5,8-difluoroquinolin-4-yl)-7-(1,3-oxazol-2-yl)benzimidazol-5-yl]morpholine	488.2	1H NMR (400 MHz, DMSO-d6) δ 9.34 (d, J = 4.5 Hz, 1H), 8.44 (d, J = 0.8 Hz, 1H), 8.12 (d, J = 4.5 Hz, 1H), 7.81 (ddd, J = 10.0, 8.8, 4.2 Hz, 1H), 7.67 (d, J = 2.3 Hz, 1H), 7.59 (d, J = 0.8 Hz, 1H), 7.49 (ddd, J = 12.3, 8.8, 3.8 Hz, 1H), 6.86 (d, J = 2.3 Hz, 1H), 3.71 – 3.63 (m, 4H), 3.16 – 3.06 (m, 4H), 2.84 (qd, J = 15.2, 7.0 Hz, 2H), 0.88 – 0.73 (m, 1H), 0.36 – 0.24 (m, 1H), 0.19 (dddd, J = 9.2, 7.9, 5.7, 4.1 Hz, 1H), 0.06 (dq, J = 9.6, 5.0 Hz, 1H), -0.12 – -0.23 (m, 1H).
222	4-[3-(8-chloro-6-fluoroquinolin-4-yl)-7-(1,3-oxazol-2-yl)-2-propylbenzimidazol-5-yl]morpholine	492.2	1H NMR (400 MHz, DMSO-d6) δ 9.31 (d, J = 4.5 Hz, 1H), 8.44 (d, J = 0.8 Hz, 1H), 8.24 (dd, J = 8.5, 2.7 Hz, 1H), 8.10 (d, J = 4.5 Hz, 1H), 7.67 (d, J = 2.3 Hz, 1H), 7.58 (d, J = 0.8 Hz, 1H), 7.29 (d, J = 8.9 Hz, 1H), 6.73 (d, J = 2.3 Hz, 1H), 3.66 (t, J = 4.8 Hz, 4H), 3.13 - 3.00 (m, 4H), 2.87 - 2.66 (m, 2H), 1.67 - 1.43 (m, 2H), 0.79 (t, J = 7.4 Hz, 3H).
223	4-[3-(8-fluoroquinolin-4-yl)-7-(1,3-oxazol-2-yl)-2-propylbenzimidazol-5-yl]morpholine	458.2	1H NMR (400 MHz, DMSO-d6) δ 9.28 (d, J = 4.5 Hz, 1H), 8.43 (d, J = 0.8 Hz, 1H), 8.05 (d, J = 4.5 Hz, 1H), 7.77 (ddd, J = 10.8, 7.8, 1.2 Hz, 1H), 7.66 (d, J = 2.1 Hz, 1H), 7.63 (dd, J = 7.8, 5.0 Hz, 1H), 7.57 (d, J = 0.8 Hz, 1H), 7.22 (d, J = 8.5 Hz, 1H), 6.69 (d, J = 2.3 Hz, 1H), 3.65 (t, J = 4.7 Hz, 4H), 3.05 (td, J = 4.3, 2.2 Hz, 4H), 2.86 – 2.66 (m, 2H), 1.63 – 1.43 (m, 2H), 0.77 (t, J

			= 7.4 Hz, 3H).
224	4-[3-(8-chloroquinolin-4-yl)-7-(1,3-oxazol-2-yl)benzimidazol-5-yl]morpholine	432.2	1H NMR (400 MHz, DMSO-d6) δ 9.28 (d, J = 4.6 Hz, 1H), 8.89 (s, 1H), 8.40 (d, J = 0.8 Hz, 1H), 8.13 (dd, J = 7.5, 1.3 Hz, 1H), 8.00 (d, J = 4.5 Hz, 1H), 7.71 (d, J = 2.3 Hz, 1H), 7.65 (dd, J = 8.5, 7.5 Hz, 1H), 7.55 (dd, J = 8.5, 1.3 Hz, 1H), 7.53 (d, J = 0.8 Hz, 1H), 6.91 (d, J = 2.3 Hz, 1H), 3.69 (t, J = 4.8 Hz, 4H), 3.10 (br s, 4H).
225	4-[2-(cyclopropylmethyl)-3-(8-fluoroquinolin-4-yl)-7-(1,3-oxazol-2-yl)benzimidazol-5-yl]morpholine	470.2	1H NMR (400 MHz, DMSO-d6) δ 9.28 (d, J = 4.5 Hz, 1H), 8.44 (d, J = 0.9 Hz, 1H), 8.06 (d, J = 4.5 Hz, 1H), 7.77 (ddd, J = 10.8, 7.8, 1.2 Hz, 1H), 7.68 (d, J = 2.3 Hz, 1H), 7.63 (td, J = 8.2, 5.0 Hz, 1H), 7.58 (d, J = 0.8 Hz, 1H), 7.22 (d, J = 8.4 Hz, 1H), 6.70 (d, J = 2.3 Hz, 1H), 3.66 (t, J = 4.7 Hz, 4H), 3.06 (td, J = 4.4, 2.4 Hz, 4H), 2.79 (d, J = 6.9 Hz, 2H), 0.84 – 0.69 (m, 1H), 0.33 – 0.21 (m, 1H), 0.13 (dddd, J = 9.0, 7.9, 5.7, 4.2 Hz, 1H), 0.02 (ddt, J = 9.2, 5.6, 4.6 Hz, 1H), -0.21 (ddt, J = 9.1, 5.5, 4.4 Hz, 1H).
226	4-[3-(8-chloroquinolin-4-yl)-2-ethyl-7-(1,3-oxazol-2-yl)benzimidazol-5-yl]morpholine	460.2	1H NMR (400 MHz, DMSO-d6) δ 9.34 (d, J = 4.5 Hz, 1H), 8.43 (s, 1H), 8.12 (d, J = 7.5 Hz, 1H), 8.06 (d, J = 4.5 Hz, 1H), 7.68 – 7.64 (m, 1H), 7.64 – 7.58 (m, 1H), 7.57 (s, 1H), 7.38 (d, J = 8.4 Hz, 1H), 6.70 (d, J = 2.2 Hz, 1H), 3.65 (t, J = 4.7 Hz, 4H), 3.12 – 2.98 (m, 4H), 2.76 (q, J = 7.5 Hz, 2H), 1.10 (td, J = 7.5, 0.7 Hz, 3H).
227	4-[3-(8-chloroquinolin-4-yl)-7-(1,3-oxazol-2-yl)-2-propylbenzimidazol-5-yl]morpholine	474.2	1H NMR (400 MHz, DMSO-d6) δ 9.34 (d, J = 4.5 Hz, 1H), 8.42 (s, 1H), 8.12 (d, J = 7.5 Hz, 1H), 8.05 (d, J = 4.5 Hz, 1H), 7.64 (d, J = 2.2 Hz, 1H), 7.61 (dd, J = 7.9, 7.4 Hz, 1H), 7.56 (s, 1H), 7.35 (d, J = 8.4 Hz, 1H), 6.68 (d, J = 2.2 Hz, 1H), 3.65 (t, J = 4.8 Hz, 4H), 3.10 – 2.98 (m, 4H), 2.82 – 2.63 (m, 2H), 1.63 – 1.43 (m, 2H), 0.77 (t, J = 7.3 Hz,

			3H).
228	4-[3-(8-chloroquinolin-4-yl)-2-cyclopropyl-7-(1,3-oxazol-2-yl)benzimidazol-5-yl]morpholine	472.2	1H NMR (400 MHz, DMSO-d6) δ 9.32 (d, J = 4.5 Hz, 1H), 8.36 (s, 1H), 8.11 (d, J = 7.5 Hz, 1H), 8.01 (d, J = 4.5 Hz, 1H), 7.62 (dd, J = 8.4, 7.5 Hz, 1H), 7.56 (d, J = 2.1 Hz, 1H), 7.47 (s, 1H), 7.34 (d, J = 8.5 Hz, 1H), 6.66 (d, J = 2.0 Hz, 1H), 3.65 (t, J = 4.7 Hz, 4H), 3.09 – 2.95 (m, 3H), 1.68 – 1.56 (m, 1H), 1.26 – 1.07 (m, 2H), 1.00 – 0.88 (m, 1H), 0.88 – 0.76 (m, 1H).
229	4-[3-(5,8-difluoroquinolin-4-yl)-2-methyl-7-(1,3-oxazol-2-yl)benzimidazol-5-yl]morpholine	448.2	1H NMR (400 MHz, DMSO-d6) δ 9.35 (d, J = 4.5 Hz, 1H), 8.44 (d, J = 0.8 Hz, 1H), 8.09 (d, J = 4.5 Hz, 1H), 7.82 (ddd, J = 10.1, 8.8, 4.3 Hz, 1H), 7.67 (d, J = 2.3 Hz, 1H), 7.60 (d, J = 0.8 Hz, 1H), 7.52 (ddd, J = 12.4, 8.8, 3.8 Hz, 1H), 6.91 (d, J = 2.3 Hz, 1H), 3.75 – 3.58 (m, 4H), 3.15 – 3.07 (m, 4H), 2.55 (s, 3H).
230	4-[3-(5,8-difluoroquinolin-4-yl)-7-(1,3-oxazol-2-yl)-2-propylbenzimidazol-5-yl]morpholine	476.2	1H NMR (400 MHz, DMSO-d6) δ 9.34 (d, J = 4.5 Hz, 1H), 8.43 (d, J = 0.8 Hz, 1H), 8.10 (d, J = 4.5 Hz, 1H), 7.81 (ddd, J = 10.0, 8.8, 4.2 Hz, 1H), 7.65 (d, J = 2.2 Hz, 1H), 7.57 (d, J = 0.8 Hz, 1H), 7.51 (ddd, J = 12.4, 8.8, 3.8 Hz, 1H), 6.84 (d, J = 2.3 Hz, 1H), 3.73 – 3.58 (m, 4H), 3.13 – 3.05 (m, 4H), 2.89 – 2.71 (m, 2H), 1.56 (qd, J = 7.4, 1.2 Hz, 2H), 0.81 (t, J = 7.4 Hz, 3H).
231	4-[2-cyclopropyl-3-(5,8-difluoroquinolin-4-yl)-7-(1,3-oxazol-2-yl)benzimidazol-5-yl]morpholine	474.2	1H NMR (400 MHz, DMSO-d6) δ 9.31 (d, J = 4.5 Hz, 1H), 8.35 (d, J = 0.8 Hz, 1H), 8.04 (d, J = 4.5 Hz, 1H), 7.78 (ddd, J = 10.1, 8.7, 4.2 Hz, 1H), 7.54 (d, J = 2.3 Hz, 1H), 7.52 – 7.45 (m, 1H), 7.47 (d, J = 0.8 Hz, 1H), 6.79 (d, J = 2.3 Hz, 1H), 3.73 – 3.58 (m, 4H), 3.10 – 3.02 (m, 4H), 1.75 – 1.63 (m, 1H), 1.25 – 1.14 (m, 1H), 1.17 – 1.04 (m, 1H), 0.98 – 0.81 (m, 2H).
232	4-[2-ethyl-3-(8-fluoroquinolin-4-yl)-7-	474.2	1H NMR (400 MHz, DMSO-d6) δ 9.25 (d, J = 4.5 Hz, 1H), 8.00 (d, J =

	(4-methyl-1,3-thiazol-2-yl)benzimidazol-5-yl]morpholine		4.5 Hz, 1H), 7.82 (d, J = 2.3 Hz, 1H), 7.75 (ddd, J = 10.8, 7.8, 1.2 Hz, 1H), 7.62 (ddd, J = 8.5, 7.7, 5.0 Hz, 1H), 7.47 (q, J = 0.8 Hz, 1H), 7.15 (dt, J = 8.4, 0.9 Hz, 1H), 6.65 (d, J = 2.3 Hz, 1H), 3.68 (t, J = 4.7 Hz, 4H), 3.12 – 2.99 (m, 4H), 2.79 – 2.55 (m, 2H), 2.51 (s, 3H), 1.22 (t, J = 7.5 Hz, 3H).
233	4-[3-(5,8-difluoroquinolin-4-yl)-2-methyl-7-(4-methyl-1,3-thiazol-2-yl)benzimidazol-5-yl]morpholine	478.1	1H NMR (400 MHz, DMSO-d6) δ 9.30 (d, J = 4.5 Hz, 1H), 8.01 (d, J = 4.5 Hz, 1H), 7.79 (ddd, J = 10.1, 8.8, 4.4 Hz, 1H), 7.76 (d, J = 2.2 Hz, 1H), 7.53 – 7.42 (m, 2H), 6.77 (d, J = 2.2 Hz, 1H), 3.72 – 3.65 (m, 4H), 3.12 – 3.05 (m, 4H), 2.51 (s, 3H), 2.41 (s, 3H).
234	4-[3-(8-chloroquinolin-4-yl)-2-cyclopropyl-7-(4-methyl-1,3-thiazol-2-yl)benzimidazol-5-yl]morpholine	502.1	1H NMR (400 MHz, DMSO-d6) δ 9.32 (d, J = 4.5 Hz, 1H), 8.11 (dd, J = 7.5, 1.2 Hz, 1H), 8.02 (d, J = 4.5 Hz, 1H), 7.80 (d, J = 2.3 Hz, 1H), 7.63 (dd, J = 8.5, 7.5 Hz, 1H), 7.43 (q, J = 0.8 Hz, 1H), 7.36 (dd, J = 8.5, 1.3 Hz, 1H), 6.66 (d, J = 2.3 Hz, 1H), 3.68 (t, J = 4.8 Hz, 4H), 3.05 (dd, J = 6.4, 3.6 Hz, 4H), 2.48 (d, J = 1.0 Hz, 3H), 1.68 – 1.57 (m, 1H), 1.28 – 1.12 (m, 1H), 1.04 – 0.93 (m, 1H), 0.93 – 0.81 (m, 1H).
235	4-[3-(5,8-difluoroquinolin-4-yl)-7-(4-methyl-1,3-thiazol-2-yl)-2-propylbenzimidazol-5-yl]morpholine	506.2	1H NMR (400 MHz, DMSO-d6) δ 9.28 (d, J = 4.5 Hz, 1H), 7.98 (d, J = 4.5 Hz, 1H), 7.83 – 7.72 (m, 1H), 7.75 (d, J = 2.4 Hz, 1H), 7.46 (ddd, J = 12.4, 8.7, 3.8 Hz, 1H), 7.42 (m, 1H), 6.67 (d, J = 2.3 Hz, 1H), 3.71 – 3.64 (m, 4H), 3.08 – 3.00 (m, 4H), 2.63 – 2.55 (m, 2H), 2.49 – 2.48 (m, 3H), 1.71 (h, J = 7.5 Hz, 2H), 0.89 (t, J = 7.4 Hz, 3H).
236	4-[3-(5,8-difluoroquinolin-4-yl)-7-(1,3-oxazol-2-yl)benzimidazol-5-yl]morpholine	434.1	1H NMR (400 MHz, DMSO-d6) δ 9.25 (d, J = 4.6 Hz, 1H), 8.73 (s, 1H), 8.37 (d, J = 0.8 Hz, 1H), 7.99 (d, J = 4.6 Hz, 1H), 7.79 (ddd, J = 10.0, 8.7, 4.2 Hz, 1H), 7.65 (d, J = 2.3 Hz, 1H), 7.50 (d, J = 0.8 Hz, 1H), 7.55 – 7.44 (m, 1H), 6.98 (d, J

			= 2.3 Hz, 1H), 3.69 (t, J = 4.7 Hz, 4H), 3.16 – 3.04 (m, 4H).
237	4-[2-cyclopropyl-3-(5,8-difluoroquinolin-4-yl)-7-(4-methyl-1,3-thiazol-2-yl)benzimidazol-5-yl]morpholine	504.2	1H NMR (400 MHz, DMSO-d6) δ 9.36 – 9.29 (m, 1H), 8.20 – 8.10 (m, 1H), 7.84 – 7.72 (m, 1H), 7.60 (dd, J = 5.1, 1.1 Hz, 1H), 7.57 – 7.39 (m, 2H), 6.93 – 6.84 (m, 1H), 3.73 – 3.65 (m, 4H), 3.17 – 3.10 (m, 4H), 1.98 – 1.91 (m, 3H), 1.66 – 1.56 (m, 1H), 1.54 – 1.21 (m, 1H), 1.04 – 0.69 (m, 1H), 0.59 – 0.42 (m, 2H).
238	4-[3-(8-chloro-5-fluoroquinolin-4-yl)-2-methyl-7-(4-methyl-1,3-thiazol-2-yl)benzimidazol-5-yl]morpholine	494.1	1H NMR (400 MHz, DMSO-d6) δ 9.36 (d, J = 4.5 Hz, 1H), 8.13 (dd, J = 8.6, 5.0 Hz, 1H), 8.00 (d, J = 4.5 Hz, 1H), 7.75 (d, J = 2.3 Hz, 1H), 7.48 (dd, J = 11.9, 8.5 Hz, 1H), 7.43 (d, J = 1.0 Hz, 1H), 6.73 (d, J = 2.3 Hz, 1H), 3.71 – 3.64 (m, 4H), 3.10 – 3.02 (m, 4H), 2.50 (s, 3H), 2.38 (s, 3H).
239	4-[3-(5,8-difluoroquinolin-4-yl)-2-propyl-7-(1,3-thiazol-2-yl)benzimidazol-5-yl]morpholine	492.2	1H NMR (400 MHz, DMSO-d6) δ 9.29 (d, J = 4.5 Hz, 1H), 8.05 – 7.99 (m, 2H), 7.90 (d, J = 3.3 Hz, 1H), 7.81 (d, J = 2.3 Hz, 1H), 7.78 (ddd, J = 10.1, 8.8, 4.2 Hz, 1H), 7.47 (ddd, J = 12.3, 8.8, 3.8 Hz, 1H), 6.74 (d, J = 2.2 Hz, 1H), 3.72 – 3.65 (m, 4H), 3.11 – 3.04 (m, 4H), 2.64 (dd, J = 7.8, 6.9 Hz, 2H), 1.71 (h, J = 7.4 Hz, 2H), 0.89 (t, J = 7.4 Hz, 3H).
240	4-[3-(8-chloro-5-fluoroquinolin-4-yl)-2-methyl-7-(1,3-thiazol-2-yl)benzimidazol-5-yl]morpholine	480.1	1H NMR (400 MHz, DMSO-d6) δ 9.37 (d, J = 4.5 Hz, 1H), 8.13 (dd, J = 8.5, 5.0 Hz, 1H), 8.03 (d, J = 3.3 Hz, 1H), 8.02 (d, J = 4.6 Hz, 1H), 7.91 (d, J = 3.2 Hz, 1H), 7.79 (d, J = 2.3 Hz, 1H), 7.49 (dd, J = 11.9, 8.5 Hz, 1H), 6.76 (d, J = 2.3 Hz, 1H), 3.71 – 3.64 (m, 4H), 3.07 (t, J = 4.9 Hz, 4H), 2.41 (s, 3H).
241	4-[2-cyclopropyl-3-(5,8-difluoroquinolin-4-yl)-7-(1,3-thiazol-2-yl)benzimidazol-5-yl]morpholine	490.2	1H NMR (400 MHz, DMSO-d6) δ 9.30 (d, J = 4.5 Hz, 1H), 8.04 (d, J = 4.5 Hz, 1H), 7.98 (d, J = 3.3 Hz, 1H), 7.87 (d, J = 3.3 Hz, 1H), 7.81 (d, J = 2.2 Hz, 1H), 7.78 (ddq, J =

			10.0, 8.8, 4.1 Hz, 1H), 7.48 (ddd, J = 11.8, 8.8, 3.8 Hz, 1H), 6.77 (d, J = 2.2 Hz, 1H), 3.73 – 3.65 (m, 4H), 3.11 – 3.04 (m, 4H), 1.73 – 1.62 (m, 1H), 1.27 – 1.16 (m, 1H), 1.16 – 1.06 (m, 1H), 1.01 – 0.84 (m, 2H).
242	4-[3-(8-chloro-5-fluoroquinolin-4-yl)-2-cyclopropyl-7-(1,3-oxazol-2-yl)benzimidazol-5-yl]morpholine	490.15	1H NMR (400 MHz, DMSO-d6) δ 9.39 (d, J = 4.6 Hz, 1H), 8.48 (s, 1H), 8.17 – 8.09 (m, 2H), 7.64 (d, J = 2.2 Hz, 1H), 7.53 – 7.29 (m, 2H), 6.96 (s, 1H), 3.69 (t, J = 4.8 Hz, 4H), 3.13 (t, J = 4.9 Hz, 4H), 1.75 – 1.43 (m, 2H), 1.40 – 1.06 (m, 1H), 0.72 – 0.38 (m, 2H).
243	4-[3-(8-chloro-5-fluoroquinolin-4-yl)-2-cyclopropyl-7-(4-methyl-1,3-thiazol-2-yl)benzimidazol-5-yl]morpholine	520.19	1H NMR (400 MHz, DMSO-d6) δ 9.42 – 9.35 (m, 1H), 8.21 – 8.02 (m, 2H), 7.63 – 7.37 (m, 3H), 6.94 – 6.85 (m, 1H), 3.68 (t, J = 4.5 Hz, 4H), 3.18 – 3.01 (m, 4H), 1.98 – 1.91 (m, 3H), 1.68 – 1.40 (m, 2H), 1.34 – 1.17 (m, 1H), 1.06 – 0.67 (m, 1H), 0.60 – 0.39 (m, 1H).
244	4-[3-(8-chloroquinolin-4-yl)-2-methyl-7-(1,3-thiazol-2-yl)benzimidazol-5-yl]morpholine	462.1	1H NMR (400 MHz, DMSO-d6) δ 9.30 (d, J = 4.5 Hz, 1H), 8.10 (dd, J = 7.5, 1.2 Hz, 1H), 7.99 (dd, J = 3.2, 0.4 Hz, 1H), 7.97 (d, J = 4.5 Hz, 1H), 7.89 (dd, J = 3.3, 0.4 Hz, 1H), 7.84 (d, J = 2.3 Hz, 1H), 7.61 (dd, J = 8.4, 7.5 Hz, 1H), 7.28 (dd, J = 8.4, 1.2 Hz, 1H), 6.57 (d, J = 2.3 Hz, 1H), 3.66 (t, J = 4.8 Hz, 4H), 3.05 – 2.96 (m, 4H), 2.37 (s, 3H).
245	4-[3-(8-chloroquinolin-4-yl)-2-ethyl-7-(2-methyl-1H-imidazol-5-yl)benzimidazol-5-yl]morpholine	473.2	1H NMR (400 MHz, DMSO-d6) δ 9.31 (d, J = 4.5 Hz, 1H), 8.43 (s, 1H), 8.11 (dd, J = 7.5, 1.3 Hz, 1H), 7.97 (d, J = 4.5 Hz, 1H), 7.61 (dd, J = 8.5, 7.5 Hz, 1H), 7.48 (d, J = 2.2 Hz, 1H), 7.19 (dd, J = 8.4, 1.3 Hz, 1H), 6.48 (d, J = 2.1 Hz, 1H), 3.67 (t, J = 4.8 Hz, 4H), 3.10 – 2.96 (m, 4H), 2.74 (s, 3H), 2.70 – 2.52 (m, 2H), 1.20 (t, J = 7.5 Hz, 3H).
246	4-[3-(8-chloroquinolin-4-yl)-2-methyl-7-pyrazin-2-	457.1	1H NMR (400 MHz, DMSO-d6) δ 10.28 (d, J = 1.5 Hz, 1H), 9.31 (d, J = 4.5 Hz, 1H), 8.83 - 8.77 (m, 1H),

	ylbenzimidazol-5-yl]morpholine		8.65 (d, J = 2.6 Hz, 1H), 8.11 (dd, J = 7.6, 1.2 Hz, 1H), 7.98 (d, J = 4.5 Hz, 1H), 7.86 (d, J = 2.2 Hz, 1H), 7.66 - 7.57 (m, 1H), 7.27 (dd, J = 8.5, 1.2 Hz, 1H), 6.60 (d, J = 2.3 Hz, 1H), 3.66 (t, J = 4.7 Hz, 4H), 3.08 - 2.96 (m, 4H), 2.37 (s, 3H).
247	4-(1-(8-chloro-5-fluoroquinolin-4-yl)-2-cyclopropyl-4-(thiazol-2-yl)-1H-benzo[d]imidazol-6-yl)morpholine	506.1	1H NMR (400 MHz, DMSO-d6) δ 9.36 (d, J = 4.5 Hz, 1H), 8.12 (dd, J = 8.5, 4.9 Hz, 1H), 8.04 (d, J = 4.5 Hz, 1H), 7.96 (d, J = 3.2 Hz, 1H), 7.85 (d, J = 3.2 Hz, 1H), 7.77 (d, J = 2.3 Hz, 1H), 7.49 (dd, J = 11.8, 8.5 Hz, 1H), 6.72 (d, J = 2.3 Hz, 1H), 3.75 – 3.57 (m, 4H), 3.07 – 3.00 (m, 4H), 1.71 – 1.60 (m, 1H), 1.26 – 1.03 (m, 2H), 0.99 – 0.82 (m, 2H).

Step 6b: 4-(4-(2-chloro-1H-imidazol-5-yl)-1-(8-fluoroquinolin-4-yl)-2-methyl-1H-benzo[d]imidazol-6-yl)morpholine



To a solution of 4-(4-bromo-1-(8-fluoroquinolin-4-yl)-2-methyl-1H-benzo[d]imidazol-6-yl)morpholine (100 mg, 0.23 mmol) in dioxane (1 mL) was added 2-chloro-1-THP-1H-imidazole-5-boronic acid pinacol ester (106 mg, 0.34 mmol), cesium fluoride (100 mg, 0.66 mmol), copper iodide (4 mg, 0.023 mmol), and Pd(II)Cl_2dppf (13 mg, 0.023 mmol). The resulting mixture was degassed under Argon and heated to 80°C for 5 days. The reaction was purified directly on silica (0 – 30% MeOH/DCM), then by prep LC to give 4-(4-(2-chloro-1H-imidazol-5-yl)-1-(8-fluoroquinolin-4-yl)-2-methyl-1H-benzo[d]imidazol-6-yl)morpholine as an off-white solid (Compound 260). 1H NMR (400 MHz, DMSO-d6) δ 9.25 (d, J = 4.5 Hz, 1H), 8.17 (s, 1H), 7.96 (d, J = 4.5 Hz, 1H),

7.82 – 7.70 (m, 1H), 7.68 – 7.56 (m, 1H), 7.49 (s, 1H), 7.19 (d, J = 8.8 Hz, 1H), 6.35 (s, 1H), 3.66 (t, J = 4.8 Hz, 4H), 3.09 – 2.92 (m, 4H), 2.40 (s, 3H). ES/MS *m/z* 463.2 $(M+H)^+$.

The compounds listed in the table below were prepared in a manner similar to that described above using appropriate intermediates and chemistry.

Compound	Name	MS	NMR
261	4-[3-(8-chloroquinolin-4-yl)-2-methyl-7-(1H-pyrrol-2-yl)benzimidazol-5-yl]morpholine	444.15	1H NMR (400 MHz, DMSO-d6) δ 11.52 (s, 1H), 9.28 (d, J = 4.5 Hz, 1H), 8.08 (dd, J = 7.5, 1.2 Hz, 1H), 7.95 (d, J = 4.5 Hz, 1H), 7.58 (dd, J = 8.5, 7.5 Hz, 1H), 7.33 – 7.24 (m, 2H), 7.01 (ddt, J = 13.3, 2.6, 1.7 Hz, 2H), 6.27 – 6.14 (m, 2H), 3.63 (t, J = 4.8 Hz, 4H), 2.99 (q, J = 4.7 Hz, 4H), 2.36 (s, 3H).
262	4-[3-(8-chloroquinolin-4-yl)-2-methyl-7-(1H-pyrazol-3-yl)benzimidazol-5-yl]morpholine	445.12	1H NMR (400 MHz, DMSO-d6) δ 9.32 (d, J = 4.5 Hz, 1H), 8.10 (dd, J = 7.5, 1.2 Hz, 1H), 8.03 (d, J = 4.5 Hz, 1H), 7.90 (d, J = 2.3 Hz, 1H), 7.65 – 7.56 (m, 2H), 7.47 (dd, J = 8.2, 1.2 Hz, 1H), 7.22 (d, J = 2.3 Hz, 1H), 6.47 (d, J = 2.1 Hz, 1H), 3.63 (t, J = 4.8 Hz, 4H), 3.11 – 2.95 (m, 4H), 2.49 (s, 3H).
263	4-[3-(8-chloroquinolin-4-yl)-2-methyl-7-(1H-pyrrol-3-yl)benzimidazol-5-yl]morpholine	444.17	1H NMR (400 MHz, DMSO-d6) δ 11.18 (d, J = 23.0 Hz, 1H), 9.34 (d, J = 4.5 Hz, 1H), 8.13 (dd, J = 7.5, 1.3 Hz, 1H), 8.01 (d, J = 4.5 Hz, 1H), 7.72 (br s, 1H), 7.63 (dd, J = 8.5, 7.5 Hz, 1H), 7.49 – 7.37 (m, 1H), 7.26 (s, 1H), 6.95 (s, 1H), 6.78 (s, 1H), 6.32 (s, 1H), 3.65 (t, J = 4.7 Hz, 4H), 3.11 – 2.96 (m, 4H), 2.44 (s, 3H).
264	4-[3-(8-chloroquinolin-4-yl)-2-methyl-7-(1-methylsulfonylpyrrol-3-yl)benzimidazol-5-yl]morpholine	522.2	1H NMR (400 MHz, DMSO-d6) δ 9.31 (d, J = 4.5 Hz, 1H), 8.34 (t, J = 2.0 Hz, 1H), 8.11 (dd, J = 7.5, 1.2 Hz, 1H), 7.97 (d, J = 4.5 Hz, 1H), 7.61 (dd, J = 8.5, 7.5 Hz, 1H), 7.43 – 7.38 (m, 1H), 7.35 (d, J = 2.2 Hz, 1H), 7.32 – 7.25 (m, 2H), 6.36 (s, 1H), 3.66 (t, J = 4.8 Hz, 4H), 3.56

			(s, 3H), 3.04 (q, J = 5.0 Hz, 4H), 2.37 (s, 3H).
265	4-[2-methyl-3-quinolin-4-yl-7-(1,3-thiazol-4-yl)benzimidazol-5-yl]morpholine	428.1	1H NMR (400 MHz, DMSO-d6) δ 9.33 (d, J = 2.0 Hz, 1H), 9.23 (d, J = 4.5 Hz, 1H), 8.93 (d, J = 2.0 Hz, 1H), 8.28 (dd, J = 8.4, 1.0 Hz, 1H), 7.98 – 7.83 (m, 3H), 7.71 – 7.62 (m, 1H), 7.41 (d, J = 8.4 Hz, 1H), 6.46 (s, 1H), 3.67 (t, J = 4.8 Hz, 4H), 3.04 (q, J = 4.6 Hz, 4H), 2.44 (s, 3H).
266	4-[3-(8-chloroquinolin-4-yl)-7-(1H-imidazol-5-yl)-2-methylbenzimidazol-5-yl]morpholine	445.1	1H NMR (400 MHz, DMSO-d6) δ 9.31 (d, J = 4.6 Hz, 1H), 9.27 (d, J = 1.4 Hz, 1H), 8.53 (d, J = 1.4 Hz, 1H), 8.11 (dd, J = 7.6, 1.2 Hz, 1H), 7.96 (d, J = 4.6 Hz, 1H), 7.61 (dd, J = 8.5, 7.6 Hz, 1H), 7.53 (d, J = 2.1 Hz, 1H), 7.22 (dd, J = 8.5, 1.2 Hz, 1H), 6.51 (d, J = 2.1 Hz, 1H), 3.67 (t, J = 4.8 Hz, 4H), 3.03 (q, J = 4.3 Hz, 4H), 2.36 (s, 3H).
267	4-[3-(8-chloroquinolin-4-yl)-7-(5-chlorothiophen-2-yl)-2-methylbenzimidazol-5-yl]morpholine	495.03	1H NMR (400 MHz, DMSO-d6) δ 9.29 (d, J = 4.4 Hz, 1H), 8.10 (dd, J = 7.6, 1.2 Hz, 1H), 7.98 – 7.90 (m, 2H), 7.65 – 7.56 (m, 1H), 7.32 (d, J = 2.1 Hz, 1H), 7.26 (dd, J = 8.5, 1.2 Hz, 1H), 7.22 (dd, J = 4.0, 0.5 Hz, 1H), 6.39 (d, J = 2.1 Hz, 1H), 3.65 (t, J = 4.7 Hz, 4H), 3.01 (q, J = 4.4 Hz, 4H), 2.33 (s, 3H).
268	4-[3-(8-chloroquinolin-4-yl)-2-methyl-7-(5-methyl-1H-pyrazol-3-yl)benzimidazol-5-yl]morpholine	459.1	1H NMR (400 MHz, DMSO-d6) δ 9.37 (d, J = 4.6 Hz, 1H), 8.15 (dd, J = 7.5, 1.2 Hz, 1H), 8.09 (d, J = 4.5 Hz, 1H), 7.77 (d, J = 1.0 Hz, 1H), 7.65 (dd, J = 8.4, 7.5 Hz, 1H), 7.54 (dd, J = 8.6, 1.3 Hz, 1H), 7.30 (d, J = 2.1 Hz, 1H), 6.58 (d, J = 2.2 Hz, 1H), 3.65 (t, J = 4.8 Hz, 4H), 3.12 – 2.99 (m, 4H), 2.53 (s, 3H), 2.31 (s, 3H).
269	4-[3-(8-chloroquinolin-4-yl)-2-methyl-7-(2-methylpyrazol-3-yl)benzimidazol-5-yl]morpholine	459.1	1H NMR (400 MHz, DMSO-d6) δ 9.32 (d, J = 4.5 Hz, 1H), 8.12 (dd, J = 7.5, 1.2 Hz, 1H), 7.99 (d, J = 4.5 Hz, 1H), 7.68 – 7.60 (m, 1H), 7.59 (d, J = 1.8 Hz, 1H), 7.41 – 7.33 (m,

			1H), 7.08 (d, J = 2.2 Hz, 1H), 6.57 (d, J = 2.2 Hz, 1H), 6.56 (d, J = 1.8 Hz, 1H), 3.91 (s, 3H), 3.64 (t, J = 4.8 Hz, 4H), 3.02 (q, J = 4.4 Hz, 4H), 2.35 (s, 3H).
270	4-[3-(8-chloroquinolin-4-yl)-2-methyl-7-(1,3-thiazol-4-yl)benzimidazol-5-yl]morpholine	462.1	1H NMR (400 MHz, DMSO-d6) δ 9.37 (d, J = 1.9 Hz, 1H), 9.35 (d, J = 4.5 Hz, 1H), 8.88 (d, J = 2.0 Hz, 1H), 8.13 (dd, J = 7.5, 1.2 Hz, 1H), 8.04 (d, J = 4.5 Hz, 1H), 7.85 (d, J = 2.2 Hz, 1H), 7.63 (dd, J = 8.5, 7.5 Hz, 1H), 7.44 (dd, J = 8.7, 1.3 Hz, 1H), 6.57 (d, J = 2.2 Hz, 1H), 3.67 (t, J = 4.8 Hz, 4H), 3.08 (q, J = 4.2 Hz, 4H), 2.49 (s, 3H).
271	4-[3-(8-chloroquinolin-4-yl)-2-methyl-7-thiophen-2-ylbenzimidazol-5-yl]morpholine	461.1	1H NMR (400 MHz, DMSO-d6) δ 9.31 (d, J = 4.5 Hz, 1H), 8.11 (dd, J = 7.5, 1.2 Hz, 1H), 8.08 (dd, J = 3.6, 1.2 Hz, 1H), 7.97 (d, J = 4.5 Hz, 1H), 7.67 (dd, J = 5.1, 1.1 Hz, 1H), 7.61 (dd, J = 8.5, 7.5 Hz, 1H), 7.35 – 7.28 (m, 2H), 7.25 (dd, J = 5.1, 3.6 Hz, 1H), 6.45 (d, J = 2.1 Hz, 1H), 3.66 (t, J = 4.7 Hz, 4H), 3.11 – 2.97 (m, 4H), 2.36 (s, 3H).
272	4-[3-(8-chloroquinolin-4-yl)-2-methyl-7-thiophen-3-ylbenzimidazol-5-yl]morpholine	461.1	1H NMR (400 MHz, DMSO-d6) δ 9.32 (d, J = 4.5 Hz, 1H), 8.48 (d, J = 2.4 Hz, 1H), 8.11 (dd, J = 7.5, 1.2 Hz, 1H), 8.02 – 7.94 (m, 2H), 7.71 (dd, J = 5.0, 3.0 Hz, 1H), 7.62 (dd, J = 8.5, 7.5 Hz, 1H), 7.37 (d, J = 2.2 Hz, 1H), 7.32 (dd, J = 8.5, 1.2 Hz, 1H), 6.41 (d, J = 2.1 Hz, 1H), 3.66 (t, J = 4.8 Hz, 4H), 3.11 – 2.97 (m, 4H), 2.37 (s, 3H).
273	5-[1-(8-chloroquinolin-4-yl)-2-methyl-6-morpholin-4-ylbenzimidazol-4-yl]thiophene-2-carbonitrile	486.1	1H NMR (400 MHz, DMSO-d6) δ 9.30 (d, J = 4.5 Hz, 1H), 8.19 (d, J = 4.1 Hz, 1H), 8.10 (dd, J = 7.5, 1.2 Hz, 1H), 8.04 (d, J = 4.0 Hz, 1H), 7.96 (d, J = 4.5 Hz, 1H), 7.60 (dd, J = 8.5, 7.5 Hz, 1H), 7.51 (d, J = 2.1 Hz, 1H), 7.27 (dd, J = 8.5, 1.2 Hz, 1H), 6.51 (d, J = 2.1 Hz, 1H), 3.66 (t, J = 4.8 Hz, 4H), 3.12 – 2.97 (m, 4H), 2.35 (s, 3H).

274	4-[3-(8-chloroquinolin-4-yl)-7-(furan-2-yl)-2-methylbenzimidazol-5-yl]morpholine	445.1	1H NMR (400 MHz, DMSO-d6) δ 9.31 (d, J = 4.5 Hz, 1H), 8.11 (dd, J = 7.6, 1.2 Hz, 1H), 7.97 (d, J = 4.5 Hz, 1H), 7.89 – 7.83 (m, 1H), 7.66 – 7.55 (m, 2H), 7.36 (d, J = 2.2 Hz, 1H), 7.32 (d, J = 8.4 Hz, 1H), 6.73 (dd, J = 3.4, 1.9 Hz, 1H), 6.42 (d, J = 2.2 Hz, 1H), 3.65 (t, J = 4.7 Hz, 4H), 3.01 (q, J = 4.3 Hz, 4H), 2.38 (s, 3H).
275	4-[3-(8-chloroquinolin-4-yl)-7-(furan-3-yl)-2-methylbenzimidazol-5-yl]morpholine	445.1	1H NMR (400 MHz, DMSO-d6) δ 9.32 (d, J = 4.5 Hz, 1H), 8.65 (dd, J = 1.6, 0.7 Hz, 1H), 8.11 (dd, J = 7.5, 1.2 Hz, 1H), 7.97 (d, J = 4.5 Hz, 1H), 7.85 (t, J = 1.7 Hz, 1H), 7.62 (dd, J = 8.4, 7.5 Hz, 1H), 7.37 – 7.28 (m, 3H), 6.41 (d, J = 2.1 Hz, 1H), 3.67 (t, J = 4.8 Hz, 4H), 3.13 – 2.98 (m, 4H), 2.39 (s, 3H).
276	4-[3-(8-chloroquinolin-4-yl)-2-methyl-7-(1,3-thiazol-5-yl)benzimidazol-5-yl]morpholine	462.1	1H NMR (400 MHz, DMSO-d6) δ 9.30 (d, J = 4.4 Hz, 1H), 9.15 (d, J = 0.6 Hz, 1H), 8.84 (t, J = 0.6 Hz, 1H), 8.10 (dd, J = 7.4, 1.2 Hz, 1H), 7.95 (d, J = 4.5 Hz, 1H), 7.64 – 7.55 (m, 1H), 7.37 (d, J = 2.2 Hz, 1H), 7.26 (dd, J = 8.4, 1.2 Hz, 1H), 6.41 (d, J = 2.2 Hz, 1H), 3.65 (t, J = 4.8 Hz, 4H), 3.07 – 2.94 (m, 4H), 2.33 (s, 3H).
277	4-[3-(8-chloroquinolin-4-yl)-2-methyl-7-(1,3-oxazol-5-yl)benzimidazol-5-yl]morpholine	446.1	1H NMR (400 MHz, DMSO-d6) δ 9.31 (d, J = 4.5 Hz, 1H), 8.57 (s, 1H), 8.11 (dd, J = 7.5, 1.2 Hz, 1H), 8.11 (s, 1H), 7.97 (d, J = 4.5 Hz, 1H), 7.61 (dd, J = 8.5, 7.5 Hz, 1H), 7.34 (d, J = 2.2 Hz, 1H), 7.30 (dd, J = 8.5, 1.3 Hz, 1H), 6.52 (d, J = 2.2 Hz, 1H), 3.66 (t, J = 4.7 Hz, 4H), 3.08 – 2.96 (m, 4H), 2.38 (s, 3H).
278	4-[7-(2-chloro-1H-imidazol-5-yl)-3-(8-chloroquinolin-4-yl)-2-methylbenzimidazol-5-yl]morpholine	479.11	1H NMR (400 MHz, DMSO-d6) δ 13.61 (s, 1H), 9.32 (s, 1H), 8.34 – 8.14 (m, 1H), 8.12 (d, J = 7.4 Hz, 1H), 8.06 – 7.96 (m, 1H), 7.70 – 7.56 (m, 1H), 7.50 (s, 1H), 7.41 – 7.05 (m, 1H), 6.46 – 6.35 (m, 1H), 3.66 (t, J = 4.8 Hz, 4H), 3.11 – 2.95

			(m, 4H), 2.46 – 2.05 (m, 3H).
279	4-[7-(2-chloro-1H-imidazol-5-yl)-3-(8-chloroquinolin-4-yl)-2-ethylbenzimidazol-5-yl]morpholine	493.2	1H NMR (400 MHz, DMSO-d6) δ 9.32 (d, J = 4.5 Hz, 1H), 8.21 (s, 1H), 8.11 (d, J = 7.5 Hz, 1H), 8.01 (d, J = 4.5 Hz, 1H), 7.61 (dd, J = 8.5, 7.5 Hz, 1H), 7.52 (d, J = 2.2 Hz, 1H), 7.32 (d, J = 8.4 Hz, 1H), 6.39 (d, J = 2.1 Hz, 1H), 3.66 (t, J = 4.7 Hz, 4H), 3.09 – 2.97 (m, 4H), 2.81 – 2.60 (m, 2H), 1.15 (t, J = 7.5 Hz, 3H).
280	4-[7-(2-chloro-1H-imidazol-5-yl)-3-(5,8-difluoroquinolin-4-yl)-2-ethylbenzimidazol-5-yl]morpholine	495.2	1H NMR (400 MHz, DMSO-d6) δ 9.31 (d, J = 4.5 Hz, 1H), 8.19 (s, 1H), 8.05 (d, J = 4.5 Hz, 1H), 7.79 (ddd, J = 10.0, 8.8, 4.2 Hz, 1H), 7.54 - 7.43 (m, 2H), 6.54 (d, J = 2.1 Hz, 1H), 3.78 - 3.54 (m, 4H), 3.14 - 3.03 (m, 4H), 2.75 (qd, J = 7.7, 3.2 Hz, 2H), 1.17 (t, J = 7.5 Hz, 3H).
281	4-[7-(2-chloro-1H-imidazol-5-yl)-3-(8-chloroquinolin-4-yl)-2-propylbenzimidazol-5-yl]morpholine	507.2	1H NMR (400 MHz, DMSO-d6) δ 9.33 (d, J = 4.5 Hz, 1H), 8.20 (s, 1H), 8.12 (dd, J = 7.6, 1.2 Hz, 1H), 8.02 (d, J = 4.5 Hz, 1H), 7.61 (dd, J = 8.5, 7.5 Hz, 1H), 7.54 (d, J = 2.2 Hz, 2H), 7.32 (dd, J = 8.5, 1.2 Hz, 1H), 6.41 (d, J = 2.2 Hz, 1H), 3.66 (t, J = 4.8 Hz, 4H), 3.11 – 2.97 (m, 4H), 2.70 (t, J = 7.6 Hz, 2H), 1.69 – 1.47 (m, 2H), 0.81 (t, J = 7.3 Hz, 3H).
282	4-[7-(2-chloro-1H-imidazol-5-yl)-3-(8-fluoro-2-methylquinolin-4-yl)-2-methylbenzimidazol-5-yl]morpholine	477.2	1H NMR (400 MHz, DMSO-d6) δ 8.18 (s, 1H), 7.91 (s, 1H), 7.71 (m, 1H), 7.60 – 7.50 (m, 2H), 7.20 (d, J = 8.4 Hz, 1H), 6.45 (d, J = 2.2 Hz, 1H), 3.67 (t, J = 4.8 Hz, 4H), 3.10 – 2.98 (m, 4H), 2.83 (s, 3H), 2.50 (s, 3H).
283	4-[7-(2-chloro-1H-imidazol-5-yl)-2-ethyl-3-(8-fluoro-2-methylquinolin-4-yl)benzimidazol-5-yl]morpholine	491.2	1H NMR (400 MHz, DMSO-d6) δ 8.21 (s, 1H), 7.91 (s, 1H), 7.70 (ddd, J = 10.9, 7.8, 1.1 Hz, 1H), 7.58 – 7.48 (m, 2H), 7.10 (d, J = 8.4 Hz, 1H), 6.45 – 6.39 (m, 1H), 3.67 (t, J = 4.8 Hz, 4H), 3.12 – 2.98 (m, 4H), 2.82 (s, 3H), 2.81 – 2.65 (m, 2H), 1.15 (t, J = 7.5 Hz, 3H).

284	4-[7-(2-chloro-1H-imidazol-5-yl)-2-ethyl-3-(8-fluoroquinolin-4-yl)benzimidazol-5-yl]morpholine	477.2	1H NMR (400 MHz, DMSO-d6) δ 9.25 (d, J = 4.5 Hz, 1H), 8.21 (s, 1H), 8.00 (d, J = 4.5 Hz, 1H), 7.75 (ddd, J = 10.8, 7.8, 1.2 Hz, 1H), 7.63 (ddd, J = 8.5, 7.8, 5.0 Hz, 1H), 7.53 (d, J = 2.3 Hz, 1H), 7.17 (dd, J = 8.5, 1.0 Hz, 1H), 6.39 (d, J = 2.1 Hz, 1H), 3.67 (t, J = 4.7 Hz, 4H), 3.11 – 2.96 (m, 4H), 2.81 – 2.61 (m, 2H), 1.16 (t, J = 7.5 Hz, 3H).
285	4-[7-(2-chloro-1H-imidazol-5-yl)-3-(8-chloroquinolin-4-yl)benzimidazol-5-yl]morpholine	465.1	1H NMR (400 MHz, DMSO-d6) δ 9.26 (d, J = 4.6 Hz, 1H), 8.66 (s, 1H), 8.20 (s, 1H), 8.12 (dd, J = 7.5, 1.3 Hz, 1H), 7.95 (d, J = 4.6 Hz, 1H), 7.64 (dd, J = 8.5, 7.4 Hz, 1H), 7.61 – 7.52 (m, 2H), 6.60 (d, J = 2.2 Hz, 1H), 3.70 (t, J = 4.8 Hz, 4H), 3.12 – 2.97 (m, 4H).
286	4-[7-(2-chloro-1H-imidazol-5-yl)-2-cyclopropyl-3-(5,8-difluoroquinolin-4-yl)benzimidazol-5-yl]morpholine	507.2	1H NMR (400 MHz, DMSO-d6) δ 9.30 (d, J = 4.5 Hz, 1H), 8.13 (s, 1H), 8.02 (d, J = 4.5 Hz, 1H), 7.78 (ddd, J = 10.0, 8.7, 4.1 Hz, 1H), 7.56 (d, J = 2.2 Hz, 1H), 7.47 (ddd, J = 11.7, 8.8, 3.8 Hz, 1H), 6.68 (s, 1H), 3.79 – 3.68 (m, 4H), 3.19 – 3.12 (m, 4H), 1.74 – 1.63 (m, 1H), 1.27 – 1.07 (m, 2H), 0.99 – 0.82 (m, 2H).
287	4-[7-(2-chloro-1H-imidazol-5-yl)-2-cyclopropyl-3-(8-fluoroquinolin-4-yl)benzimidazol-5-yl]morpholine	489.2	1H NMR (400 MHz, DMSO-d6) δ 9.25 (d, J = 4.5 Hz, 1H), 8.14 (s, 1H), 7.98 (d, J = 4.5 Hz, 1H), 7.75 (ddd, J = 10.8, 7.8, 1.2 Hz, 1H), 7.64 (ddd, J = 8.6, 7.8, 5.0 Hz, 1H), 7.55 (d, J = 2.2 Hz, 1H), 7.20 (d, J = 8.2 Hz, 1H), 6.52 (s, 1H), 3.74 – 3.67 (m, 4H), 3.15 – 3.03 (m, 4H), 1.69 – 1.57 (m, 1H), 1.28 – 1.13 (m, 2H), 1.02 – 0.80 (m, 2H).
288	4-[3-(8-chloro-5-fluoroquinolin-4-yl)-7-(2-chloro-1H-imidazol-5-yl)-2-methylbenzimidazol-5-yl]morpholine	497.2	1H NMR (400 MHz, DMSO-d6) δ 9.40 (d, J = 4.5 Hz, 1H), 8.16 (s, 1H), 8.14 (dd, J = 8.6, 5.0 Hz, 1H), 8.06 (d, J = 4.5 Hz, 1H), 7.56 – 7.46 (m, 2H), 6.58 (d, J = 2.2 Hz, 1H), 3.77 – 3.54 (m, 4H), 3.12 – 3.04 (m, 4H), 2.50 (s, 3H).

289	4-[3-(8-chloro-6-fluoroquinolin-4-yl)-7-(2-chloro-1H-imidazol-5-yl)-2-methylbenzimidazol-5-yl]morpholine	497.18	1H NMR (400 MHz, DMSO-d6) δ 9.31 (d, J = 4.5 Hz, 1H), 8.24 (dd, J = 8.5, 2.7 Hz, 1H), 8.17 (s, 1H), 8.06 (d, J = 4.6 Hz, 1H), 7.54 (d, J = 2.2 Hz, 1H), 7.36 (dd, J = 9.1, 2.7 Hz, 1H), 6.48 (d, J = 2.2 Hz, 1H), 3.67 (t, J = 4.7 Hz, 4H), 3.14 – 3.00 (m, 4H), 2.51 (s, 3H).
290	4-[7-(2-chloro-1H-imidazol-5-yl)-3-(8-chloroquinolin-4-yl)-2-cyclopropylbenzimidazol-5-yl]morpholine	505.2	1H NMR (400 MHz, DMSO-d6) δ 9.32 (d, J = 4.5 Hz, 1H), 8.14 (s, 1H), 8.11 (dd, J = 7.5, 1.2 Hz, 1H), 7.99 (d, J = 4.5 Hz, 1H), 7.62 (dd, J = 8.5, 7.5 Hz, 1H), 7.53 (d, J = 2.2 Hz, 1H), 7.34 (dd, J = 8.5, 1.3 Hz, 1H), 6.49 (s, 1H), 3.69 (t, J = 4.7 Hz, 4H), 3.11 – 3.04 (m, 4H), 1.62 (tt, J = 8.2, 4.8 Hz, 1H), 1.28 – 1.10 (m, 2H), 1.01 – 0.89 (m, 1H), 0.90 – 0.78 (m, 1H).
291	4-[7-(2-chloro-1H-imidazol-5-yl)-3-(8-chloroquinolin-4-yl)-2-(oxetan-3-yl)benzimidazol-5-yl]morpholine	521.2	1H NMR (400 MHz, DMSO-d6) δ 9.27 (d, J = 4.5 Hz, 1H), 8.32 (s, 1H), 8.09 (dd, J = 7.5, 1.2 Hz, 1H), 7.84 (d, J = 4.5 Hz, 1H), 7.63 – 7.53 (m, 2H), 7.19 (dd, J = 8.5, 1.3 Hz, 1H), 6.39 (d, J = 2.1 Hz, 1H), 5.02 (dd, J = 6.8, 5.5 Hz, 1H), 4.93 (dd, J = 6.8, 5.5 Hz, 1H), 4.68 (dd, J = 8.6, 5.5 Hz, 1H), 4.51 (dd, J = 8.5, 5.5 Hz, 1H), 4.15 (tt, J = 8.5, 6.8 Hz, 1H), 3.67 (t, J = 4.7 Hz, 4H), 3.11 – 2.92 (m, 4H).
292	4-[7-(2-chloro-1H-imidazol-5-yl)-3-(8-fluoroquinolin-4-yl)benzimidazol-5-yl]morpholine	449.18	1H NMR (400 MHz, DMSO-d6) δ 9.20 (d, J = 4.6 Hz, 1H), 8.72 (s, 1H), 8.20 (s, 1H), 7.95 (d, J = 4.6 Hz, 1H), 7.76 (dd, J = 10.6, 7.7 Hz, 1H), 7.66 (td, J = 8.1, 5.0 Hz, 1H), 7.60 (d, J = 2.2 Hz, 1H), 7.42 (d, J = 8.5 Hz, 1H), 6.63 (d, J = 2.0 Hz, 1H), 3.71 (t, J = 4.8 Hz, 4H), 3.09 (t, J = 4.8 Hz, 4H).
293	4-[7-(2-chloro-1H-imidazol-5-yl)-3-(7-fluoroquinolin-4-yl)-2-methylbenzimidazol-5-yl]morpholine	463.2	1H NMR (400 MHz, DMSO-d6) δ 9.25 (d, J = 4.6 Hz, 1H), 8.17 (s, 1H), 8.06 (ddd, J = 10.1, 2.4, 0.7 Hz, 1H), 7.90 (d, J = 4.6 Hz, 1H), 7.66 – 7.51 (m, 3H), 6.39 (d, J = 2.2 Hz, 1H), 3.66 (t, J = 4.7 Hz, 4H),

			3.12 – 2.98 (m, 4H), 2.49 (s, 3H).
294	4-[3-(8-chloro-7-fluoroquinolin-4-yl)-7-(2-chloro-1H-imidazol-5-yl)-2-methylbenzimidazol-5-yl]morpholine	497.17	1H NMR (400 MHz, DMSO-d6) δ 9.37 (d, J = 4.5 Hz, 1H), 8.18 (s, 1H), 8.01 (d, J = 4.6 Hz, 1H), 7.77 (t, J = 9.1 Hz, 1H), 7.58 – 7.49 (m, 2H), 6.44 (d, J = 2.2 Hz, 1H), 3.66 (t, J = 4.7 Hz, 4H), 3.11 – 2.98 (m, 4H), 2.48 (s, 3H).
295	4-[3-(8-chloro-7-fluoroquinolin-4-yl)-7-(2-chloro-1H-imidazol-5-yl)-2-ethylbenzimidazol-5-yl]morpholine	511.2	1H NMR (400 MHz, DMSO-d6) δ 9.36 (d, J = 4.5 Hz, 1H), 8.21 (s, 1H), 8.01 (d, J = 4.6 Hz, 1H), 7.75 (t, J = 9.1 Hz, 1H), 7.53 (d, J = 2.2 Hz, 1H), 7.44 (dd, J = 9.4, 5.7 Hz, 1H), 6.42 (d, J = 2.2 Hz, 1H), 3.67 (t, J = 4.7 Hz, 4H), 3.04 (td, J = 4.2, 2.1 Hz, 4H), 2.84 – 2.48 (m, 2H), 1.15 (t, J = 7.5 Hz, 3H).
296	4-[3-(8-chloro-7-fluoroquinolin-4-yl)-7-(2-chloro-1H-imidazol-5-yl)-2-cyclopropylbenzimidazol-5-yl]morpholine	523.2	1H NMR (400 MHz, DMSO-d6) δ 9.35 (d, J = 4.6 Hz, 1H), 8.14 (s, 1H), 7.99 (d, J = 4.6 Hz, 1H), 7.75 (t, J = 9.1 Hz, 1H), 7.54 (d, J = 2.2 Hz, 1H), 7.44 (dd, J = 9.4, 5.7 Hz, 1H), 6.53 (s, 1H), 3.70 (dd, J = 5.5, 4.0 Hz, 4H), 3.09 (dd, J = 6.5, 3.6 Hz, 4H), 1.64 (tt, J = 8.3, 4.8 Hz, 1H), 1.29 – 1.11 (m, 2H), 1.02 – 0.92 (m, 1H), 0.89 – 0.79 (m, 1H).
297	4-[3-(8-chloroquinolin-4-yl)-2-methyl-7-(2-methyl-1,3-thiazol-5-yl)benzimidazol-5-yl]morpholine	476.19	1H NMR (400 MHz, DMSO-d6) δ 9.30 (d, J = 4.5 Hz, 1H), 8.56 (s, 1H), 8.10 (dd, J = 7.5, 1.2 Hz, 1H), 7.95 (d, J = 4.5 Hz, 1H), 7.60 (dd, J = 8.5, 7.5 Hz, 1H), 7.32 (d, J = 2.2 Hz, 1H), 7.27 (dd, J = 8.5, 1.2 Hz, 1H), 6.42 (d, J = 2.1 Hz, 1H), 3.65 (t, J = 4.7 Hz, 4H), 3.09 – 2.95 (m, 4H), 2.74 (s, 3H), 2.33 (s, 3H).
298	4-[7-(2-chloro-1H-imidazol-5-yl)-3-(5,8-difluoroquinolin-4-yl)-2-methylbenzimidazol-5-yl]morpholine	481.2	1H NMR (400 MHz, DMSO-d6) δ 9.33 (d, J = 4.5 Hz, 1H), 8.16 (s, 1H), 8.06 (d, J = 4.5 Hz, 1H), 7.81 (ddd, J = 10.1, 8.8, 4.3 Hz, 1H), 7.56 - 7.45 (m, 2H), 6.58 (d, J = 2.2 Hz, 1H), 3.68 (t, J = 4.8 Hz, 4H), 3.16 - 2.94 (m, 4H), 2.51 (s, 3H).
299	4-[7-(2-chloro-1H-imidazol-5-yl)-3-(5,8-	509.2	1H NMR (400 MHz, DMSO-d6) δ 9.30 (d, J = 4.5 Hz, 1H), 8.17 (s,

	difluoroquinolin-4-yl)-2-propylbenzimidazol-5-yl]morpholine		1H), 8.02 (d, J = 4.5 Hz, 1H), 7.79 (ddd, J = 10.1, 8.8, 4.2 Hz, 1H), 7.53 – 7.42 (m, 2H), 6.49 (s, 1H), 3.67 (t, J = 4.7 Hz, 4H), 3.06 (dt, J = 5.6, 2.1 Hz, 4H), 2.74 – 2.61 (m, 2H), 1.71 – 1.56 (m, 2H), 0.84 (t, J = 7.3 Hz, 3H).
300	4-[7-(2-chloro-1H-imidazol-5-yl)-3-(5,8-difluoroquinolin-4-yl)-2-(2-methylpropyl)benzimidazol-5-yl]morpholine	523.2	1H NMR (400 MHz, DMSO-d6) δ 9.30 (d, J = 4.5 Hz, 1H), 8.18 (s, 1H), 8.02 (d, J = 4.5 Hz, 1H), 7.79 (ddd, J = 10.1, 8.8, 4.2 Hz, 1H), 7.54 – 7.43 (m, 2H), 6.53 (s, 1H), 3.68 (t, J = 4.8 Hz, 4H), 3.17 – 2.97 (m, 4H), 2.66 (dd, J = 14.9, 6.9 Hz, 1H), 2.57 (dd, J = 14.9, 7.5 Hz, 1H), 2.02 (hept, J = 6.8 Hz, 1H), 0.84 (d, J = 6.6 Hz, 6H).
301	4-[7-(2-chloro-1H-imidazol-5-yl)-3-(8-chloroquinolin-4-yl)-2-(cyclopropylmethyl)benzimidazol-5-yl]morpholine	519.2	1H NMR (400 MHz, DMSO-d6) δ 9.33 (d, J = 4.5 Hz, 1H), 8.22 (s, 1H), 8.11 (dd, J = 7.5, 1.2 Hz, 1H), 8.04 (d, J = 4.5 Hz, 1H), 7.61 (dd, J = 8.5, 7.5 Hz, 1H), 7.57 (d, J = 2.2 Hz, 1H), 7.35 (dd, J = 8.5, 1.3 Hz, 1H), 6.45 (d, J = 2.2 Hz, 1H), 3.67 (t, J = 4.7 Hz, 4H), 3.13 - 2.99 (m, 4H), 2.83 - 2.67 (m, 2H), 0.92 - 0.77 (m, 1H), 0.31 (dddd, J = 9.1, 8.1, 5.7, 4.2 Hz, 1H), 0.18 (dddd, J = 9.1, 7.9, 5.7, 4.2 Hz, 1H), -0.11 - -0.22 (m, 1H).
302	4-[7-(2-chloro-1H-imidazol-5-yl)-2-(cyclopropylmethyl)-3-(5,8-difluoroquinolin-4-yl)benzimidazol-5-yl]morpholine	521.2	1H NMR (400 MHz, DMSO-d6) δ 9.31 (d, J = 4.5 Hz, 1H), 8.19 (s, 1H), 8.05 (d, J = 4.5 Hz, 1H), 7.79 (ddd, J = 10.0, 8.8, 4.2 Hz, 1H), 7.53 (s, 0H), 7.47 (ddd, J = 12.3, 8.8, 3.8 Hz, 1H), 6.58 – 6.52 (m, 1H), 3.68 (t, J = 4.7 Hz, 4H), 3.12 – 3.03 (m, 4H), 2.76 (qd, J = 15.5, 6.8 Hz, 2H), 0.96 – 0.81 (m, 1H), 0.33 (dddd, J = 9.7, 8.2, 5.6, 4.1 Hz, 1H), 0.23 (dddd, J = 9.2, 7.9, 5.6, 4.1 Hz, 1H), 0.09 – 0.01 (m, 1H), -0.14 (dq, J = 9.6, 4.9 Hz, 1H).
303	4-[3-(8-chloro-6-fluoroquinolin-4-yl)-7-(2-chloro-1H-imidazol-	525.2	1H NMR (400 MHz, DMSO-d6) δ 9.29 (d, J = 4.5 Hz, 1H), 8.23 (dd, J = 8.5, 2.7 Hz, 1H), 8.19 (s, 1H),

	5-yl)-2-propylbenzimidazol-5-yl]morpholine		8.05 (d, J = 4.5 Hz, 1H), 7.53 (d, J = 2.2 Hz, 1H), 7.16 (dd, J = 9.3, 2.6 Hz, 1H), 6.42 (d, J = 2.2 Hz, 1H), 3.67 (t, J = 4.7 Hz, 4H), 3.10 – 2.97 (m, 4H), 2.77 – 2.61 (m, 2H), 1.72 – 1.51 (m, 2H), 0.83 (t, J = 7.4 Hz, 3H).
304	4-[7-(2-chloro-1H-imidazol-5-yl)-2-(cyclopropylmethyl)-3-(8-fluoroquinolin-4-yl)benzimidazol-5-yl]morpholine	503.2	1H NMR (400 MHz, DMSO-d6) δ 9.25 (d, J = 4.5 Hz, 1H), 8.23 (s, 1H), 8.01 (d, J = 4.5 Hz, 1H), 7.75 (ddd, J = 10.8, 7.8, 1.2 Hz, 1H), 7.62 (td, J = 8.2, 5.0 Hz, 1H), 7.55 (d, J = 2.2 Hz, 1H), 7.16 (d, J = 8.5 Hz, 1H), 6.41 (s, 1H), 3.67 (t, J = 4.7 Hz, 4H), 3.13 – 2.97 (m, 4H), 2.79 – 2.64 (m, 2H), 0.93 – 0.78 (m, 1H), 0.32 (dddd, J = 9.1, 8.1, 5.7, 4.1 Hz, 1H), 0.25 – 0.13 (m, 1H), 0.10 – -0.04 (m, 1H), -0.10 – -0.21 (m, 1H).
305	4-[7-(2-chloro-1H-imidazol-5-yl)-3-(8-fluoroquinolin-4-yl)-2-propylbenzimidazol-5-yl]morpholine	491.2	1H NMR (400 MHz, DMSO-d6) δ 9.26 (d, J = 4.5 Hz, 1H), 8.21 (s, 1H), 8.01 (d, J = 4.5 Hz, 1H), 7.76 (ddd, J = 10.8, 7.8, 1.2 Hz, 1H), 7.63 (td, J = 8.1, 5.0 Hz, 1H), 7.55 (d, J = 2.2 Hz, 1H), 7.17 (d, J = 8.5 Hz, 1H), 6.42 (s, 1H), 3.67 (t, J = 4.7 Hz, 4H), 3.12 – 2.98 (m, 4H), 2.70 (t, J = 7.5 Hz, 2H), 1.60 (qq, J = 13.8, 7.3 Hz, 2H), 0.81 (t, J = 7.4 Hz, 3H).
306	4-[7-(2-chloro-1H-imidazol-5-yl)-2-methyl-3-quinolin-4-ylbenzimidazol-5-yl]morpholine	445.2	1H NMR (400 MHz, DMSO-d6) δ 9.24 (d, J = 4.5 Hz, 1H), 8.29 (ddd, J = 8.5, 1.3, 0.7 Hz, 1H), 8.18 (s, 1H), 7.99 – 7.90 (m, 1H), 7.92 (d, J = 4.5 Hz, 1H), 7.67 (ddd, J = 8.2, 6.9, 1.2 Hz, 1H), 7.55 (d, J = 2.2 Hz, 1H), 7.47 (d, J = 8.4 Hz, 1H), 6.38 (d, J = 2.1 Hz, 1H), 3.66 (t, J = 4.8 Hz, 4H), 3.11 – 2.97 (m, 4H), 2.48 (s, 3H).
307	4-[3-(8-chloro-5-fluoroquinolin-4-yl)-7-(2-chloro-1H-imidazol-5-yl)-2-cyclopropylbenzimidazo	523.1	1H NMR (400 MHz, DMSO-d6) δ 9.36 (d, J = 4.5 Hz, 1H), 8.12 (dd, J = 8.5, 4.9 Hz, 1H), 8.11 (s, 1H), 8.01 (d, J = 4.5 Hz, 1H), 7.54 – 7.40 (m, 2H), 6.59 (s, 1H), 3.70 (t, J =

	l-5-yl]morpholine		4.8 Hz, 4H), 3.12 – 3.07 (m, 4H), 1.64 (td, J = 8.2, 4.2 Hz, 1H), 1.24 – 1.15 (m, 1H), 1.14 – 1.03 (m, 1H), 0.96 – 0.79 (m, 2H).
308	4-[7-(2-chloro-1H-imidazol-5-yl)-3-(5,8-difluoroquinolin-4-yl)benzimidazol-5-yl]morpholine	467.1	1H NMR (400 MHz, DMSO-d6) δ 9.65 (s, 1H), 9.21 (s, 1H), 8.74 – 8.00 (m, 1H), 8.00 – 7.68 (m, 2H), 7.63 – 7.26 (m, 2H), 6.80 – 6.38 (m, 1H), 4.11 – 3.72 (m, 4H), 3.24 – 2.95 (m, 4H).
309	4-[3-(5-chloro-8-fluoroquinolin-4-yl)-7-(2-chloro-1H-imidazol-5-yl)-2-methylbenzimidazol-5-yl]morpholine	497.1	1H NMR (400 MHz, DMSO-d6) δ 9.35 (d, J = 4.4 Hz, 1H), 8.17 (s, 1H), 8.08 (d, J = 4.4 Hz, 1H), 7.84 (s, 1H), 7.82 (d, J = 1.5 Hz, 1H), 7.54 (d, J = 2.2 Hz, 1H), 6.56 (d, J = 2.2 Hz, 1H), 3.68 (t, J = 4.8 Hz, 4H), 3.14 – 3.06 (m, 4H), 2.51 (s, 3H).
310	4-[3-(5-chloro-8-fluoroquinolin-4-yl)-7-(2-chloro-1H-imidazol-5-yl)-2-ethylbenzimidazol-5-yl]morpholine	511.1	1H NMR (400 MHz, DMSO-d6) δ 9.33 (d, J = 4.4 Hz, 1H), 8.21 (s, 1H), 8.09 (d, J = 4.5 Hz, 1H), 7.85 – 7.76 (m, 2H), 7.55 (d, J = 2.2 Hz, 1H), 6.56 (d, J = 2.2 Hz, 1H), 3.69 (dd, J = 5.6, 4.0 Hz, 4H), 3.17 – 3.06 (m, 4H), 2.85 - 2.68 (m, 2H), 1.20 (t, J = 7.5 Hz, 3H).
311	4-(1-(8-chloroquinolin-4-yl)-2-methyl-4-phenyl-1H-benzo[d]imidazol-6-yl)morpholine	455.2	1H NMR (400 MHz, DMSO-d6) δ 9.36 (d, J = 4.5 Hz, 1H), 8.14 (dd, J = 7.5, 1.2 Hz, 1H), 8.04 (d, J = 4.5 Hz, 1H), 7.97 - 7.89 (m, 2H), 7.70 - 7.55 (m, 3H), 7.56 - 7.43 (m, 2H), 7.25 (d, J = 2.2 Hz, 1H), 6.58 (d, J = 2.2 Hz, 1H), 3.65 (t, J = 4.8 Hz, 4H), 3.08 (q, J = 4.2 Hz, 4H), 2.43 (s, 3H).
312	4-(2-methyl-4-phenyl-1-(8-phenylquinolin-4-yl)-1H-benzo[d]imidazol-6-yl)morpholine	497.3	1H NMR (400 MHz, DMSO-d6) δ 9.24 (d, J = 4.4 Hz, 1H), 7.99 - 7.90 (m, 4H), 7.79 - 7.71 (m, 3H), 7.65 - 7.57 (m, 2H), 7.57 - 7.43 (m, 5H), 7.28 (d, J = 2.2 Hz, 1H), 6.60 (d, J = 2.1 Hz, 1H), 3.66 (t, J = 4.8 Hz, 4H), 3.10 (q, J = 4.0 Hz, 4H), 2.46 (s, 3H).
313	4-(1-(8-chloroquinolin-4-yl)-2-methyl-4-(1-	459.1	1H NMR (400 MHz, DMSO-d6) δ 9.33 (d, J = 4.6 Hz, 1H), 8.56 (s,

	methyl-1H-pyrazol-4-yl)-1H-benzo[d]imidazol-6-yl)morpholine		1H), 8.25 (d, J = 0.7 Hz, 1H), 8.13 (dd, J = 7.5, 1.2 Hz, 1H), 8.00 (d, J = 4.5 Hz, 1H), 7.63 (dd, J = 8.5, 7.6 Hz, 1H), 7.43 - 7.30 (m, 2H), 6.41 (d, J = 2.3 Hz, 1H), 3.97 (s, 3H), 3.67 (t, J = 4.7 Hz, 4H), 3.14 - 2.99 (m, 4H), 2.42 (s, 3H).
314	4-(1-(8-chloroquinolin-4-yl)-2-methyl-4-(pyridazin-4-yl)-1H-benzo[d]imidazol-6-yl)morpholine	457.1	1H NMR (400 MHz, DMSO-d6) δ 10.15 (dd, J = 2.5, 1.2 Hz, 1H), 9.44 - 9.37 (m, 1H), 9.31 (d, J = 4.6 Hz, 1H), 8.62 (dd, J = 5.5, 2.4 Hz, 1H), 8.11 (dd, J = 7.5, 1.2 Hz, 1H), 7.97 (d, J = 4.5 Hz, 1H), 7.61 (dd, J = 8.5, 7.5 Hz, 1H), 7.52 (d, J = 2.2 Hz, 1H), 7.26 (dd, J = 8.5, 1.2 Hz, 1H), 6.61 (d, J = 2.2 Hz, 1H), 3.66 (t, J = 4.8 Hz, 4H), 3.07 (q, J = 4.5 Hz, 4H), 2.35 (s, 3H).
315	4-(1-(8-chloroquinolin-4-yl)-2-methyl-4-(pyrimidin-5-yl)-1H-benzo[d]imidazol-6-yl)morpholine	457.1	1H NMR (400 MHz, DMSO-d6) δ 9.55 (s, 2H), 9.31 (d, J = 4.5 Hz, 1H), 9.23 (s, 1H), 8.11 (dd, J = 7.5, 1.2 Hz, 1H), 7.96 (d, J = 4.5 Hz, 1H), 7.61 (dd, J = 8.5, 7.5 Hz, 1H), 7.38 (d, J = 2.2 Hz, 1H), 7.27 (dd, J = 8.5, 1.2 Hz, 1H), 6.52 (d, J = 2.2 Hz, 1H), 3.65 (t, J = 4.8 Hz, 4H), 3.05 (q, J = 4.5 Hz, 4H), 2.34 (s, 3H).
316	3-(1-(8-chloroquinolin-4-yl)-2-methyl-6-morpholino-1H-benzo[d]imidazol-4-yl)-N,N-dimethylaniline	498.2	1H NMR (400 MHz, DMSO-d6) δ 9.35 (d, J = 4.7 Hz, 1H), 8.14 (d, J = 7.5 Hz, 1H), 8.02 (d, J = 3.9 Hz, 1H), 7.65 (t, J = 8.0 Hz, 1H), 7.46 (br s, 1H), 7.45 - 7.36 (m, 1H), 7.29 - 7.12 (m, 2H), 6.92 (br s, 1H), 6.53 (s, 2H), 3.65 (t, J = 4.8 Hz, 4H), 3.08 - 3.05 (m, 4H), 3.03 (s, 6H), 2.42 (s, 3H).
317	4-[3-(8-chloroquinolin-4-yl)-2-methyl-7-pyridin-3-ylbenzimidazol-5-yl]morpholine	456.1	1H NMR (400 MHz, DMSO-d6) δ 9.55 (s, 1H), 9.32 (d, J = 4.5 Hz, 1H), 8.98 (br d, J = 8.1 Hz, 1H), 8.82 (dd, J = 5.3, 1.5 Hz, 1H), 8.12 (dd, J = 7.5, 1.2 Hz, 1H), 7.97 (d, J = 4.5 Hz, 1H), 7.96 - 7.90 (m, 1H), 7.62 (dd, J = 8.5, 7.5 Hz, 1H), 7.39 (d, J = 2.2 Hz, 1H), 7.27 (dd, J = 8.5, 1.3 Hz, 1H), 6.57 (d, J = 2.2

			Hz, 1H), 3.66 (t, J = 4.8 Hz, 4H), 3.13 - 2.99 (m, 4H), 2.35 (s, 3H).
318	4-[2-methyl-7-pyridin-3-yl-3-(8-pyridin-3-ylquinolin-4-yl)benzimidazol-5-yl]morpholine	499.2	1H NMR (400 MHz, DMSO-d6) δ 9.68 - 9.62 (m, 1H), 9.26 (d, J = 4.5 Hz, 1H), 9.25 - 9.22 (m, 1H), 9.14 (dt, J = 8.2, 1.8 Hz, 1H), 8.92 (td, J = 5.5, 1.5 Hz, 2H), 8.73 (dt, J = 8.1, 1.8 Hz, 1H), 8.15 (dd, J = 7.2, 1.4 Hz, 1H), 8.11 - 8.01 (m, 2H), 7.98 (d, J = 4.5 Hz, 1H), 7.82 (dd, J = 8.5, 7.2 Hz, 1H), 7.48 (d, J = 2.2 Hz, 1H), 7.46 (dd, J = 8.5, 1.3 Hz, 1H), 6.61 (d, J = 2.1 Hz, 1H), 3.69 (t, J = 4.8 Hz, 4H), 3.17 - 3.01 (m, 4H), 2.39 (s, 3H).
319	4-[3-(8-chloroquinolin-4-yl)-2-methyl-7-pyridin-4-ylbenzimidazol-5-yl]morpholine	456.2	1H NMR (400 MHz, DMSO-d6) δ 9.32 (d, J = 4.5 Hz, 1H), 8.95 (d, J = 6.6 Hz, 2H), 8.85 (br d, J = 5.9 Hz, 2H), 8.11 (dd, J = 7.5, 1.2 Hz, 1H), 7.97 (d, J = 4.6 Hz, 1H), 7.61 (dd, J = 8.5, 7.6 Hz, 1H), 7.53 (d, J = 2.2 Hz, 1H), 7.24 (dd, J = 8.5, 1.3 Hz, 1H), 6.68 (d, J = 2.1 Hz, 1H), 3.67 (t, J = 4.8 Hz, 4H), 3.07 (q, J = 4.5 Hz, 4H), 2.35 (s, 3H).
320	4-[2-methyl-7-pyridin-4-yl-3-(8-pyridin-4-ylquinolin-4-yl)benzimidazol-5-yl]morpholine	499.2	1H NMR (400 MHz, DMSO-d6) δ 9.27 (d, J = 4.5 Hz, 1H), 9.09 - 8.97 (m, 6H), 8.42 - 8.34 (m, 2H), 8.19 (dd, J = 7.2, 1.3 Hz, 1H), 8.01 (d, J = 4.5 Hz, 1H), 7.84 (dd, J = 8.5, 7.2 Hz, 1H), 7.62 (d, J = 2.2 Hz, 1H), 7.50 (dd, J = 8.4, 1.3 Hz, 1H), 6.74 (d, J = 2.1 Hz, 1H), 3.70 (t, J = 4.8 Hz, 4H), 3.18 - 3.02 (m, 4H), 2.40 (s, 3H).
321	3-[1-(8-chloroquinolin-4-yl)-2-methyl-6-morpholin-4-ylbenzimidazol-4-yl]benzamide	498.1	1H NMR (400 MHz, DMSO-d6) δ 9.34 (d, J = 4.5 Hz, 1H), 8.35 (t, J = 1.8 Hz, 1H), 8.22 - 8.16 (m, 1H), 8.15 - 8.07 (m, 2H), 8.00 (d, J = 4.5 Hz, 1H), 7.95 (dt, J = 7.8, 1.4 Hz, 1H), 7.70 - 7.59 (m, 2H), 7.50 (s, 1H), 7.39 (d, J = 8.5 Hz, 1H), 7.27 (d, J = 2.2 Hz, 1H), 6.54 (d, J = 2.1 Hz, 1H), 3.66 (t, J = 4.8 Hz, 4H), 3.14 - 2.99 (m, 4H), 2.39 (s, 3H).

322	3-[4-[4-(3-carbamoylphenyl)-2-methyl-6-morpholin-4-ylbenzimidazol-1-yl]quinolin-8-yl]benzamide	583.2	1H NMR (400 MHz, DMSO-d6) δ 9.24 (d, J = 4.5 Hz, 1H), 8.35 (t, J = 1.8 Hz, 1H), 8.22 (t, J = 1.8 Hz, 1H), 8.17 (d, J = 7.8 Hz, 1H), 8.12 (s, 1H), 8.07 (s, 1H), 8.03 - 7.93 (m, 4H), 7.90 (dt, J = 7.7, 1.3 Hz, 1H), 7.77 (dd, J = 8.4, 7.2 Hz, 1H), 7.68 (t, J = 7.7 Hz, 1H), 7.61 (t, J = 7.7 Hz, 1H), 7.52 (s, 1H), 7.50 - 7.45 (m, 1H), 7.43 (s, 1H), 7.31 (d, J = 2.2 Hz, 1H), 6.57 (d, J = 2.1 Hz, 1H), 3.68 (t, J = 4.8 Hz, 4H), 3.17 - 3.03 (m, 4H), 2.44 (s, 3H).
323	4-[3-(8-chloroquinolin-4-yl)-2-methyl-7-pyridin-2-ylbenzimidazol-5-yl]morpholine	456.1	1H NMR (400 MHz, DMSO-d6) δ 9.37 (d, J = 4.5 Hz, 1H), 8.92 - 8.86 (m, 1H), 8.70 (d, J = 8.1 Hz, 1H), 8.20 - 8.11 (m, 2H), 8.07 (d, J = 4.5 Hz, 1H), 7.89 (d, J = 2.2 Hz, 1H), 7.69 - 7.56 (m, 2H), 7.49 (dd, J = 8.5, 1.2 Hz, 1H), 6.70 (d, J = 2.1 Hz, 1H), 3.68 (t, J = 4.8 Hz, 4H), 3.19 - 3.04 (m, 4H), 2.54 (s, 3H).

Step 6c: 4-(1-(8-chloroquinolin-4-yl)-2-methyl-4-(1H-1,2,3-triazol-5-yl)-1H-benzo[d]imidazol-6-yl)morpholine



4-(4-Bromo-1-(8-chloroquinolin-4-yl)-2-methyl-1H-benzo[d]imidazol-6-yl)morpholine (220 mg, 0.48 mmol), ethynyltributylstannane (0.181 mL, 0.63 mmol), Pd(dppf)Cl2 (31 mg, 0.048 mmol), and copper iodide (9 mg, 0.048 mmol) were combined in dioxane (2 mL), degassed under Ar_2, and heated to 70°C. After 5 days the reaction was purified

directly on silica to give 4-(1-(8-chloroquinolin-4-yl)-4-ethynyl-2-methyl-1H-benzo[d]imidazol-6-yl)morpholine. 4-(1-(8-Chloroquinolin-4-yl)-4-ethynyl-2-methyl-1H-benzo[d]imidazol-6-yl)morpholine (39 mg, 0.097 mmol) was combined with copper iodide (2 mg, 0.01 mmol) in a mixture of DMF (0.5 mL) and MeOH (0.1 mL) under N_2. Azidotrimethylsilane (0.019 mL, 0.145 mmol) was added, and the resulting mixture was heated to 80°C overnight. Purification on silica (0-30% MeOH/DCM), followed by preparatory LC, provided 4-(1-(8-chloroquinolin-4-yl)-2-methyl-4-(1H-1,2,3-triazol-5-yl)-1H-benzo[d]imidazol-6-yl)morpholine (Compound 329). 1H NMR (400 MHz, DMSO-d6) δ 9.32 (d, J = 4.5 Hz, 1H), 8.81 (s, 1H), 8.11 (d, J = 7.5 Hz, 1H), 7.99 (d, J = 4.5 Hz, 1H), 7.68 – 7.48 (m, 2H), 7.34 (s, 1H), 6.49 (s, 1H), 3.68 – 3.64 (m, 4H), 3.10 – 2.95 (m, 4H), 2.41 (s, 3H). ES/MS *m/z* 446.2 $(M+H)^+$.

The compounds listed in the table below were prepared in a manner similar to that described above using appropriate intermediates and chemistry.

Compound	Name	MS	NMR
376	4-(1-(5,8-difluoroquinolin-4-yl)-2-ethyl-4-(1H-1,2,3-triazol-5-yl)-1H-benzo[d]imidazol-6-yl)morpholine	462.2	1H NMR (400 MHz, DMSO-d6) δ 9.31 (d, J = 28.5 Hz, 1H), 8.89 – 8.72 (m, 1H), 8.11 – 7.91 (m, 1H), 7.83 – 7.70 (m, 1H), 7.69 – 7.55 (m, 1H), 7.55 – 7.36 (m, 1H), 6.67 – 6.50 (m, 1H), 3.68 (t, J = 4.7 Hz, 4H), 3.15 – 2.95 (m, 4H), 1.26 – 1.09 (m, 3H), 0.72 – 0.55 (m, 2H).
377	4-(1-(5,8-difluoroquinolin-4-yl)-2-methyl-4-(1H-1,2,3-triazol-5-yl)-1H-benzo[d]imidazol-6-yl)morpholine	448.2	1H NMR (400 MHz, DMSO-d6) δ 9.32 (d, J = 4.5 Hz, 1H), 8.86 – 8.76 (m, 1H), 8.04 (d, J = 4.5 Hz, 1H), 7.80 (td, J = 9.4, 4.1 Hz, 1H), 7.64 (s, 1H), 7.50 (ddd, J = 12.3, 8.8, 3.8 Hz, 1H), 6.65 (s, 1H), 3.68 (t, J = 4.8 Hz, 4H), 3.09 (s, 4H), 2.48 (s, 3H).
378	4-(1-(8-chloroquinolin-4-yl)-2-cyclopropyl-4-(1H-1,2,3-triazol-5-yl)-1H-benzo[d]imidazol-6-yl)morpholine	472.2	1H NMR (400 MHz, DMSO-d6) δ 9.32 (d, J = 4.4 Hz, 1H), 8.80 – 8.67 (m, 1H), 8.10 (d, J = 7.5 Hz, 1H), 8.03 – 7.95 (m, 1H), 7.66 – 7.56 (m, 2H), 7.37 – 7.27 (m, 1H), 6.53 – 6.44 (m, 1H), 3.67 (t, J = 4.7 Hz, 4H), 3.11 – 2.95 (m, 4H), 1.65 – 1.52 (m, 1H), 1.30 – 1.11 (m, 2H), 1.01 – 0.75 (m, 2H).

Step 6d: 4-(1-(5,8-difluoroquinolin-4-yl)-2-ethyl-4-(1H-imidazol-2-yl)-1H-benzo[d]imidazol-6-yl)morpholine



4-(4-bromo-1-(5,8-difluoroquinolin-4-yl)-2-ethyl-1H-benzo[d]imidazol-6-yl)morpholine (200 mg, 0.42 mmol) was combined with N,N-dimethyl imidazole-1-sulfonamide (81 mg, 0.47 mmol), PdOAc (7 mg, 0.07 mmol), and CuI (210 mg, 1.1 mmol) in DMF (2 mL). The mixture was degassed under Ar_2 and heated to 140°C under microwave irradiation for 10 hours. The reaction was filtered and the filtrate concentrated, then precipitated from water to give the protected product as a brown solid. Treatment with TFA in DCM, followed by reverse phase prep LC purification, provided the title compound (Compound 387). 1H NMR (400 MHz, DMSO-d6) δ 9.30 (d, J = 4.5 Hz, 1H), 8.01 (d, J = 4.5 Hz, 1H), 7.87 (s, 2H), 7.79 (ddd, J = 10.0, 8.7, 4.2 Hz, 1H), 7.71 (d, J = 2.1 Hz, 1H), 7.52 – 7.41 (m, 1H), 6.89 (d, J = 2.1 Hz, 1H), 3.78 – 3.62 (m, 4H), 3.12 – 3.05 (m, 4H), 2.75 – 2.60 (m, 2H), 1.25 (t, J = 7.5 Hz, 3H). ES/MS *m/z* = 461.2 $(M+H)^+$.

Step 6e: 4-(1-(5,8-difluoroquinolin-4-yl)-2-propyl-4-(1H-pyrazol-4-yl)-1H-benzo[d]imidazol-6-yl)morpholine



To a solution of 4-(4-bromo-1-(5,8-difluoroquinolin-4-yl)-2-propyl-1H-benzo[d]imidazol-6-yl)morpholine (100 mg, 0.21 mmol) in dioxane (1 mL) was added 1-Boc-pyrazole-4-boronic acid pinacol ester (91 mg, 0.31 mmol), cesium fluoride (78 mg, 0.51 mmol), and BrettPhos Pd G3 (17 mg, 0.021 mmol). The resulting mixture was degassed under Argon and heated to 80°C for 3 days. The reaction was purified directly on silica (0 – 100% EtOAc/DCM), then treated with TFA in DCM to remove the Boc group. Final purification by prep HPLC eluting with 5-95% water/ acetonitrile (0.1%v/v trifluoroacetic acid) afforded the title compound (Compound 388). 1H NMR (400 MHz, DMSO-d6) δ 9.30 (d, J = 4.5 Hz, 1H), 8.50 (s, 2H), 8.00 (d, J = 4.5 Hz, 1H), 7.79 (ddd, J = 10.1, 8.8, 4.2 Hz, 1H), 7.48 (ddd, J = 12.3, 8.8, 3.8 Hz, 1H), 7.35 (d, J = 2.2 Hz, 1H), 6.47 (s, 1H), 3.74 - 3.52 (m, 4H), 3.15 - 3.03 (m, 4H), 2.72 - 2.56 (m, 2H), 1.66 (h, J = 7.4 Hz, 2H), 0.86 (t, J = 7.4 Hz, 3H). ES/MS *m/z* 475.2 $(M+H)^+$.

The compound listed in the table below was prepared in a manner similar to that described above using appropriate intermediates and chemistry.

Compound	Name	MS	NMR
389	4-(1-(5,8-difluoroquinolin-4-yl)-2-propyl-4-(1H-pyrazol-5-yl)-1H-benzo[d]imidazol-6-yl)morpholine	475.20	1H NMR (400 MHz, DMSO-d6) δ 9.34 (d, J = 4.5 Hz, 1H), 8.11 (d, J = 4.5 Hz, 1H), 7.89 (d, J = 2.2 Hz, 1H), 7.81 (ddd, J = 10.1, 8.8, 4.2 Hz, 1H), 7.59 (d, J = 2.2 Hz, 1H), 7.51 (ddd, J = 12.3, 8.8, 3.8 Hz, 1H), 7.29 (d, J = 2.2 Hz, 1H), 6.60 (d, J = 2.2 Hz, 1H), 3.68 (t, J = 4.7 Hz, 4H), 3.15 – 3.02 (m, 4H), 2.87 – 2.74 (m, 2H), 1.59 (h, J = 7.6 Hz, 2H), 0.83 (t, J = 7.3 Hz, 3H).

Step 6f: 4-(1-(5,8-difluoroquinolin-4-yl)-4-(2-(trifluoromethyl)-1H-imidazol-5-yl)-1H-benzo[d]imidazol-6-yl)morpholine as a yellow solid



4-(4-bromo-1-(5,8-difluoroquinolin-4-yl)-1H-benzo[d]imidazol-6-yl)morpholine (150 mg, 0.337 mmol), 2-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole (117 mg, 0.438 mmol), butyl di-1-adamantylphosphine tretrafluoroborate salt (45 mg, 0.101 mmol), K_2CO_3 (116 mg, 0.842 mmol), $Pd(OAc)_2$ (11 mg, 0.051 mmol), and pivalic acid (10 mg, 0.101 mmol) were combined in toluene (0.5 mL). The mixture was purged with N_2 and heated to 100°C overnight. Purification on silica gel (12 g column, 0 – 100% EtOAc/DCM) gave 4-(1-(5,8-difluoroquinolin-4-yl)-4-(2-(trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazol-5-yl)-1H-benzo[d]imidazol-6-yl)morpholine, ES/MS m/z = 631.2 $(M+H)^+$. Treatment with TFA in DCM afforded the title compound (Compound 390). 1H NMR (400 MHz, DMSO-d6) δ 9.17 (d, J = 4.5 Hz, 1H), 8.55 (s, 1H), 8.34 (s, 1H), 7.90 (d, J = 4.6 Hz, 1H), 7.72 (ddd, J = 10.1, 8.8, 4.2 Hz, 1H), 7.58 (d, J = 2.1 Hz, 1H), 7.42 (ddd, J = 12.5, 8.8, 3.9 Hz, 1H), 6.68 (s, 1H), 3.65 (t, J = 4.7 Hz, 4H), 3.13 - 2.90 (m, 4H). ES/MS m/z = 501.1 $(M+H)^+$.

Step 7: 8-chloro-N-(5-morpholino-2-nitro-3-(1-trityl-1H-imidazol-4-yl)phenyl)quinolin-4-amine



To a solution of N-(3-bromo-5-morpholino-2-nitrophenyl)-8-chloroquinolin-4-amine (250 mg, 0.54 mmol) in dioxane (3 mL) was added 4-(tri-n-butylstannyl)-1-tritylimidazole (355 mg, 0.59 mmol), copper iodide (10 mg, 0.05 mmol), and Pd(II)Cl_2dppf (35 mg, 0.05 mmol). The resulting mixture was degassed under Argon and heated to 80°C. After 18 hours the reaction was allowed to cool and was purified directly on silica (0 – 100% EtOAc/DCM) to give 8-chloro-N-(5-morpholino-2-nitro-3-(1-trityl-1H-imidazol-4-yl)phenyl)quinolin-4-amine. ES/MS *m/z* 693.2.$(M+H)^+$.

Step 8: 4-(1-(8-chloroquinolin-4-yl)-4-(1H-imidazol-4-yl)-1H-benzo[d]imidazol-6-yl)morpholine



Formaldehyde (0.11 mL, 1.3 mmol) was added to a suspension of 8-chloro-N-(5-morpholino-2-nitro-3-(1-trityl-1H-imidazol-4-yl)phenyl)quinolin-4-amine (150 mg, 0.22 mmol) and sodium thiosulfite (113 mg, 0.65 mmol) in a mixture of EtOH (1 mL) and DMSO (1 mL). The vessel was sealed and heated to 80°C for 18 hours. After cooling, the mixture was poured into EtOAc and washed with water, then aq. $NaHCO_3$. The organic phase was purified on silica (0 – 30% MeOH/DCM), then by prep LC, to give 4-(1-(8-chloroquinolin-4-yl)-4-(1H-imidazol-4-yl)-1H-benzo[d]imidazol-6-yl)morpholine (Compound 332). 1H NMR (400 MHz, DMSO-d6) δ 9.29 (s, 1H), 9.27 (d, J = 4.5 Hz, 1H), 8.68 (m, 1H), 8.57 (m, 1H), 8.13 (d, J = 7.5 Hz, 1H), 7.96 (d, J = 4.6, 1H), 7.69 – 7.60 (m, 2H), 7.50 (d, J = 8.5 Hz, 1H), 6.76 (d, J = 2.0 Hz, 1H), 3.71 (t, J = 4.8 Hz, 4H), 3.13 – 3.08 (m, 4H). ES/MS *m/z* 431.1 $(M+H)^+$.

The compounds listed in the table below were prepared in a manner similar to that described above using appropriate intermediates and chemistry.

Compound	Name	MS	NMR
331	4-[3-(8-chloroquinolin-4-yl)-2-ethyl-7-(1H-imidazol-4-yl)benzimidazol-5-yl]morpholine	459.11	1H NMR (400 MHz, DMSO-d6) δ 9.34 – 9.27 (m, 2H), 8.57 (d, J = 1.5, 1H), 8.11 (d, J = 7.5 Hz, 1H), 7.97 (d, J = 4.6 Hz, 1H), 7.65 – 7.57 (m, 1H), 7.55 (d, J = 2.4 Hz, 1H), 7.18 (d, J = 8.4 Hz, 1H), 6.53 – 6.47 (m, 1H), 3.67 (t, J = 4.8 Hz, 4H), 3.10 – 2.96 (m, 4H), 2.75 – 2.52 (m, 2H), 1.21 (t, J = 7.5 Hz, 3H).
332	4-[3-(8-chloroquinolin-4-yl)-7-(1H-imidazol-4-yl)benzimidazol-5-yl]morpholine	431.1	1H NMR (400 MHz, DMSO-d6) δ 9.29 (s, 1H), 9.27 (d, J = 4.5 Hz, 1H), 8.68 (m, 1H), 8.57 (m, 1H), 8.13 (d, J = 7.5 Hz, 1H), 7.96 (d, J = 4.6, 1H), 7.69 – 7.60 (m, 2H), 7.50 (d, J = 8.5 Hz, 1H), 6.76 (d, J = 2.0 Hz, 1H), 3.71 (t, J = 4.8 Hz, 4H), 3.13 – 3.08 (m, 4H).
333	4-[3-(5,8-dichloro-2-methylquinolin-4-yl)-7-(1H-imidazol-5-yl)-2-methylbenzimidazol-5-yl]morpholine	493.17	1H NMR (400 MHz, DMSO-d6) δ 9.25 (s, 1H), 8.51 (s, 1H), 8.05 (d, J = 8.3 Hz, 1H), 7.84 (s, 1H), 7.66 (d, J = 8.3 Hz, 1H), 7.48 (d, J = 2.1 Hz, 1H), 6.57 (d, J = 1.8 Hz, 1H), 3.69 (t, J = 4.7 Hz, 4H), 3.12 – 3.00 (m, 4H), 2.83 (s, 3H), 2.31 (s, 3H).
334	4-[3-(5,8-dichloro-2-methylquinolin-4-yl)-2-ethyl-7-(1H-imidazol-5-yl)benzimidazol-5-yl]morpholine	507.2	1H NMR (400 MHz, DMSO-d6) δ 9.27 (d, J = 1.3 Hz, 1H), 8.54 (d, J = 1.3 Hz, 1H), 8.04 (d, J = 8.3 Hz, 1H), 7.84 (s, 1H), 7.65 (d, J = 8.3 Hz, 1H), 7.49 (d, J = 2.1 Hz, 1H), 6.57 (d, J = 2.0 Hz, 1H), 3.69 (t, J = 4.7 Hz, 4H), 3.12 – 2.99 (m, 4H), 2.82 (s, 3H), 2.64 – 2.51 (m, 2H), 1.26 (t, J = 7.4 Hz, 3H).
335	4-[3-(5,8-difluoroquinolin-4-yl)-7-(1H-imidazol-5-yl)-2-methylbenzimidazol-5-yl]morpholine	447.26	1H NMR (400 MHz, DMSO-d6) δ 9.29 (d, J = 4.5 Hz, 1H), 9.26 (d, J = 1.4 Hz, 1H), 8.51 (d, J = 1.3 Hz, 1H), 7.96 (d, J = 4.5 Hz, 1H), 7.78 (ddd, J = 10.2, 8.8, 4.2 Hz, 1H), 7.52 – 7.40 (m, 2H), 6.62 (d, J = 2.1 Hz, 1H), 3.69 (t, J = 4.8 Hz, 4H), 3.12 – 3.02 (m, 4H), 2.35 (s, 3H).
336	4-[3-(5,8-difluoroquinolin-4-yl)-	433.24	1H NMR (400 MHz, DMSO-d6) δ 9.28 (d, J = 1.4 Hz, 2H), 9.24 (d, J =

	7-(1H-imidazol-5-yl)benzimidazol-5-yl]morpholine		4.5 Hz, 1H), 8.61 (d, J = 2.6 Hz, 1H), 8.55 (d, J = 1.4 Hz, 1H), 7.96 (d, J = 4.6 Hz, 1H), 7.79 (ddd, J = 10.1, 8.7, 4.1 Hz, 1H), 7.61 (d, J = 2.1 Hz, 1H), 7.49 (ddt, J = 12.4, 8.8, 4.5 Hz, 1H), 6.84 (d, J = 2.1 Hz, 1H), 3.72 (t, J = 4.7 Hz, 4H), 3.19 – 3.05 (m, 4H).
337	4-[3-(5,8-difluoroquinolin-4-yl)-2-ethyl-7-(1H-imidazol-5-yl)benzimidazol-5-yl]morpholine	461.19	1H NMR (400 MHz, DMSO-d6) δ 9.31 – 9.25 (m, 2H), 8.56 – 8.51 (m, 1H), 7.97 (d, J = 4.6 Hz, 1H), 7.78 (td, J = 9.3, 8.9, 4.0 Hz, 1H), 7.51 (d, J = 2.0 Hz, 1H), 7.45 (ddd, J = 12.2, 8.7, 3.7 Hz, 1H), 6.61 (d, J = 1.9 Hz, 1H), 3.69 (t, J = 4.8 Hz, 4H), 3.10 – 3.02 (m, 4H), 2.72 – 2.52 (m, 2H), 1.23 (t, J = 7.5 Hz, 3H).

Separation of atropisomers: The atropisomers of compound 200 were separated on OD-H SFC 5uM 21x250mm column in 30% EtOH/CO2 at 60 mL/min to give the atropisomers of 4-[3-(8-fluoroquinolin-4-yl)-2-methyl-7-(1,3-oxazol-2-yl)benzimidazol-5-yl]morpholine, Compound 340 and Compound 341 . 1H NMR (400 MHz, DMSO-d6) δ 9.27 (d, J = 4.5 Hz, 1H), 8.42 (d, J = 0.8 Hz, 1H), 8.01 (d, J = 4.5 Hz, 1H), 7.77 (ddd, J = 10.9, 7.8, 1.2 Hz, 1H), 7.69 - 7.59 (m, 2H), 7.56 (d, J = 0.8 Hz, 1H), 7.24 (d, J = 8.4 Hz, 1H), 6.71 (d, J = 2.3 Hz, 1H), 3.66 (t, J = 4.7 Hz, 4H), 3.12 - 2.95 (m, 4H), 2.45 (s, 3H). ES/MS *m/z* 430.1 $(M+H)^+$.

The compounds listed in the table below were prepared in a manner similar to that described above using appropriate intermediates and chemistry.

Compound	Name	MS	NMR
342	4-[7-(2-chloro-1H-imidazol-5-yl)-2-cyclopropyl-3-(5,8-difluoroquinolin-4-yl)benzimidazol-5-yl]morpholine	507.2	1H NMR (400 MHz, DMSO-d6) δ 12.89 (s, 1H), 9.27 (d, J = 4.5 Hz, 1H), 8.09 (s, 1H), 7.97 (d, J = 4.5 Hz, 1H), 7.76 (td, J = 9.3, 4.1 Hz, 1H), 7.46 (ddd, J = 12.3, 8.7, 3.8 Hz, 1H), 7.39 (s, 1H), 6.40 (d, J = 2.2 Hz, 1H), 3.67 (t, J = 4.7 Hz, 4H), 3.04 - 2.96 (m, 4H), 1.59 (td, J = 8.3, 4.2 Hz, 1H), 1.22 - 0.99 (m,

			2H), 0.94 - 0.74 (m, 2H).
343	4-[7-(2-chloro-1H-imidazol-5-yl)-2-cyclopropyl-3-(5,8-difluoroquinolin-4-yl)benzimidazol-5-yl]morpholine	507.2	1H NMR (400 MHz, DMSO-d6) δ 13.19 - 12.81 (m, 1H), 9.27 (d, J = 4.5 Hz, 1H), 8.13 (s, 1H), 7.97 (d, J = 4.5 Hz, 1H), 7.76 (ddd, J = 10.0, 8.7, 4.1 Hz, 1H), 7.46 (ddd, J = 12.3, 8.7, 3.8 Hz, 1H), 6.39 (d, J = 2.1 Hz, 1H), 3.67 (t, J = 4.7 Hz, 4H), 3.03 - 2.97 (m, 4H), 1.59 (td, J = 8.2, 4.2 Hz, 1H), 1.20 - 1.12 (m, 1H), 1.11 - 1.03 (m, 1H), 0.95 - 0.75 (m, 2H).
344	4-[3-(5-chloro-8-fluoroquinolin-4-yl)-2-methyl-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	464.1	1H NMR (400 MHz, DMSO-d6) δ 9.30 (d, J = 4.4 Hz, 1H), 8.00 (d, J = 4.4 Hz, 1H), 7.79 (d, J = 7.2 Hz, 2H), 7.63 (s, 1H), 6.68 (s, 1H), 3.65 (dd, J = 6.0, 3.6 Hz, 4H), 3.11 - 2.97 (m, 4H), 2.39 (s, 3H).
345	4-[3-(5-chloro-8-fluoroquinolin-4-yl)-2-methyl-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	464.1	1H NMR (400 MHz, DMSO-d6) δ 9.29 (d, J = 4.4 Hz, 1H), 7.99 (d, J = 4.5 Hz, 1H), 7.79 (d, J = 7.1 Hz, 2H), 7.61 (s, 1H), 6.67 (s, 1H), 3.68 - 3.49 (m, 4H), 3.13 - 2.95 (m, 4H), 2.38 (s, 3H).
346	4-[7-(2-chloro-1H-imidazol-5-yl)-3-(5,8-difluoroquinolin-4-yl)-2-ethylbenzimidazol-5-yl]morpholine	495.2	1H NMR (400 MHz, DMSO-d6) δ 12.91 (s, 1H), 9.26 (d, J = 4.5 Hz, 1H), 8.24 (d, J = 1.7 Hz, 1H), 7.93 (d, J = 4.5 Hz, 1H), 7.76 (ddd, J = 9.9, 8.8, 4.1 Hz, 1H), 7.50 - 7.38 (m, 2H), 6.35 (d, J = 2.3 Hz, 1H), 3.71 - 3.62 (m, 4H), 3.06 - 2.95 (m, 4H), 2.65 - 2.51 (m, 2H), 1.20 (t, J = 7.5 Hz, 3H).
347	4-[7-(2-chloro-1H-imidazol-5-yl)-3-(5,8-difluoroquinolin-4-yl)-2-ethylbenzimidazol-5-yl]morpholine	495.2	1H NMR (400 MHz, DMSO-d6) δ 12.91 (s, 1H), 9.26 (d, J = 4.5 Hz, 1H), 8.24 (s, 1H), 7.93 (d, J = 4.5 Hz, 1H), 7.76 (td, J = 9.3, 4.1 Hz, 1H), 7.48 - 7.38 (m, 2H), 6.39 - 6.32 (m, 1H), 3.68 - 3.63 (m, 4H), 3.01 - 2.96 (m, 4H), 2.61 - 2.51 (m, 2H), 1.20 (t, J = 7.5 Hz, 3H).
348	4-[3-(3,8-dichloroquinolin-4-yl)-2-ethyl-7-(5-methyl-4H-1,2,4-triazol-3-	508.2	1H NMR (400 MHz, DMSO-d6) δ 9.37 (s, 1H), 8.11 (dd, J = 7.6, 1.2 Hz, 1H), 7.64 (dd, J = 8.5, 7.6 Hz, 1H), 7.52 (s, 1H), 7.15 (d, J = 8.4

	yl)benzimidazol-5-yl]morpholine		Hz, 1H), 6.67 (s, 1H), 3.63 (t, J = 4.8 Hz, 4H), 3.00 (s, 4H), 2.97 - 2.74 (m, 2H), 2.37 (s, 3H), 1.30 - 1.16 (m, 3H).
349	4-[3-(3,8-dichloroquinolin-4-yl)-2-ethyl-7-(5-methyl-4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	508.1	1H NMR (400 MHz, DMSO-d6) δ 9.38 (s, 1H), 8.11 (dd, J = 7.6, 1.2 Hz, 1H), 7.64 (dd, J = 8.5, 7.6 Hz, 1H), 7.53 (d, J = 2.3 Hz, 1H), 7.18 (dd, J = 8.5, 1.2 Hz, 1H), 6.65 (s, 1H), 3.63 (s, 4H), 3.00 (s, 4H), 2.54 (dp, J = 7.6, 4.1 Hz, 2H), 2.40 (s, 3H), 1.18 (t, J = 7.5 Hz, 3H).
350	(S)-4-(1-(5,8-difluoroquinolin-4-yl)-2-methyl-4-(5-methyl-4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	462.2	1H NMR (400 MHz, DMSO-d6) δ 9.28 (d, J = 4.5 Hz, 1H), 7.97 (d, J = 4.5 Hz, 1H), 7.81 – 7.74 (m, 1H), 7.52 (s, 1H), 7.47 (ddd, J = 12.3, 8.8, 3.8 Hz, 1H), 6.69 (s, 1H), 3.70 – 3.63 (m, 4H), 3.06 – 2.99 (m, 4H), 2.36 (s, 6H).
351	(R)-4-(1-(5,8-difluoroquinolin-4-yl)-2-methyl-4-(5-methyl-4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	462.2	1H NMR (400 MHz, DMSO-d6) δ 9.32 (d, J = 4.5 Hz, 1H), 8.04 (d, J = 4.5 Hz, 1H), 7.84 – 7.75 (m, 1H), 7.62 (s, 1H), 7.49 (ddd, J = 12.2, 8.8, 3.7 Hz, 1H), 6.74 (s, 1H), 3.70 – 3.63 (m, 4H), 3.06 (t, J = 4.9 Hz, 4H), 2.48 – 2.42 (m, 6H).
352	4-[3-(7,8-difluoroquinolin-4-yl)-2-methyl-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	448.2	1H NMR (400 MHz, DMSO-d6) δ 9.29 (d, J = 4.5 Hz, 1H), 7.99 (d, J = 4.5 Hz, 1H), 7.87 - 7.72 (m, 1H), 7.67 (s, 1H), 7.32 (s, 1H), 6.62 (d, J = 2.2 Hz, 1H), 3.64 (t, J = 4.7 Hz, 5H), 3.01 (d, J = 4.1 Hz, 2H), 2.46 (s, 3H).
353	4-[3-(7,8-difluoroquinolin-4-yl)-2-methyl-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	448.2	1H NMR (400 MHz, DMSO-d6) δ 9.29 (d, J = 4.5 Hz, 1H), 7.98 (d, J = 4.5 Hz, 1H), 7.77 (td, J = 9.8, 7.2 Hz, 1H), 7.66 (s, 1H), 7.30 (s, 1H), 6.62 (d, J = 2.2 Hz, 1H), 3.64 (t, J = 4.7 Hz, 4H), 3.09 - 2.95 (m, 4H), 2.44 (s, 3H).
354	4-[3-(8-fluoroquinolin-4-yl)-2-propyl-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-	458.2	1H NMR (400 MHz, DMSO-d6) δ 9.24 (d, J = 4.5 Hz, 1H), 8.00 (d, J = 4.5 Hz, 1H), 7.63 (dd, J = 13.3, 5.0 Hz, 2H), 6.58 (s, 1H), 3.64 (t, J = 4.7 Hz, 4H), 3.00 (d, J = 3.8 Hz,

	yl]morpholine		4H), 2.66 (d, J = 6.6 Hz, 2H), 1.63 (s, 2H), 0.78 (t, J = 7.4 Hz, 3H).
355	4-[3-(8-fluoroquinolin-4-yl)-2-propyl-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	458.2	1H NMR (400 MHz, DMSO-d6) δ 9.26 (d, J = 4.5 Hz, 1H), 8.48 (s, 1H), 8.03 (d, J = 4.5 Hz, 1H), 7.85 - 7.45 (m, 3H), 7.19 (s, 1H), 6.60 (d, J = 2.2 Hz, 1H), 3.64 (t, J = 4.8 Hz, 4H), 3.02 (q, J = 3.9 Hz, 4H), 2.84 - 2.52 (m, 2H), 1.72 - 1.30 (m, 2H), 0.77 (t, J = 7.4 Hz, 3H).
356	4-[3-(5,8-difluoroquinolin-4-yl)-7-(1,3-oxazol-2-yl)-2-propylbenzimidazol-5-yl]morpholine	476.2	1H NMR (400 MHz, DMSO-d6) δ 9.27 (d, J = 4.5 Hz, 1H), 8.35 (d, J = 0.8 Hz, 1H), 7.97 (d, J = 4.5 Hz, 1H), 7.77 (ddd, J = 10.0, 8.8, 4.2 Hz, 1H), 7.52 (d, J = 2.3 Hz, 1H), 7.51 - 7.40 (m, 2H), 6.69 (d, J = 2.3 Hz, 1H), 3.69 - 3.62 (m, 4H), 3.06 - 2.98 (m, 4H), 2.68 - 2.51 (m, 2H), 1.67 - 1.53 (m, 2H), 0.81 (t, J = 7.4 Hz, 3H).
357	4-[3-(5,8-difluoroquinolin-4-yl)-7-(1,3-oxazol-2-yl)-2-propylbenzimidazol-5-yl]morpholine	476.2	1H NMR (400 MHz, DMSO-d6) δ 9.27 (d, J = 4.5 Hz, 1H), 8.35 (d, J = 0.8 Hz, 1H), 7.97 (d, J = 4.5 Hz, 1H), 7.77 (ddd, J = 10.0, 8.8, 4.2 Hz, 1H), 7.52 (d, J = 2.3 Hz, 1H), 7.49 - 7.41 (m, 2H), 6.69 (d, J = 2.3 Hz, 1H), 3.69 - 3.62 (m, 4H), 3.06 - 2.98 (m, 4H), 2.69 - 2.51 (m, 2H), 1.65 - 1.54 (m, 2H), 0.81 (t, J = 7.4 Hz, 3H).
358	4-[3-(8-chloroquinolin-4-yl)-7-(5-chloro-4H-1,2,4-triazol-3-yl)-2-methylbenzimidazol-5-yl]morpholine	480.1	1H NMR (400 MHz, DMSO-d6) δ 9.29 (d, J = 4.5 Hz, 1H), 8.09 (dd, J = 7.5, 1.2 Hz, 1H), 7.96 (d, J = 4.5 Hz, 1H), 7.59 (dd, J = 8.5, 7.5 Hz, 1H), 7.50 (d, J = 2.2 Hz, 1H), 7.22 (dd, J = 8.5, 1.2 Hz, 1H), 6.63 (d, J = 2.3 Hz, 1H), 3.63 (t, J = 4.7 Hz, 4H), 3.07 - 2.93 (m, 4H), 2.36 (s, 3H).
359	4-[3-(8-chloroquinolin-4-yl)-7-(5-chloro-4H-1,2,4-triazol-3-yl)-2-methylbenzimidazol-5-yl]morpholine	480.1	1H NMR (400 MHz, DMSO-d6) δ 9.29 (d, J = 4.5 Hz, 1H), 8.09 (dd, J = 7.5, 1.2 Hz, 1H), 7.96 (d, J = 4.5 Hz, 1H), 7.59 (dd, J = 8.5, 7.6 Hz, 1H), 7.50 (d, J = 2.2 Hz, 1H), 7.22 (dd, J = 8.5, 1.2 Hz, 1H), 6.63 (d, J

			= 2.2 Hz, 1H), 3.63 (t, J = 4.7 Hz, 4H), 3.00 (q, J = 4.0 Hz, 4H), 2.36 (s, 3H).
360	4-[3-(8-chloroquinolin-4-yl)-2-methyl-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	446.2	1H NMR (400 MHz, DMSO-d6) δ 9.37 (dd, J = 4.5, 0.6 Hz, 1H), 8.77 (s, 1H), 8.15 (dd, J = 7.4, 1.3 Hz, 1H), 8.09 (d, J = 4.5 Hz, 1H), 7.83 (d, J = 2.3 Hz, 1H), 7.64 (dd, J = 8.4, 7.5 Hz, 1H), 7.57 (d, J = 8.4 Hz, 1H), 6.73 (d, J = 2.3 Hz, 1H), 3.66 (t, J = 4.8 Hz, 4H), 3.08 (q, J = 3.9 Hz, 4H), 2.59 (s, 3H).
361	4-[3-(8-chloroquinolin-4-yl)-2-methyl-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	446.2	1H NMR (400 MHz, DMSO-d6) δ 9.37 (dd, J = 4.5, 0.6 Hz, 1H), 8.77 (s, 1H), 8.15 (dd, J = 7.4, 1.3 Hz, 1H), 8.09 (d, J = 4.5 Hz, 1H), 7.83 (d, J = 2.3 Hz, 1H), 7.64 (dd, J = 8.4, 7.5 Hz, 1H), 7.57 (d, J = 8.4 Hz, 1H), 6.73 (d, J = 2.3 Hz, 1H), 3.66 (t, J = 4.8 Hz, 4H), 3.08 (q, J = 3.9 Hz, 4H), 2.59 (s, 3H).
362	4-[2-methyl-3-(5-methylquinolin-4-yl)-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	426.2	1H NMR (400 MHz, DMSO-d6) δ 9.21 (d, J = 4.4 Hz, 1H), 8.73 (s, 1H), 8.21 – 8.15 (m, 1H), 7.90 – 7.80 (m, 3H), 7.57 – 7.50 (m, 1H), 6.69 (d, J = 2.2 Hz, 1H), 3.67 (t, J = 4.8 Hz, 4H), 3.15 – 3.07 (m, 4H), 2.55 (s, 3H), 1.82 (s, 3H).
363	4-[2-methyl-3-(5-methylquinolin-4-yl)-7-(4H-1,2,4-triazol-3-yl)benzimidazol-5-yl]morpholine	426.2	1H NMR (400 MHz, DMSO-d6) δ 9.21 (d, J = 4.4 Hz, 1H), 8.73 (s, 1H), 8.21 – 8.15 (m, 1H), 7.90 – 7.80 (m, 3H), 7.57 – 7.50 (m, 1H), 6.69 (d, J = 2.2 Hz, 1H), 3.67 (t, J = 4.8 Hz, 4H), 3.15 – 3.07 (m, 4H), 2.55 (s, 3H), 1.82 (s, 3H).
364	4-(2-ethyl-6-morpholino-4-(4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-1-yl)-3-methylquinoline-8-carbonitrile	465.2	1H NMR (400 MHz, DMSO-d6) δ 9.34 (d, J = 0.5 Hz, 1H), 8.54 (s, 1H), 8.43 (dd, J = 7.2, 1.3 Hz, 1H), 7.76 – 7.67 (m, 2H), 7.60 (d, J = 8.4 Hz, 1H), 6.64 (d, J = 2.3 Hz, 1H), 3.64 (t, J = 4.8 Hz, 4H), 3.05 (dd, J = 6.3, 3.8 Hz, 4H), 2.67 (d, J = 8.1 Hz, 2H), 2.21 (s, 3H), 1.11 (t, J = 7.5 Hz, 3H).

365	4-(2-ethyl-6-morpholino-4-(4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-1-yl)-3-methylquinoline-8-carbonitrile	465.2	1H NMR (400 MHz, DMSO-d6) δ 9.34 (d, J = 0.5 Hz, 1H), 8.54 (s, 1H), 8.43 (dd, J = 7.2, 1.3 Hz, 1H), 7.76 – 7.67 (m, 2H), 7.60 (d, J = 8.4 Hz, 1H), 6.64 (d, J = 2.3 Hz, 1H), 3.64 (t, J = 4.8 Hz, 4H), 3.05 (dd, J = 6.3, 3.8 Hz, 4H), 2.67 (d, J = 8.1 Hz, 2H), 2.21 (s, 3H), 1.11 (t, J = 7.5 Hz, 3H).
366	4-(1-(3,8-dichloroquinolin-4-yl)-2-methyl-4-(5-methyl-4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	494.1	1H NMR (400 MHz, DMSO-d6) δ 9.42 (s, 1H), 8.14 (dd, J = 7.6, 1.2 Hz, 1H), 7.71 – 7.62 (m, 2H), 7.38 (d, J = 8.5 Hz, 1H), 6.76 (d, J = 2.3 Hz, 1H), 3.72 – 3.58 (m, 4H), 3.04 (dd, J = 6.1, 3.8 Hz, 4H), 2.48 (s, 3H), 2.44 (s, 3H).
367	4-(1-(3,8-dichloroquinolin-4-yl)-2-methyl-4-(5-methyl-4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-6-yl)morpholine	494.1	1H NMR (400 MHz, DMSO-d6) δ 9.42 (s, 1H), 8.14 (dd, J = 7.6, 1.2 Hz, 1H), 7.71 – 7.62 (m, 2H), 7.38 (d, J = 8.5 Hz, 1H), 6.76 (d, J = 2.3 Hz, 1H), 3.72 – 3.58 (m, 4H), 3.04 (dd, J = 6.1, 3.8 Hz, 4H), 2.48 (s, 3H), 2.44 (s, 3H).
368	4-(1-(5,8-difluoroquinolin-4-yl)-2-propyl-4-(1H-pyrazol-5-yl)-1H-benzo[d]imidazol-6-yl)morpholine	475.2	1H NMR (400 MHz, DMSO-d6) δ 9.26 (d, J = 4.5 Hz, 1H), 7.94 (d, J = 4.5 Hz, 1H), 7.76 (ddd, J = 10.0, 8.8, 4.2 Hz, 1H), 7.71 (br s, 1H), 7.45 (ddd, J = 12.5, 8.8, 3.8 Hz, 1H), 7.39 (br s, 2H), 6.44 (d, J = 2.1 Hz, 1H), 3.67 (t, J = 4.7 Hz, 4H), 3.05 – 2.98 (m, 4H), 2.60 – 2.51 (m, 2H), 1.69 (h, J = 7.4 Hz, 2H), 0.86 (t, J = 7.4 Hz, 3H).
369	4-(1-(5,8-difluoroquinolin-4-yl)-2-propyl-4-(1H-pyrazol-5-yl)-1H-benzo[d]imidazol-6-yl)morpholine	475.2	1H NMR (400 MHz, DMSO-d6) δ 13.27 – 12.80 (m, 1H), 9.26 (d, J = 4.5 Hz, 1H), 7.94 (d, J = 4.5 Hz, 1H), 7.76 (ddd, J = 10.1, 8.9, 4.2 Hz, 1H), 7.85 – 7.59 (m, 1H), 7.49 – 7.41 (m, 1H), 7.58 – 7.24 (m, 1H), 6.44 (s, 1H), 3.67 (t, J = 4.7 Hz, 4H), 3.04 – 2.97 (m, 4H), 2.56 (t, J = 7.4 Hz, 2H), 1.69 (q, J = 7.4 Hz, 2H), 0.86 (t, J = 7.4 Hz, 3H)
370	4-(1-(5,8-difluoroquinolin-4-yl)-	461.2	1H NMR (400 MHz, DMSO-d6) δ 12.21 (s, 1H), 9.28 (d, J = 4.5 Hz,

	2-ethyl-4-(1H-imidazol-2-yl)-1H-benzo[d]imidazol-6-yl)morpholine		1H), 7.99 (d, J = 4.5 Hz, 1H), 7.77 (ddd, J = 10.0, 8.8, 4.2 Hz, 1H), 7.60 (d, J = 2.3 Hz, 1H), 7.46 (ddd, J = 12.4, 8.8, 3.8 Hz, 1H), 7.37 (dd, J = 2.1, 1.2 Hz, 1H), 7.09 (t, J = 1.4 Hz, 1H), 6.53 (d, J = 2.3 Hz, 1H), 3.70 – 3.63 (m, 4H), 3.05 – 2.98 (m, 4H), 2.71 – 2.53 (m, 2H), 1.26 (t, J = 7.5 Hz, 3H).
371	4-(1-(5,8-difluoroquinolin-4-yl)-2-ethyl-4-(1H-imidazol-2-yl)-1H-benzo[d]imidazol-6-yl)morpholine	461.2	1H NMR (400 MHz, DMSO-d6) δ 12.28 (s, 1H), 9.28 (d, J = 4.5 Hz, 1H), 7.99 (d, J = 4.5 Hz, 1H), 7.77 (ddd, J = 10.0, 8.8, 4.2 Hz, 1H), 7.61 (d, J = 2.3 Hz, 1H), 7.46 (ddd, J = 12.4, 8.8, 3.8 Hz, 1H), 7.26 (br s, 2H), 6.53 (d, J = 2.3 Hz, 1H), 3.70 – 3.63 (m, 4H), 3.06 – 2.98 (m, 4H), 2.68 – 2.57 (m, 2H), 1.25 (t, J = 7.5 Hz, 3H).
372	4-(4-(2-chloro-1H-imidazol-5-yl)-1-(5,8-difluoroquinolin-4-yl)-2-methyl-1H-benzo[d]imidazol-6-yl)morpholine	481.18	1H NMR (400 MHz, DMSO-d6) δ 9.29 (d, J = 4.5 Hz, 1H), 8.15 (s, 1H), 7.97 (d, J = 4.5 Hz, 1H), 7.78 (ddd, J = 10.0, 8.9, 4.2 Hz, 1H), 7.53 – 7.44 (m, 1H), 7.44 (s, 1H), 6.45 (s, 1H), 3.67 (t, J = 4.7 Hz, 4H), 3.07 – 2.99 (m, 4H), 2.38 (s, 3H).
373	4-(4-(2-chloro-1H-imidazol-5-yl)-1-(5,8-difluoroquinolin-4-yl)-2-methyl-1H-benzo[d]imidazol-6-yl)morpholine	481.2	1H NMR (400 MHz, DMSO-d6) δ 9.29 (d, J = 4.5 Hz, 1H), 8.15 (s, 1H), 7.97 (d, J = 4.5 Hz, 1H), 7.78 (ddd, J = 10.0, 8.8, 4.2 Hz, 1H), 7.53 – 7.44 (m, 1H), 7.44 (s, 1H), 6.45 (s, 1H), 3.67 (t, J = 4.7 Hz, 4H), 3.13 – 2.91 (m, 4H), 2.38 (s, 3H).
374	3-methyl-4-(2-methyl-6-morpholino-4-(4H-1,2,4-triazol-3-yl)-1H-benzo[d]imidazol-1-yl)quinoline-8-carbonitrile	451.2	1H NMR (400 MHz, DMSO-d6) δ 9.35 (d, J = 0.5 Hz, 1H), 8.61 (s, 1H), 8.44 (dd, J = 7.1, 1.4 Hz, 1H), 7.87 – 7.60 (m, 3H), 6.68 (d, J = 2.3 Hz, 1H), 3.64 (t, J = 4.7 Hz, 4H), 3.06 (dd, J = 6.2, 3.7 Hz, 4H), 2.44 (s, 3H), 2.23 (s, 3H).
375	3-methyl-4-(2-methyl-6-morpholino-4-(4H-1,2,4-triazol-3-yl)-1H-	451.2	1H NMR (400 MHz, DMSO-d6) δ 9.35 (d, J = 0.5 Hz, 1H), 8.61 (s, 1H), 8.44 (dd, J = 7.1, 1.4 Hz, 1H),

	benzo[d]imidazol-1-yl)quinoline-8-carbonitrile		7.87 – 7.60 (m, 3H), 6.68 (d, J = 2.3 Hz, 1H), 3.64 (t, J = 4.7 Hz, 4H), 3.06 (dd, J = 6.2, 3.7 Hz, 4H), 2.44 (s, 3H), 2.23 (s, 3H).

5-(1-(5,8-Difluoroquinolin-4-yl)-6-morpholino-1H-benzo[d]imidazol-4-yl)-1H-imidazole-2-carbonitrile



4-(1-(5,8-difluoroquinolin-4-yl)-4-(2-(trifluoromethyl)-1H-imidazol-5-yl)-1H-benzo[d]imidazol-6-yl)morpholine (26 mg, 0.042 mmol) was combined with NH_4OH (5% aqueous solution) and stirred at 50°C for 12 days. The reaction was poured into water and extracted 3 times with DCM. The combined extracts were purified by HPLC eluting with 5-95% water/ acetonitrile (0.1%v/v trifluoroacetic acid) to give the title compound (Compound 394). 1H NMR (400 MHz, DMSO-d6) δ 9.23 (d, J = 4.5 Hz, 1H), 8.60 (s, 1H), 8.46 (s, 1H), 7.96 (d, J = 4.6 Hz, 1H), 7.78 (ddd, J = 10.0, 8.7, 4.1 Hz, 1H), 7.65 - 7.59 (m, 1H), 7.48 (ddd, J = 12.4, 8.8, 3.9 Hz, 1H), 6.76 (d, J = 2.2 Hz, 1H), 3.71 (t, J = 4.7 Hz, 4H), 3.17 - 3.04 (m, 4H). ES/MS m/z = 458.2 $(M+H)^+$.

tert-Butyl 4-(4-chloroquinolin-2-yl)piperazine-1-carboxylate



A suspension of 2,4-dichloroquinoline (6.4 g, 32.2 mmol), *tert*-butyl piperazine-1-carboxylate (5.0 g, 26.8 mmol) and diethylisopropylamine (6.5 mL, 38.0 mmol) was stirred in a sealed tube at 100 °C for 2 days. Upon cooling, the reaction mixture was

concentrated in vacuuo to afford material which was purified by column chromatography on SiO_2 eluting with EtOAc in hexanes (0-15%) to afford the title compound. ES/MS m/z = 348.1 $(M+H)^+$.

4-Chloro-2-(1-trityl-1H-pyrazol-3-yl)quinoline



A sealed tube was charged with 2,4-dichloroquinoline (1.0 g, 5.05 mmol), 3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1-trityl-1H-pyrazole (2.2 g, 5.05 mmol), K_3PO_4 (3.2 g, 15.1 mmol) and $Pd(PPh_3)_4$ (0.58 g, 0.50 mmol) followed by dioxane (50 mL) and water (12 mL). The reaction mixture was stirred at 90 °C for 3 h. Upon cooling, the reaction mixture was absorbed on SiO2 followed by purification on column chromatography on SiO_2 eluting with EtOAc in hexanes (0-100%) to afford the title compound. ES/MS m/z = 472.2 (M+H)+.

The compound listed below was prepared in a similar manner using appropriate intermediates:

4-chloro-2-(1-trityl-1H-pyrazol-4-yl)quinoline

2-(Trifluoromethyl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-imidazole



Sodium hydride (60% in mineral oil, 764 mg, 19.1 mmol) was slowly added to a solution of 2-(trifluoromethyl)imidazole (650 mg, 4.78 mmol) in THF (25 mL) at 0°C under N2. The mixture was stirred at 0°C for 2 hours, then 2-(trimethylsilyl)ethoxymethyl chloride (1.0 mL, 5.73 mmol) was added. The reaction was allowed to gradually attain ambient temperature and stir overnight. The reaction was quenched slowly with water, then poured into EtOAc. The organic phase was washed with water, brine, then purified on silica gel (40 g column, 0 – 100% EtOAc/hexanes) to give the title compound. ES/MS m/z = 267.1 $(M+H)^+$.

Biological Examples

The compounds of formula (I) were characterized for their enzymatic activity against the PI3K isoforms. The activities were measured using a time-resolved fluorescence resonance energy transfer (TR-FRET) assay. TR-FRET monitored the formation of 3,4,5-inositol triphosphate molecule that competed with fluorescently labeled PIP3 for binding to the GRP-1 pleckstrin homology domain protein. An increase in phosphatidylinositide 3-phosphate product resulted in a decrease in TR-FRET signal as the labeled fluorophore was displaced from the GRP-1 protein binding site.

Class I PI3K isoforms were expressed and purified as heterodimeric recombinant proteins. All assay reagents and buffers for the TR-FRET assay were purchased from Millipore. PI3K isoforms were assayed under initial rate conditions in the presence of 25 mM Hepes (pH 7.4), and 2× Km ATP (75-500 μM), 2 μM PIP2, 5% glycerol, 5 mM $MgCl_2$, 50 mM NaCl, 0.05% (v/v) Chaps, 1 mM dithiothreitol, and 1% (v/v) DMSO at the following concentrations for each isoform: PI3Kα, PI3Kβ, and PI3Kδ between 25 and 50 pM, and PI3Kγ at 2 nM. The compounds were added to the assay solution and incubated for 30 minutes at 25°C. The reactions were terminated with a final concentration of 10 mM EDTA, 10 nM labeled-PIP3, and 35 nM Europium labeled GRP-1 detector protein before reading TR-FRET on an Envision plate reader (Ex: 340 nm; Em: 615/665 nm; 100 μs delay and 500 μs read window).

The results were normalized based on positive (1 μM wortmanin) and negative (DMSO) controls, and the IC_{50} values for PI3K α, β, δ, and γ were calculated from the fit of the dose-response curves to a four-parameter equation. These assays generally produced results within 3-fold of the reported mean. As shown in Table 1, the compounds provided herein are inhibitors of PI3Kβ.

The compounds of formula (I) were also characterized for their metabolic stability in human hepatocytes by incubating the test articles (TA) in cryopreserved human hepatocytes and monitoring parent drug disappearance via LC/MC. The TA was incubated with 1 million hepatocytes/mL at 2 μM substrate in duplicate. The incubation was carried out at 37°C with 5% CO_2 and saturating humidity. Samples were taken at 0, 1, 2, and 4 hours to monitor the disappearance of TA and a half-life ($t_{1/2}$) was determined.

Table 1

example	**IC_{50}-PIP-β (nM)**
1	4
2	24
3	24
4	28
5	29
6	31
7	31
8	32
9	33
10	41
11	42
12	43
13	45
14	49
15	49
16	53
17	60
18	63
19	110
20	120
21	130
22	280
23	390
24	1500
25	2200
26	22
27	56
28	3
29	7
30	8
31	9
32	9
33	10
34	10
35	11
36	11
37	11
38	11
39	11
40	22
41	21
42	20
43	20
44	19
45	19

46	19
47	18
48	18
49	18
50	16
51	15
52	15
53	15
54	14
55	27
56	72
57	55
58	62
59	130
60	30
61	27
62	23
63	28
64	21
65	24
66	16
67	99
68	8
69	17
70	36
71	23
72	25
73	78
74	62
75	29
76	29
77	97
78	27
79	110
80	61
81	11
82	9
83	19
84	17
85	280
86	16
87	14
88	4
89	12
90	11
91	19
92	46
93	290

94	26
95	6
96	24
97	12
98	13
99	33
100	43
101	7
102	21
103	9
104	84
105	10
106	17
107	29
108	26
109	13
110	19
111	3
112	17
113	17
114	12
115	14
116	21
117	15
118	52
119	24
120	27
121	44
122	13
123	110
124	9
125	16
126	21
127	23
128	51
129	23
130	87
131	46
132	380
133	21
134	16
135	43
136	48
137	17
138	140
139	14
140	13
141	10

142	15
143	84
144	65
145	56
146	101
149	100
150	27
151	44
152	59
153	120
154	2200
155	20
156	20
157	47
160	470
161	23
162	77
163	630
164	130
165	720
166	480
167	12
168	9
169	16
170	7
171	100
172	100
173	140
174	13
175	10
176	510
177	230
178	12
179	44
180	42
181	210
182	34
183	170
198	120
199	610
200	9
201	19
202	>10000
203	120
204	8
205	12
206	40
207	13

208	14
209	15
210	27
211	22
212	34
213	16
214	56
215	630
216	380
217	9
218	11
219	8
220	7
221	11
222	12
223	9
224	3
225	18
226	5
227	10
228	10
229	5
230	7
231	16
232	56
233	8
234	100
235	17
236	5
237	50
238	4
239	12
240	2
241	27
242	6
243	26
244	9
245	21
246	1100
247	12
260	22
261	24
262	27
263	13
264	770
265	460
266	11
267	2100

268	317
269	7000
270	36
271	46
272	65
273	2600
274	27
275	88
276	420
277	620
278	4
279	10
280	13
281	15
282	25
283	71
284	13
285	4
286	14
287	56
288	5
289	24
290	68
291	27
292	42
293	38
294	6
295	12
296	17
297	3800
298	10
299	17
300	14
301	20
302	24
303	21
304	81
305	13
306	370
307	8
308	6
309	50
310	36
311	47
312	967
313	9800
314	7800
315	490

316	2500
317	690
318	5200
319	8600
320	>10000
321	4400
322	>10000
323	417
329	7
330	5
331	7
332	2
333	9
334	24
335	15
336	5
337	20
340	1900
341	6
342	>10000
343	5
344	5
345	4462
346	10000
347	7
348	13
349	439
350	10
351	460
352	7
353	270
354	8
355	2500
356	>10000
357	5
358	10
359	1200
360	2800
361	2
362	28
363	8000
364	25
365	9100
366	17
367	5600
368	18
369	>10000
370	13

371	6800
372	6
373	1000
374	22
375	7100
376	70
377	35
378	27
379	8
380	240
381	24
382	130
383	11
387	13
388	1100
389	16
390	840
391	10
392	9
393	21
394	860

From the foregoing it will be appreciated that, although specific embodiments have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the present application.

What is claimed:

1. A compound having the structure of formula (I):



Formula I

wherein n is 1, 2, 3 or 4;

m is 1, 2, 3 or 4;

s is 1 or 2;

t is 1 or 2;

each R^1 is independently selected from hydrogen, halo, cyano, hydroxy, amino, $-C(O)R^a$, $-C(O)OR^b$, $-C(O)NR^aR^b$, $-N(R^a)C(O)R^b$, $-S(O)NR^aR^b$, $-S(O)_2NR^aR^b$, $-S(O)R^a$, $-S(O)_2R^a$, $-NR^aR^b$, $-OR^a$, $-SR^b$, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, C_{6-10} aryl, 5-10 membered heteroaryl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S, and 4-10 membered heterocyclyl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S;

wherein each C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, C_{6-10} aryl, 5-10 membered heteroaryl and 4-10 membered heterocyclyl is optionally substituted with one to four R^{100};

R^2 is selected from hydrogen, halo, cyano, hydroxy, amino, $-C(O)R^a$, $-C(O)OR^b$, $-C(O)NR^aR^b$, $-N(R^a)C(O)R^b$, $-S(O)NR^aR^b$, $-S(O)_2NR^aR^b$, $-S(O)R^a$, $-S(O)_2R^a$, $-NR^aR^b$, $-OR^a$, $-SR^b$, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, C_{6-10} aryl, 5-10 membered heteroaryl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S, and 4-10 membered heterocyclyl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S;

wherein each C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, C_{6-10} aryl, 5-10 membered heteroaryl and 4-10 membered heterocyclyl is optionally substituted with one to four R^{101};

R^3 is selected from C_{6-10} aryl, 5-10 membered heteroaryl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S, and 4-10 membered heterocyclyl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S;

wherein each C_{6-10} aryl, 5-10 membered heteroaryl and 4-10 membered heterocyclyl is optionally substituted with one to four R^{102};

R^4 is selected from hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, acyl, C_{3-8} cycloalkyl and C_{1-6} alkyl sulfonyl;

each R^5 is independently selected from hydrogen, halo, cyano, hydroxy, amino, $-C(O)R^a$, $-C(O)OR^b$, $-C(O)NR^aR^b$, $-N(R^a)C(O)R^b$, $-S(O)NR^aR^b$, $-S(O)_2NR^aR^b$, $-S(O)R^a$, $-S(O)_2R^a$, $-NR^aR^b$, $-OR^a$, $-SR^b$, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, C_{6-10} aryl, 5-10 membered heteroaryl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S, and 4-10 membered heterocyclyl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S;

wherein each C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, C_{6-10} aryl, 5-10 membered heteroaryl and 4-10 membered heterocyclyl is optionally substituted with one to four R^{103};

each R^6 is independently selected from hydrogen, halo, cyano, hydroxy, amino, $-C(O)R^a$, $-C(O)OR^b$, $-C(O)NR^aR^b$, $-N(R^a)C(O)R^b$, $-S(O)NR^aR^b$, $-S(O)_2NR^aR^b$, $-S(O)R^a$, $-S(O)_2R^a$, $-NR^aR^b$, $-OR^a$, $-SR^b$, C_{1-6} alkyl, C_{2-6} alkenyl or C_{2-6} alkynyl;

each R^a and R^b is independently selected from hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl and C_{2-6} alkynyl;

wherein each C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, is optionally substituted with one to four R^{200};

each R^{100}, R^{101}, R^{102}, and R^{103} is independently selected from hydrogen, halo, cyano, hydroxy, amino, oxo, thioxo, vinyl, $-C(O)R^a$, $-C(O)OR^b$, $-C(O)NR^aR^b$, $-N(R^a)C(O)R^b$, $-S(O)NR^aR^b$, $-S(O)_2NR^aR^b$, $-S(O)R^a$, $-S(O)_2R^a$, $-NR^aR^b$, $-OR^a$, $-SR^b$, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, C_{6-10} aryl, 5-10 membered heteroaryl and 4-10 membered heterocyclyl;

wherein each C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, is optionally substituted with one to four R^{201}; and,

each R^{200} and R^{201} is independently selected from hydrogen, halo, cyano, hydroxy, amino, oxo, thioxo, vinyl, $-C(O)R^c$, $-C(O)OR^d$, $-C(O)NR^cR^d$, $-N(R^c)C(O)R^d$, $-S(O)NR^dR^d$, $-S(O)_2NR^cR^d$, $-S(O)R^c$, $-S(O)_2R^c$, $-NR^cR^d$, $-OR^c$, $-SR^c$, C_{1-6} alkyl, C_{2-6} alkenyl and C_{2-6} alkynyl;

each R^c and R^d is independently selected from hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl and C_{2-6} alkynyl;

or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

2. A compound of claim 1 having the structure of formula IB:



Formula IB

====== represents a single or double bond;

X^1 is N or C;

each X^2, X^3, X^4 and X^5 is independently selected from S, O, $CR^{10}$and NR^{11};

wherein each R^{10} is independently selected from hydrogen, halo, cyano, hydroxy, amino, $-C(O)R^a$, $-C(O)OR^b$, $-C(O)NR^aR^b$, $-N(R^a)C(O)R^b$, $-S(O)NR^aR^b$, $-S(O)_2NR^aR^b$, $-S(O)R^a$, $-S(O)_2R^a$, $-NR^aR^b$, $-OR^a$, $-SR^b$, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, C_{6-10} aryl, 5-10 membered heteroaryl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S, and 4-10 membered heterocyclyl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S;

wherein each C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{1-6} C_{3-8} cycloalkyl, C_{6-10} aryl, 5-10 membered heteroaryl and 4-10 membered heterocyclyl is optionally substituted with one to four R^{104};

wherein each R^{11} is independently selected from absent, hydrogen, halo, cyano, hydroxy, amino, $-C(O)R^a$, $-C(O)OR^b$, $-C(O)NR^aR^b$, $-N(R^a)C(O)R^b$, $-S(O)NR^aR^b$, $-S(O)_2NR^aR^b$, $-S(O)R^a$, $-S(O)_2R^a$, $-NR^aR^b$, $-OR^a$, $-SR^b$, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, C_{6-10} aryl, 5-10 membered heteroaryl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S, and 4-10 membered heterocyclyl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S ;

alternatively, one R^{10} and one R^{11} group, together with the atoms to which they are attached form a five, six or seven membered fused or bridged ring; p;

each R^{104} is independently selected from hydrogen, halo, cyano, hydroxy, amino, oxo, thioxo, vinyl, $-C(O)R^a$, $-C(O)OR^b$, $-C(O)NR^aR^b$, $-N(R^a)C(O)R^b$, $-S(O)NR^aR^b$, $-S(O)_2NR^aR^b$, $-S(O)R^a$, $-S(O)_2R^a$, $-NR^aR^b$, $-OR^a$, $-SR^b$, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, C_{6-10} aryl, 5-10 membered heteroaryl and 4-10 membered heterocyclyl;

wherein each C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, is optionally substituted with one to four R^{201}; and,

each R^{201} is independently selected from hydrogen, halo, cyano, hydroxy, amino, oxo, thioxo, vinyl, $-C(O)R^c$, $-C(O)OR^d$, $-C(O)NR^cR^d$, $-N(R^c)C(O)R^d$, $-S(O)NR^dR^d$, $-S(O)_2NR^cR^d$, $-S(O)R^c$, $-S(O)_2R^c$, $-NR^cR^d$, $-OR^c$, $-SR^c$, C_{1-6} alkyl, C_{2-6} alkenyl and C_{2-6} alkynyl;

each R^c and R^d is independently selected from hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl and C_{2-6} alkynyl;

or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

3. A compound according to any of claims 1 wherein R^3 is selected from:



wherein t is 1 or 2;

wherein each R^{13} is independently selected from hydrogen, halo, cyano, hydroxy, amino, $-C(O)R^a$, $-C(O)OR^b$, $-C(O)NR^aR^b$, $-N(R^a)C(O)R^b$, $-S(O)NR^aR^b$, $-S(O)_2NR^aR^b$, $-S(O)R^a$, $-S(O)_2R^a$, $-NR^aR^b$, $-OR^a$, $-SR^b$, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, C_{6-10} aryl, 5-10 membered heteroaryl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S, and 4-10 membered heterocyclyl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S;

or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

4. A compound of claim 3 having the structure of formula IC:



Formula IC

or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

5. A compound of claim 3 having the structure of formula ID:



Formula ID

or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

6. A compound of claim 3 having the structure of formula IE:



Formula IE

or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

7. A compound of claim 3 having the structure of formula IF:



Formula IF

or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

8. A compound of claim 3 having the structure of formula IG:



Formula IG

or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

9. A composition comprising an atropisomer of formula IE:



Formula IE

or a pharmaceutically acceptable salt thereof, and a carrier; wherein the atropisomer of formula IE or a pharmaceutically acceptable salt thereof, is present in excess of its corresponding enantiomer or a pharmaceutically acceptable salt thereof.

10. A compound of claim 3 having the structure of formula IH:



Formula IH

or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

11. A compound of claim 3 having the structure of formula IJ:



Formula IJ

or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

12. A compound of claim 3 having the structure of formula IK:



Formula IK

or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

13. A compound according to any of claims 1-12 wherein R^1 is selected from hydrogen, fluoro, chloro, bromo, iodo, methyl, ethyl, propyl, butyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl and trifluoroethyl; or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

14. A compound according to any of claims 1-13 wherein R^1 is fluoro or chloro; or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

15. A compound according to any of claims 1-14 wherein R^2 is C_{1-6} alkyl, C_{3-8} cycloalkyl, 5-6 membered heteroaryl containing 1 to 3 heteroatoms selected from the group consisting of N, O, and S, and 4-6 membered heterocyclyl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S; wherein each C_{1-6} alkyl, C_{3-8} cycloalkyl, 5-6 membered heteroaryl and 4-6 membered heterocyclyl is optionally substituted with one to four R^{101};
or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

16. A compound according to any of claims 1-15 wherein R^2 is selected from hydrogen, amino, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, furanyl, tetrahydrofuranyl, oxetanyl, and cyclopropyl; or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

17. A compound according to any of claims 1-16 wherein R^4 is selected from hydrogen and methyl; or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

18. A compound according to any of claims 1-17 wherein R^5 is selected from hydrogen, methyl, ethyl, trifluoromethyl, carboxamide, cyano, piperazinyl, cyclopropyl, phenyl and triazolyl; or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

19. The compound of claim 1, wherein the compound is selected from Table A;

TABLE A

Example	Structure	Example	Structure

1		172	
2		173	
3		174	
4		175	
5		176	

6		177	
7		178	
8		179	
9		180	
10		181	

11		182	
12		183	
13		198	
14		199	
15		200	

16		201	
17		202	
18		203	
19		204	
20		205	
21		206	

22		207	
23		208	
24		209	
25		210	
26		211	

27		212	
28		213	
29		214	
30		215	
31		216	

32		217	
33		218	
34		219	
35		220	
36		221	
37		222	

38		223	
39		224	
40		225	
41		226	
42		227	
43		228	

44		229	
45		230	
46		231	
47		232	
48		233	

49		234	
50		235	
51		236	
52		237	
53		238	

54		239	
55		240	
56		241	
57		242	
58		243	
59		244	

60		245	
61		246	
62		260	
63		261	
64		262	

65		263	
66		264	
67		265	
68		266	
69		267	

70		268	
71		269	
72		270	
73		271	
74		272	

75		273	
76		274	
77		275	
78		276	
79		277	

80		278	
81		279	
82		280	
83		281	
84		282	

85		283	
86		284	
87		285	
88		286	
89		287	

90		288	
91		289	
92		290	
93		291	
94		292	

95		293	
96		294	
97		295	
98		296	
99		297	

100		298	
101		299	
102		300	
103		301	
104		302	

105		303	
106		304	
107		305	
108		306	
109		307	

110		308	
111		309	
112		310	
113		311	
114		312	

115		313	
116		314	
117		315	
118		316	
119		317	

120		318	
121		319	
122		320	
123		321	

124		322	
125		323	
126		329	
127		330	
128		331	

129		332	
130		333	
131		334	
132		335	
133		336	

134		337	
135		340	
136		341	
137		342	
138		343	

139		344	
140		345	
141		346	
142		347	
143		348	

144		349	
145		350	
146		351	
160		352	
161		353	
162		354	

163		355	
164		356	
165		357	
166		358	
167		359	

168		360	
169		361	
170		362	
171		363	

or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

20. The compound of claim 1, wherein the compound is selected from the group consisting of:

Compound No.	Structure

341	
344	
347	
348	
350	
352	

354	
357	
361	

or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

21. The compound of claim 1, wherein the compound is selected from the group consisting of:

Example	Image
149	

Example	Image
150	
151	
152	
153	
154	

Example	Image
155	
156	
157	
247	
364	

Example	Image
365	
366	
367	
368	
369	

Example	Image
370	
371	
372	
373	
374	

Example	Image
375	
376	
377	
378	
379	

Example	Image
380	
381	
382	
383	
387	

Example	Image
388	
389	
390	
391	
392	

Example	Image
393	
394	

22. A compound having the structure of formula IA:



Formula IA

wherein n is 1, 2, 3 or 4;

m is 1, 2, 3 or 4;

s is 1, 2 or 3;

each R^1 is independently selected from hydrogen, halo, cyano, hydroxy, amino, $-C(O)R^a$, $-C(O)OR^b$, $-C(O)NR^aR^b$, $-N(R^a)C(O)R^b$, $-S(O)NR^aR^b$, $-S(O)_2NR^aR^b$, $-S(O)R^a$, $-S(O)_2R^a$, $-NR^aR^b$, $-OR^a$, $-SR^b$, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, 5-10 membered heteroaryl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S, and 4-10 membered heterocyclyl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S;

wherein each C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, C_{6-10} aryl, 5-10 membered heteroaryl and 4-10 membered heterocyclyl is optionally substituted with one to four R^{100};

R^2 is selected from hydrogen, halo, cyano, hydroxy, amino, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, 5-10 membered heteroaryl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S, and 4-10 membered heterocyclyl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S;

wherein each C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, C_{6-10} aryl, 5-10 membered heteroaryl and 4-10 membered heterocyclyl is optionally substituted with one to four R^{101};

R^7 is selected from hydrogen, halo, cyano, hydroxy, amino, $-C(O)R^a$, $-C(O)OR^b$, $-C(O)NR^aR^b$, $-N(R^a)C(O)R^b$, $-S(O)NR^aR^b$, $-S(O)_2NR^aR^b$, $-S(O)R^a$, $-S(O)_2R^a$, $-NR^aR^b$, $-OR^a$, $-SR^b$, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl;

wherein each C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, C_{6-10} aryl, 5-10 membered heteroaryl and 4-10 membered heterocyclyl is optionally substituted with one to four R^{102};

R^4 is selected from hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, and C_{3-8} cycloalkyl;

each R^5 is independently selected from hydrogen, halo, cyano, hydroxy, amino, $-C(O)R^a$, $-C(O)OR^b$, $-C(O)NR^aR^b$, $-N(R^a)C(O)R^b$, $-S(O)NR^aR^b$, $-S(O)_2NR^aR^b$, $-S(O)R^a$, $-S(O)_2R^a$, $-NR^aR^b$, $-OR^a$, $-SR^b$, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, 5-10 membered heteroaryl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S, and 4-10 membered heterocyclyl containing 1 to 4 heteroatoms selected from the group consisting of N, O, and S;

wherein each C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cycloalkyl, C_{6-10} aryl, 5-10 membered heteroaryl and 4-10 membered heterocyclyl is optionally substituted with one to four R^{103};

each R^a and R^b is independently selected from hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl;

wherein each C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, is optionally substituted with one to four R^{200};

each R^{100}, R^{101}, R^{102}, and R^{103} is independently selected from hydrogen, halo, cyano, hydroxy, amino, $-C(O)R^a$, $-C(O)OR^b$, $-C(O)NR^aR^b$, $-N(R^a)C(O)R^b$, $-S(O)NR^aR^b$,

$-S(O)_2NR^aR^b$, $-S(O)R^a$, $-S(O)_2R^a$, $-NR^aR^b$, $-OR^a$, $-SR^b$, C_{1-6} alkyl, C_{2-6} alkenyl and C_{2-6} alkynyl;

wherein each C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, is optionally substituted with one to four R^{201}; and,

each R^{200} and R^{201} is independently selected from hydrogen, halo, cyano, hydroxy, amino, $-C(O)R^c$, $-C(O)OR^d$, $-C(O)NR^cR^d$, $-N(R^c)C(O)R^d$, $-S(O)NR^dR^d$, $-S(O)_2NR^cR^d$, $-S(O)R^c$, $-S(O)_2R^c$, $-NR^cR^d$, $-OR^c$, $-SR^c$, C_{1-6} alkyl, C_{2-6} alkenyl and C_{2-6} alkynyl;

each R^c and R^d is independently selected from hydrogen, C_{1-6} alkyl, C_{2-6} alkenyl and C_{2-6} alkynyl;

or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

23. A compound of claim 22, having the structure of formula IL or IM:



Formula IL



Formula IM

or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

24. A compound according to any of claims 21-23 wherein R^7 is selected from $C(O)OR^b$, carboxamide, bromo, and cyano; or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

25. A compound according to any of claims 21-24 wherein R^1 is selected from hydrogen, fluoro, chloro, bromo, iodo, methyl, ethyl, propyl, butyl, fluoromethyl, difluoromethyl, trifluoromethyl, fluoroethyl, difluoroethyl and trifluoroethyl; or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

26. A compound according to any of claims 21-24 wherein R^1 is fluoro or chloro; or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

27. A compound according to any of claims 21-26 wherein R^2 is C_{1-6} alkyl; or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

28. A compound according to any of claims 21-26 wherein R^2 is selected from methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, furanyl, tetrahydrofuranyl and cyclopropyl; or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

29. A compound according to any of claims 21-28 wherein R^4 is selected from hydrogen, methyl, ethyl, propyl, isopropyl, butyl, isobutyl and tert-butyl; or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

30. A compound according to any of claims 21-28 wherein R^5 is selected from hydrogen, methyl, ethyl, trifluoromethyl, carboxamide, cyano, piperazinyl, cyclopropyl, phenyl and triazolyl; or a pharmaceutically acceptable salt, isomer, or a mixture thereof.

31. A pharmaceutical composition comprises the compound according to any one of claims 1-30 and at least one pharmaceutically acceptable vehicle.

32. A method of treating a disease or condition in a human in need thereof comprising administering to the human a therapeutically effective amount of the compound or composition according to any one of claims 1-31 wherein the disease or condition is selected from cancer, hematologic malignancies, leukemias, lymphomas, myeloproliferative disorders, myelodysplastic syndromes, plasma cell neoplasms, solid tumor, inflammation, fibrosis, autoimmune disorders, allergic conditions, hypersensitivity, cardiovascular diseases, neurodegenerative diseases, renal disorders, viral infections, obesity, and autoimmune diseases.

33. The method of claim 32, wherein the disease or condition is selected from rheumatoid arthritis, osteoarthritis, atherosclerosis, psoriasis, systemic lupus erythematosus, multiple sclerosis, inflammatory bowel disease, asthma, chronic obstructive airways disease, pneumonitis, dermatitis, alopecia, nephritis, vasculitis,

atherosclerosis, Alzheimer's disease, hepatitis, primary biliary cirrhosis, sclerosing cholangitis, diabetes, acute rejection of transplanted organs, lymphomas, multiple myelomas, leukemias, pancreatic cancer, bladder cancer, colorectal cancer, breast cancer, prostate cancer, renal cancer, hepatocellular cancer, lung cancer, ovarian cancer, cervical cancer, rectum cancer, liver cancer, kidney cancer, stomach cancer, skin cancer, gastric cancer, esophageal cancer, head and neck cancer, melanoma, neuroendocrine cancers, CNS cancers brain tumors bone cancer, or soft tissue sarcoma.

34. The method of claim 32, wherein said disease or condition is selected from prostate cancer, pancreatic cancer, bladder cancer, colorectal cancer, breast cancer, renal cancer, hepatocellular cancer, lung cancer, ovarian cancer, cervical cancer, rectum cancer, liver cancer, kidney cancer, stomach cancer, skin cancer, gastric cancer, esophageal cancer, head and neck cancer, melanoma, neuroendocrine cancers, CNS cancers, brain tumors, bone cancer and soft tissue sarcoma.

35. A method of inhibiting the activity of a phosphatidylinositol 3-kinase polypeptide by contacting the polypeptide with the compound or composition of claim 1-31.

36. A method of inhibiting excessive or destructive immune reactions or growth or a proliferation of cancer cells, comprising administering an effective amount of the compound or composition according to any one of claims 1-31.

37. A method of treating a disease or condition in a human in need thereof comprising administering to the human a therapeutically effective amount of the compound or composition according to any one of claims 1-31 in combination with therapeutically effective amount of a compound that inhibits or modulates the activity of poly(ADP-ribose) polymerases (PARP), Tankyrases (TANKs), matrix metalloproteinases or androgen receptor, wherein the disease or condition is selected from cancer, hematologic malignancies, leukemias, lymphomas, myeloproliferative disorders, myelodysplastic syndromes, plasma cell neoplasms, solid tumor, inflammation, fibrosis, autoimmune disorders, allergic conditions, hypersensitivity, cardiovascular diseases, neurodegenerative diseases, renal disorders, viral infections, obesity, and autoimmune diseases.

38. The method of claim 37, wherein said disease or condition is selected from prostate cancer, pancreatic cancer, bladder cancer, colorectal cancer, breast cancer, renal

cancer, hepatocellular cancer, lung cancer, ovarian cancer, cervical cancer, rectum cancer, liver cancer, kidney cancer, stomach cancer, skin cancer, gastric cancer, esophageal cancer, head and neck cancer, melanoma, neuroendocrine cancers, CNS cancers, brain tumors, bone cancer and soft tissue sarcoma.

39. A method of treating a disease or condition in a human in need thereof comprising administering to the human a therapeutically effective amount of the compound or composition according to any one of claims 1-31 in combination with therapeutically effective amount of a compound selected from enzalutamide, abiraterone, abiraterone acetate, apalutamide, galeterone, olaparib, niraparib, veliparib, rucaparib, flutamide, nilutamide, bicalutamide, ketonazole, orteronel, finasteride, dutasteride, bexlosteride, izonsteride, turosteride, episteride, dexamethasone, prednisone, leuprolide, goserelin, triptorelin, histrelin, estrogen, cyproterone acetate, spironolactone, flutamide and hydroxyflutamide, wherein the disease or condition is selected from cancer, hematologic malignancies, leukemias, lymphomas, myeloproliferative disorders, myelodysplastic syndromes, plasma cell neoplasms, solid tumor, inflammation, fibrosis, autoimmune disorders, allergic conditions, hypersensitivity, cardiovascular diseases, neurodegenerative diseases, renal disorders, viral infections, obesity, and autoimmune diseases.

40. The method according to claim 39 wherein said disease or condition is selected from prostate cancer, pancreatic cancer, bladder cancer, colorectal cancer, breast cancer, renal cancer, hepatocellular cancer, lung cancer, ovarian cancer, cervical cancer, rectum cancer, liver cancer, kidney cancer, stomach cancer, skin cancer, gastric cancer, esophageal cancer, head and neck cancer, melanoma, neuroendocrine cancers, CNS cancers, brain tumors, bone cancer and soft tissue sarcoma.

41. A kit comparing the compound or composition of any one of claims 1-31, a label and/or instructions for use.

42. The compound, a pharmaceutically acceptable salt, isomer, or a mixture thereof according to any one of claims 1-30 for use in therapy.

43. The compound, a pharmaceutically acceptable salt, isomer, or a mixture thereof according to any one of claims 1-30 for use in a method of treating of claim 32.

44. Use of the compound, a pharmaceutically acceptable salt, isomer, or a mixture thereof according to any one of claims 1-30 for the manufacture of a medicament for treatment of a disease or condition of claim 32.

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2017/052817

A. CLASSIFICATION OF SUBJECT MATTER
INV. C07D413/14 A61K31/4184 A61K31/4196 A61K31/4709 A61K31/5375
C07D413/04 A61P29/00 A61P35/00 C07D405/14 A61K31/341
A61K31/4025 A61K31/4155 A61K31/4178 A61K31/4245 A61K31/427

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
EPO-Internal, WPI Data, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 8 435 988 B2 (QU ET AL) 7 May 2013 (2013-05-07) cited in the application the whole document -----	1-44
Y	MESHRAM H M ET AL: "Synthesis and Cytotoxicity of New Quinoline Derivatives", INDIAN JOURNAL OF CHEMISTRY, SECTION B, vol. 51B, no. 9, 22 January 2013 (2013-01-22), pages 1411-1416, XP055418074, ISSN: 0376-4699 page 1414; table I; compounds 5l, 5m, 5n -----	1-44
Y	WO 01/40217 A1 (PFIZER) 7 June 2001 (2001-06-07) page 23, line 14; claim 1 -----	1-44

☐ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
3 November 2017	15/11/2017

Name and mailing address of the ISA/	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Fax: (+31-70) 340-3016	Elliott, Adrian

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/US2017/052817

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 8435988 B2	07-05-2013	AR 083296 A1	13-02-2013
		AU 2011312594 A1	11-04-2013
		CA 2812608 A1	12-04-2012
		CL 2013000935 A1	05-07-2013
		CN 103124496 A	29-05-2013
		CO 6700852 A2	28-06-2013
		CR 20130192 A	03-10-2013
		CY 1118792 T1	12-07-2017
		DK 2624696 T3	13-03-2017
		DO P2013000059 A	31-05-2013
		EA 201390302 A1	30-09-2013
		EP 2624696 A1	14-08-2013
		EP 3170813 A1	24-05-2017
		ES 2616238 T3	12-06-2017
		HR P20170279 T1	07-04-2017
		IL 225140 A	29-09-2016
		JP 5719028 B2	13-05-2015
		JP 2013539753 A	28-10-2013
		KR 20130099142 A	05-09-2013
		LT 2624696 T	10-03-2017
		MA 34591 B1	02-10-2013
		MX 337662 B	14-03-2016
		NZ 608069 A	27-06-2014
		PE 01922014 A1	24-02-2014
		PL 2624696 T3	31-07-2017
		PT 2624696 T	21-03-2017
		SG 188974 A1	28-06-2013
		TW 201307297 A	16-02-2013
		US 2012088767 A1	12-04-2012
		US 2013196990 A1	01-08-2013
		US 2013197221 A1	01-08-2013
		US 2014018534 A1	16-01-2014
		US 2014142321 A1	22-05-2014
		US 2014378456 A1	25-12-2014
		US 2015246889 A1	03-09-2015
		US 2017112844 A1	27-04-2017
		UY 33648 A	30-04-2012
		WO 2012047538 A1	12-04-2012
		ZA 201301951 B	27-08-2014
WO 0140217 A1	07-06-2001	AP 1895 A	08-10-2008
		AR 026633 A1	19-02-2003
		AT 316528 T	15-02-2006
		AU 782077 B2	30-06-2005
		BG 65862 B1	31-03-2010
		BR 0015911 A	06-08-2002
		CA 2392973 A1	07-06-2001
		CN 1402721 A	12-03-2003
		CN 101289442 A	22-10-2008
		CO 5251455 A1	28-02-2003
		CR 6643 A	07-11-2003
		CU 23132 A3	22-05-2006
		CZ 20021759 A3	18-06-2003
		DE 60025747 T2	31-08-2006
		DK 1235825 T3	15-05-2006
		DZ 3327 A1	07-06-2001
		EA 200200509 A1	31-10-2002
		EE 200200276 A	16-06-2003

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/US2017/052817

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
		EG 24433 A	25-06-2009
		EP 1235825 A1	04-09-2002
		ES 2256052 T3	16-07-2006
		GE P20033141 B	11-08-2003
		GT 200000198 A	23-05-2002
		HN 2000000026 S1	01-10-2002
		HR P20020475 A2	31-10-2005
		HU 0203725 A2	28-02-2003
		IL 149841 A	08-07-2008
		IS 6341 A	12-04-2002
		JP 4522635 B2	11-08-2010
		JP 2003515603 A	07-05-2003
		JP 2007126468 A	24-05-2007
		MA 26847 A1	20-12-2004
		MX PA02005343 A	11-12-2002
		MY 128765 A	28-02-2007
		NO 20022556 A	29-07-2002
		NZ 518280 A	28-05-2004
		PA 8507601 A1	14-02-2003
		PE 08992001 A1	05-09-2001
		PL 355917 A1	31-05-2004
		SI 1235825 T1	30-06-2006
		SK 7172002 A3	07-07-2004
		SV 2002000232 A	07-06-2002
		TN SN00228 A1	10-11-2005
		TR 200201430 T2	21-01-2003
		TW I258475 B	21-07-2006
		UA 75055 C2	15-08-2002
		US 7019147 B1	28-03-2006
		WO 0140217 A1	07-06-2001
		YU 30702 A	10-06-2005
		ZA 200204244 B	28-05-2003
